Form 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-14-402854.txt : 20141107 0001193125-14-402854.hdr.sgml : 20141107 20141107131121 ACCESSION NUMBER: 0001193125-14-402854 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141107 DATE AS OF CHANGE: 20141107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 141203752 BUSINESS ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 10-Q 1 d793512d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2014.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from to .

Commission file number: 001-35347

Clovis Oncology, Inc.

(Exact name of Registrant as specified in its charter)


Delaware		90-0475355
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2525 28^th Street, Suite 100 Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)

(303) 625-5000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of October 31, 2014 was 33,964,440.

CLOVIS ONCOLOGY, INC.

FORM 10-Q

TABLE OF CONTENTS


PART I. Financial Information		3
ITEM 1.	Financial Statements (unaudited)	3
	Consolidated Statements of Operations and Comprehensive Loss — for the three and nine months ended September 30, 2014 and 2013	3
	Consolidated Balance Sheets — as of September 30, 2014 and December 31, 2013	4
	Consolidated Statements of Cash Flows — for the nine months ended September 30, 2014 and 2013	5
	Notes to Unaudited Consolidated Financial Statements	6
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	20
ITEM 4.	Controls and Procedures	20
PART II. Other Information		21
ITEM 1.	Legal Proceedings	21
ITEM 1A.	Risk Factors	21
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
ITEM 3.	Defaults Upon Senior Securities	24
ITEM 4.	Mine Safety Disclosures	24
ITEM 5.	Other Information	24
ITEM 6.	Exhibits	24
SIGNATURES		28

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share amounts)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Revenues:
License and milestone revenue	$	—		$	—		$	13,625		$	—
Operating expenses:
Research and development		34,965			16,063			87,556			44,001
General and administrative		5,267			4,312			15,852			11,022
Acquired in-process research and development		—			—			8,806			250
Amortization of intangible asset		—			—			3,409			—
Accretion of contingent purchase consideration		888			—			2,571			—

Total expenses		41,120			20,375			118,194			55,273

Operating loss		(41,120	)		(20,375	)		(104,569	)		(55,273	)
Other income (expense), net		1,770			55			1,934			(56	)

Loss before income taxes		(39,350	)		(20,320	)		(102,635	)		(55,329	)
Income tax expense		(292	)		—			(2,489	)		—

Net loss	$	(39,642	)	$	(20,320	)	$	(105,124	)	$	(55,329	)

Basic and diluted net loss per common share	$	(1.17	)	$	(0.68	)	$	(3.10	)	$	(2.00	)

Basic and diluted weighted average common shares outstanding		33,921			30,047			33,871			27,614

Comprehensive loss	$	(58,809	)	$	(20,299	)	$	(126,126	)	$	(55,314	)

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except for share amounts)


	September 30, 2014			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	516,585		$	323,228
Prepaid research and development expenses		2,241			976
Other current assets		7,925			4,392

Total current assets		526,751			328,596
Property and equipment, net		2,846			955
Intangible assets		220,723			244,518
Goodwill		68,482			74,811
Other assets		12,725			755

Total assets	$	831,527		$	649,635

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,428		$	4,420
Accrued research and development expenses		23,832			12,548
Other accrued expenses		4,719			3,984

Total current liabilities		30,979			20,952
Contingent purchase consideration		55,445			55,754
Deferred income taxes, net		69,307			74,955
Convertible senior notes		287,500			—
Other non-current liabilities		6			88

Total liabilities		443,237			151,749
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013		—			—
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2014 and December 31, 2013; 33,964,065 and 33,897,321 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		34			34
Additional paid-in capital		778,700			762,170
Accumulated other comprehensive (loss) income		(16,306	)		4,696
Accumulated deficit		(374,138	)		(269,014	)

Total stockholders’ equity		388,290			497,886

Total liabilities and stockholders’ equity	$	831,527		$	649,635

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Dollars in thousands)


	Nine Months Ended September 30,
	2014			2013
Operating activities
Net loss	$	(105,124	)	$	(55,329	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,772			185
Share-based compensation expense		15,585			6,663
Change in value of contingent purchase consideration		(309	)		—
Deferred income taxes		761			—
Changes in operating assets and liabilities, net of acquisition of a business:
Prepaid and accrued research and development expenses		7,152			1,990
Other operating assets		(3,941	)		(5	)
Accounts payable		(1,889	)		(1,463	)
Other accrued expenses		892			81

Net cash used in operating activities		(83,101	)		(47,878	)
Investing activities
Purchases of property and equipment		(2,191	)		(80	)

Net cash used in investing activities		(2,191	)		(80	)
Financing activities
Proceeds from the issuance of convertible senior notes		287,500			—
Proceeds from the sale of common stock, net of issuance costs		—			259,071
Proceeds from exercise of stock options and employee stock purchases		763			1,403
Payment of debt issuance costs		(9,165	)		—

Net cash provided by financing activities		279,098			260,474
Effect of exchange rate changes on cash and cash equivalents		(449	)		11

Increase in cash and cash equivalents		193,357			212,527
Cash and cash equivalents at beginning of period		323,228			144,097

Cash and cash equivalents at end of period	$	516,585		$	356,624

See accompanying Notes to Unaudited Consolidated Financial Statements.

CLOVIS ONCOLOGY, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (the “Company”) commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. In the first quarter of 2014, the Company exited the development stage, with the recognition of $13.6 million in license and milestone revenue related to its lucitanib collaboration and license agreement with Les Laboratoires Servier (“Servier”). The license and milestone revenue recognized is the first significant revenue from principal operations and therefore, the Company is no longer considered a development stage company.

Basis of Presentation

All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.

3. EOS Acquisition

On November 19, 2013, the Company acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”). The initial purchase consideration was comprised of a cash payment of $11.8 million and the issuance of $173.7 million of the Company’s common stock to the former EOS shareholders. The Company may make additional purchase payments to the previous EOS shareholders if certain lucitanib regulatory and sales milestones are achieved. The range of the potential contingent milestone payments are zero to an estimated maximum of $65.0 million and €115.0 million. The Company recorded a liability for the estimated fair value of these payments, which totaled $55.4 million and $55.8 million at September 30, 2014 and December 31, 2013, respectively.

4. Financial Instruments and Fair Value Measurement

Cash, Cash Equivalents and Marketable Securities

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.

Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:


Level 1:		Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of money market investments. The Company does not have Level 1 liabilities.

Level 2:		Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.

Level 3:		Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired in 2013 with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of the Company’s 2013 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.

The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	Balance		Level 1		Level 2		Level 3
September 30, 2014
Assets:
Money market	$	447,986	$	447,986	$	—	$	—

Total assets at fair value	$	447,986	$	447,986	$	—	$	—

Liabilities:
Contingent purchase consideration	$	55,445	$	—	$	—	$	55,445

Total liabilities at fair value	$	55,445	$	—	$	—	$	55,445

December 31, 2013
Assets:
Money market	$	318,886	$	318,886	$	—	$	—

Total assets at fair value	$	318,886	$	318,886	$	—	$	—

Liabilities:
Contingent purchase consideration	$	55,754	$	—	$	—	$	55,754

Total liabilities at fair value	$	55,754	$	—	$	—	$	55,754

There were no transfers between Level 1 and Level 2 during the nine months ended September 30, 2014.

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:


	For the Nine Months Ended September 30, 2014
Liabilities:
Balance at beginning of period	$	55,754
Accretion		2,571
Change in foreign currency gains and losses		(2,880	)

Balance at end of period	$	55,445

The change in the fair value of Level 3 instruments is included in accretion of contingent purchase consideration and other income (expense), net for the change in foreign currency gains and losses on the Consolidated Statements of Operations and Comprehensive Loss.

5. Other Current Assets

Other current assets are comprised of the following (in thousands):


	September 30, 2014		December 31, 2013
Receivable from partners	$	6,544	$	2,921
VAT recoverable		45		950
Prepaid expenses and other		1,336		521

Other current assets	$	7,925	$	4,392

6. Intangible Assets and Goodwill

Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the purchase accounting of EOS in November 2013. The intangible asset balance at September 30, 2014 and December 31, 2013 was $220.7 million and $244.5 million, respectively. The balance decreased $20.4 million over the prior year due to changes in foreign currency translation rates. In addition, the Company recorded a $3.4 million reduction in the intangible assets driven by lower expected future milestone revenue cash flows from our lucitanib development activities due to the receipt of a lucitanib milestone payment from Servier during the first quarter of 2014. This reduction was reported as amortization of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.

Recurring amortization of these assets will commence when the useful lives of the intangible assets have been determined. IPR&D intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value will be recognized as an expense in the Consolidated Statements of Operations and Comprehensive Loss.

The acquisition of EOS in November 2013 generated a goodwill balance of $74.8 million at December 31, 2013. This balance decreased to $68.5 million at September 30, 2014 due to changes in foreign currency translation rates.

7. Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):


	September 30, 2014		December 31, 2013
Accrued personnel costs	$	3,404	$	3,356
Accrued corporate legal fees and professional services		132		257
Accrued expenses – other		1,183		371

Other accrued expenses	$	4,719	$	3,984

8. Convertible Senior Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning March 15, 2015. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the Notes, the Company incurred $9.2 million of debt issuance costs, which is included in other assets on the Consolidated Balance Sheets. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Notes. As of September 30, 2014, the balance of unamortized debt issuance costs was $9.1 million.

The fair value of the Notes was $297.3 million at September 30, 2014 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.

The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):


	Three Months Ended September 30, 2014		Nine Months Ended September 30, 2014
Contractual interest expense	$	439	$	439
Amortization of debt issuance costs		72		72

Total interest expense	$	511	$	511

9. Stockholders’ Equity

Common Stock

In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions were $259.1 million.

Accumulated Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):


	Foreign Currency Translation Adjustments			Total Accumulated Other Comprehensive Income (Loss)
Balance December 31, 2013	$	4,696		$	4,696
Period change		(21,002	)		(21,002	)

Balance September 30, 2014	$	(16,306	)	$	(16,306	)

Balance December 31, 2012	$	53		$	53
Period change		4,643			4,643

Balance December 31, 2013	$	4,696		$	4,696

The period change between December 31, 2013 and September 30, 2014 was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes associated with the acquisition of EOS in November 2013.

10. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Research and development	$	2,991	$	1,138	$	8,005	$	3,095
General and administrative		2,445		1,653		7,580		3,568

Total share-based compensation expense	$	5,436	$	2,791	$	15,585	$	6,663

The Company did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2014 and 2013, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of September 30, 2014. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013.

The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:


	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2013		2,520,170		$	21.19
Granted		1,449,457			62.00
Exercised		(60,449	)		8.96
Forfeited		(23,813	)		34.96

Outstanding at September 30, 2014		3,885,365		$	36.52		8.29	$	64,790,012

Vested and expected to vest at September 30, 2014		3,620,712		$	35.23		8.22	$	63,341,213

Vested at September 30, 2014		1,503,631		$	19.47		7.30	$	41,643,182

The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $45.36 as of September 30, 2014, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:


	Three Months Ended September 30,
	2014		2013
Weighted-average grant-date fair value per share	$	27.85	$	43.43
Intrinsic value of options exercised	$	4,391	$	85,589
Cash received from stock option exercises	$	341	$	34,711

	Nine Months Ended September 30,
	2014		2013
Weighted-average grant-date fair value per share	$	39.13	$	18.43
Intrinsic value of options exercised	$	2,754,669	$	5,801,963
Cash received from stock option exercises	$	541,508	$	1,223,023

As of September 30, 2014, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures, was $51.6 million and the estimated weighted-average remaining vesting period was 3.0 years.

11. License Agreements

Rociletinib (CO-1686)

In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. The Company made an up-front payment of $2.0 million upon execution of the license agreement and is obligated to pay royalties on net sales of rociletinib, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of rociletinib in the U.S. or European Union as a first line therapy. Such notice was provided to Celgene on June 4, 2014, and on September 2, 2014, we received notification from Celgene that the company elected not to exercise this option.

In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant EGFR inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If rociletinib is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales.

In February 2014, the Company initiated a Phase II study for rociletinib which resulted in a $5.0 million milestone payment to Celgene as required by the license agreement. This payment was recognized as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $110.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved.

Rucaparib

In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made a $7.0 million up-front payment to Pfizer.

In April 2014, the Company initiated a pivotal registrational study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. This payment was recognized as acquired in-process research and development expense.

The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $258.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved.

In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib.

Lucitanib

In connection with its November 2013 acquisition of EOS, the Company gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for up-front milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. The Company is obligated to pay Advenchen royalties on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, the Company is obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, the Company recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an up-front payment and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, the Company is entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. The Company is also entitled to receive royalties on net sales of lucitanib by Servier.

The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to the Company if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.

The Company and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between the Company and Servier. Beginning in the third quarter of 2014, depending on the expense type, reimbursements are determined using a standard rate approved by the Company and Servier or actual costs incurred. Previously, reimbursements were determined based on actual costs. Reimbursements are recorded as a reduction to research and development expense in the Consolidated Statements of Operations and Comprehensive Loss.

The Company recorded a $6.5 million and $2.9 million receivable at September 30, 2014 and December 31, 2013, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three and nine months ending September 30, 2014, we recorded reductions in research and development expense of $4.1 million and $7.9 million, respectively, for reimbursable development costs due from Servier.

12. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

13. Income Taxes

Income tax expense of $2.5 million was recorded during the nine months ended September 30, 2014 due to taxable income earned in a foreign jurisdiction resulting from milestone revenue received during the first quarter of 2014. This expense was partially offset by a deferred tax benefit recognized upon the write down of an intangible asset in the first quarter of 2014 (see Note 6). The Company maintains a valuation allowance against the majority of the net deferred tax assets held at September 30, 2014 and intends to maintain this valuation allowance until there is sufficient evidence that consistent future earnings can be achieved, which is uncertain at this time.

14. Commitments and Contingencies

Royalty and License Fee Commitments

The Company has entered into certain license agreements, as identified in Note 11, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded in the Company’s Consolidated Balance Sheets at September 30, 2014 and December 31, 2013.

Development and Manufacturing Agreement Commitments

In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first 12 months of any forecast. As of September 30, 2014, no purchase commitments were established under this agreement.

15. Subsequent Events

The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Information

This Quarterly Report on Form 10-Q and the information incorporated herein by reference includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our products, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein.

Any forward-looking statements that we make in this Quarterly Report on Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

You should also read carefully the factors described in the “Risk Factors” section of this Quarterly Report on Form 10-Q to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised, however, to consult any further disclosures we make on related subjects in our other reports filed with the SEC and on our website.

Overview

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations and seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients that are most likely to benefit from their use. We are currently developing three product candidates:

•

Rociletinib, an orally available, small molecule epidermal growth factor receptor (“EGFR”) covalent inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (“NSCLC”) in patients with activating EGFR mutations, including the initial activating mutations, as well as the primary resistance mutation, T790M;

•

Rucaparib, an orally available, small molecule poly (ADP-ribose) polymerase (“PARP”) inhibitor, that is currently in Phase II/III clinical trials for the treatment of ovarian and pancreatic cancers; and

•

Lucitanib, an oral, selective tyrosine kinase inhibitor in Phase II clinical trials for the treatment of breast and lung cancers.

We hold global development and commercialization rights for rociletinib and rucaparib and U.S. and Japanese rights for lucitanib.

We commenced operations in May 2009. To date, we have devoted substantially all of our resources to identifying and in-licensing product candidates, performing development activities with respect to those product candidates and the general and administrative support of these operations. Through September 30, 2014, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Les Laboratoires Servier (“Servier”), but have generated no product revenues. We have principally funded our operations using the net proceeds from the sale of convertible preferred stock, the issuance of convertible promissory notes, public offerings of our common stock and our recent convertible senior notes offering. The convertible preferred stock and convertible promissory notes converted into shares of our common stock immediately prior to the closing of our initial public offering in November 2011.

We have never been profitable and, as of September 30, 2014, we had an accumulated deficit of $374.1 million. We expect to incur significant and increasing losses for the foreseeable future as we advance our product candidates through clinical development to seek regulatory approval and, if approved, commercialize such product candidates. We will need additional financing to support our operating activities. We will seek to fund our operations through equity or debt financings or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We expect that research and development expenses will increase as we continue the development of our product candidates. We will need to generate significant revenues to achieve profitability, and we may never do so.

On November 19, 2013, the Company acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”) using a combination of cash and the Company’s common stock as the initial purchase consideration. EOS was a biopharmaceutical company located in Italy that focused on the development of novel medicines for the treatment of cancer. The primary reason for the business acquisition was to obtain development and commercialization rights to lucitanib. The Company paid $11.8 million in cash and issued $173.7 million of common stock at the acquisition date and may make additional contingent future cash payments of $65.0 million and €115.0 million if certain regulatory and sales milestones are achieved.

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of our 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and December 15 of each year, beginning March 15, 2015. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased. For additional information regarding the Notes, see Note 8 to our unaudited consolidated financial statements included in this quarterly report.

Product License Agreements

Rociletinib (CO-1686)

In May 2010, we entered into a worldwide license agreement with Avila Therapeutics, Inc. (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the EGFR gene product. Rociletinib was identified as the lead inhibitor candidate under the license agreement. We are responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. We made an up-front payment of $2.0 million upon execution of the license agreement, a $4.0 million milestone payment in the first quarter of 2012 upon the acceptance by the U.S. Food and Drug Administration of our investigational new drug application for rociletinib and a $5.0 million milestone payment in the first quarter of 2014 upon the initiation of the Phase II study for rociletinib. We recognized all payments as acquired in-process research and development expense.

We are obligated to pay royalties on net sales of rociletinib, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of our development expenses. This option must be exercised within a limited period of time after Celgene is notified by us of our intent to pursue regulatory approval of rociletinib in the U.S. or the European Union as a first-line treatment. Such notice was provided to Celgene on June 4, 2014, and on September 2, 2014, we received notification from Celgene that the company elected not to exercise this option.

We may be required to pay up to an additional aggregate of $110.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we may be required to pay up to an aggregate of $120.0 million in sales milestone payments if certain annual sales targets are achieved.

Rucaparib

In June 2011, we entered into a license agreement with Pfizer Inc. to acquire exclusive global development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule PARP inhibitor which we are developing for the treatment of ovarian and pancreatic cancers. Pursuant to the terms of the license agreement, we made an up-front payment of $7.0 million.

In April 2014, the Company initiated a pivotal registrational study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer Inc, as required by the license agreement. We recognized all payments as acquired in-process research and development expense. We are responsible for all development and commercialization costs of rucaparib and, if approved, we will be required to pay Pfizer royalties on sales of the product. In addition, we may be required to pay Pfizer up to an aggregate of $258.5 million in milestone payments if certain development, regulatory and sales milestones are achieved.

Lucitanib

On November 19, 2013, the Company acquired all of the issued and outstanding capital stock of EOS and gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for up-front milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an up-front payment and is entitled to receive additional payments on the achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, the Company is entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. The Company is also entitled to receive royalties on net sales of lucitanib by Servier.

The Company and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for the initial €80 million in global development costs under the agreed upon plan. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between the Company and Servier.

CO-101

In November 2009, we entered into a license agreement with Clavis Pharma ASA to develop and commercialize CO-101. In November 2012, the Company reported results from a pivotal study of CO-101 in metastatic pancreatic cancer, which failed to demonstrate a difference in overall survival between the two study arms. Based on the results of the study, the Company ceased development of CO-101 and terminated the license agreement.

Drug Discovery Collaboration Agreement

In July 2012, the Company entered into a drug discovery collaboration agreement with Array BioPharma Inc. for the discovery of a novel cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. Under the terms of the agreement, the Company was responsible to fund all costs of the discovery program, as well as costs to develop and commercialize any clinical candidates discovered. This drug discovery program did not identify a compound to be used in further development activities, and the program was terminated in the fourth quarter of 2013.

Financial Operations Overview

Revenue

To date, we have generated $13.6 million in license and milestone revenue related to our collaboration and license agreement with Servier. In the future, we may generate revenue from the sales of product candidates that are currently under development, as well as from milestone payments or royalties pursuant to our sublicense agreement with Servier. If we fail to successfully complete the development of our product candidates or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be adversely affected.

Research and Development Expenses

Research and development expenses consist of costs incurred for the development of our product candidates and companion diagnostics, which include:

•

license fees and milestone payments related to the acquisition of in-licensed products, which are reported on our Consolidated Statements of Operations and Comprehensive Loss as acquired in-process research and development;

•

employee-related expenses, including salaries, benefits, travel and share-based compensation expense;

•

expenses incurred under agreements with contract research organizations and investigative sites that conduct our clinical trials;

•

the cost of acquiring, developing and manufacturing clinical trial materials;

•

costs associated with preclinical activities and regulatory operations; and

•

activities associated with the development of companion diagnostics for our product candidates.

Research and development costs are expensed as incurred. License fees and milestone payments related to in-licensed products and technology are expensed if it is determined that they have no alternative future use. Costs for certain development activities, such as clinical trials and manufacturing of clinical supply, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors.

Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We plan to increase our research and development expenses for the foreseeable future as we seek to expand our clinical and companion diagnostic development activities for our rociletinib, rucaparib and lucitanib product candidates.

The following table identifies research and development costs and acquired in-process research and development costs on a program-specific basis for our products under development. Personnel-related costs, depreciation and share-based compensation expense are not allocated to specific programs as they are deployed across multiple projects under development and, as such, are separately classified as personnel and other expenses in the table below.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
CO-101 Expenses
Research and development	$	—		$	(20	)	$	—		$	946

CO-101 Total		—			(20	)		—			946
Rociletinib Expenses
Acquired in-process R&D		—			—			5,000			250
Research and development		17,905			4,133			40,983			11,509

Rociletinib Total		17,905			4,133			45,983			11,759
Rucaparib Expenses
Acquired in-process R&D		—			—			400			—
Research and development		10,225			6,441			25,636			13,746

Rucaparib Total		10,225			6,441			26,036			13,746
cKIT Inhibitor Expenses
Research and development		—			1,135			—			3,398

cKIT Inhibitor Total		—			1,135			—			3,398
Lucitanib Expenses
Acquired in-process R&D		—			—			3,406			—
Research and development		(1,870	)a		—			(1,518	)a		—

Lucitanib Total		(1,870	)		—			1,888			—
Personnel and other expenses		8,705			4,374			22,455			14,402

Total	$	34,965		$	16,063		$	96,362		$	44,251

a-	This amount reflects actual costs incurred less amounts due from Servier for reimbursable development expenses pursuant to the collaboration and license agreement described in Note 11 to our unaudited consolidated financial statements included in this quarterly report.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs for personnel in executive, finance, business development, legal, investor relations and information technology functions. Other general and administrative expenses include facility costs, communication expenses, corporate insurance and professional fees for legal, consulting and accounting services.

Accretion of Contingent Purchase Consideration

In connection with the acquisition of EOS in November 2013, we recorded a purchase consideration liability equal to the estimated fair value of future payments that are contingent upon the achievement of various regulatory and sales milestones. We re-measure the fair value of contingent consideration arrangements on a periodic basis and record changes in fair value as accretion of contingent purchase consideration on the Consolidated Statements of Operations and Comprehensive Loss. Changes in fair value are primarily attributed to new information about the likelihood of achieving such milestones and increases to the liability associated with the passage of time. In the absence of new information, the changes to fair value represent the passage of time as we progress towards the achievement of future milestones.

Other Income and Expense

Other income and expense is primarily comprised of foreign currency gains and losses resulting from transactions with contract research organizations, investigational sites and contract manufacturers where payments are made in currencies other than the U.S. dollar. In addition, a significant portion of the contingent purchase consideration liability will be settled in Euro-denominated payments if certain future milestones are achieved and is subject to fluctuations in foreign currency rates. Other expense also includes interest expense recognized related to the Company’s convertible senior notes.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, revenue and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a description of our critical accounting policies, please see Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have not been any material changes to our critical accounting policies since December 31, 2013.

Recent Accounting Pronouncements

Results of Operations

Comparison of Three Months Ended September 30, 2014 and 2013:

The following table summarizes the results of our operations for the three months ended September 30, 2014 and 2013:


	Three Months Ended September 30,
	2014			2013			Change			Percent Change
	(in thousands)
Revenues:
License and milestone revenue	$	—		$	—		$	—			—
Operating expenses:
Research and development		34,965			16,063			18,902			117.7	%
General and administrative		5,267			4,312			955			22.1	%
Accretion of contingent purchase consideration		888			—			888			100.0	%

Total expenses		41,120			20,375			20,745			101.8	%

Operating loss		(41,120	)		(20,375	)		(20,745	)		101.8	%
Other income, net		1,770			55			1,715			3118.2	%

Loss before income taxes		(39,350	)		(20,320	)		(19,030	)		93.7	%
Income tax expense		(292	)		—			(292	)		(100.0	%)

Net loss	$	(39,642	)	$	(20,320	)	$	(19,322	)		95.1	%

Research and Development Expenses. Research and development expenses increased during the three months ended September 30, 2014 compared to the same period in the prior year primarily due to expanded development activities for the rociletinib and rucaparib programs. Costs associated with clinical and nonclinical development activities for rociletinib were $8.4 million higher than the third quarter in 2013 driven by higher enrollment in the ongoing Phase I/II study in NSCLC, as well as the initiation of the TIGER1, TIGER2 and Japanese Phase I studies in 2014. Clinical trial costs for rucaparib were $5.0 million higher than the same quarter in the prior year primarily due to the initiation of the ARIEL2 and ARIEL3 studies in ovarian cancer. Our development costs for rucaparib were also $1.3 million higher than the third quarter of 2013 due to the expansion of our collaboration with Foundation Medicine, Inc. to incorporate a coordinated regulatory strategy for the development of a novel companion diagnostic test. Clinical supply and related manufacturing development costs for both programs were $1.2 million higher than the third quarter in 2013, as we increased production to support expanded clinical studies. In addition, salaries, share-based compensation expense and other personnel related costs were $4.4 million higher in the third quarter of 2014 driven by higher headcount to support our expanded development activities. These increases were partially offset by $1.1 million lower costs due to the termination of the cKIT program in late 2013.

General and Administrative Expenses. General and administrative expenses increased during the three months ended September 30, 2014 compared to the same period in the prior year driven by $0.8 million higher share-based compensation expense.

Accretion of Contingent Purchase Consideration. Accretion of contingent purchase consideration totaled $0.9 million for the three months ended September 30, 2014, and there was no similar liability for the three months ended September 30, 2013. This amount relates to the increase of the contingent purchase consideration liability associated with the passage of time.

Other Income, net. Other income, net increased during the three months ended September 30, 2014 compared to the same period in the prior year driven by $2.2 million net currency gains primarily due to the translation of our Euro-based contingent purchase consideration liabilities into U.S. dollars. The contingent purchase liabilities originated from the November 2013 EOS acquisition and did not exist in the third quarter of 2013. The net currency gains were partially offset by $0.5 million interest expense recognized in Q3 2014 related to the Company’s convertible senior notes issued in September 2014.

Comparison of Nine Months Ended September 30, 2014 and 2013:

The following table summarizes the results of our operations for the nine months ended September 30, 2014 and 2013:


	Nine Months Ended September 30,
	2014			2013			Change			Percent Change
	(in thousands)
Revenues:
License and milestone revenue	$	13,625		$	—		$	13,625			100.0	%
Operating expenses:
Research and development		87,556			44,001			43,555			99.0	%
General and administrative		15,852			11,022			4,830			43.8	%
Acquired in-process research and development		8,806			250			8,556			3422.4	%
Amortization of intangible asset		3,409			—			3,409			100.0	%
Accretion of contingent purchase consideration		2,571			—			2,571			100.0	%

Total expenses		118,194			55,273			62,921			113.8	%

Operating loss		(104,569	)		(55,273	)		(49,296	)		89.2	%
Other income (expense), net		1,934			(56	)		1,990			(3553.6	%)

Loss before income taxes		(102,635	)		(55,329	)		(47,306	)		85.5	%
Income tax expense		(2,489	)		—			(2,489	)		(100.0	%)

Net loss	$	(105,124	)	$	(55,329	)	$	(49,795	)		90.0	%

License and Milestone Revenue. License and milestone revenue increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 due to the recognition of $13.6 million of milestone revenue from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office in the first quarter of 2014.

Research and Development Expenses. Research and development expenses increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 primarily due to expanded development activities for the rociletinib and rucaparib programs. Costs associated with clinical and nonclinical development activities for rociletinib were $14.5 million higher in 2014 driven by higher enrollment in the ongoing Phase I/II study in NSCLC, as well as the initiation of the TIGER 1, TIGER 2 and Japanese Phase I studies in 2014. Clinical trial costs for rucaparib were $9.9 million higher in 2014 primarily due to the initiation of the ARIEL2 and ARIEL3 studies in ovarian cancer and a Phase II study in patients with pancreatic cancer and a known BRCA mutation. Our development costs for rucaparib were $2.3 million higher in the first nine months of 2014 due to the expansion of our collaboration with Foundation Medicine, Inc. to incorporate a coordinated regulatory strategy for the development of a novel companion diagnostic test. Clinical supply and related manufacturing development costs for both programs were $11.6 million higher in 2014, as we increased production to support expanded clinical studies. In addition, salaries, share-based compensation expense and other personnel related costs were $8.0 million higher in the first nine months of 2014 driven by higher headcount to support our expanded development activities. These increases were partially offset by $4.3 million lower costs due to the termination of the CO-101 and cKIT programs in late 2012 and 2013, respectively.

General and Administrative Expenses. General and administrative expenses increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 driven by $4.0 million higher share-based compensation expense. In addition, we incurred $0.5 million higher facilities and information technology costs during the first nine months of 2014 to support our expanded development activities and the operation of our EOS subsidiary acquired in November 2013.

Acquired In-Process Research and Development Expenses. Acquired in-process research and development expenses increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 primarily due to a $5.0 million milestone payment made to Celgene in the first quarter of 2014 upon the initiation of the Phase II study for rociletinib, a $3.4 million payment due to Advenchen recorded in the first quarter of 2014 pursuant to terms defined in our license agreement and a $0.4 million payment due to Pfizer recorded in the second quarter of 2014 upon the initiation of a pivotal registrational study for rucaparib.

Amortization of Intangible Asset. The fair value of the IPR&D intangible assets was reduced by $3.4 million during the nine months ended September 30, 2014 due to a fair value adjustment in the first quarter of 2014 to an asset’s expected future cash flows resulting from the receipt of the lucitanib milestone payment.

Accretion of Contingent Purchase Consideration. Accretion of contingent purchase consideration totaled $2.6 million for the nine months ended September 30, 2014, and there was no similar liability for the nine months ended September 30, 2013. This amount relates to the increase of the contingent purchase consideration liability associated with the passage of time.

Other Income (Expense), net. Other income (expense), net increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 driven by $2.5 million net currency gains primarily due to the translation of our Euro-based contingent purchase consideration liabilities into U.S. dollars. The contingent purchase liabilities originated from the November 2013 EOS acquisition and did not exist in the first nine months of 2013. The net currency gains were partially offset by $0.5 million interest expense recognized in Q3 2014 related to the Company’s convertible senior notes issued in September 2014.

Income Tax Expense. Income tax expense increased during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 primarily due to recording foreign tax provisions during the first quarter of 2014 related to milestone revenue recognized under the Servier license agreement, partially offset by a deferred tax benefit recognized upon the reduction of the carrying value of the IPR&D intangible assets in the first quarter of 2014.

Liquidity and Capital Resources

Through September 30, 2014, we funded our operations through the private placement of preferred stock and convertible debt securities and the public offering of our common stock. As of September 30, 2014, we had cash and cash equivalents totaling $516.6 million.

The following table sets forth the primary sources and uses of cash for the nine months ended September 30, 2014 and 2013:


	Nine Months Ended September 30,
	2014			2013
	(in thousands)
Net cash used in operating activities	$	(83,101	)	$	(47,878	)
Net cash used in investing activities		(2,191	)		(80	)
Net cash provided by financing activities		279,098			260,474
Effect of exchange rate changes on cash and cash equivalents		(449	)		11

Increase in cash and cash equivalents	$	193,357		$	212,527

Operating Activities

Net cash used in operating activities for all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities increased $35.2 million during the nine months ended September 30, 2014 driven by higher rociletinib and rucaparib research and development costs associated with the expansion of clinical trials, drug formulation and manufacturing costs and higher salaries, benefits and personnel-related costs resulting from higher headcount to support the expanding development activities of our product candidates, partially offset by the milestone revenue payment received from Servier.

Investing Activities

Net cash used in investing activities for all periods reflects the purchase of property and equipment.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2014 includes $278.3 million in net proceeds received from our recent convertible senior notes offering and $0.8 million received from employee stock option exercises and stock purchases under the employee stock purchase plan. Net cash provided by financing activities for the nine months ended September 30, 2013 includes $259.1 million in net proceeds received from the sale of our common stock in June 2013 and $1.4 million received from employee stock option exercises and stock purchases under the employee stock purchase plan.

Operating Capital Requirements

Assuming we successfully complete clinical trials and obtain requisite regulatory approvals, we do not anticipate commercializing any of our product candidates until at least the end of 2015. As such, we anticipate that we will continue to generate significant losses for the foreseeable future as we incur expenses to complete our development activities for each of our programs, including clinical trial activities, companion diagnostic development, drug development, establishing our commercial capabilities and expanding our general and administrative functions to support the growth in our research and development and commercial organizations.

The net proceeds raised to date from the sale of equity securities and issuance of debt will not be sufficient to fund our operations through successful development and commercialization of our product candidates. As a result, we will need to raise additional capital to fund our operations and continue to conduct clinical trials to support additional development and potential regulatory approval, make milestone payments to our licensors and commercialize our product candidates.

We believe that our existing cash and cash equivalents will allow us to fund our operating plan through at least the next 12 months. If our available cash and cash equivalents are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity and debt securities may result in additional dilution to our shareholders.

In addition, if we raise additional funds through the issuance of debt securities or preferred stock, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations. Furthermore, any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned development and commercialization activities, which could harm our business.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including but not limited to:

•

the number and characteristics of the product candidates, companion diagnostics and indications we pursue;

•

the achievement of various development, regulatory and commercial milestones resulting in required payments to partners pursuant to the terms of our license agreements;

•

the scope, progress, results and costs of researching and developing our product candidates and related companion diagnostics and conducting clinical and preclinical trials;

•

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates and companion diagnostics;

•

the cost of commercialization activities, if any, assuming our product candidates are approved for sale, including marketing and distribution costs;

•

the cost of manufacturing any of our product candidates we successfully commercialize;

•

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and

•

the timing, receipt and amount of sales, if any, of our product candidates.

Contractual Obligations and Commitments

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2013 Annual Report on Form 10-K. There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2013. For further information regarding the Company’s contractual obligations and commitments, see Note 14 to our unaudited consolidated financial statements included elsewhere in this report.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk related to changes in interest rates. As of September 30, 2014, we had cash and cash equivalents of $516.6 million, consisting of bank demand deposits and money market funds that primarily invest in U.S. government obligations. The primary objectives of our investment policy are to preserve principal and maintain proper liquidity to meet operating needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in short-term securities. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our portfolio.

We contract with contract research organizations, investigational sites and contract manufacturers globally where payments are made in currencies other than the U.S. dollar. In addition, a significant portion of the contingent purchase consideration liability will be settled with Euro-denominated payments if certain future milestones are achieved. We may be subject to fluctuations in foreign currency rates in connection with these agreements and future contingent payments. While we periodically hold foreign currencies, primarily Euro and Pound Sterling, we do not use other financial instruments to hedge our foreign exchange risk. Transactions denominated in currencies other than the functional currency are recorded based on exchange rates at the time such transactions arise. As of September 30, 2014 and December 31, 2013, approximately 8% and 24%, respectively, of our total liabilities were denominated in currencies other than the functional currency.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (“Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. With the participation of our Chief Executive Officer and Chief Financial Officer, management performed an evaluation as of September 30, 2014 of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2014, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

ITEM 1A.

RISK FACTORS

Our business faces significant risks and uncertainties. Certain factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the risk factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in our other public filings with the SEC. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations.

There have been no material changes to the risk factors included in our previously filed Annual Report on Form 10-K for the year ended December 31, 2013, except as described below. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

Risks Related to Our Financial Position and Capital Requirements

Servicing our long-term debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

In September 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”), resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. Interest is payable on the Notes semi-annually, and the Notes mature on September 15, 2021, unless redeemed, repurchased, or converted prior to that date. In addition, if, as defined by the terms of the indenture, a fundamental change occurs, holders of the Notes may require us to repurchase for cash all or any portion of their Notes at a purchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. As of September 30, 2014, all $287.5 million principal amount of the Notes remained outstanding.

Our ability to make scheduled payments of interest and principal on the Notes, or to pay the repurchase price for the Notes on a fundamental change, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may not have sufficient cash in the future to service our debt. If we are unable to generate such cash flow or secure additional sources of funding, we may be required to adopt one or more alternatives, such as restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

Risks Related to Our Business and Industry

We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. In addition, the competition in the oncology market is intense. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. For example, Tarceva^®, Iressa^® and GilotrifTM are currently approved drugs that are used to treat EGFR mutant NSCLC, and in addition, we are aware of a number of products in development targeting EGFR for the treatment of NSCLC, including Pfizer’s PF-299804 (dacomitinib), AstraZeneca’s AZD9291, Astellas Pharma’s ASP8273, HEC Pharma’s Z650 (larotinib), Novartis’ EGF816 and Hanmi Pharmaceutical’s HM61713 and HM781-36B. Also, we believe the products in development targeting the PARP pathway include AbbVie’s veliparib, Tesaro, Inc.’s niraparib, Eisai’s E-7016, Teva’s CEP-9722, Biomarin’s BMN-673 and Astra Zeneca’s olaparib. AstraZeneca has filed a Marketing Authorization Application with the European Medicines Agency (“EMA”) for olaparib for the maintenance treatment of BRCA mutated platinum-sensitive relapsed serous ovarian cancer, for which AstraZeneca has received from the EMA’s Committee for Medicinal Products for Human Use a positive opinion recommending approval. No currently approved drugs specifically target each of FGFR1, VEGF and PDGF, as does lucitanib, however, there are a number of FGFR inhibitors in development including Novartis’ dovitinib and BGJ 398, AstraZeneca’s AZD4547, Johnson and Johnson’s JNJ-42756493, Eli Lilly’s LY 2874455, Debiopharm’s Debio 1347 and GlaxoSmithKline’s GSK3052230.

Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products that are more effective or less costly than any drug candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs, as well as drugs that are in the development pipelines of our competitors and later enter the market.

Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA, EMA or other regulatory approval or discovering, developing and commercializing medicines before we do, which would have a material adverse effect on our business.

Risks Related to Our Intellectual Property

Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including interference and reexamination proceedings before the U.S. PTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.

Third parties may assert that we are employing their proprietary technology without authorization. There are or may be third-party patents with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications, which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly.

Risks Related to Ownership of Our Common Stock and Convertible Senior Notes

The price of our stock has been, and may continue to be, volatile, and you could lose all or part of your investment.

The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. During calendar year 2013, the price of our common stock on the NASDAQ Global Select Market has ranged from $15.96 per share to $86.29 per share. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

•

our failure to commercialize our product candidates, if approved;

•

actual or anticipated adverse results or delays in our clinical trials;

•

unanticipated serious safety concerns related to the use of any of our product candidates;

•

adverse regulatory decisions;

•

changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our product candidates;

•

our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;

•

our dependence on third parties, including CROs as well as our partners that provide us with companion diagnostic products;

•

additions or departures of key scientific or management personnel;

•

failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;

•

actual or anticipated variations in quarterly operating results;

•

failure to meet or exceed the estimates and projections of the investment community;

•

overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;

•

conditions or trends in the biotechnology and biopharmaceutical industries;

•

introduction of new products offered by us or our competitors;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

•

issuances of debt or equity securities;

•

significant lawsuits, including patent or stockholder litigation;

•

sales of our common stock by us or our stockholders in the future;

•

trading volume of our common stock;

•

publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•

ineffectiveness of our internal controls;

•

general political and economic conditions;

•

effects of natural or man-made catastrophic events; and

•

other events or factors, many of which are beyond our control.

In addition, the stock market in general, and the NASDAQ Global Select Market and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors,” could have a dramatic and material adverse effect on the market price of our common stock.

Because our outstanding Notes are convertible into shares of our common stock, volatility or depressed prices of our common stock could have a similar effect on the trading price of our Notes. In addition, the existence of the Notes may encourage short selling in our common stock by market participants because the conversion of the Notes could depress the price of our common stock.

The conversion of some or all of the Notes may dilute the ownership interest of existing stockholders. Holders of the outstanding Notes will be able to convert them at any time prior to the close of business on the business day immediately preceding September 15, 2021. Upon conversion, holders of the Notes will receive shares of common stock. Any sales in the public market of shares of common stock issued upon conversion of such Notes could adversely affect the trading price of our common stock. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price of our common stock. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or convertible debt securities.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.

Pursuant to our equity incentive plan(s), our compensation committee (or its designee) is authorized to grant equity-based incentive awards to our employees, directors and consultants. As of December 31, 2013, the number of shares of our common stock available for future grant under our 2011 Stock Incentive Plan, or the 2011 Plan, is 1,661,642. The number of shares of our common stock reserved for issuance under our 2011 Plan will be increased (i) from time to time by the number of shares of our common stock forfeited upon the expiration, cancellation, forfeiture, cash settlement or other termination of awards under our 2009 Equity Incentive Plan, and (ii) at the discretion of our board of directors, on the date of each annual meeting of our stockholders, by up to the lesser of (x) a number of additional shares of our common stock representing 4% of our then-outstanding shares of common stock on such date and (y) 2,758,621 shares of our common stock. Future option grants and issuances of common stock under our 2011 Plan may have an adverse effect on the market price of our common stock. In addition, a substantial number of shares of our common stock are reserved for issuance upon conversion of the Notes.

Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third-party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. These provisions include:

•

authorizing the issuance of “blank check” preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;

•

limiting the removal of directors by the stockholders;

•

creating a staggered board of directors;

•

prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;

•

eliminating the ability of stockholders to call a special meeting of stockholders;

•

permitting our board of directors to accelerate the vesting of outstanding option grants upon certain transactions that result in a change of control; and

•

establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.

These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. Additionally, certain provisions of our outstanding Notes could make it more difficult or more expensive for a third party to acquire us. The repurchase price of the Notes must be paid in cash, and this obligation may have the effect of discouraging, delaying or preventing an acquisition of the Company that would otherwise be beneficial to our security holders.

We may not be able to raise the funds necessary to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. We may not have or be able to borrow the funds required to repurchase the Notes on the fundamental change repurchase date. In addition, our ability to repurchase the Notes may otherwise be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase the Notes at a time when the repurchase is required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes when required.

We may incur substantially more debt or take other actions which would intensify the risks discussed above; and we may not generate cash flow from operations in the future sufficient to satisfy our obligations under the Notes and any future indebtedness we may incur.

We may incur substantial additional debt in the future, subject to the restrictions contained in any debt instruments that we enter into in the future, some of which may be secured debt. We are not restricted under the terms of the indenture governing the Notes from incurring additional debt, securing existing or future debt, recapitalizing our debt or taking a number of other actions that are not limited by the terms of the indenture governing the Notes that could have the effect of diminishing our ability to make payments on the Notes when due. Our ability to refinance the Notes or future indebtedness will depend on the capital markets and our financial condition at such time. In addition, agreements that govern any future indebtedness that we may incur may contain financial and other restrictive covenants that will limit our ability to engage in activities that may be in our long-term best interests. Our failure to comply with those covenants could result in an event of default that, if not cured or waived, could result in the acceleration of some or all of our debt.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

INDEX TO EXHIBITS


Exhibit Number		Exhibit Description

3.1(5)		Amended and Restated Certificate of Incorporation of Clovis Oncology, Inc.

3.2(5)		Amended and Restated Bylaws of Clovis Oncology, Inc.

4.1(3)		Form of Common Stock Certificate of Clovis Oncology, Inc.

4.2(1)		Clovis Oncology Inc. Investor Rights Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and certain investors named therein.

10.1*(4)		Amended and Restated Strategic License Agreement, dated as of June 16, 2011, by and between Clovis Oncology, Inc. and Avila Therapeutics, Inc.

10.2*(4)		License Agreement, dated as of June 2, 2011, by and between Clovis Oncology, Inc. and Pfizer Inc.

10.3+(1)		Clovis Oncology, Inc. 2009 Equity Incentive Plan.

10.4+(4)		Clovis Oncology, Inc. 2011 Stock Incentive Plan.

10.5+(1)		Form of Clovis Oncology, Inc. 2009 Equity Incentive Plan Stock Option Agreement.

10.6+(4)		Form of Clovis Oncology, Inc. 2011 Stock Incentive Plan Stock Option Agreement.

10.7+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.8+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Erle T. Mast.

10.9+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.10+(3)		Employment Agreement, dated as of August 24, 2011, between Clovis Oncology, Inc. and Andrew R. Allen.

10.11+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Paul Klingenstein.

10.12+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and James C. Blair.

10.13+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Edward J. McKinley.

10.14+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Thorlef Spickschen.



10.15+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and M. James Barrett.

10.16+(1)		Indemnification Agreement, dated as of May 15, 2009, between Clovis Oncology, Inc. and Brian G. Atwood.

10.17+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.18+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.19+(1)		Indemnification Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.20+(1)		Indemnification Agreement, dated as of May 13, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.21+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Patrick J. Mahaffy.

10.22+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Erle T. Mast.

10.23+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Gillian C. Ivers-Read.

10.24+(1)		Restricted Stock Purchase Agreement, dated as of May 12, 2009, between Clovis Oncology, Inc. and Andrew R. Allen.

10.25+(4)		Clovis Oncology, Inc. 2011 Employee Stock Purchase Plan.

10.26+(4)		Clovis Oncology, Inc. 2011 Cash Bonus Plan.

10.27+(6)		Employment Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.28+(6)		Indemnification Agreement, dated as of March 22, 2012, by and between Clovis Oncology, Inc. and Steven L. Hoerter.

10.29+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Ginger L. Graham.

10.30+(2)		Indemnification Agreement, dated as of June 13, 2013, between Clovis Oncology, Inc. and Keith Flaherty.

10.31(7)		Stock Purchase Agreement, dated as of November 19, 2013, by and among the Company, EOS, the Sellers listed on Exhibit A thereto and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ Representative.

10.32(7)		Registration Rights Agreement, dated as of November 19, 2013, by and between the Company and the Sellers signatory thereto.

10.33*(7)		Development and Commercialization Agreement, dated as of October 24, 2008, by and between Advenchen Laboratories LLC and Ethical Oncology Science S.p.A., as amended by the First Amendment, dated as of April 13, 2010 and the Second Amendment, dated as of July 30, 2012.



10.34*(7)		Collaboration and License Agreement, dated as of September 28, 2012, by and between Ethical Oncology Science S.p.A. and Les Laboratoires Servier and Institut de Recherches Internationales Servier.

10.35(8)		Indenture, dated as of September 9, 2014, by and between the Company and The Bank of New York Mellon Trust Company, N.A.

31.1		Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2		Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1		Certification of principal executive officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of principal financial officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from Clovis Oncology, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2014, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) Notes to Unaudited Consolidated Financial Statements.

(1)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on June 23, 2011.

(2)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on June 14, 2013.

(3)	Filed as an exhibit with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on August 31, 2011.

(4)	Filed as an exhibit with Amendment No. 3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-175080) on October 31, 2011.

(5)	Filed as an exhibit with the Registrant’s Annual Report on Form 10-K on March 15, 2012.

(6)	Filed as an exhibit with the Registrant’s Registration Statement on Form S-1 (File No. 333-180293) on March 23, 2012.

(7)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on November 19, 2013.

(8)	Filed as an exhibit with the Registrant’s Current Report on Form 8-K (File No. 001-35347) on September 9, 2014.

+	Indicates management contract or compensatory plan.

*	Confidential treatment has been granted with respect to portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: November 7, 2014	CLOVIS ONCOLOGY, INC.

	By:	/s/ Patrick J. Mahaffy
		Patrick J. Mahaffy
		President and Chief Executive Officer; Director

	By:	/s/ Erle T. Mast
		Erle T. Mast
		Executive Vice President and Chief Financial Officer

EX-31.1 2 d793512dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

I, Patrick J. Mahaffy, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2014;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-31.2 3 d793512dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

I, Erle T. Mast, certify that:

I have reviewed this quarterly report on Form 10-Q of Clovis Oncology, Inc. for the quarter ended September 30, 2014;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 7, 2014

/s/ ERLE T. MAST

Erle T. Mast

Executive Vice President and Chief Financial Officer

EX-32.1 4 d793512dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission (the “Report”), Patrick J. Mahaffy, as Chief Executive Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2014

/s/ PATRICK J. MAHAFFY

Patrick J. Mahaffy

President and Chief Executive Officer

EX-32.2 5 d793512dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission (the “Report”), Erle T. Mast, as Chief Financial Officer of the Company, does hereby certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to his knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 7, 2014

/s/ ERLE T. MAST

Erle T. Mast

Executive Vice President and Chief Financial Officer

EX-101.INS 6 clvs-20140930.xml XBRL INSTANCE DOCUMENT 115000000 65000000 0 33964440

72.00

90000000 250000000

356624000

0.025

61.88

287500000

33964065

19.47

3620712

100000000

36.52

45.36

35.23

0.001

10000000

0.001

3885365

1503631

30979000

55445000

34000

-16306000

2428000

-374138000

69307000

287500000

55445000

4719000

388290000

6000

1183000

831527000

778700000

132000

443237000

3404000

516585000

51600000

68482000

2846000

447986000

1336000

41643182

63341213

6544000

45000

831527000

220723000

7925000

12725000

526751000

2241000

23832000

297300000

447986000

55445000

447986000

-16306000

55400000

68500000

220700000

9100000

6500000

53000

144097000

53000

33897321

100000000

21.19

0.001

10000000

0.001

2520170

20952000

55754000

34000

4696000

4420000

-269014000

74955000

55754000

3984000

497886000

88000

371000

649635000

762170000

257000

151749000

3356000

323228000

74811000

955000

64790012

318886000

521000

2921000

950000

649635000

244518000

4392000

755000

328596000

976000

12548000

318886000

55754000

318886000

4696000

55800000

74800000

244500000

2900000

173700000

11800000

1.50

P30D

1.00

16.1616

278300000

18.43

-47878000

27614000

-2.00

5000

-55329000

-55273000

-55314000

-56000

80000

-55329000

185000

11000

55273000

212527000

1223023

260474000

259071000

250000

81000

-80000

44001000

11022000

-1463000

1403000

6663000

5801963

-1990000

3568000

3095000

<div> 7. Other Accrued Expenses Other accrued expenses are comprised of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,404</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,356</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">257</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,183</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">371</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,719</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,984</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Basis of Presentation All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business. </div>

<div> 14. Commitments and Contingencies Royalty and License Fee Commitments The Company has entered into certain license agreements, as identified in Note 11, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded in the Company’s Consolidated Balance Sheets at September 30, 2014 and December 31, 2013. Development and Manufacturing Agreement Commitments In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first 12 months of any forecast. As of September 30, 2014, no purchase commitments were established under this agreement. </div>

<div> 12. Net Loss Per Common Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. </div>

<div> The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="15%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">For the Nine Months Ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accretion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,571</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in foreign currency gains and losses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,880</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent purchase consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total liabilities at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent purchase consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total liabilities at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P8Y2M19D

8.96

10-Q CLOVIS ONCOLOGY, INC. CLVS

<div> 6. Intangible Assets and Goodwill Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the purchase accounting of EOS in November 2013. The intangible asset balance at September 30, 2014 and December 31, 2013 was $220.7 million and $244.5 million, respectively. The balance decreased $20.4 million over the prior year due to changes in foreign currency translation rates. In addition, the Company recorded a $3.4 million reduction in the intangible assets driven by lower expected future milestone revenue cash flows from our lucitanib development activities due to the receipt of a lucitanib milestone payment from Servier during the first quarter of 2014. This reduction was reported as amortization of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss. Recurring amortization of these assets will commence when the useful lives of the intangible assets have been determined. IPR&D intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value will be recognized as an expense in the Consolidated Statements of Operations and Comprehensive Loss. The acquisition of EOS in November 2013 generated a goodwill balance of $74.8 million at December 31, 2013. This balance decreased to $68.5 million at September 30, 2014 due to changes in foreign currency translation rates. </div>

<div> The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,520,170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,449,457</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,449</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,813</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,885,365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36.52</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,790,012</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Vested and expected to vest at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,620,712</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">63,341,213</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,503,631</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.30</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,643,182</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

39.13

Large Accelerated Filer

<div> Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27.85</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.43</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,391</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">85,589</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,711</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.43</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,754,669</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,801,963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">541,508</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,223,023</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

P3Y

-83101000

<div> Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,991</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,138</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,095</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,580</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,568</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,436</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,791</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,585</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,663</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

23813

<div> 5. Other Current Assets Other current assets are comprised of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Receivable from partners </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,544</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,921</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> VAT recoverable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">950</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid expenses and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,336</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,925</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,392</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Other accrued expenses are comprised of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued personnel costs </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,404</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,356</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued corporate legal fees and professional services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">257</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Accrued expenses – other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,183</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">371</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other accrued expenses </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,719</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,984</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

1449457

P7Y3M18D

<div> Use of Estimates The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </div>

33871000

2014-09-30

<div> The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. </div>

<div> Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. </div>

<div> The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign Currency Translation Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total Accumulated Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Period change </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21,002</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21,002</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,306</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,306</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Period change </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,643</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,643</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Other current assets are comprised of the following (in thousands):   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="64%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"> December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Receivable from partners </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,544</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,921</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> VAT recoverable </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">950</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Prepaid expenses and other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,336</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">521</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Other current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,925</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,392</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

P8Y3M15D

34.96

<div> 9. Stockholders’ Equity Common Stock In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions were $259.1 million. Accumulated Other Comprehensive Income (Loss) The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Foreign Currency Translation Adjustments</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total Accumulated Other Comprehensive Income (Loss)</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Period change </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21,002</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(21,002</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,306</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,306</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance December 31, 2012 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Period change </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,643</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,643</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,696</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The period change between December 31, 2013 and September 30, 2014 was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes associated with the acquisition of EOS in November 2013. </div>

false --12-31 2014

<div> 3. EOS Acquisition On November 19, 2013, the Company acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”). The initial purchase consideration was comprised of a cash payment of $11.8 million and the issuance of $173.7 million of the Company’s common stock to the former EOS shareholders. The Company may make additional purchase payments to the previous EOS shareholders if certain lucitanib regulatory and sales milestones are achieved. The range of the potential contingent milestone payments are zero to an estimated maximum of $65.0 million and €115.0 million. The Company recorded a liability for the estimated fair value of these payments, which totaled $55.4 million and $55.8 million at September 30, 2014 and December 31, 2013, respectively. </div>

<div> 13. Income Taxes Income tax expense of $2.5 million was recorded during the nine months ended September 30, 2014 due to taxable income earned in a foreign jurisdiction resulting from milestone revenue received during the first quarter of 2014. This expense was partially offset by a deferred tax benefit recognized upon the write down of an intangible asset in the first quarter of 2014 (see Note 6). The Company maintains a valuation allowance against the majority of the net deferred tax assets held at September 30, 2014 and intends to maintain this valuation allowance until there is sufficient evidence that consistent future earnings can be achieved, which is uncertain at this time. </div>

<div> The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Nine Months Ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contractual interest expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Amortization of debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total interest expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">511</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">511</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 8. Convertible Senior Notes On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets. The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning March 15, 2015. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased. Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances. On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes. If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. In connection with the issuance of the Notes, the Company incurred $9.2 million of debt issuance costs, which is included in other assets on the Consolidated Balance Sheets. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Notes. As of September 30, 2014, the balance of unamortized debt issuance costs was $9.1 million. The fair value of the Notes was $297.3 million at September 30, 2014 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.   The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="62%"></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="16%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Three Months Ended September 30, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Nine Months Ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contractual interest expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Amortization of debt issuance costs </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total interest expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">511</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">511</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> 1. Nature of Business and Basis of Presentation Clovis Oncology, Inc. (the “Company”) commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. In the first quarter of 2014, the Company exited the development stage, with the recognition of $13.6 million in license and milestone revenue related to its lucitanib collaboration and license agreement with Les Laboratoires Servier (“Servier”). The license and milestone revenue recognized is the first significant revenue from principal operations and therefore, the Company is no longer considered a development stage company. Basis of Presentation All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business. Use of Estimates The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. </div>

62.00

<div> 2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures. </div>

<div> 15. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure. </div>

0001466301

<div> 10. Share-Based Compensation Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="59%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,991</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,138</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,005</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,095</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> General and administrative </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,653</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,580</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,568</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,436</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,791</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,585</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,663</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2014 and 2013, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of September 30, 2014. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013. The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="57%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of Options</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Exercise Price</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted- Average Remaining Contractual Term (Years)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate Intrinsic Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,520,170</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.19</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,449,457</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.00</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(60,449</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(23,813</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">34.96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,885,365</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36.52</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.29</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">64,790,012</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Vested and expected to vest at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,620,712</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35.23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">63,341,213</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested at September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,503,631</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.47</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.30</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">41,643,182</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table>   The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $45.36 as of September 30, 2014, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date. Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27.85</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.43</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,391</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">85,589</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">341</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">34,711</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="8"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Nine Months Ended September 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Weighted-average grant-date fair value per share </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.13</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18.43</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Intrinsic value of options exercised </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,754,669</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,801,963</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash received from stock option exercises </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">541,508</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,223,023</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> As of September 30, 2014, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures, was $51.6 million and the estimated weighted-average remaining vesting period was 3.0 years. </div>

-3.10

<div> 4. Financial Instruments and Fair Value Measurement Cash, Cash Equivalents and Marketable Securities The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations. Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"> <tr> <td width="6%"></td> <td valign="bottom" width="2%"></td> <td width="92%"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Level 1:</td> <td valign="bottom">  </td> <td valign="top">Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of money market investments. The Company does not have Level 1 liabilities.</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Level 2:</td> <td valign="bottom">  </td> <td valign="top">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.</td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="8"></td> <td height="8" colspan="2"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top">Level 3:</td> <td valign="bottom">  </td> <td valign="top">Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired in 2013 with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of the Company’s 2013 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.</td> </tr> </table> The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Balance</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> September 30, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">447,986</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Contingent purchase consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total liabilities at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">318,886</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Contingent purchase consideration </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total liabilities at fair value </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> There were no transfers between Level 1 and Level 2 during the nine months ended September 30, 2014. The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="79%"></td> <td valign="bottom" width="15%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">For the Nine Months Ended September 30, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Liabilities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at beginning of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,754</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accretion </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,571</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Change in foreign currency gains and losses </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,880</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at end of period </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">55,445</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The change in the fair value of Level 3 instruments is included in accretion of contingent purchase consideration and other income (expense), net for the change in foreign currency gains and losses on the Consolidated Statements of Operations and Comprehensive Loss. </div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures. </div>

<div> Liquidity The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. </div>

60449

-21002000

3941000

-102635000

-104569000

-126126000

9165000

1934000

2191000

-105124000

761000

3772000

-449000

118194000

72000

-309000

511000

439000

2571000

193357000

-20400000

2489000

541508

279098000

8806000

892000

-2191000

87556000

3409000

287500000

15852000

-1889000

763000

15585000

2754669

-7152000 13625000 <div> 11. License Agreements Rociletinib (CO-1686) In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. The Company made an up-front payment of $2.0 million upon execution of the license agreement and is obligated to pay royalties on net sales of rociletinib, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of rociletinib in the U.S. or European Union as a first line therapy. Such notice was provided to Celgene on June 4, 2014, and on September 2, 2014, we received notification from Celgene that the company elected not to exercise this option. In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant EGFR inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If rociletinib is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales. In February 2014, the Company initiated a Phase II study for rociletinib which resulted in a $5.0 million milestone payment to Celgene as required by the license agreement. This payment was recognized as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $110.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved. Rucaparib In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made a $7.0 million up-front payment to Pfizer. In April 2014, the Company initiated a pivotal registrational study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. This payment was recognized as acquired in-process research and development expense. The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $258.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved. In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib. Lucitanib In connection with its November 2013 acquisition of EOS, the Company gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for up-front milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments. In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. The Company is obligated to pay Advenchen royalties on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, the Company is obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, the Company recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.   In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an up-front payment and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, the Company is entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. The Company is also entitled to receive royalties on net sales of lucitanib by Servier. The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to the Company if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement. The Company and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between the Company and Servier. Beginning in the third quarter of 2014, depending on the expense type, reimbursements are determined using a standard rate approved by the Company and Servier or actual costs incurred. Previously, reimbursements were determined based on actual costs. Reimbursements are recorded as a reduction to research and development expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company recorded a $6.5 million and $2.9 million receivable at September 30, 2014 and December 31, 2013, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three and nine months ending September 30, 2014, we recorded reductions in research and development expense of $4.1 million and $7.9 million, respectively, for reimbursable development costs due from Servier. </div> 258500000

-2880000

2571000

7580000

8005000

-21002000

2018-09-15

2015-03-15

Semi-annually

2021-09-15

P7Y

9200000

1.00 2 --03-15 --09-15 7900000 P12M P24M

5000000

110000000 120000000 250000 700000

400000

7000000

3819444

259100000

80000000 0.25 250000 2000000

4643000

3400000

13600000 13600000

43.43

30047000

-0.68

-20320000

-20375000

-20299000

55000

-20320000

20375000

34711

16063000

4312000

2791000

85589

1653000

1138000

27.85

33921000

-1.17

-39350000

-41120000

-58809000

1770000

-39642000

41120000

72000

511000

439000

888000

292000

341

34965000

5267000

5436000

4391

2445000

2991000

4100000 0001466301 clvs:LesLaboratoiresServierMember 2014-07-01 2014-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0001466301 2014-07-01 2014-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2013-07-01 2013-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2013-07-01 2013-09-30 0001466301 2013-07-01 2013-09-30 0001466301 clvs:LesLaboratoiresServierMember 2014-01-01 2014-03-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:AdvenchenLaboratoriesLlcMember 2014-01-01 2014-03-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2013-01-01 2013-12-31 0001466301 2013-01-01 2013-12-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRociletinibMember 2010-05-01 2010-05-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorGatekeeperMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRociletinibMember 2013-01-01 2013-01-31 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:AdvenchenLaboratoriesLlcMember 2008-10-01 2008-10-31 0001466301 clvs:LesLaboratoiresServierMember 2012-09-01 2012-09-30 0001466301 us-gaap:CommonStockMember 2013-06-01 2013-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorPfizerMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRucaparibMember 2011-06-01 2011-06-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorPfizerMemberclvs:LicenseAgreementsRucaparibMember 2014-04-01 2014-04-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs:LicenseAgreementsRucaparibMember 2012-04-01 2012-04-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAstraZenecaUKLtdMemberclvs:UpFrontLicensePaymentMemberclvs:LicenseAgreementsRucaparibMember 2012-04-01 2012-04-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:LicenseAgreementsRociletinibMember 2014-02-01 2014-02-28 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorAvilaTherapeuticsMemberclvs:RegulatoryMilestonePaymentMemberclvs:LicenseAgreementsRociletinibMember 2014-02-01 2014-02-28 0001466301 2013-02-01 2013-02-28 0001466301 clvs:LesLaboratoiresServierMember 2014-01-01 2014-09-30 0001466301 clvs:SemiAnnualPaymentSecondPaymentMemberus-gaap:SeniorNotesMember 2014-01-01 2014-09-30 0001466301 clvs:SemiAnnualPaymentFirstPaymentMemberus-gaap:SeniorNotesMember 2014-01-01 2014-09-30 0001466301 us-gaap:SeniorNotesMember 2014-01-01 2014-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2014-01-01 2014-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0001466301 us-gaap:FairValueInputsLevel3Member 2014-01-01 2014-09-30 0001466301 us-gaap:LicenseAgreementTermsMemberclvs:LicenseAgreementsLicensorPfizerMemberclvs:LicenseAgreementsRucaparibMember 2014-01-01 2014-09-30 0001466301 2014-01-01 2014-09-30 0001466301 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-09-30 0001466301 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-09-30 0001466301 2013-01-01 2013-09-30 0001466301 us-gaap:SeniorNotesMember 2014-09-09 2014-09-09 0001466301 clvs:EthicalOncologyScienceSpAMember 2013-11-19 2013-11-19 0001466301 clvs:LesLaboratoiresServierMember 2013-12-31 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2013-12-31 0001466301 clvs:EthicalOncologyScienceSpAMember 2013-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2013-12-31 0001466301 us-gaap:MoneyMarketFundsMember 2013-12-31 0001466301 us-gaap:FairValueInputsLevel3Member 2013-12-31 0001466301 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2013-12-31 0001466301 us-gaap:FairValueInputsLevel1Member 2013-12-31 0001466301 2013-12-31 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2012-12-31 0001466301 2012-12-31 0001466301 clvs:LesLaboratoiresServierMember 2014-09-30 0001466301 us-gaap:SeniorNotesMember 2014-09-30 0001466301 us-gaap:InProcessResearchAndDevelopmentMember 2014-09-30 0001466301 clvs:EthicalOncologyScienceSpAMember 2014-09-30 0001466301 us-gaap:AccumulatedTranslationAdjustmentMember 2014-09-30 0001466301 us-gaap:MoneyMarketFundsMember 2014-09-30 0001466301 us-gaap:FairValueInputsLevel3Member 2014-09-30 0001466301 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2014-09-30 0001466301 us-gaap:FairValueInputsLevel1Member 2014-09-30 0001466301 us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember 2014-09-30 0001466301 2014-09-30 0001466301 us-gaap:SeniorNotesMember 2014-09-09 0001466301 2013-09-30 0001466301 clvs:LesLaboratoiresServierMember 2012-09-30 0001466301 us-gaap:CommonStockMember 2013-06-30 0001466301 2014-10-31 0001466301 clvs:EthicalOncologyScienceSpAMemberus-gaap:MinimumMemberclvs:RegulatoryAndSalesMilestonesMember 2013-11-19 0001466301 clvs:EthicalOncologyScienceSpAMemberus-gaap:MaximumMemberclvs:RegulatoryAndSalesMilestonesMember 2013-11-19 iso4217:EUR iso4217:USD shares iso4217:USD shares pure utr:D

EX-101.SCH 7 clvs-20140930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - EOS Acquisition link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Financial Instruments and Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Other Current Assets link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Intangible Assets and Goodwill link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Other Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Convertible Senior Notes link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - License Agreements link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Net Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Nature of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Financial Instruments and Fair Value Measurement (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Other Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Convertible Senior Notes (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Share-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - EOS Acquisition - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Other Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Convertible Senior Notes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Component of Other Comprehensive Income (Loss) (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Summary of Stock Options Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - License Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 clvs-20140930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 clvs-20140930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 clvs-20140930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Other Accrued Expenses Accounts Payable, Current Accounts payable Accounts Receivable, Related Parties, Current Development cost receivable Receivable from partners Accretion Expense Accretion of contingent purchase consideration Accrued Liabilities, Current Other accrued expenses Other accrued expenses Accrued Liabilities [Line Items] Accrued Liabilities [Line Items] Accrued Liabilities [Line Items] Accrued Liabilities [Table] Accrued Liabilities [Table] Accrued Liabilities [Table] Accrued Professional Fees, Current Accrued corporate legal fees and professional services Carrying value as of the balance sheet date of obligations incurred and payable for research and development activities which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include contract research organizations, contract manufacturers and other research and development vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Expenses Accrued research and development expenses Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss), Net of Tax Ending balance Beginning balance Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Translation Adjustment [Member] Foreign Currency Translation Adjustments Additional Paid in Capital Additional paid-in capital Amount of additional nonrefundable milestone payments to be received from collaboration and license partners upon the achievement of product milestones, as defined in the respective collaboration and license agreement. Additional Payments Receivable On Milestone Achievements Additional payments receivable on achievement Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Advenchen Laboratories LLC [Member] Advenchen Laboratories LLC [Member] Advenchen Laboratories LLC Amount of the aggregate payment due to a product licensor upon the achievement of product sale targets, as defined in the respective licensing agreement. Aggregate Payment To Be Made On Attaining Sales Target Additional payments receivable on attaining the sales target Amendment Flag Amendment Flag Amortization of Financing Costs Amortization of debt issuance costs Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Disclosure, Recurring Assets at fair value Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Change in value of contingent purchase consideration Business Combination, Contingent Consideration, Liability Contingent purchase consideration Fair value of contingent consideration Business Combination Disclosure [Text Block] EOS Acquisition Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Increase in cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Collaboration and License Agreements [Axis] Collaboration and License Agreements [Axis] Collaboration and License Agreements [Axis] Collaboration and License Agreements [Domain] Collaboration and License Agreements [Domain] Collaboration and License Agreements [Domain] Commitments and Contingencies Commitments and contingencies (Note 14) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock [Member] Common Stock Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Issued Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2014 and December 31, 2013; 33,964,065 and 33,897,321 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss The number of months for which the entity is obligated to purchase product from the supplier based on the demand forecasts provided, as defined in the supplier agreement with the entity. Contractual Agreement Obligated Forecast Period Contractual agreement obligated forecast period The required time period for providing demand forecasts to a supplier, as defined in the supplier agreement with the entity. Contractual Agreement Quarterly Forecasts Required Period Contractual agreement quarterly forecasts required period Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Instrument [Axis] Debt Instrument [Axis] Long-term Debt, Gross Convertible senior notes Convertible senior notes, aggregate principal amount Debt Instrument, Convertible, Conversion Price Convertible senior notes, initial conversion price per share Debt Instrument, Convertible, Conversion Ratio Common stock initial conversion rate per $1,000 in principal amount Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt instrument conversion, consecutive trading day period Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Last reported sale price of common stock Debt Instrument, Convertible, Threshold Trading Days Debt instrument, conversion in effect for number of trading days Debt Instrument, Convertible Trading Days Preceding Redemption Notice, Maximum Debt Instrument, Convertible Trading Days Preceding Redemption Notice, Maximum Debt instrument, trading days preceding redemption notice, maximum Debt Instrument, Date of First Required Payment Debt instrument, beginning date of periodic payment Debt Instrument, Fair Value Disclosure Debt instrument, fair value Debt Instrument, Frequency of Periodic Payment Convertible senior notes, frequency of periodic payment Debt Instrument, Interest Rate Payment, Day and Month Debt Instrument, Interest Rate Payment, Day and Month Interest payment date on senior notes Debt Instrument, Interest Rate, Stated Percentage Convertible senior notes, interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Convertible senior notes, maturity date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Redemption, Description Debt instrument redemption description Debt Instrument, Redemption Period, Start Date Debt instrument, redemption period start date Debt Instrument, Redemption Price, Percentage Debt instrument redemption price percentage to principal amount Debt instrument repurchase percentage. Debt Instrument Repurchase Percentage Debt instrument repurchase percentage Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument term Debt Issuance Cost Debt issuance costs Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Income Tax Expense (Benefit) Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred income taxes, net Depreciation, Depletion and Amortization Depreciation and amortization Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Compensation Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share Earnings Per Share [Text Block] Net Loss Per Common Share Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Employee-related Liabilities, Current Accrued personnel costs Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Capitalized share-based compensation expense Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options Cash received from stock option exercises Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized stock-based compensation expense related to nonvested options, weighted-average remaining vesting period Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized stock-based compensation expense related to nonvested options Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Share-based compensation expense, tax benefit recognized Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Name of acquired company - Ethical Oncology Science SpA. Ethical Oncology Science, S.p.A. [Member] Ethical Oncology Science, S.p.A. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfers between Level 1 and Level 2 Asset Class [Domain] Asset Class [Domain] Asset Class [Axis] Asset Class [Axis] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Financial Instruments and Fair Value Measurement Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in foreign currency gains and losses Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance at end of period Balance at beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value, Accretion Expenses Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value, Accretion Expenses Accretion Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Translation Adjustments Decrease in intangible assets due to changes in foreign currency translation rates Amount of potential cash payments that could result from the achievement of specific development and regulatory events defined in a drug product in-licensing agreement. Future Expected Development And Regulatory Payment Future expected development and regulatory payment Amount of potential cash payments that could result from the achievement of specific development, regulatory, and sales events defined in a drug product in-licensing agreement. Future Expected Development Regulatory And Sales Milestone Payments Future expected development, regulatory and sales milestone payments Amount of potential cash payments that could result from a contingent consideration arrangement associated with a business acquisition. Future Potential Cash Consideration Payments Future potential cash consideration payments General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Intangible Assets and Goodwill Impairment of Intangible Assets, Finite-lived Amortization of intangible asset Impairment charges for intangible assets Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Line Items] Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Income Tax Expense (Benefit) Income tax expense Income tax expense Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, net of acquisition of a business: Increase (Decrease) in Other Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Operating Assets Other operating assets The net increase (decrease) during the reporting period in the amount of outstanding money paid in advance for research and development goods and services that bring economic benefits for future periods or in the amount of other research and development expenses incurred but not yet paid. Increase (decrease) relates to amounts paid in advance, or incurred and not yet paid, to contract research organizations, contract manufacturers or other research and development vendors. Increase Decrease In Prepaid And Accrued Research And Development Expenses Prepaid and accrued research and development expenses Amount of cash payments incurred to license the use and development of a drug product from the licensor. The upfront payments are expensed to acquired in process research and development if it is determined that the in-licensed product does not have an alternative future use at the time the in-license agreement is executed. In Licensing Arrangement Costs Up Front Payment Up-front payment In Process Research and Development [Member] In Process Research and Development Intangible Assets And Goodwill [Line Items] Intangible Assets And Goodwill [Line Items] Intangible Assets And Goodwill [Line Items] Intangible Assets, Net (Excluding Goodwill) Intangible assets Interest Expense, Debt Total interest expense Interest Expense, Debt, Excluding Amortization Contractual interest expense Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes Legal Entity [Axis] Legal Entity [Axis] Les Laboratoires Servier [Member] Les Laboratoires Servier [Member] Les Laboratoires Servier Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Fair Value Disclosure, Recurring Liabilities at fair value License agreement license terms. License Agreement License Terms [Axis] License Agreement License Terms [Axis] License agreement license terms. License Agreement License Terms [Domain] License Agreement License Terms [Domain] License agreements licensor Astra Zeneca UK Ltd Member. License Agreements Licensor Astra Zeneca U K Ltd [Member] License Agreements Licensor Astra Zeneca U K Ltd License agreements licensor Avila Therapeutics. License Agreements Licensor Avila Therapeutics [Member] License Agreements Licensor Avila Therapeutics License Agreements Licensor Gatekeeper [Member] License Agreements Licensor Gatekeeper [Member] License Agreements Licensor Gatekeeper License agreements licensor Pfizer. License Agreements Licensor Pfizer [Member] License Agreements Licensor Pfizer License agreements licensors name. License Agreements Licensors Name [Axis] License Agreements Licensors Name [Axis] License agreements licensors name. License Agreements Licensors Name [Domain] License Agreements Licensors Name [Domain] License agreements payment type. License Agreements Payment Type [Axis] License Agreements Payment Type [Axis] License agreements payment type. License Agreements Payment Type [Domain] License Agreements Payment Type [Domain] Name of drug product in-licensed by the entity - Rociletinib. License Agreements Rociletinib [Member] Name of drug product in-licensed by the entity - Rociletinib License agreements, Rucaparib. License Agreements Rucaparib [Member] Rucaparib The entire disclosure for product in-licensing and collaboration agreements entered into by the entity. License Agreements [Text Block] License Agreements License agreements type. License Agreements Type [Axis] License Agreements Type [Axis] License agreements type. License Agreements Type [Domain] License Agreements Type [Domain] License Agreement Terms [Member] License Agreement Terms Amount of up-front fees and ongoing milestone payments from collaboration and license partners that are recognized in revenue during the applicable period by the reporting entity. License fees and milestones Revenue License and milestone revenue Sublicense agreement consideration Liquidity Disclosure [Policy Text Block] Liquidity Long-term Debt [Text Block] Convertible Senior Notes Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block] Marketable Securities Maximum amount of reimbursement of development costs by collaboration and license partners during the term of the respective collaboration and license agreement. Maximum Collaboration Development Costs Reimbursable Initial global development costs reimbursable Maximum [Member] Maximum EX-101.PRE 11 clvs-20140930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Component of Other Comprehensive Income (Loss) (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 4,696	$ 53
Period change	(21,002)	4,643
Ending balance	(16,306)	4,696
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	4,696	53
Period change	(21,002)	4,643
Ending balance	$ (16,306)	$ 4,696

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References+ Details

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!(8>].!`(``)T<```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=UJVS`8AL\'NP>CTQ$K MDKRN&W%ZL)_#K;#N`E3K2VQB2T)2N^3N)SMM&25+"0WL/8E)+'WO$X&?`[^+ MJ^W0%_<48N=LS40Y9P79QIG.KFOVZ^;;[)(5,6EK=.\LU6Q'D5TMW[Y9W.P\ MQ2+OMK%F;4K^$^>Q:6G0L72>;+ZSLFFGO^Z[1*9/R>VN>I

$LJ\DK,5=SI@<^J+QK+/D/F0#:?RL7E'P`` M`/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T M'4\4"_'L)MI<3_3_ MMCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\# M`%!+`P04``8`"````"$`)NK?!#("``#0&P``&@`(`7AL+U]R96QS+W=O7 M3Q_N3!%3U375ON]":8XAFL?U^WF]*,SXU34[P&@&(3=H`0V M*,\VQ1Z:8C8-A&$GSI0W]NI_N/5/````__\#`%!+`P04``8`"````"$`S*3< M+W$$``!1#@``#P```'AL+W=O&-*K'C%GML5!72S MN:(^[!L(M[Y`1`CM%%L)PLR=+T6:?2]A"F_4E MK"P*`W7.X8=:%I$-'*O<0!)EQ0L**2*9@8O-LB9R11XV#*G$2"4^J7)-*RIR M1C(;@$82Z0QIN&2_&TE7@SQ2+(-4TI.1=-=S0W$PD/AC5B9]E7MJ&L5L$JX; MS073VF7YFFH.J<&Q@%>.,HX*O*2LJ6NJ]E8GXVO!`60J#+G*<]D(@V7.D,RL M'\WB(8,YOQJNN84>S9L`8,?7?^G/N^4"-H+3"KC01CG_M`NYI5QA&8S(65_F MP91,D9M&*2"#7&G=W=4))B,:]V04.=?FRF$X2 MM);(`[6-`E*G&B!UL8-BHZ$PH?DIGC^$*-0\XP+)F.!2D7MIN@J8B<@#-#,R M?RUE54"A(0O8#K/'KY_BUWM<9B55#/B!V&]D;8-W!0P+8'=$'I)W4`1AQ>1J MK5CK43P78QAY'-XS0^XD0/QH-U+6M13@3@@(2V`$(X_!)72(FI$GNNND;(H! MC#P"[;NX:2N*+5-0;0RT&6@WO"N#`8P\`K/F1;-?C<5O\6;+$XI[BO&#@MNK M;Z>=#*\]\C?%_,4>?Z?-U!'"(,8>B$-V@KR"03K+PBS&'HO#;AB0P53&'I6P M'X.F:(5P\XPH^G(^.1_*XC7)91LH:<]0=$I#/#3D\\F&W3@=,\5%`(Z'<)@EN* ME=!5.-))L+M@T(_G'9>V#1GII-A<,/B@C@=SBF&&05\'';%L?X93J_LP@`.3 MX6\X'@QSZL&,]\OOU5@'\YQZ//MM&M<-I#/#^YYZ..-^BQ7:$S[223&',.CE MYV0')E@'\Y,ZGD>N4L)G1TZK'+Z'[,6>U-QFC@Y?@Y?_`P``__\#`%!+`P04 M``8`"````"$`7K#F;/.\.]?]X,)1DJ3 M)B>5:%B&7YG"-_//GV9;(9]4R9A&D-"H#)=:MU/?5[1D-5&>:%D#(X60-='P M*->^:B4C>3>IKOPH"!*_)KS!-F$J+\D01<$INQ-T4[-&VQ#)*J+!7Y6\56]I M-;TDKB;R:=,.J*A;B%CQBNO7+A2CFDX?UHV09%5!W2_AD-"W[.[A(+[F5`HE M"NU!G&]%#VM._=2'I/DLYU"!:3N2K,CP;3A=IMB?S[K^_.%LJSZ\1ZH4VZ^2 MYX^\8=!L6":S`"LAG@SZD)L_P63_8/9]MP`_),I903:5_BFVWQA?EQI6>P0% MF;JF^>L=4Q0:"C%>-#))5%0@`*^HYF9G0$/(2_=[RW-=9CA.O-$XB$/`T8HI M?<]-)$9TH[2H_UHHW$79D&@7$H/];CSRHLDH'"7_3_&M45?@'=%D/I-BBV#3 MP/]4+3%;,)Q"LJDLAOXGM'J/RCXWDW`V<87M_=PGULI[^P2-J)AU\&<7]X>7*X)P7-NES* MP(Z4TXZ%11(K%=@?1^PLTI,;7B-G8$?.:'>U+C:Z0,[$@ECI1%^OO)7;KS M3$_/W&0?SHGSGT$#.WIC1\\B5B^.TV08)$Y;EWUDDH[CZ/V3W)-+KY$SL",W M<>0L)/6U;LF;?B5SS1J&*%7`V!=X8MJJTEXE]T*+M3M65T'`) M=&]+N/,9'+F!!W`AA'Y[,-?5_EO$_!\```#__P,`4$L#!!0`!@`(````(0`] MK-<;0`8``*X?```9````>&PO=V]R:W-H965T5R/YX91"4K8H#9V?WOKXINU"J9`F<> M=(2O/^OKJJZOI1\_?B\/UK>\;HKJN+(]9V9;^3&K-L5QM[+_^?OSAX5M-6UZ MW*2'ZIBO[!]Y8W]\^OFGQ]>J_MKL\[RU@.'8K.Q]VYX>7+?)]GF9-DYURH]P M9UO59=K"QWKG-JJMYZ2Y=8'IZW!2@`*?=JO/MRO[D/:@@ MLMVGQVZ"_BWRU^;J?ZO95Z^_UL7F]^*8PVQ#GC`#SU7U%:%?-G@)!KLWHS]W M&?BSMC;Y-GTYM']5K[_EQ6[?0KI#4(3"'C8_5-YD,*-`X_@A,F75`0*`5ZLL ML#1@1M+OW?MKL6GW*SN(G#">!1[`K>>\:3\72&E;V4O35N5_&N09*DWB&Q)X M-R1>Z,S],%[PG!*_LV+9@WAJHB&]/03A[=+]!%C.#230&7J\P M'L6L;S$,H7H$%@A$>@X7\C`]7`1CN%@;&'^B+]#8?!;;+88A5$][K?""(>%" MPJ>'BV`2KKY`PPU8N!,PZHJ81`?YGAX=@F$)D;S.:3")QL#K.?H\.',1U1#2"1&,D'1H1B3HD%J(#VL)U/N0\()C''[/X-4:*?Q2A)`2)'G<- MD_L@@L?6@L9(T8\BE(0@T2]I]-/6`@[B.>!K06,D%:,(I1%O51G1X<$"GIZ& M#LT5+%@5&9`D81RB>HA9\XY>\MVZQQ?OEP]O.("'3G956--2TXWBROCZ-B`S ML?$BZ,*A\M<&),A7(H2F!ZWO?C':,&G37=(X$T^#A#C7`Y`@XFUW`'2I:2H& M;?%^,=I,B9B([5X23X-$,1H2=KUW[L]B5K=*Y*!"X'O>(01'L1*++D6L-TR> M!HE"-,0(F<]#MBE0(@<5@IYY?T:TT]*,L&U2@C\<0*TH9!2B#,NR2UKD.8M+ MTJ@0-,W[A6BKI4+8;"9>[\>X^_8BQXL\UA?69\AEDW-9`EU>E0BA4M!![Y>B M?9=*84$DGC%GW5,]A]U?]_>O-FL,HD0(U8%>>K\.[2X0(L9G9C_- M&KM1O&]Q-S&@N2DMZC7K_JY06"*$JA@P>'\^^D/$QV%,1LQJ)S$@J6L-0(*8 M^9$:`+V5$RB2^PO,QU%<#/<2`Q+%:![C)4$0LOI3(@=-RX"[SZ'#RS]+_`%W MC[F7&)`HI-\`="V!EI\2QU,1\!WOR`:.XMG@/N)KD"C"0`87D1()J`HTUJNF M-9(";<.D6<67:C4/HW/Q&`6].YX"<]NX8\G0F*A$IBACT@8,/*8NX;? M&_E0T]?==@`2Q*QOJP'09;:H"&;E(R(&+)QO4A/?6/C;G71M("8/WF`>)!8J M8<#%)ZSJ`1>/;RQ#,F&3CU&(\B4(E<*L?"0;VE6AK5P]N+I9TY+U&@FC$.5+ M$"(!'[=-7]@=FK6E!5N2B0%);6D`$BRXXPV`WE@5P8!_CY=4-XJ+X8YG0*(8 MO0T0($IDH?E@YBV75*#-5BXI`Q+B6X]#E`BA$M`X)WM%H&V6>,5M26F0*.$6 M$BR8[2OS9<,\5`1@KD5,V]@&.(J7%%_B!C0N(R''L[A\2E^V3"/ M%J&/1_6179G7NWR='PZ-E54O>/3IPY.(\]7SL>RG`(^\V'7EPW$M7G?/-^"T M])3N\C_2>E<<&^N0;X%RYL0P^[4^;]4?VNK4'10^5RVO!KF!`@``Q@8` M`!D```!X;"]W;W)K&ULE)5;;]HP&(;O)^T_6+YO MG",G$:I"U:W2)DW3#M?&<8A%$D>V*>V_WV<;:!-6QFX@CM_OS?,=XLQOGYL: M/7&EA6QS'`4A1KQELA#M)L<_?SS<3##2AK8%K67+<_S"-;Y=?/PPWTNUU17G M!H%#JW-<&=/-"-&LX@W5@>QX"SNE5`TUL%0;HCO%:>&"FIK$83@B#14M]@XS M=8V'+$O!^+UDNX:WQILH7E,#_+H2G3ZZ->P:NX:J[:Z[8;+IP&(M:F%>G"E& M#9L];EJIZ+J&O)^CE+*CMUN"*:EE:0*P(Q[T/.8:Z4KN/RE1?!$MAV)#FVP#UE)NK?2QL+<@F)Q% M/[@&?%.HX"7=U>:[W'_F8E,9Z'8&"=F\9L7+/=<,"@HV09Q9)R9K`(!?U`@[ M&5`0^NS^]Z(P58Z349"-PR0".5IS;1Z$M<2([;21S6\OB@Y6WB0^F"1`?]C/ M@C3.QI,K7(@G<@G>4T,78(2LH-F>:Z))WW)ZEP2G10$^$Z0D/H0,ODGI`WJ0Z8#@.6Y M)#X!N$Q7EQ0]1*C=6\3+];-BF`&,7NN7I?TG+[TF?:/)^HK5)46/#4RN9[/B M'$/>)[8X'%1EZ343U_DTF0ZXWMOM,<'<7\]DQ4.FI/_4I=>DCFD\`%Z]L]DC M&OT/D14/B88=]!I?I2QZ'6T_6>_M>B9_%/DWM:,;_I6JC6@UJGD)?0F#,62D M_$'D%T9V;MC7TL`!XBXK^%YP>%W#`,2EE.:XL$?=Z0NT^`,``/__`P!02P,$ M%``&``@````A`!P3UK`7`P``"`D``!D```!X;"]W;W)K&ULE%9;;YLP&'V?M/]@\5[,)82`DE1-4+=)FS1-NSP[8()5P,AVFO;? M[[,=2$BJ-'W!V)SO^'PWF_G]2U.C9RHDX^W"\5W/0;3-><':[<+Y\_OQ;N8@ MJ4A;D)JW=.&\4NG<+S]_FN^Y>)(5I0H!0RL73J54EV(L\XHV1+J\HRU\*;EH MB(*IV&+9"4H*8]34./"\*6X(:QW+D(I;.'A9LIQF/-\UM%661-":*-`O*];) MGJW);Z%KB'C:=7Z`,<;:A4 MCTQ3.BC?2<6;?Q;D'Z@L27`@@?%`XD?N)(CBV4=8P@,+C#U+X`:SR(^F']`R M.;#`V+/)`-"?FX;&UT M+GLV\!L-*XN)G:.&X"C!0-9O0,8DV1L;)=Z`&3D"-7'JR/6X:[!VH(_8RBZ8 M+K3:SA>RWN3$'^^8JI$42/_M4C082N4D3F%REN"5Q174., MU$-3WZY>@Q<.I&E0=E&_%G)-_+N(S"*FAP[QD\ED,@1@)'[Z$?$:/!8?)L'` M:\O88JZIMXC$:)M$;C@=,V3V^\Q\CX_T(]G0)JEM;:`*_[!U:2W&2A\[[P![FX,!2'L568GBG?F0-IP M!5>0>:W@CX/":>BY`"XY5_T$-L;#/\SR/P```/__`P!02P,$%``&``@````A M`)R``^D0`P``-0H``!D```!X;"]W;W)K&ULE)9= M;YLP%(;O)^T_(-^'[Y`0A51-JFZ3-FF:]G'M@`E6`2/L-.V_W[&=,`PM2VY* M*,]Y]?H]/ICUW4M56L^DY935"?)L%UFD3EE&ZT."?OU\G"V1Q06N,URRFB3H ME7!TM_GX87UB[1,O"!$6*-0\0840S%J0"G.;-:2&)SEK*RS@MCTXO&D) MSE1153J^ZT9.A6F-M,*JO4:#Y3E-R0-+CQ6IA19I28D%^.<%;?A%K4JOD:MP M^W1L9BFK&I#8TY**5R6*K"I=?3G4K,7[$M;]XH4XO6BKFY%\1=.6<98+&^0< M;72\YMB)'5#:K#,**Y"Q6RW)$W3OK7:>AYS-6@7TFY(3[_VV>,%.GUJ:?:4U M@;2A3[(#>\:>)/HED_^"8F=4_:@Z\+VU,I+C8RE^L--G0@^%@';/845R8:OL M]8'P%!(%&=N?2Z64E6``_EH5E5L#$L$OZGJBF2@2%$3V?.$&'N#6GG#Q2*4D MLM(C%ZSZHR&UHD[$/XO`]2SBS>W0GR^6MZ@$9Q6X7E2BJU4+-N MV8/E3O96H"SS"2#EM_.!8&3-O2Q2I4!S:.KS)HB#M?,,C4C/S';, M>":Q&Q-!'':,`P8[EY#<[2YED>DR7';R:B';,>*;Q&Y,A'&'&!XAO=L]RB)( M'%F]).>=OC:IF;#'#(C=%&%X!)&^Q^DN2SA!$$#/6S3PIIFEV@-A%`\>[_J/ MY_]VB.$)YNAZ3Q(V/?G^8%]M-1,I3S/?<]UA3_M`&(7O^(IN\25ATU<0+P99 M:>;LRXL"=YA6'S#"-/):F+ZNFUA9-/0W'`;-0,NZ?@_WV11A>)3'Y\UO%5GT MOUG0S)3'*<+P&)L>IV=!PL/\!NW;:D;WUVB?&N.=?ARJ;?G>+'CPZNT'-VU* MT::K\32[^?883H223)!^?&@F#,$+5O=0'OS[1 M&GP@WW![H#6W2I+#+G;M!$3C67!O@G#%Q MN9$?%MT'W^8O````__\#`%!+`P04``8`"````"$`QU]CU]D"``"9!P``&0`` M`'AL+W=OGDWB$&N3.++-LOOW'=L0$J@H?4EBSYGC,Q=/%O=O38U>F51< MM$OL>Q.,6)N+@K?;)?[YX^ENAI'2M"UH+5JVQ.],X?O5QP^+O9`OJF),(V!H MU1)76G=L*23>%KI8X3+QX.@E]@*,-4_J)&TJ,\IW2HOGM0/Z!RI$$!Y(0U!_L@1?, M8C]._LU"G"(;X"/5=+608H^@:>!,U5'3@GX*S":R$/+S]\@@)./S8)RL*Z`5 M5.-U%4;3!7F%%.8'S-IAIACUF&",R"X1T;R'$-#7BX30_U^D<1J+C&8]O8UC M[2"V<>Q&-M@8"8#,#`5LCATF<)G\6GF7,F9WD<.KWUI$HN"G#A%T7 M9Q49"?*C4(W*1HFMRQC=:U0+G9FS`40 M:;_K)O#:3^$ZP>@[V\]@,MM]TAM@,G9TR[Y2N>6M0C4K@7+B3:%VTLU6M]"B ML_=W(S3,1/M9P2^0P02:>``NA=#'A9G>_4]U]0<``/__`P!02P,$%``&``@` M```A`,?QOIJ/`P``S0L``!D```!X;"]W;W)K&UL ME)9=;YLP%(;O)^T_(.X+F(^$1"%5DZK;I$V:IGU<.V""5<#(=IKVW^\8`\.A MI=E-".3UF\?G^!S.YO:Y*JTGP@5E=6(CQ[,M4JX M9#5)[!TY3A*257^T"'56VL3O3.#:F:#("?UH&?^/2]"YP+5W\:]%S!"PM^(%@5(F=\HEL9>V!:$0D.2G;1#Z M&_<)$I-VFIW6P.>@0:9BWRM4/@%O8(2PC1E?3UV/HL0*1:52L>WT@_'_7I#M MIXIP-:`9)!"A,8F*5@!'*PQ\*!JQG@JA.&;]=@G M52TR,8,P-!EV6K-H.6]\+P2"":?6`.V_[0XN!N5B2OE^HM6B2\J+-.ZT1E,& MH;>:,FK%%8Q0;N-(SB=:B4VV:#EL79]!+=%HBSB,X4UUF>>Q9!G&"(TE1@#5 M^W/45^;AE-B$"\++8Z@UKX>EY=_/*0RVE]5L=;,,7Z M`+9J,X*3.NXT.K^JD"%WDP2;(JAD4V0BJGY]=8Z1[N[C5A.@^.((=J*Y",Y* M3#[5UT=\U^49Z;?!?+ON1+.E*6P4G92$Q."5CL\'::Y.[^=QX8?8)AJ\)%\ MP_Q(:V&5)(>EGK.$5LSU.*9O)&O::>3`)(Q1[=<"QF8"KW#/`7'.F.QOU(`P M#.+;OP```/__`P!02P,$%``&``@````A`#JTO%[2`@``B`<``!D```!X;"]W M;W)K&ULE)5=;]L@%(;O)^T_(.[K;^?#2E(UKKI5 M6J5IVL/5]7-3HR M@!%KJ2AXNU_C']_OKA88*4W:@M2B96O\PA2^WGS\L#H*^:@JQC0"AU:M<:5U ME_F^HA5KB/)$QUJ8*85LB(97N?=5)QDI[**F]J,@F/D-X2UV#IF\Q$.4):?L M5M!#PUKM3"2KB09^5?%.O;HU]!*[ALC'0W=%1=.!Q8[77+]84XP:FMWO6R') MKH:XG\.$T%=O^W)FWW`JA1*E]L#.=Z#G,2_]I0].FU7!(0*3=B19N<8W89;/ ML;]9V?S\Y.RH!L](5>+X2?+B"V\9)!O*9`JP$^+12.\+,P2+_;/5=[8`7R4J M6$D.M?XFCI\9WU<:JIU"0":NK'BY98I"0L'&BU+C1$4-`/"+&FY.!B2$/-O_ M(R]TM<;QS$OG01R"'.V8TG?<6&)$#TJ+YI<3A2V/$=@G`*JC"TR9.@I7_ M!*FC)\W6:>88]9IHK,C/%7 MZ=M1'"'-_@?)B*=(\PF2T\PL4AC'$^+<33OB]&]Y@@MR>9Z,>`R5QA,F)W'% MFR^C::*&TTF\?+N2+E.N\[G&T#"Y9SFK:X6H.)BN%D&D_:AKN-LP@UL$G6XR MGD,CMN-^/P&-L"-[]D#DGK<*U:P$R\";0^VD:Z7N18O.7MN=T-`"[6,%7SP& MC2?P0%P*H5]?3+/NOZ&;WP```/__`P!02P,$%``&``@````A`&PGCG6:`@`` M#@<``!D```!X;"]W;W)K&ULE%7);MLP$+T7Z#\0 MO$>4K,6R83E($*0-T`)%T>5,4Y1%1!(%DHZ3O^^0]"8YBWNQ1.O-F_=FAN3B M^KEMT!-76LBNP%$08L0[)DO1K0O\^]?]58Z1-K0K:2,[7N`7KO'U\O.GQ5:J M1UUS;A`P=+K`M3']G!#-:MY2'=_"EDJJE!I9J372O."U=4-N021AFI*6B MPYYAKB[AD%4E&+^3;-/RSG@2Q1MJ0+^N1:_W;"V[A*ZEZG'37S'9]D"Q$HTP M+XX4HY;-']:=5'35@._G**%LS^T69_2M8$IJ69D`Z(@7>NYY1F8$F):+4H`# M6W:D>%7@FVA^FV.R7+CZ_!%\JT_>D:[E]HL2Y3?1<2@VM,DV8"7EHX4^E/8O M""9GT?>N`3\4*GE%-XWY*;=?N5C7!KJ=@B'K:UZ^W''-H*!`$TQ2R\1D`P+@ M%[7"3@84A#Z[YU:4IBYPG`7I-(PC@*,5U^9>6$J,V$8;V?[UH&A'Y4DF.Q)X M[DBB-$@FZ32_@(5X1<[@'35TN5!RBV!H(*?NJ1W!:`[,UED&]7G=&5BR,3"C@?>L67&#@/K&>'GA=>6X])CG!'!$#ZP`96T_>'*M]\6T0#-`)>QS/1@H\ MY@(%D.U4P?O>+7CH/*^IK[C&9RPM[ MXHU9FP[3VFG_>-9LT#A]-K+M,3[]U23/P\/W@6U['YSLMO?+;<'CO.-&>\R^ MW$ER+(O/ZX\TO^-[NN;?J5J+3J.&5^`]#*;0+^4/-+\PLG?[:B4-'$3NM89[ MA\.V#P,`5U*:_<(>F8>;;/D/``#__P,`4$L#!!0`!@`(````(0!@D5*Q*@(` M`*`$```9````>&PO=V]R:W-H965T8&,/SG._]91/9X MDBTZ<&V$ZG(95 MCI^BY2K!I,B&_GP7_&ANGI%IU/&#%N4GT7%H-HS)#6"KU,Y)GTOW"H+)7?1F M&,"+1B6OZ+ZU7]3Q(Q=U8V':*13DZEJ6YS4W#!H*F"!.'8FI%@S`%4GA-@,: M0D_#_2A*V^0XF0;I+$PBD*,M-W8C'!(CMC=6R1]>%%U0'A)?('"_0*(XB.=I ME$[_3R'>T5#@FEI:9%H=$2P-Y#0]=2L8+8'L*DN@/W^N#$IR,4\N:`@%M8%I M'(HDF6;D`"UD%\WJ7A./"@+)1P>0]7<'D[_V]NK`!8%3C%X=Q(N1/[A<>&PO=V]R:W-H965T M>7J@R>"1>4U:L0C<9A0.J< M%;0^K,)_?CU^FH6!D+@N<,EJL@I?B0@_KS]^6)X9?Q)'0F0`#+58A4OG!8_:$W`;G4OYDYV^$'HX2TIU!1"JP1?'Z0$0.C@+-*,X44\Y*$`!_@XJJI0&. MX!?]_TP+>5R%R6243<<)`GBP(T(^4D49!OE)2%;]9T"HI3(D<4N2@/IV/![% MLPQEDV&6R"C2`3Y@B==+SLX!K!KXIFBP6H-H`P,&\Q&X.9AD&'B6W$]A*1SCM(!/HZD1"Z*S*!)%ZW_TVDFF2+ M3%V-!C+5-JO`MKT7E@!PQA4P[)*:!)GN.9#$?P+43FX,)NUALLX"C=CZ$)9& M(.EK])NCP*L0PNVRDR1C^\L;@YGI_*;I=#Z;V(!M'Y"@V:P'L)3!>KI?F0+; MRB:.)1L#F6AA69:FSOC6'I]F::?;DC5YCRP%MF4E">IX33(-YK8N>_RF+JB9 M^^U28%>74V@;@X%L=2&6<^C_=0.SD?LW.DT- MO<6S"+T06Z?:IWO+<,!'LZO[-SMD0)XD6PAOEM66W5.G>NIPNT)FH[=5_MFY MS`[3@KPNWMTP$-"X.H>[FIXU5,TMR*M3??W6@K"S_:[^HWDSA.>Z0@#->UK&^;T@GP06Z?36@9J MVG2#?K5<'!.0P=SNQP[@9D.&JX55*`/2KK44]ZB@*5>A.5Q=.\,X@$MMYK)B MSO(5X0>R)64I@IR=U$4DAL-1]]9W'_,@6:-/V#LFX=:B?Q[AEDK@*#T>`7C/F'Q[4/>K M[MZ[_@T``/__`P!02P,$%``&``@````A`)ICBX:&`P``,PP``!D```!X;"]W M;W)K&ULE)9=CZ(P%(;O-]G_0+@?^48QZF049G>2 MW62SV8_K"E6;`4K:.L[\^SVE@A1GP+U1X3Q]Z7O.H9[%_6N1&R^8<4++I>E, M;-/`94HS4NZ7YN]?CWW:-#= MCJ0XINFQP*50(@SG2,#^^8%4O%$KTEOD"L2>C]5=2HL*)+8D)^*M%C6-(IT_ M[4O*T#8'WZ^.C])&N[ZXDB](RBBG.S$!.4MM]-IS9$46**T6&0$',NT&P[NE M^>#,$\B90TC?3(!2W^*L@Y2RD1]RP"*\XB MCCMQ9X$3A.,JEMI1;3!&`JT6C)X,Z!IX)J^0[$%G#LJ-,[6/UNM'5L&C%'F0 M*K46N.!0GY>5%T4+ZP5RFIZ9M6*FIM$R[DQ'-@TB,RAUX^;&98VC+TD:0I8/ M++6^(%M]7Q[4_?V*-3;D(MV&W]OB^AIQ]1UMWB%ZJ8C?0721Y!WB(J(9]:Z- M^A^V9F-4+H(F[-3"MVU]"VO%^!TFT(G-*!&/$LD0H?F$C70+.EQ("2]-2&+; M:Y&G;WZMD%G=K('OA7IXTPV[TZC7=G$W[`3!K)>:I!L/P_#R<,T3U.EV3Q+6 M/7D7V?IU62L$GMW:[NUK,TK$HT0R1&CV0MV>/%O&6U,N&FM-Q0SY'"7B42(9 M(C2?<*;=7D8)ZV6\:DV%A'5KNE&_]S;=L.-XO1,J[H9GMMWK@*0;]NSH$M8L MR M)9(A0O,)0]%_U+&F]4)>]>:94>>FZ_N7_JF/H(T6=\*@=T3%6GP:S'K_.G*, MDUE6^EX07KI;&5,SFAIA"LSV>(/SG!LI/Y`L:#WOU8 MSHSUU-<&8&2KT!Y_1VQ/2F[D>`>2]F0*!QY30Y^Z$+2JIX0M%3"LU3\/,)QC MF%CL"<`[2D5S(>>2=MQ?_0,``/__`P!02P,$%``&``@````A`+_`>/B%`P`` MUPL``!D```!X;"]W;W)K&ULE%;;CILP$'VOU']` MO"^W0"XHR6H)T%9JI:KJY=D!)[$6,+*=S>[?=XP#`9*%;!Z28)\YGG/&-K-\ M?,TS[04S3FBQTFW#TC5<)#0EQ7ZE__D=/\QUC0M4I"BC!5[I;YCKC^O/GY8G MRI[Y`6.A`4/!5_I!B-(W39X<<(ZX04M&1[DY<,H[0*RC/3L:RI MF2-2Z(K!9_=PT-V.)#BDR3''A5`D#&=(0/[\0$I>L^7)/70Y8L_'\B&A>0D4 M6Y(1\5:1ZEJ>^-_V!65HFX'N5]M%2:UZ8"Q.8 MULN4@`)IN\;P;J4_V7X\U\WULO+G+\$GWOJO\0,]?6$D_4X*#&9#F60!MI0^ M2^BW5`Y!L'D5'5<%^,FT%._0,1._Z.DK)ON#@&I[($CJ\M.W$/,$#`4:P_$D M4T(S2`"^M9S(G0&&H-?J]T12<5CIDZGAS:R)#7!MB[F(B:34M>3(!8GD1K9]8*[]46H:Q]XS#)R2)$^29:7/=`V\X%#DE[5KV4OS!2J3G#'! M-<:9=R&;&B+K('G#>N#"VV.-:D0=$JL!^&Y2F2S<9AT39#?:H2YM[;?W1"U1 M@J7$>J%`#;07DBHAN('DE\#7$OD([B25>QK+;[[FFH ME[F[WE6KVB!PHSKPY!SZ7-P%PX,!<-S,5J#KZ;G"[.=Q1#G3^N6`;U%4^Z ME0T4YG8&ZB",(L(:(:^.GFM1/7=+8<4?UXAN=$<]W&UM]<-UEN"^ZLL=4JT9 M*,Q"77:>,9EV7=FH^0%7PA&&:)0A'D)TU,/-W%9_W[F707T7+GM+N:`P:K=[ M]M22GYX1"C)DQ#A)-$H2#R$Z7LC.KO?&FXZ>?!G4]Z)7\4!A!H1N1A'A-<*U M9EU#HVM,KRK04,EL;V>BO%`-D^H$(.SC&L)/N.![<-K^WH\M'UX-\.XV01`7U6B/?Z!V)X47,OP#I:RC!F<7J8Z,_4@:%GU M)5LJH*.J_AZ@@<;0$%@&@'>4BOI!+M"TY.O_````__\#`%!+`P04``8`"``` M`"$`S_'46C4$```_#P``&0```'AL+W=OOQ,^/Q"UY]>Z]*ZXTUHN#UVB:.9UNLSGA>U/NU_<_?+P^Q;0F9 MUGE:\IJM[0\F[&^;GW]:G7GS*@Z,20LBU&)M'Z0\+EU79`=6I<+A1U;#/SO> M5*F$RV;OBF/#TKP=5)4N];S(K=*BMC'"LOE*#+[;%1E[YMFI8K7$(`TK4PG\ MXE`0D4ILF7\\,Y%!12&,0T,5*>,E`,"[516J-:`BZ7O[>2YR M>5C;?N2$"\\G(+>V3,B70H6TK>PD)*_^0Q'1H3`(U4'@4P>AOA/07ZURJD*,*\JBBK.V%;4$6`M;G M;1-X\9E5C-K(JN4)[PA_XT='H: M?SB-RCR87=/+=&H0K%XOB<#SNOA(@)J@IPD[Q2!1D/03500^].:/$U:#UC9D MV94Q\)(N/A*@)FH7@H;4(PO#.""`?&\G4(-&!,3$1P+4(`$)@B0(%QWC@""Z MAT`-&A.89D("U"#!0^0!PS0`-.WM)5"#Q@"FS1``-1J`^C'QIP'436*T`S_O M`C5H#&#B(P!J$,"/X]"/9OHPN8=`#1H3!%V&2(`:31!1;T%,D09=0*#M;R]" M.VK,8')$!BU""!)Z?N2;5AE"*(>Z>24(^MI@0Y)H5`@M2G!'$H?,-"-1[G4[ M`GK>$,'L-UT'%,4M0C2W#A.F^'DS$G2\X?Q7]H\B+$'L))'7?\W5XRZ+)!,> MV:NXK@>*D,B_34$.>NPR43#@H-4VI>5"$/"1Q@CF$NRR43'@H-477 M""B"7C&W6VIL;EB)"1_]_(F"3!@IO3(Q%`TQ9AJ6WN6E[:B1EU)3;ZR&%@TQ MS$8?5(..W/3'3S6M>CR],04]/5JMMK!@D7C>W`V%*K>[V4C;42,*?[QKM0AO M*)'O!X3.W=KA3#*@^*0&$S;:NU?I&J`(:Q"0*/!);/8-K@">8_`QOV+-GOW" MRE)8&3^I,PJ!.T#W:W=^>J3M":C[`XXOQW3/_DB;?5$+JV0[&.HY"_"U!@]` M>"'YL3U$;+F$@TO[]0`'50:/XIX#XAWG\G*ACEC=T7?S/P```/__`P!02P,$ M%``&``@````A`+^256`S!0``!Q0``!@```!X;"]W;W)K6.`G:@"-@;_^^ M8X8$QDE)5EKM+OCS9W\SXYG!JV\?Y=%X$W53R&IMLKEM&J+*Y;:H]FOS[[^> M9H%I-&U6;;.CK,3:_!2-^6WS\T^K=UF_-`*SW5G.J1;;M)I5'B]NV;Y5949G(L*P?X9"[79&+1.:OI:A: M)*G%,6MA_\VA.#5GMC)_A*[,ZI?7TRR7Y0DHGHMCT7YVI*91YLL?^TK6V?,1 M='\P-\O/W-W#%7U9Y+5LY*Z=`YV%&[W6'%JA!4R;U;8`!@63K:O93YT' M_JB-K=AEK\?V3_G^JRCVAQ;<[8$B)6RY_4Q$DX-%@6;./<64RR-L`'X;9:%" M`RR2?71_WXMM>UB;CC_W%K;#`&X\BZ9]*A2E:>2O32O+?Q'$>BHDX3T)S.A) M&)_SP&.>?Y_%PAUU`I.LS3:K6KX;$#6P9G/*5`RR)3"?E>$^+EK_3RIH5"3? M%4O'!2H:\,_;AOLKZPU,FO>0""$+TQ@@`87$9X@RH*)-SB^&.8Q.2<\(Y3U0 M=)$%QM)E.>#VVPX[JU"3-!4+NEYT`T(1\0U$2"')#0A%I#<0`PD1ZE"ATP(5 M&&)OY`/'IBM'"'%'$(\BXKN(Y"XBG4(0>;"1L1^GY2GPV@3;74+,T>(E0LB4 MO+N(!!%!%^;,@<-'#91.,1!Q<-X>%Z?`FN\X73A"R)2XNXCD+B*=0A!Y_E?D M*;#F.T>3AQ"_L[OCAKYF]W@\SGS;U^8GX_%@X7E:ADK'XZYKVT/L$%F0PA[W MF@)KLEQ-%D)0EL=]+>/$XV$7"@:=G8R'F1=XVGA*QIG-AW$B2G4J6AFXGR_5 M)$V1>1(`(-%`2V[K8S05=UO"&?$7TAU3>=1Q18TZ4M&B%D2M== M1(*(-TM3J<5>U&/<[L@%P56]5@NOS0DK)#T# MBN3>8CA3*/*RPI"SAQ"B*E6I'X7HM`L9-@:D%FC;CWH,[LUEC`^QTVTN)@!N M.XMA:WU_@JL@`V,!"[7#G1(*S^.+(2E1=:KB/ZX.^P.B3@N?B"$&]S:[*8\@ M;NHC"&:[GJ\MD])EIA2JFO^X0NP0Q@I=S3T10TQO_<5"&X_[<8Q>[\IW9';H M7'D.QW'V;%0LJ-\@^+^@2J'IF7.U$Q$QQ/1^N`GE@*SO M.YK\E$(\S^ ZE"5>\?]QMV!\1O0\GI]A^I+Z.A-AY?QF_EA/[@ M(45O).X&P^8[0#K)0?6ILO^X/FP2B+[A2/?ZQHW$S`E]]THA0=ST($$PVV/\ M*D`)9,J#J@<8*53?>/>+.\/.@2C5MA#UF+"K#S,V9UH!B2G`GOM:#DXHP)EK MIR'MQ['9G@UVI"Y4+<#7!6+C0`1JIR1BX][#<4*N[2^F`-MV-0LD%.`$UQ5P MO`1?^&PP,A6I^H&1R#OU#[L'(D[O8>#&1)W#WK8>M%;:*8HI@ML\U!`)13#N MPP_M4-7%S'@9S[E2B/"U1BGHO8G$\-D8N7]6="H?HNKS%^YZ(+>&R`+[Y MM?>)N@?J;G(N`W`-<\KVXO>LWA=58QS%#BCM^0(22(T7.?C0RE/WZ?\L6[B` MZ?X]P(6;@&L(>P[@G93M^4%=-ERN\#;_`0``__\#`%!+`P04``8`"````"$` M)78^_)D%``!9%@``&````'AL+W=O`9N+(>KT:&`TNR/M2JO57IYIXB2H0XB`OLS?;]GEQAI?YWC!6IVUU M[$Y\XW_G@__IX>>?[E^[_FDX<#YZ8.$T;/S#.)[703#4!]Y6PZH[\Q.L[+J^ MK4:X[/?!<.YYM94/M<>`AF$:M%5S\M'"NE]BH]OMFII_Z>KGEI]&--+S8S4" M_^'0G(=W:VV]Q%Q;]4_/Y[NZ:\]@XK$Y-N-W:=3WVGK];7_J^NKQ"'Z_D;BJ MWVW+BYGYMJG[;NAVXPK,!4AT[G,>Y`%8>KC?-N"!"+O7\]W&_TS6943\X.%> M!NB?AK\.QO_><.A>?^F;[6_-B4.T(4\B`X]=]R2@W[;B%CP^3!^;81)WZN?A[%K_T60]&@R0I61"-BK=;JB M64*2],=6`F0D'?Q2C=7#?=^]>E`UL.=PKD0-DC58_M@C<$5@/PNP?`3(#I"& MEX>8W0@2YN\Y1/.1PS";S MTHT"(4PF2OA5&C)Z&S,4)B$V(CRFL(BQH864Y-@#<^ M>#DE)2'VQ@5",IG4A*1)EMB`T@1$-*)41]4B!@5M$EN6-/&00]`IFP(AJ21( M:>SP+W$YELLY2R?R%K?4YG8]GP+L<(HFLUA("$%.+*=NR,SE.,JU1Q8I."MF MP*Z3$F"'5.R00@B22FC*W%27)B`"`*RRF"B'[:"E=_"28`=3LZF!4+>JRIDU$EQ:0'B."$7RIZ`,"V/ED0[U&9* M*BQN?.269G&FZP<#IHP@@,49T6?"BAFY3>-1GRVQT#YCW4N+[]0(9;/*5P!, M)KN43")T=W&%2;03,]TX%#%4<@Q)%I&$.E$ME145U3A/HPN51H04+R>'P@V_ MD\2FKOI+BQL?A'3"Z+U52A?K/Q%ZO)P>JK>9U%17BXH=8C`R-#;T77$SU^.8 M:O?L:OM?#4"\33EG-77JO5`813#*(@=06@!XM8IUW=H4;^H#9-X(4D1UC$Q5:O;@[4%1VLWDQ+0,JLX@Q";KG59GY&&+3 M^Z!',+AW_=U7?.4Z/8*Y0JPP)H=Y'-'.!8Q-U.D4\L,__#'3>P7+*7$*&6;G-,P%IZ5>>,P M/N94Y!"#).](&H4SI3$1<7KI`X?>U#@DVM8_YBA)H3"*6L1B$FF=D^Q+&T+3 M/"0Z^58$Q:QC^2&6:(>>LW>A,$@ORC*:.SI46H@X9UFF8VN3-H$"_&[BSG4(_= M"",]^>\!1K@&POMN',F5 MY[\OL.^0:&A6$D"R>9'4ZG';`S8E]=!62[)(>>$=S(=B59(L=[&J7!>I:>P' M8UYA]\L`NX`>8)Y"C^(GV=__G(C(R,@LDI(]&"PP@"]496;DB1/G\C^7B/SN M'WZ^FE3OZ\5R/)O^\JN]G=VOJGHZG(W&TXM??O7N],7VTZ^JY6HP'0TFLVG] MRZ^NZ^57__"K__I?OELN5Q7/3I>__.IRM9K__==?+X>7]=5@N3.;UU.NG,\6 M5X,5_UQKKZY5?[!_L'7U7K MZ?B/Z_K(?WKTS<%7O_IN.?[5=ZM?/9L-UU?U=%5!1_5\NAJOKJOCJ;\`NK_[ M>O6K[[[6K7[[M]6/L^GJY6M;^[]ZB\^'JXXN)>_\5$ M1O;NZI]>CJ=U=;RJKY;_7(YVO_PAC7!Z/:_+B_?W=K=_6_YXR+Q'-O<7D\%% M>?7^^6"R[`R4WO*F7HQGXMBH>C98;;[OQ7@Y'$RJW]>#1?4"7B\[[^GC57I- M>#R\K7^`WQZ48YXN!I*RZN3ZZFPV*:_>/WKYNY/RQ[#T;^N+\7*U&"`0KP97 MG6GQZ.O?'9]4KU\=O7[Y^H??;U7'KXYV-HQUA%@MF/LQHO)S]9OZNKSO_NXN ME$=L4@7LT67AI># MQ45='0Z'-;=QTXAW\E=)4!CL:'9U-9M6)ZO9\*>MZN1RL*B7U>OURO08EI>/ M'S]1*-76Y5]<_#>KZJD!`GI^)=@RT4?E(SQ&QU62\^C)=U MM9S7P_'YN*NT!W=6Z8ZK$;AN,KL93$^85'"WO M/!S^<3U>L-KCZ?9\,1N*6:SEG=YR>#5;K,9_LL732HZG6/&+\=F$"2^7=875AGD31*9S5WW@\E@.JQ1+CSL'77R[LKWK!XFI]A1KV@$3:BZ2G8T6+I"#/5'C3R_ M'TQD74KNO5G4\\%XM%&^XT)V'GQMXC,,MMC)*`=W\;SYGC<+@,L"9"&0(4)- M>7O%\+C0I0Y-/\QFHP_C2<>K.:TWT=A_+3)Y,AZ(&>GUB-]QPA$T8K]QE2G8PE#[! M(HXZ'O/_IXZ>/)7/,9U_.)MC9Y7V3PM5UQW&A*H$CN"RY^#FX M#;5:U]6]W1W@BIDJLU&_J/9VMT`P^F]EO^#(UZO+V6+\IWH$$V?QU_%R*>G0 M!#*[5`U6%8`91'"&]8NHV>["*H1?'2YW+4.PE4YCI"R1*G-J%&U!XPU$?@X) MOZ@.#K:^??)H:_?)8R.2?S[]]INM@_V]O]T\MZ1"`!5Y[$D'JQV.1NCG;(H[ ME#W;'D^KX6`^QCV6:XU"KJ_6$T-=!H'D'N8-O'H@L_\P2/U-#X_J\_%PW/'H M+K@F(H5$E8-U1-QX=YX#F4H]O/FV6\ENCQIN[Z>Y]]8;"=Z(]2P")2XIP>6E8]T:!G?X3TOQE-04K.V#%B=*Y.HH:9NOQ9P=@OQLL2(:9V!Y:LK"?!@,OZ3?F,!9N]A`NDE M\GOC[:%4;5$1/"NT@111_6XZ5E1MJ2JR2\_7LA'&3L=1Y#KJQ=18"0R[&BQ^ MPKBV:2>E80_H5E)4%4[)<3L@FK\G(3=$!&&VEY5;*):W&W%HQDB;*3$7CT/8 M8#)1IOP"S&]:E/(_._"[D7=R%S8'&TZO"@PQ:G!4B1O0<8E(-"_9LN[T:?`VSZ,5X3@&N<,%8TIGO5\&Y.F!(^K/GQLDF#Q-R-J M,;L>3!1R:B7/UR:',E]PE(D-`MZ]`W7$MJ3Q??8@:.63+)J5J"SBR*/%^B+R MQ$R2:6O&%Y^!6<;VDH98#HZX\$(PRZ*-3$),:BX(B^,,DP'HV6F/Y.:(\LZ>J2&!:45R[F,[.*#10R3DORS\<+ZBY_7`\62+@H46*^ M-0W$P91#=V=)2!?-+1<&71,PNT"/0L;OWM[!SA-)P$0_P+>H`6)_(Q@A.\K3 M'K<@OV-$;[(F_AA,QV=0/YD,SD2_QM'#::"+16V)9:?A)-<$F8N MWH^9U`-L4OA;-LG7.`VR@1J;"Q&M;%+#I^68&1(;J5(0*3<_SF+B^.<8AVS! M12S/$ER37FSSE%&)E*F`74"@R00!.F\;=%G,9;.GG8+#G2S](48D.%*(&S7ZC/3M&!&6 MXNH].7?,8@;*JS//)KI8JLZRE"0FG3BK:^S99$SFVF)7A$4L\0H"M_F*K:># M-9$P;V[F@WG,:@O];BG,;E1I)1B:Y9@(,\B\#IK88LN7P:'D;.IJ.57)<<(C M,@7F8?('/ER.AY<2;?%I-B?OCH3"MJO!%*OMM@8[/R6OL5P.%M#\8*Q MC7#R(E@I1SF\93YS0&[I@/4$+6"L0IP,S)Q;2!7MON,*LG1Q/:7;*//X"KJ7 M-LX5WG8Z$QZ!VA'B:^XP+'"\:74)8M&=W*609FBL#L[E?`VWKJD3[%1'),0& M3#J7)4GZ^6RVXB48"8I_9!H`)Q)R,9`)IU7@R1O7D6F0?3*I-%E,2E*=`4& MEWR8-7I^E"P1#KD1@4R>EQ2[)N!@&=:!S0@:_[">FN(T5C?RLE&830HBNK4^ MIN949F:5RR_,;JV.A/)P.ETCD6]K',=*7OH%ZTA6;?LWYEG%#`D#E?T1KXN) MNT\?0Z'[P.X"RBUF`^R:2<3:IR^1Y@4QW#0VN?KH513L#1<8C\?+G^1PI;:L M`4NZ7*-N\7L5. M+Q#*,%CI,\Q,W7:`Y%QCP2YF4A*2%>,E,*RQ1P%%(`3RLHG6K2`!>BC] MR-O\#4P-\?(4]*;ZG;LW5'TFZ^)VL+_2IW>U*X>0.)Q@/=4RL%J`W,7Z!0+H MRK:\)?'B[B'X*6:+0!/NK@A9N.X,PR@XH M)\P$R/[`#_V/2:MQ1L\Q?:KGXJ`$QH72'1DSM-\R#[6Z7,S6%Y=@&")^\59Z M0@$L&+CI!?/_,1-&\S()(R-[@1@S5?6%NZG,Y25!)*:*[D_8:EG7QG2/)>"Q M0YDX?Q=>*O8RY,:(\"*$5F#$,2O7`-7GP,X00X#11C6:AV-85>LY+-!R8H3D MSG&(.53;J@9SQ4J27>8][(076!LQ,,+V`JH/AI?(D0&,"G&K@9'GL-[[#$`I M\%%9#4AN+\@TG8'97;3X9Y"LF30'OKFET$21A9_:A,Q5*V'M7#8'"Y;< MT=G2W:@Z?VB387"`QXH@&(D,VNBV88G'DNZ6N9N3]15FP^*WDTRK#AN4\@8, MJZ)=^>0^D>,7/YRIMBU]KM'R65H_(:3P[DH.'G0_7(S/6"PM+@;/1'P8(-5`KA7PL;.AQ^"W1&^7*.DF)@AE0*N=#A MZW',+,48MIE"-@:SH?UP,5I6W\_X/X-D+PY/OC=,Z%61_)7-[>_FM!G14D)` M>7CRSFY_-=OY]%$Q\_;NMUO*?KUUK75K?H3;7!#K!$D[6N.$R,=0#SDE7AA6 M3W:?/-QAG(KA+/)FE-2SY$8L6U&9O(@`S%G(L&7#DQT+PTNA\2$8Q3$]DMBQ M!,D9P+"+L4_6'2.+L*#"6DSB+ZP'.J]8C-*)V07290+\V/'&*+F54\K3@Q&B M0#S(A<\:!,+B8/B#9>HG4C8*$[MVGO)7;=!(B3I-=.`05"3(="BKY0"%;_+I/( M/7]]@G'%!CGL*CWC`13>?,=K.;#WUBGRZ>,>1A?>'+1A2LBPCRS'$]Q<5L(V M>`:ITI)YN_5%.OE\15X'08GEC>H$%\[2T_FZ,]\YI-"!$D"D[+^O*;&+B59_ MP%-]0-I!A(`92S"@]5Z4"DEQO?/>WM[.TY0M%6%:PE2VLSN^.=CY)MT29M6& M@$WE+QITC!_^QEAJ853HVVB;+,$FBUUSY!5*IBF;'T>$8>_'].%VQJS&M'D& MT6_2MR%30@^RL=O2_$WZ%RL@#794.G*J#)Z))^+`''#B:NL:J:I-\WA#G(;Y M4[W`B\UD??!]E@3`U`Y^'E^MKXS'3Q[O["8&BL=_^9=_V]O+?FRS10GMA9#. M((7C7E@08>=0B0;]D"Y\U1Y%- M"7L*C'/=)(OE"5/;4`<[-=#G>*K`P#V^IOU"%/_.VKM^I.")Q]>U4A,?[60` M\,N&4'%SBR9T8,)S-)[HB/1PG?DGM M#/\ZL?`7@*`>`)^@)0J)]*F\HL-D@M8Q(>=>U1`8Q<54;.C_ M#>49`N(`A0JMX6='9K)563:IS(TLI0`#Y)`C1N<(L!HF!J=L*X;PY1>RF6?3\U5*U2_+ M2F27R1/<3!`VQ=VL;``+UBBZ5G8]9?84F;EX`3SV%8X)#![-`R5`_(V=>=RK M7G5\DFS+48[OVIW8.]7;32\EC,^ZER0SF.JK,:DGXX-\LJ<91;S!"'0F7!*0 MD322TQ4^U>KEY,"P6(^&HA*6!PG! M0E[H,7US1Y+I!ZS@&?/37+MJM,DBG.XPB#=60XE5+:8)5K`\F#(@..P<1/U3 MT8=@R5)4M@Y^BR%H&#A2G35JL0N#JSS=0%1F\>W<1,L->XKL+HD1B^2"%S.= M@0:$SL-2LU-&A.K9]E;+5Z?,7IC[=<=*9?Z+YWO]7.E)[!&?E,V'J$ER[B%V M:AW"`),$M5E_:*HOPYJ8U.:UK'$]F#K+TBMTM,XX5L72B,KAYE#A`39#M7/9 M]6&MOEM;!/X52\6*/:6#(R68,6Z"5=$[:+D1U_2J6!%0*4TT")HH++57>SF5 M15Q]4"TUC#%70*"JM!47@@@T#E][ID*FT&VW91Y-S\93U"Q$4$*'&.^U=$@" MZ`/DUC"8BDY[Y4L"L0D8O7/A4T^C^F_70#WA<7AE?1::$[D`GXN'\:ZRPN;& M%@OV(E^L"GW:``;3-:.@VHNW!X\BT6^YXLSDM"%@"H`LSHFCY:\L!2W,>;\S MY]=G2_H1#/`$[F:*%$?VV6]YI0OI_&.+*;*&2S(S$RIOO0PPT6BSC4>B]6Z6 M5'9KUM##/>2CM<@`WL7,FBU8BC-AA41TD"ED9F`:FH74DD(8;]D5,WWP-\GN MC8MD*6:+,#,&[_=/KF,&`JL/.JQ^-\WHSD59\PX)=)\?.U]6:IO4MHZH-29W M)*]NEX2#0&CT7TH96("2L&4$K1YHQXR,#`;\`O])0&.)&!M4_*3"AV^9TA<8A*9AZ0D0\972SP=20G%!<,"Z!?]UZ1-\ MT2HUGZ\7W%66D)U]W546J8G":E4/+VT'N)6Q,'9FP/0LZW++6B7V=,3N5*). M'\SL@W"(G!G^-6`)+)>&S^<4%%64Q3&5*',GH_Q5,*AXHQ;$5'X"E"._KO>X M:WQ@/B3L@GW8$?R`%7MM4M79*1Q-5?_MG=TW:==.$YB63QY:TWF'K!^SL*=\ MY%[YPU_^_+_[W(/O*(G,S#E5#O"R*9UW*.G9EW+34-V8NWP9PL`2?M#_8$$B M#`!R!D\<#;N6W__>KT9$I)(.>K1_`!9@KAUF(FBVHM>,8F2+RPYYR5\^OA99XFJ5P15%ED%;^>B#_:VG M3W?+7Q]VM]AEI+*&LFO]1"(KH2\]0L';EPB;F@=BQ)$^3[WE=B,FJ8O>G]"I MW`R=D#;0/6Q5N95+?Y-XKV3J:^1U41W9RE#M,RM2WO.8YI8[W.;WQ&@HV@O4 M4Z%C2L":?B0;?HM5;5D!D]:.;52=D@R17(&W@X9"RJ8K3Z.;R\MO MU/O&EN78$,3#0M8WGG_O[NUEF73R_M__HT<[C MF*@M$JVV92&^;E3[IA$]LYOE=K7$9AT1.NRD=5$L MAIC^G(36[W&U(>4+Z81C,">/ZSL3D3'=7@G>T;VFUOX"52?/1(ZB6=T,Y#E M"*E$;=-I5@/YRUR56!K*4[AG)BQT M>6TP*J&)6"'"H+H(ARTDF$#][YYU*[3=(U)$,:N94#G[SUYVMB333;JB^Q# M.6%W@`)$VGW_/+2.EG=1"+[;C7Z7<(>&:QS37^51(W7@I.6,C@CUE/7L2XRW M-1M8)C0%LI^A1C-DIM7&AC_"U/&K,A7*'953C:,DVO_RY__EJ*B\$\'#:OMI M#R=^VL,K-4>5]SVE"'3'6U]S:E(\[>#31R]6L[WF@^.1":HK@<-'6)O;?,*F MMY@7O;?_])M<9BZHME"W4?->3"!ZX[!LZO[.X[\3($STYZ=5F!W>W^7(@KA% MSZ9E_MFSLXI'4%;U@YJ/U_[4D*4(L:Q>K8^Q.8;O]B),*1`R,L92JYQX,8J% MQ;V*')GGS)(K5:")Q1!1MP0F,P5@@<[-6/AL-/#WJB;"_5=DR7\_6_Q4_4@6 M&B)/%VN,;GKR%9T)]CSA'46SD-AMJ`H"L6:3`]X)ZK)*F"G3F1KZ<33$LC+F M_(>N3B\^2KH^?41;#!`[$`:5NQIO)X^!`-%Q#9XI M`;\PFYJB?QBMB>_2,];4`>)O&&O.PTHQI.M:2N4]7_N<&1):6*&`GF7;5B5U MT*DDS-=+&(@,\"#T-HPZD?4_^D$IY*VL_*C'O8=$5=9KNA&P#KP=^K5J@;G< MPC4:#DSD>$/0'&V"@=CSM&4ABE;*_V<7U8J3/Y!84-(H)@="X8G^ M<*[N5._FO+E1$%>8T,]!5M`ZVZQ4$0\FX>[*S]X1>HZ6:[JTQB-X4.^R%Y>UH%*\P)K!'(97(-7UM#I4M,DWF*?`- MMUJ+-.T8/ME[3VAY>:I8V5_FJYT]9])'`$RF^0_L1K)QT_:KIB%[1FW50GI[ MQY`EHQH+TD'-5+E:-GVO6C-0B^O?%LNR_3-0DCRP4<)\95WZ MYDALZ?$(:![BICF6/-1\DJ!V$^*XX9/.U:EK!J;3,A1F#IS97Z:7K[^:5\C,A?4DXR&!K$\+H79C]8,K)Y7]NRR*#(&'GV'C""T[=>Q@_T MRE"=[A6VX!*2\$F,T6L4'_"%SG/F4N(-ET*-LX$H8K\+&3>?*0P(-GD^6>.+ M-^L:@[NR4J>EOX;9NNW+9,TMY"NV1XRG/XD=5EK'=H2)N4XG"CIV__AD9M/P M3"IBM?:LO'Q8_XRFI@2:]S9`CJ@/"09OH$`;S(3G8_P"EF'^@(K:+H24)6+$ M3>:5WVSWSAB7C$]36ZG(F@9U-+.$$7%4R`EC@2LJ$:<=XN4"'W<]C4C/G5Y: M"-?W&(GP7CE\,F[?[NRG:(1W6H-7&L!"RMB`B1`XN:Z]/IO`)@RAWG24IQV^ M;YU_Z="D9WC#^R')P\A"[Q%`AW"S2HE`_6![JB?C=_8@NHK M$%,;W,-N?$^M,>T^QNC%K,]>7)^.R=5TLN000S;\L(?WO_TF#S8WIW5U=\80 M9V8LMH7R?RIPZR4(M_6^VT8X&F30$-M=QE89"]HB7FG:0L@$3=F,+!,?O/@$ M/E)PR\F.LA9UG[TW`AF(E^R3*Z/M;D[]1HP7.CSL)E_S[1$=?N@:IRK.!)5' M=H^GA)?7#'G5S\M4SO"2M!W_!?+CJ!;K/FX$*DBF@)(5]V5@5/U5CZJ>/-Y8D5<.\ MY1;L`XOONW=++2^-VV&1=N[1D/(1+TW?-O")HKB`Y>];4W5WZR^'*N6WT0BU MX48,JB)#N[DD!_/\ZS7%Z>[F"K8>C2I.P63KQ:-'CV*@B"*HR[D5;+(LY+9\ MWV9*#N&1[WVSSZ&B9>3G1Y6=LYM%^AA/26OZ/&VKUVASMLG?$`Z:7=WO_PYCM[C(,M;'^P]V3K8?5+^'$?HT-=YE\2'W(@^ MMQ#*\S%AV'GVP$2_ARC;>40`0!N6SIG*RG$A91+:1WV5HS.[H8BTU=1&9)Z) MAVI#8D%"[2!EH<^9#M7$<\5.9A2!4.?F$DS'JYW8N0_?D]4869HS'KA9\G1O M%X-WQWO]/D<#4K(X9LQ9>]0.`%8^BQVO?B?6Z&(QN%I&ERD+Y?FT_&A$N:X- MQR,2.0VF6S;XES@X\=H-,6%,VO$#W@#Y9'[5U-^SZP83168+U7ZFTQ:>#;:E MT_S3YU0_?6S+8+E0/4[VMD?<*RYM=3>O6ODBZ8YLB'!7K!\D/N&3=(S_&9HR!OZS9 M]AI_=[MC"<+>_.,;9P2$M/AT9MND%.&3"<:XVH$"<&E,+J#$/>).&R5D!9// MC7&C_^B8E&0BXB=A0"K3U;:E^+/\2BJSE3*9=+/9PQQYE'A7/F-;8--*6<=6 M/E&$V\U0QYX=;O(OGE_2ELJ4);C5&V>>FR]O2(E8K4`[Z7HK%?*+[';2-OXA M':<`#IBS--/CO>R84G%9-IZQPO[Q^,6=[]E2ZU32UE>0'E*[1#MA@KMQ: M=V?M2PPP)9[J,!Y:VN$-)P!4M]_U%FA-VPAV^ZQZ^_)TR<=0WRL.U%;_$2(?'U0[E8"[YQ5.F,9K-\P[1_&8P`$73# MDN\BD\U1?QS?RREM&O-JC0M8:?&:WHEZ#JEV(.?%8O:!Q-8YGIW;)8ES_6$' M,_SPXJUUMAA)('>UI[!M-N.;5BKMV+"LK7A$_QL1C0X+3H=S:1)G.CPI;M.Q M]()QM,,PSQ%'1I-O%E0GT6#?CI$,RFQA4>-)=VSD#F?>*3=FQTG&0Q(\!Y#U M4;9.$`W4]/"2G$F4C38U5YP@QOV4EMM'-(O1]\C%Q"2MUY[17E4B!=X\*=N9 MJ[V;*886$@0*1I'^KUHG.PMCJL)J.I_1ECD0\?W];,+9!'I7./*G>:XY&"** MF`"O'G(UUVL)/;WR[>^&!N`\=5L.WU&9.Z`]>O^OSM8+%)",5+N+(^]=#:E1 M*Q9XC2'T$1U%5LU;T-KR"A^&_F(YL[C7?R%=H%R-A!\";9!C%1_B+=,Q.?/#RUGM=W8> M+0RCGFFG/-M68+B',K.[[42G:>K]%'&E$1H?I+V\BIO90TMWU?L"O(!AQ^0&)^JCGJ;U&](=)L3IY/ MUHX#7YJ;S+I`:>B,S\8/>_;<2LP9E:6DZ877ABUS)40(5NXY-JLQ?Q[:>=G' M=&>%@-OI%CO5&TF%#"/O%Q,QYXU][$RO;?QOM@*/_9-.UGW2L0#)+238AL!D MOEI"]AF?%H1ERKS0U$3AO27*C&-2CCS(9C:^PBQ)>S[6^-*V.G"E62?):>AG M3R:E3Y)>U&<<-NJBA(2+KYE9\O(Q@(K='9`5KF.6F'LM&Z`A'P[JQF,3WQ:.ONW6(+3;+YAKW,"EQ(P)&J`DL,$<<7\1WPI(;8?*Y597-R.Q8AQ&8V^;HH.@5`YMG MUOMEO?#%,.=\MXXS!C!)=NJS,AVN.?$D3OX%3F]\"$8CTM]>Y5MGG6(HFRK[ M/%I3=1^79M6:37!I?@L'=%W81WERLKXKVJ#>KLF@D*\]*R_(YH6*#+V.N92V M#=[MJ.[-.H8?S^9[!T/.V#60JE`$\_@1%A.5(:IQ0DN+@/ M,\]!%#HFG`XF?/9:&VIS+,A)EM?5@\-G;[9A"SV5#W6V)9^764@AA?G>'+ZU M`[VC=+?\6MI9*5R8J'?25N-=G ME0X)I2?!Z;;FDYFD^?B]?285Y:+6[(>LH)J9@8J9M6)I^T#V[=)KK2$&HR)_A&NL23"ZGZT@V.W.VA:^U:HDQZ+1 M]`,HR@..EK4);(1@CE/V;^:R^`$M!?-*+3+?($X<>][L/B8.@QKLKM&;FQ5 MR.;<"2DXJ!`S2A+_!_'@<%"]^PTAK2/A7D,3 MS$@)BY+!\)8\`=@!XFE-7@ZKW-+W02S#E\/)@/-"2PAEP3I(C'F$`UEE.!I; M(]B?FE5CDP@AG`=3<;JU'?#M84C&=D/&74/),C:SB=:'+5XDRD4C2,$C#"Q9 MF-G?PO!L"O7^8T!>KK.?YVOS?9FL3<=$M7QM!C$^'QN$[G0RCUML0&XDV$`F M)]$WVMJR`0I@6C8@+7;'IK^,FQY[-&Y8]%RKE2(>KERR-#`.FR@C/%MAQ<$[8M8@_3A[;NP!39`#^VA-B+2H2R8YJ/'T`' MDOTU$S6:;6/T."8YHP:BP?,Z21L7F6@U.DES4_^OQ%C[62#OOQ[6"ECTC"` M@41!_C;B/II<..8P8%[\(&E'`GJ!Y-PJJ?56=D^6*7Q3N".9Q]/J-8DT?9"7 M;[+1::^)M(W]':+HM`1W75?",_9:3F9G0!9*"OI212$B;GA3,,:"^-F%"#I\ M5F32O+3%Q)9*)D9^2>()WO0'#?CR#C40U1"TSXX\K+\L!.IM)R%:%B"?92): M3CL4/BSQ$T)\/=PL.[Z?3C:UI?MQ6-G$R()Y:[Q)2KK//7(02-NS(D'JW4K= M-B=Y8/D%@;TFGN]);^#G7)*J"03VM`6[F6&;9S9>ZX-BB5VM_>*6O="0E&3U MS&P>/ZIDB@&XH[=2%W1/8E_PO'&_7DJ@O?$,SNMSOOA5]VE-RH+)1@.6NGK# M-.[X^;)H-=@8LJB#,6F6W@0^WM(DM#[;LBG(LKV79CFB?0L,D8G;"O9-=L3, MM$E-RX[!._Q"M.J:7K>"DWV$VS]]Q/;&#]))!A*:MFENU/0^ MX@M8WQLM,]A]G&8B.C32P MTD=P,C9*C/5;2*E`M!8E3#F%79_/_E12)K\[W>:P;?R1G9-"^_C:"\U4OM-I MB[;)KB%"2R=>)!?0Y(F2$VVG>>2^]80G_HPY"&MSLP=YXD(3PW1<`5N6,ZE19+G($682B+A2T0V%1)H MD9=>71H1B*J'A%-H/)9J99*SCZ0()%(C8TQ59\454V$1'L:PL$R>*H)#L*0[ M*4^$VQR;KZYT#.EIML!Z5S1S>F<0."&81F%:'C+>8K9";7;N0XS(V#$I"LBI MJ?D>;!CA67_V(-C"N$4VX)-,\%ETSBH(D:G-35Z9':(R7$9`,CE/6WIZY*W` M6HI-H[ITZN0\Q!BCJTU,$(3.:ZC&>EE4@&JO"$1*'4^E;E)[NX),?[M-5.)CWDL:$E2-[&_CXNW<%!=V#EH[8C!*^KF MVE%0O2$@0TULCX84O?3(>WQ&ZLXW?T^$-32W;[VD*G::]1`V&PXF9-W-M.-[ M1V/JP-)]802[F1]E!#J],-/8SFB.D$6T$3UNCAU\6<\3[Z2=?:=Z-IZLY4;2 M^&UBJ`O;Y;\!*=;&[>TE;:J:'7>J!.#`B;/L@`3/&:8Z@?\8&Z(D=&+$^'R; MD`[WJ5D43[S2B3&6*\G=MFK[<;HXW*ALSA'5WBTJ4O))"'W.&.`1L^DC,4L^ M8^B2X(NF]O0X+S.`T!,/VQ>4V4Z/B6:[PV-K"#;ATS08$4Y;4"HO8X_T+DM' M1(]]X\OIX.?NZ3B$:2HM:1]9[_5P39V%T9A*R_8S(Q=+FV:<,P$J%!Y:>_0] M;7,8_&PV#.,C6DB/A*W;=GZQG07YAS4G`K(7T)I=6`(PEN3>&-0@L/C)K1"U M$(3P&+>)A;VAM%"G(AXO6N!2 M.&L[FC@LF7H:O`+CT"?2/OXN^*->>JH'?!3/]MY7?&[,#E4Y"LT73;_YX-;6 M\:O!'T@X^6?`-'?)-^7`@C6+^)NG0ZT@ZS8N[,)H";DISP<@!EQRAS*-UG/?#6LG_^ M>9R7H0WO!>N5#5*^XQ3NQQ6T+0!Y6U^<4JQ7I&00^36"B:SQ#;[+6E5[U)/# M3AVAP8"4G:]HCWW31`L>(WK9"F^),]`M"Y/EWI/B^/L^V)GY8.TPS1CH0:Y[.P\O"1"[S#*_ M&!=ZU1"[Z?N?&0=B`X()RQ#A43>L/A623*UFG3+'H62(TW@&-'"2PI?X0L0' M@5E$!E_U?!#SY"OB\G@\'+^;3%20I#R$>[^+.C9<\*D?J1!B\U>+JQ/8RISYOTXI@/56?-/`?M MG"8RD#>_EB),6)^]+VF-:P9[AA0I;4LWE))54Q<(*OEQK_IF/9/6O:GJ"72/ MS%[IWJ8Z1'?>B`&TD'><>'LRWOP4CFW1*+WT`4'(/T)$M?](C?'JF647*&>+ MR-XI\:)SHP@D_2N,L1B9C`L*.HC1H>)+9>E;"B8M::7!)3@^+8)*S*2XQ8XU M;W(,\N1.:H^S&T211;B6/@B4W7@,`0)+^#^T7BRI5JAI!(B368V8>X#`M)8= MF3M)=:+JN1T855I:O@Z6%9,VW'0*^Z,Y;D[81)R5W_)D@"FL-2S9:5Z-7LL9 MZMN6S78"YI!_QC&+;&W%8`!IX5#=PG2"#<7DU++5?'NO,]M7?J(>YOM[X5\E M%V2[%1G8(KQQ%.I6ZD'\=FVGNUS=_]VO>I6G&K%GZY''D7HR._^=H_*$[?$AB'HV(F+]5C09C+/I MEX2]16WTE2H[31V&Y0^?AY/<#X"Y.D+%$PJW'J9>OL)V/A>'7F^RV.SEMB)YP'&@MN%!"R(=W(" MDG\0[GBX9=$HS&TYB<_,BFAEXO&P;QLW_:KO(,Z3GM,0-DY1&IJVV0?F\U.S MS3Y.1[%W1^A/;`LJL@(#-%+:.+Q)(C<^$/F9S1.[R-(Z))>QWL2R4H1.LF]( M6_3ZVK<1,IJ;A5\@]75F"O_II;H>CK&]RW\N;U>1ZS#;PGXK\>4`FLJ#[ESH\=BIXC=, MRV=N^PYI>?_;]BZ2$]MZ\6/L.NX$*C_ZES'+49Z_>TM'Q;_\6Y?OI,3YDF9Y M?W(E.7]NXF5ZP#K&0TN+G7860P/"0IHNA#T:EF]\;7:/"F66+?.LC4Z",3>B=FE!/.O3+.>/.- M/]KV34^.>YB/>Q-)!-:^_0T, M02P1R1NXRG_)B?*E>!VS32M\)6`("+H(Z>O.RSK/3:G:^?="WN;=:5FX6S[B M"])%N;>L8WP@E[6;>!;O#PG:)0LW(T!;E.1L1-%?O-"[LCP*>9_KR(CR?22S M=ZK=;_N1S;/R[F><](MU+ MJFI(K=L*&%=R=BG*R$9VU178>XUVK>+@_,KOPX_+W_ M/"_;6IX:,0E+'!L%IO]Y7G8I4(48JK4AR:'KAUIZ./)!9N[6AW,-57T[?-@@ M&Y,E0%?TD5"^"=`-+`MR9%EBXK=1KWXR"/S4>H>V]WQ5IAP7?]():N]_X\=X ME,._N_G4V_+VW&#W.SYB$3F;ZM`^NU2%],H6'[5>8$R#?^IE.)C1'6%^DX+F MW/&5!-W?WMX]V-Y[7/[^Y822V]4GT7,BRL'UTF^_]*5Y+-$.^3HG)A8+RW%[ M&Z/1_S_2G5D4UA]H]>8_OQB<'D]I#0BGZ-HF!R&T4,1'^E;W,:0D(.DPM2B(B$A%`4)=S9#I$X('H.^7Q>N197 MES<\@>M,NVR7EW:]>GX=A_R\>\[%-68@>)"F(>V&6/3F)V(7.J6ESG5/M81P MT9,,]]B;EUE(A=TI^'?H>F2O>D=YA!@F_"IA9AMK[G;RG9TN<4^&=K78,802 MA!DW_KUET5?),^#\FR`&9+\):NWHN'K0=X-WOP"^'CJ5*_U:@NP.DDX4]03& M\W.R92X)D>YZLMFEDU>,;R_!]Y84D,@2*=LJL2<.XK MA>QS?7]!0XS5*9=&,",X>)":CGM(`F[E0%N$)6"DO5HN@,=4 M\]5"^+3:%YKM!:15:23_!`"HU&B,S?N$3UG1.3GI[@C;$$#JWAB(PN\'8D54 MHKT72XRVH`UB9_DT;#HC(C"W1&C@6>CDOM MRA1X?2AJ;@H*Q"1)#T=K;_1O8O(W_R=W=%H`S,BC)^LXUBLMDY-!(IMM#K7Q+(8VX0[ M%1'&2D2"?:^\;S@]BP/0^"7.'*(SD!-UQMGV4+35/60TQX1R@^?=H!YDVHWX MB4:"Q`>T8L?'+H9Q7/A(A'Z*2(CSR.YA:G:T]4&R#I7[8WS]SU^DBH5=%C'! M?*X+\=%[O?*%/:\]YR1D2_/=5[R99]RN>(,K5BA$LG3[9?PR:7$!-E9ZZ4R$ MYT:#)?8&K6+XGZ\GG%Z_?V\5*,V=0K&Y:K+U560D\$@2\1FFLVBI,BH=32TN[B4PV+\IUY%YC=K%:UTD5&: ML^&S=3V^_0,``/__`P!02P,$%``&``@````A`-:/^`,["P``'&$```T```!X M;"]S='EL97,N>&ULW%UM;^.X$?Y>H/]!T+;%'="L+5F.[5R@MLT\-M MBA;H%85LRXD:O;B2O)M&>IM:%L2%=,FV@MN8\GBS#/S#(=#4E*NOW\) M?.V+&R=>%$YUXWU?U]QP&:V\\'&J__G!OACK6I(ZX&;=10'3@J'\6,OV<2N MLTJP4>#WS'[_LA+Z7OC)9NA8LKSX^ MAE'L+'R`^F)8SK*0S0[VQ`?>,HZ2:)V^!W&]:+WVENX^RDEOT@-)-]?A-K"# M--&6T39,I[I9GM*R;SZNIOJEKF4FSZ,5@/C=O[91^MUOLE_O?O_N7?\?WW[W MMY_G MX7/U`.QP*<1SX6`?!5E=+$JI,DY] M[+J6JQ]CY]4P66THUB")?&^%*![GK!;/:Z'YY9T]OV-Z"3)1%#5";7L^.H'0 MN]ED+A_I?#*1+=2TX4>RT`]#_)$LU(;_YM)\FH^&EBR0I3PM]7#NW'\_FDPF M8^-R/!Y/K(%A6\TVL"_BRA-83/JYGKE.8]1Z/CPL5>T*'XWM(3M.MB9 MF^KID[=\!F7<>D&&-U-Q*@UE)K*PPK=&5G]D#LI#3)]B"4O[GW%`_NNZK`%@J>OF^F5-;O"`NV[P#@B\ M?P0_PGIR_C$;[[,#\'%=([.VD>9L-O[K_398N+'-;L5A*MA97+>NCF:L4*F. M/_C>8QBX;+%.S\3\&$>INTS9K4)LGZ8.SZ`&CY$+$L%SC'ZK1C_X2=@?Q^B' MQ:"#)()?E.J'X!+6+S,>\*:H/*B!`AK437AD(H`I?X$`2%"!`&_BRGT`X:D" M`4RE"@00H!4"@-,0%>5KD`#AI<8,.H*V?(,^IROC*'D*0+ M&"J/0!IH\HB\J"0Y%W16`)H],I-8AY"@P%2D&@+`40*!$&$H&G\-BD'1"$RC M0=$03"%P8_`9^P1E@ALA%6$`/$IZ154G&-R(<48W$`BJ,B2)!E-5BJ085.7( MB@I358HD$%1E2,J$JA1),:C*D80*52F20`"/*,F0E`E5*9)B4)4C*RH&JE(D M@:`J0Q(F!B=.D3VZ;)HMHI+UTV'_3>NGVLNZ=2'5J)LT`>]%\VSVE,T<@0LV MER)3:7QLSBG63K6G*/9^@4DF/CZWA,54-];Q<O]0*28GUC-QAYA+68*OVPN*YK791+]\\16(YW1*OE;%+?NC"_$QG\XG9K MA+2"P,4=U1C0USD&Z2$@J8M@SU7M)A@DE6.@5,&`*98K;/`<)I^6;-8:JU0Y M.B-?$;37`'#)ZH3*,>IC#+EPKI/DJ$[N[UA7Q$GQE+=>$2ZQVF95"Q=@MDD M*^SG#V:5R@V20P:[T]*F?FRSA>36E$*S/]XS0LNCO?)$P^="LDP%4=MK*I-H MZ)X"=Y?HH5BD1,__JM.DXB9U$75P"]F'JS-^"'I#Z+*;ESK6TB2YMH`^#$\P M<;])=DLA0(G,3&_KC[49%%XJLE-`\];.\OV@UDS2VB-K`J:Y1XK$2^TXON^F M;K,M$B'-*'F7=<#S=MI@.&Y*__)H`\O7>6%/:X!3A'5K"!$L=&"43H[,D="L MVZK'+5$I%-(P+Q8Y.KGR]''>J=_1,)-";1=GU-+5PI90IW\+.Z!7K.ZN1=#% M?.G=JHMRI=-&6L2!5C67"HZ>)V:ODITCK-3V\HU.#5#.I\HU3Y.8D1 M'_+8N\4:)W^U.=2`&O#_?\B3ZDK9.R*MB8'=-*IZ)9>N_(NO>$N;+!3C=+5> M5IPYY#ZV708;9.1Q`_YA@W([3<,W0<&;*_N_U2ZT#TL46DZ_<.1=;#T?'B3& M?3+;I:=S#>GFF25"A>:+(*+ MRJIX!,\1&P=@55?$("(DL"Y1TE57Q""Q061!N7665/%I8 MN%6^'PKZ_O(@CWRLXIZ[""XJJ^*1C]6!8*Q2616/?*RBR5UQ53R"5.(O"[[H M*JOBD<\3EF">H#96//*^'PKZ?C>C\A%O"D9$J7B#CX1'V&!+.*C3$K%&A_E M`\$HSZ14?/'Q;0G&=R:E8@KD$8LL^$+]=2]"[,V=59%T^8'"<$8$! M+ZM;;GUX]W2$;ZYF]Y3@&B8Q"-^$ M3AK%KQK>1U**XTD?"HK[0Q25/N(EF'`H`N@'>,\WO$)<`[]D'N)C&"NJ+F+* MOL"[!V\J[R(&6F=H^/C#64X7,=`Z$\,G5:R?1,1\##?;DB$^E^+0+2+BDQ<^ MNRL^YUD\!9O7G_?P'&GA M1*RT2=_!ZE\$^)^V*7$C>[JC&G=-P;STX*7P_'_1B7D<`$L$QT,$]W:5(G8R MBJ",OSAQB+V%Z[H[,5IC476G'%3_JY?J(6/F]Q3?A,\>/R[G`^#>E;MVMG[Z M4'XYU:O/?V1OUH!@RJ_ZT?L2I4S$5*\^?\)7ED`OANT#2#>?$G@-!OS6MK$W MU?]]-QM-;N]L\V+:9F6 M6%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6 MU8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/, M>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7 M$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29- MG!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6: M]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W! M&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&+ M+Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<% M#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y* M#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8 M**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS M=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*& M'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D2 M7UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/ MEN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC M`S5GY*8TO;>$#6C M\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@ MSK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z M&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5'; M:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@ M58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`- M005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)") MJ(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK M<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M- M^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@ M^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^ M/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\ M-I@Q)4TPP:4K@Q`(``&`'```9````>&PO=V]R:W-H965TTT[;_?,0Z$D"WK=L/G MZY?GO,TEW@C7&F2A6$P/\NN*M[MT$?8N=(.IIUUY1 M*5JPV/*:F]?.%"-!EX]E(Q79UE#W2Q@3VGMW-V?V@E,EM2R,!W:^`SVO^=J_ M]L%ION5DGL$ M4P_(=4OL1`Z7X-SGXZH9$OM38)"4-;FU+AF>8P19:&CR\SI.DY7_#)VA!\V= MT\!QT,P6UZ>:3:^Q+07`@1*2&U/^OGL]C!5;&-M-2W?G'HR_'*?IY,OGFFA0 MG*!`2&,4&]@,IN5E)#L(=*/:XW0^^#M*IXE'FDF"FTN*$T8P&3->9K/B#$/] M0U_B=#%AEIP=-*6;S)H[IQG3Q?,C0Y?NYEQS M3/>$,OT?2CMH0CD/AQ1M?````__\#`%!+`P04``8`"````"$`&_I4 M1E`"``"@!0``&0```'AL+W=OFXISBX"A,1FNK&T30@RKN*0F4"UO8*=46E(+2[TBIM6<%EV1K$G4ZPV) MI*+!GB'1SW"HLA2,SQ7;2-Y83Z)Y32WH-Y5HS8E-LF?H)-7K3?O"E&R!8BEJ M80\=*4:2)>^K1FFZK,'W/HPI.W%WBSMZ*9A61I4V`#KBA=Y[GI`)`:8\+00X M<+$CS@:\$VC@I=T4]OO:O>9BU5EH=L#,.1\)<5AS@V#0($FB`:.B:D:!,`O MDL+=#`B$[KO_G2ALE>'^,!B,>OT0X&C)C5T(1XD1VQBKY&\/"H]4GB0ZDO1! M_7%_$,318#1^@H5X19W!.;4T3[7:(;@T<*9IJ;N"80+,SED?\OFW,[#D:MY< M45<*:`/=V.;QL)^2+43(CICI/28:7T-F]Y#PC""@[RP2K/^_2%=T(_)&P/0> M$IT%=$YGCQ!7$B&[2XF/\W-@R!FCB_SBZY.G'A-?8`;7B-DCQ)4V('E>FP-G M&'S_U783RM1#QEWCH\G-+LRA(SCNQN/)6;77Y(?,W\&6KOA7JE>B,:CF)9S8 M"T8P$=J/F%]8U79M7"H+H]$]5O`EY'`1>P&`2Z7L:>&&^/QMS?\```#__P,` M4$L#!!0`!@`(````(0#U@H4<20D````^```9````>&PO=V]R:W-H965T]^L3^_7XTLO>CLGZ*=]HO^NI_?ZH MMU]O#UV187)LDR-]?MYN$CW=O.^3PTDD.2:[]8FU/WO=OF5EMOVF3;K]^OCC M_>VO3;I_8RF^;W?;T^\\:;>SWTR/^I6CK39D[_Z62?K_='-,L M?3[=L'0]T=#J,=_U[GHLT^/]TY8=`>_VSC%Y?NA^4R:QVN_V'N_S#OIGFWQD M5S]WLM?TPSING[SM(6&]SY6MS?P,A,?.4_*\?M^= MHO3#3K8OKR=VNH?LB/B!39Y^ZTFV83W*TMRH0YYID^Y8`]C?G?V6EP;KD?6O M_-^/[=/I]:$[&-T,;_L#A?'.]R0[F5N>LMO9O&>G=/^O0$J12B11BR0::WWQ M_^J-.AXJP]$GLK#]Y4VY.V=1U1M-'=Z./],6A76A."+>EU\^).7<,>S@RC3J MS7@XU$;CV_9=HPS*YK`?RCR?[V&%=:TX*K;K(HTZ^GP?*Z,RS^TYSQ=.N,*F M#]$<]D-Y5%_I'7:N\SQLB)SSM.Z=GJCE?&CHZ]/Z\?Z8?G38?,/.7?:VYK.7 M,N&9RT$A2O@\3/XT2MCPX%F^\30/7=91;`!D;&C_?-0&@_O>3S8<-X695HTB MBUDI^-CC:741$".(!XPR<-G/8'PG9S'++!>CCF5BE:396G*O!$-K&@@ MO@KT6$F=ZXI-!5)=U4^R9?EPSU9#&^%6A::14@SI# M!OVB:BI=$PJCW8EYHS]027.7U22:-I(/.ZHS9-BOZ@PYJ+C&7'6Q5./L8^H3 M-QRW*P*6!E<^X ML&HJPV198S0RE*(Z0X;2JLZ081+7F*MA*Y43NT7\0CGQK:1R$H&K*JN6Z/5#OL9EFJG>;/4*ZEFA&!JYJA`9T&#!HP:<"B`9L&'!IP:6!.`QX- M^#00T,""!L(R<#G/E7EDV<)$+^>-C^H1%8W-,\_GF6[%KJZL; M8&U()K.I,.S3[WR33"XC9U#H4!A0F%!84-A0.%"X4,RA\*#PH0B@6$`10K&$ M(H)B!47<)*0R9X\GI3)O+F^N'[KL7OM%#X4`10+*`(A1CG3WS8,AC_(]_T+"4QK(+H&MSF&4B*U;50:U+$ M`M17F%37FM$"CO"_&X_ZHTABX?&5?C3ZY\_H"?7K[@1SY\3;`RP9,'CM,"-13M#!,=$P,3$Q,+$QL3!Q.W M(.+L*(J8V\CD-L=Y/$Q\:5=B%I6'4("3+#`),5EB$F&RPB1N)'+Q\\6`Z^)O MOJA1Q-J!?%5#'K!-"]18]")/`]%Q%@,3$Q,+$QL3!Q.W($71%]<$E:*'/>/A M7?F8!)@L,`DQ66(28;+")&XDKGF]%+?;):.>5?36*HL?HAT7$6`Q,3$PL3&Q,'$Q>3.28>)CXF M04G$O2G_*J`\?A8EN'IV04B(R1*3"),5)G$CD2N?+WQLD\A7.V1- M9LJ_7\DJOOA4'[#O.-;VMN*FV) MCTF`R:(@YQ-9TS$A3K/$),)DA4G<2.2RYVLVUV7?\MF.6.J1RY^LJT[Y=TC1 MA`^)CK,8!1&GYZ[VCM'$:2Q,;$P<3%Q,YIAXF/B8!)@L,`DQ66(28;+")&XD M%J7RR*2=4_(H\JIOQ[_VCJ MAT3'68R"B.H?_Z'XX9XLO"<;$P<3%Y,Y)AXF/B8!)@M,0DR6F$28K#")&XE< M_'SUZ[KXP>6^6"R3BYXNV2H"B5H<#36^$"+?/LT*TO"IH$M9U#N5/P&7LQ@X MBREE&=4]"K%P%AMG<22BBHLON;DNWM$<$P\3'Y,`DP4F(29+3"),5IC$C42J M>?Z&DU3S_%I_!+_`G&]&'NZ,Z#IN@1H*>X:)CHF!B5D0\0Q#$RM()C$F"RP"3$9(E)A,D*$_["[)\O,T3MBQ=BQ5M_^^3X MDLR2W2[K;-)W_K(KGZO/T?.+N-_R=[%(?*I,V"MZ[,N8)&XJ$_9&737N*A/V M!EPU[BL3]@I;-1ZR%X#S>.^\`_;^[=OZ)?'7QY?M(>OLDF?6Y/X-?ZOT*-[@ M%;^9O_^,K>M$[8.X/]&X:?T_14_L)VW#N_N_WX?P```/__ M`P!02P,$%``&``@````A`)A#894E`P``RP@``!D```!X;"]W;W)K&ULC%;;CILP$'VOU']`?E_`W$*BD-4F9-M*K515O3P[8(*U M@)'M;';_OF,<$B![RP/!GC.'.3.#A^7M4UU9CU1(QIL$8=M%%FTRGK-FGZ`_ MO^]O8F1)19J<5+RA"7JF$MVN/G]:'KEXD"6ER@*&1B:H5*I=.([,2EH3:?.6 M-F`IN*B)@J78.[(5E.2=4UTYGNM&3DU8@PS#0GR$@Q<%RVC*LT--&V5(!*V( M@OAER5K9L]791^AJ(AX.[4W&ZQ8H=JQBZKDC15:=+;[M&R[(K@+=3S@@6<_= M+:[H:Y8)+GFA;*!S3*#7FN?.W`&FU3)GH$"GW1*T2-`=7FPCY*R677[^,GJ4 M@WM+EOSX1;#\.VLH)!O*I`NPX_Q!0[_E>@NZ%FRG@%`<#5JIGN#$@(>>K^CRQ798+\R`YG MKH\!;NVH5/=,4R(K.TC%ZW\&A$]4AL0[D8#'B01[MA>'.(S>9W%,1)W`E"BR M6@I^M*!IX)FR);H%\0*8M3(?\F/B.&M]32IHU"1WFB5!,V2!NX3R/*X"WULZ MCY#3[(197V.\>`S9]!"=0KE2??@:K,/O MG[LV&\!]UC-1LWD!,1^'EKX`&2.V+R`N)",Y_EB.+E/P:@/VLK03E'.@(G#= M<0AK@PD&F'",V+R+2-]%;-]"C'1"(,.R]>WX=OFT4X(@F9=JA9/66AO,O.M- M;V;'4Y5#>^#;@3_.0CJT^W,;^^[@-P%OAV`<#\E&8J&`0[%OB]3@J.*>#NW>+`RB:(+8#A%A[.)Y=)$^DA:-I7VLCMII M(C&:]JO!&(E^,%4XML[PQ)X.[6&`0W?2)C!$=`B&'GN>[WI3@69(F#.TIF)/ M-[2JI)7Q@QX`/N3^O'N>37>>/EHF^VN\@`/O>C^%6=;M.V<'F"4MV=,?1.Q9 M(ZV*%O`HUYY!.8291F:A>-N=Z#NN8(ITMR5\-%`X2ET;P`7GJE_H`_/\&;+Z M#P``__\#`%!+`P04``8`"````"$`O:[*R9$#``!+#```&````'AL+W=OW9)`&U9F+)YZN,A-QN1\GN9 M[@M>&FNB>,X,\.N=J/3)K4C[V!5,/>ZK=ZDL*K!8BUR8E]J4!$4Z_[0MI6+K M',;]3,6IX!C-'`IR1M92/^.HG MN#6$(+H68!#]YQ3F+L(H81.F?7X*^5!/VU<59'S#]KGY)@\?N=CN#$2:0!HP M&_/LY9[K%*8!8@VB";JF,@<+^`T*@>L)TLB>+9W(S"XFH^E@U-`L<=VKBQ;`U;BL'EEDG0E M5]AFKV%#L<=VMK5L5N*P>862="5G$Z<,*'S+^B>N5GMT7@6NCAH'SZN6Y(+F M&A]NOKTGEMJMNKV%4*\.5T=-FR_R2B:YH+G&AYMT?SZ[I;?Y(K\J\,L(*\#A M\TOV@N8:'V[5_?GLQN[P^95!NYM_Y)?&!\MCD-0^@*ZO8EG]A:BM*'>1\`Z\.!S?P25"VK[,71E9U>[.6!OJQ M^G0'33N'=F$X`/%&2G.ZP&:D^1NP_`L``/__`P!02P,$%``&``@````A`"6$ M:;`'!```0!$``!D```!X;"]W;W)K&ULE)C;CILZ M%(;OM]1W0-PWG$).2E)-0CA(K51M[;;7!)P$#>`(D\G,V^]EG%!L$/;,128L M/O^V?Q]7UM_>BUQ[0Q7)<+G1K8FI:ZA,<)J5YXW^ZS__ZT+72!V7:9SC$FWT M#T3T;]LO_ZSON'HE%X1J#11*LM$O=7U=&09)+JB(R01?40EO3K@JXAH>J[-! MKA6*TZ90D1NV:TGE^Q*GFI% MHB)7Q-7K[?HUP<45)(Y9GM4?C:BN%XBH\Y]/O=FL;)4[MYZ,D765)A M@D_U!.0,UM!^GY?&T@"E[3K-H`?4=JU"IXW^8JTBR]2-[;HQZ'>&[J3S72,7 M?`^J+/V>E0C\_A??0Y2=+S4, MMPL]HAU;I1\>(@DX"C(3VZ5*"1&:ES\89#UD&(B]D/$@=8_WML3>^%:[NP3*M.'RJQ5L9>3 MJ>W.%Y]IR_RALFQ5'%-9Q6#N-&9[<1UOUQ6^:S"#H?_D&M/U8*U`>=A=L)6R M+Q3>Z-`0,([`E'C;.I:[-MY@&),'LV,,?+:,S1/[/C%=\HC71QQKSC.'/B-4 MY/<)L:*@C_0J"A68:)PQP.S6<9A3ZHY3F#I.YS<=@AT+0'6MO8XUXYW9*S#> M$+/@=0X*C*_`!`I,J,!$XPQG,BQ8=9,IS)G,`FPKH*[OQ8#W#(P,PT&!\168 M8(@1%DRHP$3C#&BX("[_<("Q+=ZI:(#IZ'`N MP*FE[@*%X:3M;D^VP]>]8PR,0[N%"6?(7DIX4N(@)7PI$4B)4$I$8P3G,QRK M79_I?<>!6]/XB4P+;738&%LO'7LJ^,V8,;^EA,>(17/F6];"I']\-0>IB"\E M`BD12HEHC.`,IYE"Y^JC9C@M)!HN3-\=8\8,EQ(>(V;,\+DS'W)'&LV/,F.-2PI,2!RGA2XF`$6Q<9VXSJL)""KN( M90TRT;,B>@?_6YXS&Y(SSNWQC:2A19N%*_?N`;%MP'6G4]HX?AO8"\ST1WE.M`3? M:))JP4)NHVT"_=(DKD;[`O+7:WQ&/^+JG)5$R]$)BIJ3.9S6%&UL MK)W;*/[>O^;%\> M=E\?7[Y_O/R??Z7_N+V\V!_N7[[>/^U>MA\O_]KN+__YZ;__Z\.OW>MO^Q_; M[>&"%%[V'R]_'`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`YR`T$#Q=P3$ MR-!S1W]UGII;-P1WC5%(XTMK-')-9JU)&R8@"9`42`8D!U(`*8',@51`%D"6 M0%9`:B!K()LN<:)&8S5$;3BZ:N>RLP<[(W2,&[?W74-"FK?:(`V'$Q6FUHB+ MQ4`2("F0#$@.I`!2`ID#J8`L@"R!K(#40-9`-EWBA(GB`6$*:.%!O'_!Q7.0 M*>B&I2'1<75WG%!F0&(@"9`42`8D!U(`*8',@51`%D"60%9`:B!K()LN<6)` MHXT3`W_#&VNWX2UI5K!F)I\!B8$D0%(@&9`<2`&D!#('4@%9`%D"60&I@:R! M;+K$:7A:03D-WRS'CIW_\./QX;>['0TPM$[H"4A(RZYF,69$W'A8,F[G_EE+ M9,0*0C5BQ8U12-.@#&OAP!W6DM:(A[442`8D!U(`*1L2B-?SEHA#X'75"HG1 M,%1+S45KQ%XO@:R`U$#60#8-:;QV8DNKZ_\\MD;$C:TETDJSED@#0"O%C5$T M.B[6AX,@4F%MKW,#I:TLDZPEGHKR5LCL"JBBT*VH:*^S;-G*,IFWQ%-1U0K9 MBM0=+=KK++ML99FL6N*IJ&Z%^N]HW5YGV4TK2\3I$[1B&9M:(?4]=6D M1YZ\STB[4SCN!$&HEL[E.>[,^VK2[E1]1MJ=A>/.[6"@ENG+<]Q9]=6DW:G[ MC+0[:\>=<#!1[FS><,?IIB:]XO33_]>\=%1Q^Z]%0YK2VBX3J@=WQN6Z1MB# MQ8H?NX35;YH.&T6J#5(NX^^Q;.6M/Q^ M0JT%HJ5HL?Q*D$>^1JTUHHUHD;P;5Y-FT3G((65@:7MR_J+7)'YUN!L4=7O7 M,-0Y+ELP],^/UFKH6.GG.6&K9H8<1>'87>RD;-!U";I;=I9+.6MY72K8RD[: M-WK2+MG`Z]+\+)V28QCE_[7[B<-3;W[N,YZSZ0&=9^VJ#N$M$SBK!N>SC[D MC4C9E%LW4@WJIH,CC6Z'<(D>M[1(9J\D#.E->478L7R2T8BOT)4 M,W+D=3IJ+58LOV&$<35;T7?$]6CNID,LZL854TML@)8F/503%;=8-HK02E;"7-D"'*&;G-H%*+A5AQ,Y2,1'Z. MJ&+DRJNLS4*L6'[)2.17B&I&-?H0XQ\6*1J:)S@VKU,6,K)]FD![A8K+@9$D8V33>B M%Z4WZI%*V<:["LO82G[UD@L2WP.=O"RL510T;TN"JT`E'DK6\3HP9RMO&U1B MQ6VP0+1$M!+4N1G=Q+58L?P:T<9!SJII:#(Q[QB8C;D:F!L4T9:RTV'4@F5V MK.>XRQ$K6(C&8L5WDU@T;-YM!5$TB4:J-Z9LY7W_BNQXOM?(%HB6@F25H*^6(L5RZ\1;1SD M=A:34>J.(YV,U?DOM^@M(_0AFZIRAI>16NO.N&"W*\!-QF+%-YE81(^[M,YP MI)[ZE`LZ@<0^9+WO#C"`"JG1]*$PHD[DYKW+WMJPV[32XCG<N)+=A!J6BQ M588H1U0@*A'-!7EY033YL/_\V6^R:LZ> MKT'N6E2OYV9#FX[SCI^QM:)9AF\R8=1,]>'M[2@RC;.DZ^?Q4Q<8/&< M"SI>:=\+:V77HN:X')UYE#]J7U&RJ->;N7CCB7K%6M(@"]>;6SH;-NG^48/N MDA6\WJS.\J9F+6]SK=G*+LZBF\E@$*C!>L-&I]QR^Z[)YOGZ[GEOL.EU,PQ, M%G4'IA9Y`A-;K>X;;$0IURCR&:(<48&H1#07Y'&U$BON]PM$2T0K01[Y6JQ8 M?HUHXR`GN.:W+A#<=__BYJCB+FPM,MF3=H89CE3Z>L8%NTL7F*%CMI(9.F'Y M9L\3CH>#&]W+4RYVJI9MK;:UHCC2+NG$8 M1L%0_P)\PU*GW'+[+E4(?;>;?SMO8`J-C.J\%LG(,6,K_XK)6M'SQH]C@B@5 M+;;*$.6("D0EHKD@>?3@H:K$BIU8(%HB6@GRR-=BQ?)K1!L'N<$UR4#?K'-6 MZ0,_@\^X?\='K&CO\B+=AH-)O=];*^R,^L>$[BA$EB%)$&:(<48&H M1#1'5"%:(%HB6B&J$:T1;1SD!M)D-KNSB/]E3]@D0KL;;(O<'_'I]/I,K"0\ MC1859)2@58HH0Y0C*A"5B.:(*D0+1$M$*T0UHC6BC8/<\)@$73<\G4'TC4B9 MDFK1UJ#.+_9FYI$BJPZ*$26(4D09HAQ1@:A$-$=4(5H@6B):(:H1K1%M'.2& MQ>3]NF%Y(Q9-FM!Y:BR2#D@]Y[_E@Q=B!DZ1K*_ MG`F2::%G<6F3=K16:Y>@0SAS;;5H[<+#3(HH0Y0C*A"5%M$//DG>;;"WTD+G M+=`Q*V2&6O-H=QNL1=(4/0W66)T^R&R5R4#:JE5FE$G]GLIRT3J>@,7#S&+` MRJ4HZ\:D$Y[VM2UCFUM&YV/&SE]2GOM=(^%:Y/47BE?X%2LLXIGYS>;MZ@OF-( M/)JKL#0Y!9404^]#9UR0C-N''GMZKY5N@L1:V8Q+%.KS7BG+G&H!&Q6;#/&Z ME+.68Z5=*ER7Z`MGMZH!2M8YY9,;%;.//7^BBIIM;W>BLLA]6,9JA3YC*V_' MC'NM=!,DUHKNLWFYJ5X9I*QRJ@%L4.P.WNM1SEJ.E?:H8"O[DB>Z"91/)5N< M\LD-BMG(O2,H=M_7^2%C!%O!&:/CMQV/31`C2A"EB#)$.:("4>D@]YZI99Q[ M[BQDSW^W;WX%HA:UC#J3H2#O$-%HF9Q&.Y#`MT\2J]5=/2#*$.6("D2E13VK M!YJ#_XX&P_W:4=A=/0B2IN@94QLM,K83NGI7D5@9^HLG]%24&66"/)7EHG5B M]2`&K%R*,JP>^K919ZT>P>K!6SL""JX<^*SW\)+9&'A`G M5T$HKW<'`Y4\3-G!4V.1'1_[JM8.YJSEW(9VL'`=#&Y[EA*VME,^N6/%^W97 M$>ZN+'IK*=%NN#P],69Y[[R=<(WV\QDW]&72L9JY4U8ZU0@V,.=XE;.6UZO" M]8J^:1%,]&'MDI5.>>6&1F\"WUA\XVZ//CZ,CP^N)ZR5T^]T[XQ9R['2O3-A MJV;V'D7TRD$]K2F;G&H#&YESG,I9R^M4P5;V+8 MFP_5/F]?OV]GVZ>G_<7#[G?SF>61Z9`M;KX!38>BI^9<+XV2<&5$5X[C-UP9 MTY7C)*NN?`ZCZ6=RM4>-KIC48]\5JH>R7GU7J!Y*O."5.!I-S12#5VBRF!:] M5^AKUY^/^W[E\QU]!?N8>=%\.-WTV7\.IY^;1;$N$)*W/2[=T9WWWCC==]\M M?*:0?*9T.]X=-GK&QWAFYJS":A&Q_:FYE!>WY4)7>GSC4X33GS@`Y^3LU9%2Q#YS^GYL@*7J%CH%-SR+/O"O6#7J_IW-G4 MG"KK*4->%[U>T^D8NM+GP1UY<-=[A<[)3LVA':PGIBOFY&O?%>K7O5[3R;NI M.6K74X:\3GJ]IO-!=*77@YLI?6(1M:J;Z;J/Q^1PG[\Y-7\?KZ@S]?&:'HTC MOVZ'&?HV_L_[[]O%_>OWQY?]Q=/V&PWJ@^-'+E^;K^LW_SC8CZ1\V1WHJ_BT MO*?/D]/_"\*6C@P/S&=[O^UV!_X'W=AU^_^K\.G?`@```/__`P!02P,$%``& M``@````A`/@T<*2+`@``FP8``!D```!X;"]W;W)K&ULE%5;;YLP%'Z?M/]@^;T82,D%A53IJFR5-FF:=GEVC`&K&"/;N?W['6-" MDR93LQ>,#]_YOG.SF3_L98VV7!NAF@Q'08@1;YC*15-F^-?/U=T4(V-ID]-: M-3S#!V[PP^+CA_E.Z1=3<6X1,#0FPY6U;4J(8167U`2JY0U\*926U,)6E\2T MFM.\*D63I<]DH3=;"WHIF%9&%38`.N(# MO-:')VX8 M%!1H@CAQ3$S5$``\D11N,J`@=-^M.Y';*L/Q#*,U-W8E'!5&;&.LDG_\QZBG M\,YQ[PQK[SP:!\DD'$6@]0X)\8%T>3U12Q=SK78(9@4D34O=Y$4I$%]/!#)P MV*4#9WB"$<1JH/C;1329SLD6*L9ZS*/'P/,5,R`(B`[*H':[L@,[95=2%\JC M-YS*Q-=E1O\CX\!0"5A>H[_(T(/N3S#)=6F`W)ZA`W?20XJ]!8;T))C9=2D8 M@%,I-Y=QD@23?\[FL:7.\5RVMYR6-IJ&UV7'E[)1E`3OJCJ_<]7>% M`7R;[/C^?5'G=B[:6\Y%W\Z1OPS\H9%I2-`;5O`#*L&N;]K>+WUC50N1PR)6%VZ%[K>`G MP.$DA"[Q0BE[W(`P&7XKB[\```#__P,`4$L#!!0`!@`(````(0!I?IOWP@4` M`-`6```9````>&PO=V]R:W-H965T-P0(N:`DJTFXJY6J:ML^,\1)T(0X`N;V[7N,;<`V83/2O@R37X[_]KGX MX'C]_:.X:&^HK')\W>CF9*IKZ)KA0WX];?1_?@3?EKI6U>GUD%[P%6WT3U3I MW[>__[9^Q^5+=4:HUD#A6FWT=*KCE(QKX>,PSY.'LM4#7FHJ4Z)+6L/[JG-\JKE9D MC\@5:?GR>ON6X>(&$L_Y):\_&U%=*S(W/EUQF3Y?P.\/5;B M"A_K"<@9=*&JSRMC98#2=GW(P0,2=JU$QXW^9+J).=.-[;H)T+\Y>J]Z_VO5 M&;^'97[X([\BB#;DB63@&>,78AH?"(+!AC(Z:#+P5ZD=T#%]O=1_X_<(Y:=S M#>EVP"/BF'OX]%"5041!9F(Y1"G#%U@`_-6*G)0&1"3]:)[O^:$^;W3+FBP= M9S9?+D#F&55UD!--7JQH7_U$KDVE1%8NIP).IV/.)LYC:)DSZJ(C-1.#) M1,ROKV3&1.#)1&83H_HS9 M[`9L1(L]MR"E3F0]&?@R"&00RB"202R#I`<,"$L;&]@1OR(V1(;$AGNUXZ`+ MEB4%@EOP(9X,?!D$,@AE$,D@ED'2`T(@8%?_BD`0&:@S>(Q4"36R87.V1HX4 MG=:D#8]"?(4$"@D5$BDD5DC2)T*4H&T)41INXWS'$.LF&-R)'26VN(EFDN^M M$1_F*<172*"04"&10F*%)'TB^`Z]ZPN^$VO1=TILZ(IMULVEG/?6J/5=(;Y" M`H6$"HD4$BLDZ1/!=RA5P7?:0B>DGX^7`!DHAH&267-L:#K@7B&>0GR%!`H) M%1(I)%9(TB>"SU"D@L_CCA)KT5%&Z$F$M/J]0CR%^`H)%!(J)%)(K)"D3P1' MR5E;?3\VR:W/>?:RPU"P\`(9"(`-[T'Z=B0BHO^,S-N7PKXEO1U@K\3=[U$C M&_ITMTWFTGO6;XWX-@E:;4["EO2$Y-FB5JAGM)`:4MP:<>VDU08BQ!)VMQ#+ M@9C!48\'C5B+0:/$$KQ?SL40[9D1'&6Z$,F>>4-&CAQ'9D32^+:U9U/)\X!] M#SWQ_DSAT$SR9\6KR6?(IFDP;>FH%/`AXVG@5J/31YT5GSX6I[<< MR:^$#[DWO1AVF%X)N^E\L9N81$7*`472UEC*.6!6XWN#R5O=2\CGB.5`.=H' MW.!>%)HV&'*KT?FCSJI+`EWXS*1;<6&*CB5\R+WIQ2204VZ_I8^W(9,>BN'4 MRI>SXZ@[TN\[U-L$:GE3+:MK^SX;V$-!I\5G##LT(A^I6K&*DDX+Y,7(D*-M M/S*]D\SC+SMROI?+DR*A1.KH^H(63J4!&=E=PK?:9E+9J"F2U, MZ44:\,GN50PK6#;9Z)(BKC6ZI%A)N42_F:F:HE;5J-XK/Y'LHX#-V\F&'1N0C52M6$;FN:QQJ MY&G$Z/4;O?0H4'E">W2Y5%J&7\G5&O3O[;K%]-[/6[IPB(+=(?%HZ<)Q1^5P M3_AD#?`=N3\ MN-%Z!O>)M_2$_DS+4WZMM`LZ0E#@1@I.`B6]D:0?:E9/S[B&B\2FM,YP&ULK)K;;N)($(;O5]IW M0+X?P#9'*S`*^*Q=:;6:W;UVC`E6`"/;26;>?JO@`*YVIE'.KZXHQ&57K(3DDU+"[9&9[LB_*4U/"U M?!Q5ES)+=DVATW%DC<>ST2G)SP93<,KW:!3[?9YF;I$^G[)SS43*[)C4T/[J MD%\JH79*WR-W2LJGY\NWM#A=0.(A/^;UKT;4&)Q2)WH\%V7R<(1^_S0G22JT MFR]$_I2G95$5^WH(,#3:(8+"(U+:;T;@KW*PR_;) M\['^NW@-L_SQ4,-P3Z%'V#%G]\O-JA0Z.J&2\)$Y^7?*.J)2\` MGQ^LRH119*;B<'+#>OLU8J/1#*Z;U,GZKBQ>![!BP._JDN#Z,QV4$\/*K)$# M?6V<88!1Y1YE5L;<&,`05C`Y7];F8GDW>H$)E?*834^,&K$5$3A[4-;5@:<# M7P>!#D(=1#J(.V`$MDAO8)9]A3A M#B(=Q!V@&`&KYRN,0!F89_!Q8Y:P(!M6D0R::N[($&D/(1XA/B$!(2$A$2%Q MER@NP<)37.K?&<6*P>C&#-&)#2.VLHB68ZWO,D@4;2U'R10=(70CQ"?$("0D)" M(D+B+E%\@6E,?+&F0XC_X`:+0JHMC&BVZ!N)#)*V$.(1XA,2$!(2$A$2=XEB M"\QQ8LL4MN$/FH(RJBF,:*;8VER10=(40CQ"?$("0D)"(D+B+E%,P4Q9_RG^ MW!I")=471C1?)IHO,DCZ0HA'B$](0$A(2$1(W"6*+[#PB2^?6D,HI-K"B&:+ M_G,C@Z0MA'B$^(0$A(2$1(3$7:+8@MG:U_C2**G&<*0Y,],F3!LEK:'(H\BG M**`HI"BB*%:0ZA`F=E^SHDR6(T+N(GJZX4BS:*Y;Q`I"E"CHM@4%\BCR*0HH M"BF**(H5I%J$*9]NT:<6E\F21\4AAC2'%KI#,DK8X7*MCFD>13Y%`44A11%% ML8)4AS#?ZSIT.ZW#[%;;9#B:M'-G2Y%+D4>13U%`44A11%&L(+7/F.=U^XSI MW.=F!TF>> M^DWD8MB:$G4.-[:V&%P1!9-"'H'@^E/=2+TV2BP97Z"VQJ!%K9:IUQB**+5& M[=`5M5&BQEB@ID;5/TSPNOZQJZ9FR=2'/'W:%-`Y^+GLF4LV7"GQBR:6)BJV M\LRQ[>36),@5"'YMI(?F3#L:>&V4Z)$O4"L?4!0*=%,^:J.$?"Q0CV&8^G4- MZS$&#MC2&98I*LXP9'4;98WU,Z+)HR"?;)W19X3;&S4E_C&MB=G<`4YT%5^H MP&_`];H"$76S16%OE-ZBB$==:U$L5*ZU2)G#5E_.S;?]]\_A1D7-MSFR8/I+ M7ZRQYNY6%.Q&D;7KME%BDGDRQ*7*M='0&H_0.+`@W5TC&!V@O9;8M:]WM\95K63&[?'B_807ZK)?H?M.B& M?$BU(HKB5@OD56YJ:]9 MCT?Q-3LUM=\=7ZATQU:/(%S6V\D&+;LB'5"NB"%]?-AUJ MY)EC['4D>V-URLK';)L=C]4@+9[Q52.LN_6=Q.P]Z,:T'#S.P?(@3VQXTIQ$ MR),)/&E^@,#=3ZGL`;Y?M^'Z%`3QT;,+XO_MX& MG5[;83QZ.8Q&[V#`6/0.!71AT]L%R*\=3`:I(9!3.Y@Q]SU9P).^,I!..Y@. MTC*053N8%<*3D1PM>/M]21ZS/Y/R,3]7@V.VARD[;O+=DKT_9U]JOMH?BAK> M>S<+_P!_YY#!F6B,;PKV15&++UB!_,N)]?\```#__P,`4$L#!!0`!@`(```` M(0#`1HX48`@``.(E```9````>&PO=V]R:W-H965TW=7WTAL-JO\EU>_VB,]GO[ MM1>_'(HR?=J!W]^=2;I&V\T?S/P^7Y=%53S7`S`WE!/E/L^'\R%8>KC;Y."! M"'NOS)[O^X^.E[BS_O#AK@G0/WGV7AG_[U7;XCTL\\WO^2&#:,,ZB15X*HI7 M(1IO!`+E(=,.FA7XL^QMLN?T;5?_5;Q'6?ZRK6&YI^"1<,S;_%AEU1HB"F8& M[E186A<[F`#\V]OG(C4@(NGWYO<]W]1;^-]\X-Y.G>D,Y'M/654'N;#9[ZW? MJKK8_ZNDE"UIQ556X%=9&<\&TYO1V!%&SBB.E>)$*]X.G,FH&?N,&AAM9@V_ M:CSWYJ+Q9DH1?I7B[45Z-TH/?J]S$/99,U/XU0->X.!W!'4WOAM\@I]=*9L%E'"JQ1`F1P,+LR@:^#0(;A#:(;!#; M(#'`$,*B8P-Y_C-B(\R(V*!7"P1&L*Q`H`2JK&S@VR"P06B#R`:Q#1(#D$#` M_OT9@1!F(,_@YTR62*$Q;%TM9"724HOH\##B,Q(P$C(2,1(SDIB$1`FJ&XE2 M=W'&'2.DFV"@$PM)QG03S:S,T$*HMF+$9R1@)&0D8B1F)#$)\1U*]!6^"VGJ MNR1CJ)]ZU=W1C>6[%M*^,^(S$C`2,A(Q$C.2F(3X#JE*?!5<][[N0IKY+0M?=&5F^:R'M.R,^ M(P$C(2,1(S$CB4F([Y"LQ'?940QN8#^<#X-0I&&09-+TQDU#L&1DQ8C/2,!( MR$C$2,Q(8A+BL^B1S%'`41HLT5I=$2S9B9%@242"Q=#*48A.W:65PV^E<.H!(C,R MS'R$4M2\U:/$K12:3Q!U1$;T4U=$1K9?)#*J(VNGOA0])M02(U@K1'3J8SLR M2E$^1(MGD``56_,A1Q$B:M[J8.)6JHV,.56:,Z+;NB(RLCF#(=#VPE']6COU M)4?(&ILT<%XV.:,FNR!O9P9&\D<@EDW+M_L-14G#OTU/OJ-5=4E.V M[Y246)UO#Y/9W*HI`0X&*7=ZL!"EVHXA:I&A:(\?H]2I\1,4.#4^70'1&)HK M\+G\E.TE61B)7$AM'077M6Y\2T`9HGH9A9 M&SI$J;:AB3B*+QHQ0<53(]+@B\[4#'Y'$8#S2ET%9"-+HJQ0>V2S=#1J(],1 M4BDE3X*;(N,K10,%K2T,?,A1Q!5CCA*B2,,@FE4S#)_+0=GRDNA(9!4':T,O M'2DU_J`X*%M$RMZ.HV9F1P8X;>QQ`9&=RBVOC*&AM81!#CB*N M&'.4$$4:'EAO$I[S&UD41>MVKI!5+JU&?HF*<`O258_O;90RD]!AJ:JDH(** M^YA].4`C)#WLQYL0I9H72DW:1HC.CAZ?'SU!(Z=&I]$7W?__KA^B2MB+(I%5 M/^Q[F%+\H'XH*<@A3$0?$=[))U9E"E#@5!1DG6C'1\L1*K:#Q8A.#9:@P*G! M:,C%HX`9\@\27CXYF+795"KCLX2@0KG3-&H["X$K7K%O@/``#__P,`4$L#!!0`!@`(````(0"``&JD MI@4``(T6```9````>&PO=V]R:W-H965T-X1+D@E*LIJ$NUJIJK;M,T.?/TLKMH[JNH:O_]2WX\J1K=9.6Q_2*2[35 MOZ-:_[K[]9?-!ZY>ZPM"C08*9;W5+TUS: MJQ79(W)%6KV^W;YDN+B!Q$M^S9OOK:BN%9D;GTM6VL#5#:;8XY1$#2KE7HM-6?33> MK#)9SF9C#6SAR>? MWKROQ$3V36@:6D/2/;0^4S,T:`NT'>6E3;K;5/A#@V4*1:YO*5GTIDM$>2_1 ML;ONNM=NS(WQ#EV<,9O]B(UH<>`6I&6)K"<# M7P:!#$(91#*(99`,@`%IZ7(#K?TSN_W0$/"O$4XBLD4$BHD$@AL4*2(1%BAB85 M8IX.E%B+@3)B=IOB02&>0GR%!`H)%1(I)%9(,B1"H.3,K+X?V^(VESQ[W6-H M6'B!C"3`AO<@?3L2$3%^1I9]_!T9K`![+:X`CQK9L$_WRV0I+1._,^++).BT M.0D[,A"21XLZH8'1RA&G%'=&7#OIM($(N835+>1R)&=P>.1)(]9BTBBQA.A7 M\LN!&<%1ID^1')DW9K20\\B,2!G?=\N%(T4>L.]A3[P_4C@VDCR=:,Q(GDXL M3,=:6]+Q*OF/Z0B5(">]'RA%:R[6@B$+6K^/?K44F^/`'04K.7ROM^(]Y#-D MT^0[4I$#[C&=>VXU.7K46_'18W'T]6(NAI5PEWO#B[F&X85<#]X/CV\A)E&1 M2D"1M!Y6XEP/S-&:7A"]%4^"SQ$M@6G;4G$#;G`O"^W>%W*KR?&CWHJ/'S/D MF.WZ6RC]SEWN#2\6@1QMA_OX]-YCTI,P'%7Y=/8<]>?X0X\&:T#M;JIE]7N] MSQP'*.BU^(AACR;D(U4K5E'2:X&\F!ERGAUFYO^U)ST5"PFC2-@AY$WM0'X, MD+:&@T:_C:@I9%;"0I:U?*9EK=J&6:TM9==@,OAA9/!BA:LI92MA:-C<'9JL#+6RUMU"\9G\ M``5\Q%X^[-&$?*1JQ2HB=VUM0*T\S1B].Z,W'06JSNB`KM=:R_`;N1>#_7NW MZ3"]M/.>7#@YP>J0>/3DPAE'Y7#)]VR-\#VY_!OCE@N_KT=T;/<9`E"_V-LN M_-8<`/7@&UK7>#:%\'5S'P&QB>,&_Z!#-!=)._^!0``__\#`%!+ M`P04``8`"````"$`OD@]0Z\1``"_9```&````'AL+W=O M[[Y]&APT`?0_!$=.;I;KCXU_>M!`HX&11N__^>?3X]D?J]?M>O/\X7QT<75^ MMGJ^WSRLG[]]./_7;^$_;L_/MKN[YX>[Q\WSZL/Y7ZOM^3\__OUO[W]N7G_? M?E^M=F>D\+S]+\=75]>73W?KY_-.8?XZ1&/S]>OZ?K7/=COS? M?E^_;%GMZ7Z(W-/=Z^\_7OYQOWEZ(8DOZ\?U[J^]Z/G9T_T\^?:\>;W[\DCW M_>=H>G?/VOM_@/S3^OYUL]U\W5V0W&7G*-[SN\MWEZ3T\?W#FNY`=?O9Z^KK MA_-/HWD[NSF__/A^WT'_7J]^;JW_/]M^W_R,7M%J/$EM`[W$:A?SQY67^]^/.[:S<]XM?[V?4?AGM$=J1N;/_RU7&WOJ4=) MYF(\4TKWFT=R@/Y[]K160X-ZY.[/#^=CNO#Z8??]P_GD^F)VUL-KV^O?'[?:-;TB0R+0?<[SO=CC[?YNJ(QL7^)D,2Q4?^C+SH>FPA[^F?$X1DY/33@/D?<0>I_^$ZG%X/Z=D2=VMWJP-Z] M[$;T?H(L[W9W']^_;GZ>4=:A,;M]N5,Y;#17JCPUNEL^3)9C&9- M9S2A['(PFHDH'4P.80(2``F!1$!B(`F0%$@&)`=2`"F!5$!J(`V0UB9.U"A3 M.U'K7_TYHRGK?7"X4S]W9.(F.3EC#D;<;`DD`!("B8#$0!(@*9`,2`ZD`%(" MJ8#40!H@K4V<6%#I\(98*&LW%AV9T()UF!6CR43,BX/1(19``B`AD`A(#"0! MD@+)@.1`"B`ED`I(#:0!TMK$B06EEC?$0EF[L>C(A.HU*Q93$8N#T2$60`(@ M(9`(2`PD`9("R8#D0`H@)9`*2`VD`=+:Q(D%)1(@RNR)22 M&Z>.B#C)M>1@=(@3D`!(""0"$@-)@*1`,B`YD`)(":0"4@-I@+0V<>)$B<>) MDW\M4=9N+#HB\M>UF#,'HT,L@`1`0B`1D!A(`B0%D@')@11`2B`5D!I(`Z2U MB1,+2CQOB(6R=F/1$3$O;D0L#D:'6``)@(1`(B`QD`1("B0#D@,I@)1`*B`U MD`9(:Q,G%FH/[@2CVT]>J+,"_QS9MW0#H]%T?[BSWQ`N$"T1!8A"1!&B&%&" M*$64(U$:6?"H_WS2*/N3$MMSA>( ME@YR/5![*=L#-3"N)T,&1K<+J!*:MN#_02[HEL] MX4I7BCNN:.3>N3BU6:@#K@&]V*ME-D?N/=`5G7LXX;HR%YE!([L7-;)[T4:N M!ZH`@UZ\N;V@%B>[ M:L9Q_5#@V*[+FE`=4)+KM$)R.E@B"A"%B")$,:($48HH0Y0C*A"5B"I$-:(& M4>L@-SRJ8K'#,WPM[&H=)U(=[+"/$0B-[+02T'`$*$(6((D0QH@11BBA# ME",J$)6(*D0UH@91ZR`G%F-/N;C[OK[__?.&4BJ5'CTQFM!CAN[APU[%72`8 M71]2UL(@*]=-9#F@K2:TH%K)7.S,`F/%&3$T\HPB@RPM><78:%E64['_2(P5 MRZ=&GE%FD*4EKY@;+F21CXT5RR>( M4D2901[YW%BQ?(&H1%09Y)&OC17+-XA:![FA5H7\\(P]UG6_M7O12%W"!'$F M2UUNZ%AAJ+6\R?Z!:<@W&"**#+*L@-]1R@V753&]8$'#?->Z0NK(U`LP&14]V;75BLO=9S43!'_`5 MU3KUQ\?I].;=K5A&0C:AS9-Q2HZ(B*V\3L6]5M*IA*V..Y6RB=>IC*V\3N5L MY6A)IPJVF9"M'2W96Q59>OVJV?UJVX.B95+[M#5\R'5D$X/ MCB>2)5LYZYL<]8&V&M]X\I:^'(V[XY>+^')>IV*V\CJ5G'8J92&O4QE;>9W* MV?UJ!OG5]FH=S5ODEW=\_[9YH?'7 MNU&C"QUV:DI&#'"-['QV0%:_6I[MUX,E)3*E-3:G4@&B4",ZI>&,$!GDD8]1 M*T&4&BV6SPSRR.>H52`JC1;+5P9YY&O4:A"U1@ORV=N.%BE90%P[)`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`4HGQDD$<^1JT$46JTN%S(#/+(YZA5("J-%LM7 M!GGD:]1J$+5&"ZH1&F].7'\M;RD5D;JX5Y2W<#33^3 MON6.K^S5DIU5#?*K[M62?C5LY?6K9:MC_>7F+74R;>>1CE$\0I4:+$TYFD$<^1ZT"46FT M6+XRR"-?HU:#J#5:D,_4X;$=;_\9H/JE+)FX.B0*+ODL@QO23#)3"$.MY^9BMC%:"*$64,?+*YVQEY`M$):**D5>^9BLCWR!J'>1.;77` M:H=:3NU!/T^J?A5,C@!]2]@*SY1NI&Y.&2+ M8SE/+UR=XWZ?XEXMZ5/"5MYM`E%IM%B^,L@C7Z-6@Z@U6G)]FJHSV?\Y:>U5 M1+B5,%45[C9:/LO@AM[,O&0K5TN>$V@K?4XPFV'68IUC([[+6FSE]2EF*T=+ M9H>$?:)UURS+,INFO5IR\<[8RNM7SE9>OXI!?I6]6M*OBJV\?M5LY8UAPW[Q M$UB(8>1CU$H0I4:+TTUFD$<^1ZT"46FT6+XRR"-?HU:#J#5:D,W>=L`]Q0-N MC=3::((X$[\LLC!6?(-+1`&B$%&$*$:4($H198AR1`6B$E&%J$;4(&H=Y$Y' MFK3.8G.BB%#F8E7ID!N>:_EK,].#E0D/H`"M0D01HAA1@BA%E"'*$16(2D05 MHAI1@ZAUD!L>JF&=\%C9\D2D5$L1J0Y1Y<$Q6$P!+1$%B$)$$:(848(H190A MRA$5B$I$%:(:48.H=9`;%EI8G;"XJ&HK&F`F:U^+QY(!RW=O656OD0@9[:_H MWHTZ*GG#W>B3%>L!P[1#SMT`6K*5Z[IXGA88*^Z9D%&/ZVK;;;MNS>/AO\0UO!@&I=-QP?8AUR0[RCV=MVGWMS=PIH)([_Y2D: M6SE;:QAMQHJ#$2`*'>0,K9G:&MGQ\4^4O;FX&Z4@-U?7XI>6%MS0*;GQ;CHM M]?84$RZYD0FTEF=SQ5>CA=;H6%=SNT`6YB>Z``OP68?<@,*I&%N="*C6,FM5 MP`V[XY/Q[$8DDY`-AMVNK$O5C!Q?[U^M-GQ&SK!EV M)BQO5HE`(_5C!B:FUV(3'W)#IRNNS<__N)%7A=@;!K\R%X-?(VOK-3L@RT^\ MP<[*/DC2#2T4&BV:W:[KJGZQ7?^EO#KKJB`[KVHDQK+<=&@K_ZGEDK6<$8_3 MN7-"/YOL^[E/UJ$^,Z&WNM3M&5FBR)X9ML^>8>G"R`ZVMJ(UO] MW6]^J'?HT^3X^/Z`NQ?\?Y[.YJJ\IOZ5W\QN^-W_\IMW\W8?$[I*+2YI6_VKX:2WTPGY-F^9(1OIO3-OA`2W]"?*_BTKYD$_TQ_QF"? MN24?S]L^^T^3^2?JWIX;(9_Z72*/^NRI=WL[]WK>[G_]0#I$_=1[7>JE_DZZ MF7^FTA`]74QOYHO>;Y;TC2KWL0W5V_1-WW6H;J5O^JY#NX2Y*DY1C5Z?-E?O M2^O[9D;?]/7+M<*?D-O39FK=Z+@-_1VD[EZ=PE]NW]?/V[''UE:;&U?YU=Z_='Z#H_K'3OS?Y9;.C/QQ!JRR] M@I_^4,B*=D97ZFUD7S>;'?]#7>#PIT<^_E<`````__\#`%!+`P04``8`"``` M`"$``EG7;,`%8P1K9S^_N.@;#I)EJE M+Q@/9\XY,QXS?3ZJDNS!6*FK&8V"D!*HA$YEE<_HKY_KAR=*K.-5RDM=P8R> MP-+G^<&E!(EDI>\TH9O2JS[&`VY.',WFRMZ)8715F<(F M#)GFTU1B!;[MQ$`VHXLH68XHFT^;_OR6<+`7[\06^O#9R/2KK`";CZ'_KP!61>.#SM$1;DZTK2TPJLP(8B31`W M-H0NT0`^B9)^,K`A_-BL!YFZHLW>@'5KZ:DH$3OKM/K3??1F^N2X2\:U2QX\ M!J-Q.(A0B[Q/PEHC35TK[OA\:O2!X*R@I*VYG[PH0>+;A:`)CUUX$R.*4&O M%IN_GT?QTY3ML6.BPRQ;##Y?,3V"H6BOC&KW*WNP5_;]\%:6;>!2)KXM,_@? M&0_&3N#RZOZJPA8TO,",;DLCY/X*/;B1[DOL(CBD%V8FMZ5P`"ZE_%S&0S3Z M_GGZK'\UN\AE7Z-!^$:SO1[M&"DP.7R"LK1$Z)T?_1@'HX_VMW(1^[-[&Q\D MB^::L/X#WI::Y_"-FUQ6EI20(648C-&8:>];NW&Z1N"_PM`LY& M&"`XT]J=-RC,^A_M_"\```#__P,`4$L#!!0`!@`(````(0!NTUH>I@(``.D& M```8````>&PO=V]R:W-H965T&ULE%7;;J,P$'U?:?_!\GMQ M(+<6A53I5MVMM)56J[T\.\:`%8R1[33MW^\,)!22M,J^D'@X/N?,C#TL;E]T M29ZE=KJXI<9Y7*2]-)1/Z*AV]77[^M-@9NW&% ME)X`0^426GA?QXPY44C-76!J6<&;S%C-/2QMSEQM)4^;3;IDT6@T8YJKBK8, ML;V$PV29$O+>B*V6E6])K"RY!_^N4+4[L&EQ"9WF=K.MKX31-5"L5:G\:T-* MB1;Q8UX9R]+$WJMA#7.9#X`.M8:/QD M]T/3@!^6I#+CV]+_-+MO4N6%AVY/(2',*TY?[Z434%"@":(I,@E3@@%X$JWP M9$!!^$M"(Q!6J2\2.IX%T_EH'`*'C"&(@/GEJ&SN5[)L$=DJR0):%S2D#?06&?EV$4+=@S5$/L M,7H^TB]R&$W.J\Z&JA]W$\%#J7T$NMI+$VRPOD[3C":0%,^UL1=0\U] M9)C>['QZ.)N/[\\-N/U8$W<--?>1H>;\2+,=+>W]U=+F\HLL2T>$V>+8B.#B M==%NHJTBO!O'\7&\:B8=ZU[`I*EY+I^XS57E2"DSH!P%<^BU;6=5N_"F!N

XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Other Current Assets [Line Items]

Receivable from partners $ 6,544 $ 2,921

VAT recoverable 45 950

Prepaid expenses and other 1,336 521

Other current assets $ 7,925 $ 4,392

X

- Details

Name: clvs_OtherCurrentAssetsLineItems

Namespace Prefix: clvs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_ValueAddedTaxReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001193125-14-402854-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-402854-xbrl.zip M4$L#!!0````(`'%I9T637P@='8\``'VM!0`1`!P`8VQV#+95M8F722U)N.[\^ITA9EBC*HB2*EK/` M;GM%4JKOJU/G5G4.?_G[T_UD\*BS/$Z33T-R@H<#G8S2<9S M#O(B2L;1)$WTI^&SSH=___RO__++OR$TN+P<^&F2Z,E$/P_^&NF)SJ)"#\X3 M\\1(P\71]%XGQ7\.?D2Y'@_29/"7>_G;@)Z0P>"N*![.3D]__OQYHL>W48;2 M9!(G^F24WI\.$'KYC3^JX9T-!M8))2=LX=)E.DW&9P-KX2,OTU$!MP_&,)"S M`<6$(T(0%E>4G7%ZAM7_+-Z=/CQG\>U=,?B/T=_@9BP0/,$&ER>7)PO(_GWP M+4URN/O^(4J>!\YD,K@T3^6#2YWK[%&/3V9?^O0CFPR`U"3_-%S`9SX^2;/; M4_@)=AK/Z!E6=YZ9JY,W[@=6_F'XF]]O/EBZ_R<`$ M,?+RR%B__E`YHER/3F[3QU.XT'#[:/*X3.EHDC["V$%:)^GM2*![ES4^4EQHP MQ+2&N'C4\!N)OH6%/UXK\.HT2R?Z=';;_*GI??,3XR([ M-9)R"G?H+![-'P#=L/F9-$&UYZ9%]L;0X.H0M,A@4.J1R5E>KK9+?3,H%_69 M^=9/PSR^?YB8I5=^%F4C@ZB=^BB?N,OTS:>A65#H9<6\5U6L$R M/WH63HMIIB_2`@Q#'$V\*+_S0+W&8V,\0'5?1,_&9N2#49H4^JFX-,/5Z>3Z M(K"Q9#9!B'""T7^!3B+7WZ[\:WQMY(80HN!/A0EF]$EAR86$_V=S2ST1`*J8 M=:T(/"J?%%?<8L/!-(FKKY]IP>O@^^5P,-:C^#Z:@'0C,1S$($SQ^%I0V[;A M"T-&O0![%'&A',2IQY`3V@K!T#R&0VP1%L!P,+VFP\^$"%S^YY?3K:!_$+:^ M?_,[8HL8MJP/0Y8B6.Q+EK4;6/; M793I_.NT*/T\\/VVI`<^8N0:+V#.RV]<<6P^6\2YAS MF'>BC*5IFMKK!YU=MX-M!=1B/OP:M5T%L!V!'.RY2%D."1Q?@*PYU9H@P\^2 MGI@%L0IE0>J=\3@V4QU-7B;[4H]T_!C]F.BOR>_Q!"PK^.[.Z"[6CWJ7!4"- MD3!$"&YSVXB\XF0W_8D#5_H^92A0@B#N*!>YH8>1DCYA'J4@`?*:&/1X^%GA M)8VP`]!%FFYOL]+LSQZ^2EW]>S2&)YVBB.($Y.9;!%]Q%66WNO@(#(%\4%&C M:"N0R^O$Z`XG&9M_@G].@=:)8=`IO"C+GN'!/Z+)=/LE5/+20A^RU87BN=0& MK0<*P0(EX5H>`U18T<4E$/JM,![CA1Y'H>-Q)6W;#T)K+A?X!%/QRD1[6&_1`8;E46=% M#,NM^M,$YJ4V(AVSL9MF)0X+E$U!3%P.FM53(7*EI9!%;5])*@.7AW/=8I$3 MVU['T!M(WR1H)EC.O8G0#L?))J^KM:0`#]268J9!VH"JJ8RZ$3[/\ZD>;X^\ MIB3:S3>@E,+U!+*I`IR88N02$:"0,AD&H>=*ZER#MT1G'@2V%I;$FJ%OP+>' MEW1@D*P5R+>=)-=DZ4R:2R=YZ3TZ618EMZ4I=9]?;YD9%^=GE(V_/I@;\S]` MG^@Q:-O@Z4&/X,^KU'P4/(%FB7-CH?_4)F<&]\!R`D4SN[*38[;*Y6:%05>8 M]9ET1,C!U789V!>'$60SVT<;%F/U+8HEH0>?F!4R M-N@)9UKG"\$W('CN,[88?[>RML#C!]8'W`C>B>A0[%KRTE%@NPM? M34(7VCQTB6'F5T=P)97UJ]?:K;D%77D39UZR*H,I8$L*H8-.K_=9@V+]1CM7G4>K5Y;R_7=59O^=Z/.>LF1U*;]7:P-D_\ M,09]5&Y4SDT!7X=V_$B=9N.[P"-L,4SL''7?L>61QSKWR^,(.:;6= M,]`MATU@GAE64BT9F-61KT461G%6SHD?YZ-)FD\S?:G-:8TN?-[V M0UT@81L\:_W*`ZS/+N2<*I!SOBYQT+";8J[&1;D19_9A``_,OTY&("''J'WH MBO9Q1J/I_71B?**OQ9W.C,K.]!UH[?A1GR>C]%[_EN;Y%UU\O;F*GHYORAAX M?8A8#%M+T[8EKA52C/3F8)R,N3E>MOQNG0O]7VUGCK?'4]_GOXV8)?D;4MO;=Q'')7\^"(U9Z[F.XTAR62YR`#/^*D M],?GMJI8.DWUPMWS$;(@FWRR':"M*'LPJ>,/X8:#K>.@!^KZOGG\M1#5>#!W MZ038R,U9D6.<82;+T)VJ93E?'?HRM-+`?Q#E1EA@QW8<9ID]D?)TL,U6L;84V(7KX%I_"/$%PV0S(JA< M%S4V`JFIHX4C@/'X//&BA[B()D>(%D)D*6U9,TIKQM^H,J--:G<-A+6B?'SS2`$M+W7I8W\$583+J'XY MKM\(X_!'1_N87'"9B"7L99]IAV.C+W1]T]EC/-+-.=XO:5GDI,=E.C>_2F'A M+U[WTKSXDA;_K0'M*+U-S#Y4J0]GF=^#\==P@E!83&%;(,9\B+=\BR'%`X8P MEY3`YPQ;8I[]`@IK6JX7.I9GX->I4\?=%8\ M7TRBI#`I?A"_!Q.]?-GZ0'H/P"P3=G&KMJNZ'D'-R)7YT0^7^:;&'$AEU_)I M&\&L;,<\@/TW6SA)KH&GRO4KOZ5_.R$\186P?$0!%N+"MI%M21=9D@4^F`Y& M'#5S61FKS_=&('WO!1"GV) M*&.!&RA+><*KE*<1)F*!8;8/?X)Q,T-]GU#Z0!,%3J#%&">4]'HHJ=5$O62T M7VNA9D[;192]C]_94I^86%]PWIB>WP!FF8%JOVT\+M.;KT\>+7`34BR[G&\C M:#*1I.ID?GC=>0D^#L42[JV[H,XY'/F(!`C%I2D(;5 MUSA=RZ[;T>(RF[B4DS>\SB5T515LE7TRW7FB;&2">=^<03MD7LU]I$)=F;NWIS=/W$EJ]LP)UMFCSL'FG2CB+-?J@P+1*(M$UK M#*RLPQ$C##&D$V(.>OSNE1U)[#8+97=!X1T>QNMM([Q7?MA!-L;GK/ZN(T.I M44=_QL7=]R3]89K"&?_]/'F8EK$,N!3P%>77Y7/N(2Z,\_FW=Z*D=V;35L+B M$EL(VT`IMPA!KO(Q`H85\V7@2"FO^=JCGP+QJ M]F+21G;]L%=SI'VX/(.!#)B?3"/B>1/=I5IB-M-*-SO.IZ>(Y"R-V)6+OD,!U9<`#VT'4 M,T?MS3XCF!L',8@)`M`2W&>SJ0>76)$:#6^#ZC%5NKGWTV8JB**.'RJ)N`JQ MT9BP"L`P(U_X3)K\,_9%U1L,S_OE[9D\/:PQH836>L-U;#Y*N3!*D75G.@YQ MFF$?(EHUPJJZ*`(3A(-`+N=@=SC1T(M8].5CO!0^=BHDG;0^8BMBT6$5+)VU M/K(5L-%<[=U+ZZ-#@V2M0*[MQ=!=\Y9#`_U_V;QEE;2#=9=XL9R4G!#USLU; MNFUU9_W8^F4<>M(_9K^,75EI MU<-A;BX$_)*LMV$^7+^,_9LUO+E6.BF7I@=IUK!AW/MOLM*R60/%2BR?QWV? M9@W[P&V5="X#']ND#*7@ZP"W3SSOV:*@A]E]QQ8%O:RYOEL4]#!EID4!M]2Q M-2CH0Q4QLQU$FY-XO38HZ&.:38,":BF3+]VG04''%?E]3#,H8,F56-XRW:XB M__"[67T0(9LLT=&4J/?!@&EMJ>R5,\^]E*CWL;G'RKO4J._E.[8I#"VWVY@DJU#?IT2]#_$UM7I<66SM6:K>2M3[0&L.>5OP ME>]=HMZ#*)>ORI%-:O?`)>I]:"2S+2`(N!CO4Z+>P_29$G4FEHW*$92H]S&Y M@)PR6NMBML.&[H[G77J`6+K'-EDV-`HK6_.T M8WWE_#0+-_U3NWR5QUH&#GRPM)^LGNDY2^RZI_W^A>C[H&]5/UGJ1$'?J@AJ M48=^F*-@/8`ORV)JZ-^_:K8'X,1HTV57]>!ELWVD!'!CS-%3V6P/`$W9+.>" M+'LP[U`VVP-6B*@X4[0A9#YLV6P/T!1X::+7HMD>0)ET'+5%??/AL$6S?83V MH"OE6YU:^JF9[4-]FA.O5'![KYK90_F`?16,EJ>@N_$(^Z&BKZHK:H@1G1!S MT",`?15$$E,0V=V!@-ZVI7KEYS#;5,=0,-H=FZT*1E]Z)ZVR^1$+1E_)ZTMU MD8Y45R]G1/HJYF`OA;2=GAGI4Y/U5BXZZPU@'TFY:(<,M"T7+5.+DM<9Z*U< M=`%R3^6BU8G5JD!_OX#[H"FRWJHERZKI,FG61;5DN?E;'83VIT;17N@L3JL# MX,[HG],XC[?LU4LJ4@A1_>J&JFVW9/6RXK8(:W%QE7[/K]+RGDR_Z!B=_YJ! MTOT(?."R)7^][&$#L#=?G&(Z'(,L@6A=W64Z-X<&@,T17(IN]=>;JHS`E`9= M9?'M[3:'W\FL\!BK-TJP'\`CV%`UA3FC+K7-&YLYXH[E((7]$)F7"#F$>T[@ M^:_DG(CUKU?9%NJVO%UED=%4?O2\K2QM8FGCJ^#:DV1.&6Q%T0*J;0DQ=AJ\ MO0)\F\ZYV9D`.OQ\P;"_#07-.-YBXU*/]7VYQ5<*U*N8'7CY["<;S"R@]9W, MUH)J*1?5G^88RZ7QW,B!N>"KQMAA@;(I1[;+P2/SP#]QI:6016U?22H#EX=5 MGLK8'>N$6,1J(2=U7"OG`49:C_,P2^\7'C+?UC$!6Q@$> M4I['4>AXY=%(/PBM>3L+*NUZA[LW,'5[0N!7N+'(SY/*P-DH'$H>N&U;8HL4]XA^V9MZ1G M>6[`NS:'SBUMYCVVH M[J2[Q#4!:45%-IU:H<=H-6.[S=#*ICI-I6!A;^!@=<-9VH8%[A81@5-69.Q0+M>,, M+W/Q^HO'2),J6:*R]@:^U<&OE(O6<\K;9\U[%`:K$@:R4A*[#D7#V128]729 MEX-KTST08X.XX1V2:U%L2&2M/;%[C`K36%E[0P)K+:`5#_:X5["IGFU0=$OC MK@?/(/6C:B,1_I[H,B!(QD[50+#\_!AGU:0.['KUZ&8H-0?JYD:/8(T'3Z,[ M$P%!.*V_)LV%!,=(`BW?F+I<`;(%I#5&:ON#3?T)>'E,8ZV%:C[(U`R^"F'K MSM-1SK)YW0.A]9?(;`-KA[C!?&^U#:3'QCUZ:=LURUMO_?[%_8.'EED/LR8H M!:EA6X80[1"WRFF$X!\FHP^9TS"5<]3"7/(V.8V60-=G*%]ZTWZ]6>A)U=P\F$/[.X*'3R M]>;F&'6T2?;4BA*ZAMTJF%\MR3Y*N8+U9I,V$?TJGE:ZZ+Q\I>R'U$4F;XAJ MOOM^*-NLQID7,3\)\B*AYTFYV(U('F>:HVR=`[_;8NFUPE@[X*038'%B'.KQ M?9S$>6$X?3SFP)>7[C&MO6;X;1R;5$NM%]%1+AL3[Q-NU5_*MP%*&R-==3W\ MGHQU!M\'@@3$F?X/C0Z5B:9SN*T2L7[?;>;LR\.^7P#LGP_^JZ5W+T%).:PMXV)LCKE1K]NBQI@WY'Z@YE76KJW5Z_WFRUP22)+T/_PPXO3>ON M'Y/P$F:`OSP2A'.;?:S,J#^Q'"ETO0M9]\)+$C\8N6'HSB[J^&@,!$N!]1>[ MD+/?8SJS[/G%K34#(?_&[LEW=T:=2FZ,$?[=JA&^!R$Q-B21&'SC`W^%_^4] M0EQS`VV(I&2!077""^WM3K0*^FA,'TL4ERBJ/?-\T)8F<<<$7H/N;-N]Q^LN M[RP'VH93-PJH8P;O+S9/(T>3`C3E9E7/?F:32C&D,^_REY^=^BI"H?`@F6T' M'L4H"KU9N; MP47RQX.8+0-<(=2V)L['"CHSS,\O?^CG?Y@)-4WM;25=]=!WV=?SXXW]81$I?X%M'E\&/<LL@< MR<0$+R8O5[`>JR26-\K0YGB4J MX*XL@R(O@J+N%Y055AU-8&(NZ)5?>KW!8#BL/)%YY?I&[@7]F/^79:-@LW'( M46*S12L@)0]W,`6)D?*8'[B.P_"&4A`&*_KW)5D%__'-5CP5__0Q&XXW4ZM: M75O;U''O?>I]K(C_5O9-[U'F"G[JR\[UF8KY1'G;<'W/]6G(B,TFU"9CALZ. M`TR?*]Y(`G'@=7C6?Z)>7>$+657.30*>.V6ET3JP(!14[:>^?PP&&M!+XN+^ MX/SDH"KKZFN3!+4E']$D"*;S?EYNX8\?`,QE"8H=3+[51^_RYQKO\H$]YPD, M>5B?_75B6"RG9WUL9S=E#O^"(ZZ*?+(#W\AH^.I3I'Y'EUBKMN3V453^R4.C M5MOZ"^^,"F(:5*%C3#?"$.-A]-I>QCPIXU!8%!>Y_`,/1.$6:WCU[5:Z^?S_@PLB9P^&G:^?O_QQ M05;,:MS%[=4UO+\4YTUC>A;^P0'"0XIKGP5XUQV/J_B"6*E.>>2P9<_T\@.; MV\&_;Z7/W_J#;[<7)`[\XW[+MLE8)(!2FUC.V/5GXKS0$^2#K;9XX@/TC\K,LXU:^S(@]U/7MN>2>^]`!T$T"BS3HCXP6(T/&8`P66/+ MH$X(/5@8?35$-V1$;WT)-YE7QVC%HR79.` MO\(LA_AL;#,C!$MF$VK^)PK$9_6J?%2+)ZQ!)ZYCS[%7!P&TH5%2C&VAR?W4 M,J8P`H?2]2P'D7;'T!Y6C8JT`7[FL\']WC*09`M"J<)Z^*B M>+`TAN79,,I$Y)+9MA`,$?'W*1GY+@5;S+DI$@"A4,!0HS@E&2G\ M^]]B,<1A,:\A`=BW@O\&0!R2#BL%5`81$)^TK:V:[A5;NYV9W/J;G2^9O*!U M!OU>4^Y*K6$/[*S<:DO=9G<@#;1.6]6&:EOI#XZ>O"!K-9+#AR_3`D+;V-4M MDAAVI)&;]N_NG-KAG-/VQ3)X1NV0L3S=2W[`$5,MT$;&EAN45D#X"2@721!6 M(U;4=CP+.O$9BTT8135KX=!@P(4,?P-))S*(8*PK+!_TG*@V)ZQ#+/#"\(A, M.#298V)F^5MY'>B"W0/B61"Z('`X)KEG:'X#X@N04=7'-T"K)/)<)W9.IA;T MR+N#WL$82-`'.+M6,`52YD.QHTD+!-FY($F"@%R%@:U/$J+_DUN%M#[ M1-@R7Q3:BU4[X+:*'[%$'IXH2LDIC]40J!@T^6`N%^AEI\CF9&!$^E'++$XX#>!'A%>AR"39CF+@*8PVOP=#Q86:$4_(P:; M.R>)9N0V$^R$X)8J1U$879B>#?Z4XQ(Z$^YBYKR!:X0[I<3(;O(@>WDCTQ5. M(;F9,JSI`"RU/@T!.D--QRG9;"56%?@A]!@7^_X2PW^E3C0&!Y>7)"2=A$]. M4V=\!LO,1GZ$;BGB*'@ET2(+&H0NB[9P<7-S364B=LZ$WI!0;X"K&WF>;8$% MC^T_]^PX+^?8'/<%=\B-T)-I84_XMA\9%#JQ1C7"L[OCYEL"OS@E7AG5$]=4 M8C%=2R4E<>T(HFC2#("<(BD,W.Y0*$#>$?>/(T]P]&B^,!)ZPN1/0!8PM'$3 M!.[#@OHA?*L2*QNA8WB\@??R)WJ46+HW`.<[5>+2Q.48_%;P.KD3:>3L\#TL.KB#T M`CZ2WNRVNQU%4MJM!OA(LB:UZ_)0ZLNMAMZN@P/5TX_O(RDU@A^,XY4-``LB MKC`2CLF>_*,]:!%>#PDVN"&QD5#8B!)>D(F;1FH;HM0U"@C@:*$IR5X64@.= MW,>%IR0J*D\1AY>>0DXVQ*Q%D2=P^M,J5,04PA[K$[X!!LL8EYG:0!!(7[2) M'.@E%N,MR2$LN^6-TIRC#?<6$Z%A?%X['O?[R,(S%D[=;#LM'KKB"@&799,_ MM\:2(:KJ`;%+;=`_"[B@TWC7GFR'8";0!\Z%/1`:J/+81^H,V`B%S4M;QK.# M/E;F)U2#$9?=!J)014EI0Z1;*(^?8C.(NU/?G7$*!.JI3V-N7*)M-,M&[;#A M.P:Y:&AR!I'4[3:FK#EI8:+^I MUCLM_(3,P<.@2A8&O5U(R!8YT6@2.5/AG1=AC`!BC*1'/(;T!2TR47D\(*F0 M&9!WN=`@&),,9W@+OYOP7EBV.-?[@53OQV:+^=\+\WE*OG<\QA/16\[SQE14 MFWH!JVR;0-[4WZXDK6;YY`N'7HOG%TD">GN'E._&L=*N<_#JCZ%[U,3KQ3S^ MA.7B:#^0B)TAQDSU,%+GE<$,^\LF'F(*OW*_+Z!M@C&SIG<.G M;&^QHH\+3&4UN>UIZ0R[*;)9(!#B]X`#P]Q/^?@R[=CWD2C46TUUB=.++==2J1X?N)$4<06 MS[M9>AY[3CFD2K6Q(:'RQ!;_5):Z)X[(P%G$2`<00<2'/(TYF5`K/A<5&Y^S M8X9W2E77Z[MRP_OG,H'W\S13IV+WBSOSF>\5)VF^1,;/7@=\[2Y5SDHSQWRN M?;87TR`7=Q(GD0<)]ES3&L=7Z>R\1H%JJ'&%, MF1G9[&JCX>Y$]Y%@\XJ:A/+\[&[%R%.W%BA+'168PT*L5\\,SA@=PD MPXP?%D$?[_*1L8>J(!0R--96GA<:P]#:MKHN:7/$8@CET&4H+7-WGRTA4["K:!2]%[()5D"=%B1) MBM@5%O'DJZ2YI/EE9?AT#?A7UV%S3/K[+PL/+MJ[7K376M6VOK[ZU-["J.5L M=V^[CH[M9K]<#F`%C2P:A:[E7BDLD2H/(E['L6*)7XE?B=_YXE>LC27_!$)Z M,I8_]-K-(;5//@W@F"Y=BU#KCB)WP#H-R!E4OFKV*`[;2RRY]P1+94T/VQ`6Z M:%YVD0+S)8(E@B6"YXY@L6+8.,P(_]Y<=)Y/>I0:A5/VM(_Y7CG'=9FS4"M=SK&SF(6Z9RP1+!$ ML$3PW!$L5K2ZO#I;SK&A[_M=\F?;%/X]9[L!*9$MD"R301=OX%RGYE%+(G+M!%\ZF+%(8O$2P1+!$\=P2? M_.7XO7[7?>F3\5/JLQ$-F(G?.&=.P(/,'=^GSH3-F!-VY]DKUW2.CSKWU#>O M/'PQ^)T%(3.!CL%/CQGPYZV+CZZB,`BI@]_X_A=#\P7OW#&?3MAW-J.6`\\Q MTNU3(XRH?;PC+]D.I_*K7VLVE13L8.&)A3&9= M]%TCPJYNY]XS(%L"82#7V\W>0)'47@.FKC05J:/VNI(B-YK#7K<[;`U5`*%> M^15[_;\/RX1DY`VV/S)ZF##H=#99);]0EK5GO2&UM M"$(FPV(-AJUFIS\40M;[7JTQ]5\OE;KR;H7D=A1O^M3U%@ M;N:SD6L?FO`Z$O[[C:!S@9)%P?SDNN:]9=L@\I\=$/&)!;I6*.>^%1BVBQHY MU;U[FT6[(6N:K@^D=E=6):W=U*2NUNE*PZ$^K'<'K;;:T<4LT*+$!F79ZLVH M/[$<*72]"UG'>$O\0!C*"QZ"P8V-%%A_L0LY^SVF,\N>7SP0[1GAW\T:R3") MKRD3T((D`8U;NU&Z6?`>(;*Y@49$5+(<$R3@0GN[$\TY.JGQ9V2!%24PBN>[ M!@L"`JJ+4=^8 M*)I6:R2/J@@/6CL+<)D+FF("H#DH?)^AWH56]9J6]@/S\''&Q`.%ZY,YX$O, MB)'0)3!]4-P!3`S:CUT?E+%#T*%ACC$GJ"D"FZMXXM.0!9A'+:!2P<80!Y3L6Q*W6,-"4WH$D,&AE,EB)F>4P$Y=A04NL:4=116!@ MFL,+`D`L8&?+%UP3$AOD":6<.@YXB_:-/5, MNSZFPX7J@"XRK;F-SES=Q*[L.I_FVBSM5](=ZWKG_":$)K'WW1%Z<+ZX3=V; MJZ0WVXU6I]F3AHK2DK1Z:RBU>]V&U%":C7ZSJ[?Z2N=15RD^:^I>W=Y>?;T@ MV>G4DX^K>(Q!,/3"<97V-L^18]<&(\(5.J)"@F@&[`^,'7!=$YN..4@GKBJ^ MYJ;2R$U?YGRT+T$4!=+X5BZK;#8#=@AP);B2P8YA)PIF#9"?HB?"]T*$.6@_ M'^#!U1S:!W&[[GP:2-WO@\X_I>Y@>/4=\*/V/9T'BQC5O3#O46[??WY=.,Z; M>MT_S%)%;V^)L\ MFG9@E(N'=QI`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`4 MYDCM+N2&I#[^M- MM:GU=.VDKLI?8V$>3.%/JKB(B]LC9KOWO(S&V'*H8UC4QA(WX)-K\KE:*N'49XS'E[.K\8&X$@]-'RNN@Y>2GG@[_NQOK[>: MS[N]WM*>?GO]@2;[>GZTH M:CGMHWUM"LM5>^1V;1HQVAODIS]A]>`\=M91Q_2Z/!5N(9F@7RAAH:E\I2KP M=0GW=7?:^#YG&[3K?=A633].JMOAYZJI->T$CLK.)Z,A+240<[<[3MU2=K3+ M9;LN?E5M'R=8?OBYZHUJ0W_A5,2B*_P>5L_D!3#OL/`AEK?,;\Q2`0C.10!4 M[;6POZI56_(+3W:K"'ZXQ,U3[D1\K/R/O2OM<=M8MM\#^#\0A@/8`*G'G50" M&*`H*<\/-[9A.Q?()X.B6C-,*%+A8GORZU]5-5=)LVOA<`COZML/%-'<_;#<[U]C^QOW8^]#Z)A.]:Q21NV8\-V;-B.[7-=F-EX M)FY:L8?MV+/=CJE('B>:YI.KQ?50MCS1EA5Q;#X)A>^NW>_=KLS0$`D>#O#/EMOPOB*,6+'\-G^]M_'T3?.UX4MI402W/S> MC=/L?9S]R;)/%0D"QRO,XZ3X")\[''79W#"UL8P)>&UJ2/K4U*2Q/M,D6;=4 M!3[79-,HJ,NT/VM1GG:T;4F_9QD:B(])_"V`;=WDZ@]X[[NH8'Z(+IR*Y03+ MSP91#I\U:"$."GMI8ETD;4>ZICM1;=E4)$LQ)Y(^,77)'AN.Y+K.5%%<>:[, M2+KJR[>2K2FR`CN-6LB/&^AU]`AWFCHG!`VG?WU8;4\.3EMZ!-8$UW#=\70B M31Q5D_2Y/9,& M`OLG1^($_N0FB6$3LTY%:"&(_#"G:@QM,`CB.!`)PHJ9*KZN>!0VH1>)V/R+ MGVY#C-P)+X)]:1(JB05/3T7#4D!=D!Z*J!ZPRTT.%I3&_5A8D-F%,TZDSPVM M\FBNA?']T2KF^=`JPZL'C,YQ3MN>($:G^S(;SM&[-VG#.?KV@`]\CM[]`0\S M/&1*;CHQ^W0-7>Q3.2!3Q?&SP>THHJ(]EZ-`6Y3EYP(\U$1Y?.2Q]BO3]1L1 MG(:<&G:Y#B(B9</';0BFL:32V,_=M"6:-A/CQKD MD8/61,,\LLOJVV7Y9U0H>Y#?(+]!?IV5W]/?^][,94)Y90X`O"$=]["0,NQ\ M,1M#U+7S<(5T7S:J:)WI5*'[LE'P]M`3*']_%N&8HMD%#-]3BG>?57&H08*# M!`<)=ER"CRCH=6",W&'K?!7O=^O@/2,PQK;FFZ+3F3 MV5S2QYHJ.8KF2/"?/IVK8T5WE:_*5^WE6Q7>?L#J77L&W9;JA^R2)6Z>)/C# M-&7'@"A:CCRV5$67+$-Q)=TR#D>5LW#7EN#M%D00(MZ0`P01 M;/@ZB%X@UC'.4R]:IF]NP`PV>H3PP"UI[PRIDM]M<,'[U**JX7Q;EJ^"#9;_ MN%%BV^*]`;MS#5;0?$!E*T4['VSN^.^^+NR^XS38.[>]3XN\N#N@HAP8U\52 MXY61+)?PC-(%[YB0:V!=U1^=PZ.<1"I3YF\+16D+Y=B8E9T3N'LJKR)?J[W7 MG=H5]C)DJXRDA`=Q31\@E1\^P!%\H@M>9%SIBM?&2[*()4_F4I?TS8Q@N69<*%7_V),=I_+P#CK!:>Z]KF MQZ_=//(N`D;<1U*T^&-/M'C@T[(#O_*T,?CSE&&_8IA])S4/,^5A.^.WNY\^ M=\+/@OCV/!%/YT6#)37W$^4,CJ%M831N87@VXT16[2#O[)1KZ*T4[YV/NB&E M<5UQ!\?WDYPM_Q-XBR"DTA!MQIG#U0UQIH8U-0UI9AF:I.O.1')D1Y.4PI!R&E$,W#M>'E,.0;&!GBA)!=>*&P8L51 M[":)5RQ-@SA"N#Q'-IU>]1]]-*L=>3/:O2&KQGZVXR$S<<^E4<7^A3#0@?[Z M9%,4BKT?HM[CE:!90XKB&1^O#S(<4A1W.=MYF#$/NW\2;RG[*ZD_^R2%)H[M M(^^,>N(:>GN\/DCQ+$F*N^<>CLEV_UN"184[=@M&>?E6T?6Q;EC'8K&G8>^1 MZ^+V%RRN><%_><7V:#G[@06AV?)+C!_-..4"3FC)RN-P4IY/;.T%41!=8!'R MQ/.SW`N_L&1]N!KULF6K;LF[$^)H3],?*5XS2S/0LHP]0G.W1*498]>=3&00T%R1='L,FBG# MOS1]@KIJ&=KXY$74E:T,1G5:'>`_0!"8?*M$058FJ!QE?;3]H`KA!ZSW_N62 M"1N$./+*YD7&$.N\!Y$7^0$>JM5%T(.(RJ4G2_B*"=^#[!*:^&/T>23\YC@? MA02+PH.E$:`+'E=$(8OAK[^9P"JMH,)H:9JON2Z^P'RDEPG>:@6J2/E*Z$^< M@/()WCK.B^+K'*@C"F%MB,4J-.:UWK^Q*.<5XQ,68@5W85EQ8Z0CX0-T'@88 M7<28"86E$4`+=4^A"0:N*Z<^!O#2JL=BHZ9]/8SR'3!`GX@*+G@C54%[^#0- MED7)>)'7FJ\N5^*0KGGR!=;0SV`E!^@1RW'[(:P_'Z8C2W!2:',`IIR&VZ@2 M`C_>5R=D1!/M\D+W5+1_:XP@%^$R2+,XP9>@+."'2Y]CQJH@6/F09]A-U`=P:($/=G0:A'G&CG-C=0\#ASR?3C59MB77"Q_*%L_4^2QZ(C4CR6-)@ M;-?VJSVK2#P"0\+_FX&I@N6.9NUC'`;^U1&X/\:SN3V=:9([D1U)=RU+LK6Y M+DU5TY+!:RGZ9-HE[H^FB2A-4DID'Y>@,>$5V%X0&A)G(`$.]PCH`V#I!1?@ M+G"UPE+*$[+.@L>-.?$:-JT=N1CD]B@H/6#AABPM;`/:+^3)8O7TC#AS%EJA M[:\*P\S`HD5_PY*!X:(%7(+_2-&\X6_@+>RJL%S""NQ-6I@E&@4X/UAF20"C M(VB,SY(,35O1Z;(E$:WJ&J,CL+T;#[D9L6UR?1=X'28B9\=?O_,I>`;_2H@7 ML"_R[FR=[J2K;?7^G0:)=O4S\XMI<+YY08@?S>/DL]?\AC=U,&TWI\I4=Z:F M-#=<5](GXPEL'V15FEI3:Z*.W=E$FYT\2%-O4/=:6D):":6MT$UUO@"OE9&O M\B*NP*CN7(4YZHJO&!X2@)?S2LE+JSB14J_]'JXJMP(2B' M`3%6"3XK5N2RB!7S=<[#)!XG^"W.''@V7L,ZXY@TUF+?$29>2%'FYTO&T`A\ MVGEQ\5H,F"!0A'7[;QU:)6P=0#3!*X=#%,CC2/PK0/P*KGS^%9)0@4W`B,=+ M(ASTUB!XQXNNOB[BJ3>B$($YB8E""'[;ZOD]68,H-J.X#3H%/VB:5V1;`L,) M1HA18RB_'&--H9H'/@/[)J:$/<>^10D,PFG*Q MXA-NP.&6ZYFC>)NZ_(Y6""KTD<"YMC.>**X^E^2YHTNZ`H&5K2BFI-BV8KBV MKCE6Y\*II@5<<(/6VCDRS[^D10W+B4\[*5*QB]NQE*]Q1;^A)0<['8Q;R`)4 MK&/WP??VDH:,4,-;2,7[T)!9ZOUQOO;Y8+Y'?_7`4W0+J0M84-A.1^U3O44B M_,_VT2"_\>!?W?[DE\2+TI`%=89W1^;PX[#4^_S/'-;!EEE+\7%"Y46/`G`&/617-\ MGI+%/1IAOZA@RC*&EYB6.[D>/Q:6^%I51%G>CTN^PX2_.84F=WF,?:N%W!_N M@$-IW_.2VG,)16X@%W^8#0\[7QG^M6**FOQ@W_X04W\OH?1$%'WS"'VJJWU* MG]`GN?4K8K]U.ZKVU06S!U@*WO"=?,8[>1NFCJ/5T_3T`T M?0NK^K-E'#;:0TAUK!/^[H=4Y\L(=#6JZD@&X2DY@S[M%8<]]B$2+KA3"5[[&J2-C4TPU1M=>[JG:K#.!`_ M#548S_'NH0KC4(5QJ,)XYUW.0/QT?6P^$#\==*S]JD@T$#^=6K,?.^*!^&D@ M?AJ(G\YFX9].Z:R>5@0<9'B\1,33-.@#\=,)#'[G13,0/]W5PO2V&N`@Q3,G M)6[+(QRV]E^CIM$=J]JIIR[R)[]\^]'&(G_&`8O\/6#<]RQFF=Y2UG$>)RL6 M9%A^K:SMN-63HN(@^Y@$_B-J2%75LX(TUE7%^OK'Y^G7#4N^[E;34G?F:*I9 MCC'7'4F?:!-)=S1%LC5[*ND6>`K7=EUWCG4OM9=O-7TT-N]1]?+`\MF:G0Q6 MRF4<8I$F+!"47;V/,S:M*MX=/BL'\I#UV5R33%G50)E=37)4RY0T2S4-UU5= MR[([489Q/!*:TBFL&-4;$;BHR$+51]LGJL*XTU'\!U6%!`5:QQ'O-?6H.[4B M[:J@Q;M(^+\\8H39$8N"/;Q:&.Q"EH(FVLI8U'6=UR.D>C6\=`J-+<6QO?B) MZ@()&_!,6#\0R_EA1M3+A%>6"FX+28SX[WG)0JJR4SZU26*?,2K64Y>_66%1 MIB5X%I_JXE0/M\YMJ,S@]R3(MM0!6FI7!\+.!D0GDPK?6<*$5ZHQ'BD";"Q" M^'"WXLIYZHLVTOK%OJ9=5VCW1GIW%&JHD#)42&E'F0?X_&RO'BJD#!52[O&+ MH4+*4"&E&_CITV?=APHIG;DXUA7E'BJD'%N3NSS&OF'U^W,%:;BX]1"I/9=0 M9*B0<@I3?R^A]$04??,(?;J%--S>.J=7Z)H/&"JDG&COVE4W,%1(.?O6]X1K MYM$`_*%"RAE%T[>PJC];QF&C/8140X64'GJ%[DJD;\Z@3WO%88]]"(>P`T8^ M"[\@42LW@WQAP;+OC$4W&/J"S>V&`U;ANY3=QT_4&/XWW4/X_>9`&YYA`7.?PRB\\$_F)88X^D32;4.6=%-VI+$^UR1+ ML;3Q;&Z9SG3.X4LL:9?ML$1;OVS+8,=2K)J@P3(%NF-)$G4\FQYKH^GQB63?CQ M.QX#& M9&O0*B$K,;=LT$!PBI,U M(65QY@E371C7-AL\$JL3B2:"17$`S9$5/28R=]XJ2/5;$(,=V&Y5"%9$G^P% MD1#F?@`S$BR$A%T@SBQ.T"\16;T7@A+`F!AT-BI88SW_$@GBE[QG=(&B'.XF M1G[0@-BE<L?Y$@*:P'K82!MPA"<%$5*6?]N@9G+A]#0XZB\!TT\)+$F8$D MEL(KPQCIK?[@)PW5R&X*!PJA7A]1B$@TNF%^%GQCX9T80^]F/MLFE^/[OG@_ MCFEHQY.Q!<9V(BEC?2;I.G@ZVW)D::K:LHE_*O/;&::/;6@AU"G1]U\P9.J. MF7U7!7+EW0BR0^K(J'0-8\M*S9C\( MZUZ$D)Q@^45Q!63%<<'"7_":=!GX9#HY*2Z^EFHHU8LA+4::,2+7]@BJYI#4'H[W* M\;);S8/L@YE>U-:_,(Z<-SF/2F?B9;P;8%_970S83<9HVVQQ+G#^"R=:EA_, MN-(T&CA.H4MC:L^G+H2-"@2\DFY-'NZ"/L._F@47MAQEP]+]IWA.H\V/DOJ MKH_ZB/N6ANX/ MNF:07Q?02=T-7K[LW>4_S*2'G<==7"3L@IY+@L@/-N#0O366 M0:-,U1,OP>771$PT4GI!A$?\T%A9 MQZT\DR\38)2.M.R15O?SFNINF&0JZKMANA6KB,7)DO:7#5P:U77#GUWD`7TI M%KDR/C:L\B:LF$>+3CE8L`'*4\X?F MDSTR;.51/@UW[,T[^ M%GYG(4A,^)+D$&"6OX1&WH^<$;60X3>L*!)8]ZQ0TQP4P\\Q$1HOP.K7R2)H M8L&\I`Y>/?B?D.!"*/2^7F%8B?`*'A81O.&5RV`=2%X4Y91$QMQDDL`C*<[D M[U[B7S8`3`8-;\_2A6]H35)I._Z&!;L((LR)[K9"Z]QH#I10FFNNMG&T_WR6 M_TY51)!%R-(4AGV1&E^]\"5X0`I:+; M'/>5"&@M-GC*5,.B"B7(Z#M,%9.A06TH\;'@&VF:%P7`I5Q^U=]+>%&P!HD@ MPC6\H@:8SY9EHI!DCDEW7*DCX0]$!=2FA"/52C`43A))E?`*C9*8<9ZTT5K4 MY0I3UC!-A5I"*XHY4DS%+%M!S7R%95ED5,%]%IR$(0KLGQR\0`E4.I7IC*R[:TZG&V;21VCI/_B+^9GU')59:T&2\1^`4DN M1E'F\Q'*D8&T60HV=D%9X;;E@/609US-T20C0H":)]C'JIA^,.])CN:5RGL2 M54NYJKE+*-!L8B-A7?2`1I.`_N`XBMX05(%ZW-::UIRCZM'P8!*AD09:#T0+ M72T$B@MKO>$O_\[X0&".P%*DC*MB)4M4$6P81U6ISF4LL+`0;*GXM8H'I'01 MXX@9='=HF'*P)=[VL+"_C41WF0JO^U<"U+E,BOGQ@\3/UXBH]%E7'!`$03CO M%`Y<:^X4F^2-]H+;MEIJX#1P#>#BBXN9@9&"I$.:5%Q&7I*)B&'$WX1>B@`@ M-#&,0Q:KY5*TTEK"8#5!2QE!54*&OU4,^>?2,FVO.1X\X)(7&,0S,,^DT^5/ M51GQ^V1TP""EPNOOEXP0$SS^XDL1_1M"^MZ4\XM+0I/_G[UO[6T;21;]OD#^ M`Q',`1*`U)(2]9K9'4#/078S8V^<[,&]7PR*;,G<4*2&3=K1_OI35=TDFQ1M MRTYL2S*!W8DED=U=U?7NJFKU)W64;)\9)M MXD!XX<,2J9Q:&J]0IN.B'12]J#ZHTH1,)(\M_;!.NE858T7$+56NN5)T<,PH M^5I+N=B]PF(@-%&&\S[Z&87XSI+5T>4'+V5E@@A`<_GF$<6$&E!D30) MB.%@#H".!S<&\X`%*=6,)YTAFOX7N6VWS2S2]E&`9GZ0S\2TN*%`7"B8>%2: M]A@=H.`CV(Y?6?QDV0>WL6\(*JE'3M&7&))GYKI"JI%;547X1 M.>S@?KC`-.0%R`4)Z*H(S2^-*\'[3B3$D7P%L-$41*;[:=AJJR4--:?#11ZHFCF8-_Z6B:U[.,_$%C43 M2%ISQ$&U\-&KYQD:.KF28C!_'IX*_&4&)*D-9#?T'826S(FT&&H-BCORRF4$ M'D-WV1>9T+<-+Q:-881<"N*W'*TZ`UU&\KD%L13J21N1AW%'SJ+8%=EG7;R> MA@4::E!%B_CI95K@WR?P=@HM,@<9E]P>]M5`4E+O)Y=2H&](:V;;([?V(^`\ MT-JPJ9N4*(?N6\FH#YC=Q[C0M=!:=$L!WFW`KT1X)+.I?3`!A7]$(X1?.:K) MS.8*<`Y>X1_!`YE,##"%FJ8%(LI%%$D3T%I".<&(?Z91_IB@0\-C8+Z"2DZ3 MB.I3X&5\2J1G\"T,NW[(GGXK[RE^KFQ:<2)S>["\25YNDI>;Y.4?GD#<)"\? M<.)MD[S<)"^?0OY/D[S<)"__<'(_%.)NDI)3RTP[G>3;!G]-\G*3 MO-PD+[\X9DY-19Q2ZFV#P1^K)O9(7JY-.RYG)I_%*R>4IG<10\4KM4/O'*0U M'L3BQ[/EW`_!'/>=H(BN/F7C(7,XF\RM8=\8V:.!8<^Z,V/8FXR,WJ0W&W6G M9KL_:!]$4K/5TOZ0>8%++>OC1,'AL<-].F!0$4D[]=*)SD7#S$D07<,BL]YL M.G8L:NWF&._T/\,L8TS'P4PS/-V(BA"[CVF96ZUMFL/R*9R/2;D+/]I<.?': M<5F:4%\X5_S\!M/,W%2>\XBF1">^X:+;&&O.BDX`9"K&E]#/CP:XKLW2&)9<'!6_D9D)HO>6@[F>\=?\ M.#.#`'..E+X],EC3*&N#1UQ_8 M=UBL/*R0X"*#44Y=?M*4I<6((W@83SZY@Q69[,19,5'Y9!@0P\0YNC@'I=5E MV47BH%4``C/2B3,FN>6-R9"BTXVQC-'8*'JLY7VCX.VB/1PL+8ZV3D"'9ICZ M+;H144.Z2LJ@LD(8HG:-#N?IFLF<(K[!)D=*1S@YMA>GJS(>=S`DX*#`0GF# M1?)D0GFH@J1%\A^VP^)L)3;EPL>P!/YGL[/R@D.&O_`R7UPYURQOS.0I_60I MXI'3N!\:DHJ0KY0=9+(E%#P3`J/#?F&&?JD5K(L-&3U:M$B\EEA40GR'"VCDY^L3JL'HV1'PMBF4+(( M[DE=K['\\`WOL<][&A(J@L!91++A([Z>#[6*F:B[H'5\!/`_BBV3E..1@,/A+D&IADD-$3=74%*JH?!I) M[;RP,5LE>X.#&4PE#"*!G'I=RD:(.QN0R=!GS!.H4X7X!]UY?[OF\W/-=S@Z M<`02>)E9-T"BV,/3D@&$QM*J44T MI4(LF?:1VY@EBT@"P<;2CJL($4I[98&_SE/$WH@$U=QZ$V2F?;$E)4>CLBK2SD$H27DF$ERC4$BS$!$8()>`."6] MK;XB\XQDOCK(/"$K4$HX(1"SD-B8@L$`!=R)MR@-,.\$4^,2RI=,8P6D323$ MGTZ4*KD,HAN>:U*1H,N+;<;,5"KP\]?Y2)B%*3/BE<03F3:2 M/40Y?/CD`JDASR[*)EJF@#=,(6IIDSPYI2`S7-XRBA*L]$+VSLUJ+E%)=2]% M4M9=N_J&"B@V3BP?K11I*05:4B9A9]AR`/W2NFAIOXU& MYV6[,*=1094>Z3(TB:(U)BY[V.D68_M)EF(1IX&D==FYEC8M9RZ:YJ+(O<$' M9YE5!)RW]CDE>I>%^VRR*]@I@[26%_A5E`:>R&-U/)GO_Y\TK*3=2Q)SQSYR**`>-LDS@ M_3OZV5-FN[:((\?#0CZ@IE0@2&:!+A0G19B*P"LX;1H6"(Y]_A5-'UQZ2`TV M*2\S>_=0-,T745XTDXV`^<$JF<^BC3,PIGI%`*9QU]'.+N=F?(#LEF6%.:4*UWV\K.W:`A"B)Q,%V:O<"1% M=&()GJ`$U<>H!W$J5!J0_ M(D-<1%4RN%)#6.H5!K(1`A4W4TZV*^@.EBJ)+NLF(#"+L@:(Y&MY,1N`-R"I M)F>(Z78"H1K)%@/\P3PK&!Y+"$.LEHJDN,K">1Q,G=I:RMTX^8\.@I=#[!>H M-,:H,R:*PA@I,(VWQ3/G(G0VNG%B[TR(V-_@R81_",7MI?_+,/['O!$0"6S7 M[!O2,F?G5+_UZ.@[FG[TEL\CNVWU+[]<3"]AKR]%^?-;V$87Y'_`*5FP$JN? M=OJC[MP>&?:X,S;L4<P[RZ8.T_0H:4WZ-E3:VH`/@:&W>V;QJ`_;AM69]8?=L?MT7`\ M/8C#C#8X6NEZC3XW%K4HBJE`DY;AZ7#U:UGBJOI5]7\E&!1KR`OC2?2)VP+: M.V6..Y4&N3Q0:@XJSMVMBN!^CP]&*GR^.SR^0['!/C%,'RZ12AR%$=XJ0)@Y M6-/L0W9DE55K%?NJ`'.!]QV![.':.()_JN'D^>AB7`Z$4,L5KWZ(+QM/V`RE M,4877\I#_!&URFG3ACG42T=SG]0XDI0VA8IQL\+"-UGW"V+6[/`/`X19]+#H(R-:)>SRJ=5%7Q.6T!/F M9)!'(9E/7AW%!V.6Q%%V;1":,^O(P[WPR#=3?W,\T4^AI)Y'M&P",>'$3U4]2)"`;MH@3^3".C!UP2S6V#I&0!U?*;XI*ZZ?#R2 MC,25<02`..`H#I_5T/<-]NO(^Z-DG<%$]!2(5'A.69>Q$L^J'+O+I3`:LJ*4 M+GX>[J?>"6@7R#<`WCCKH59W3"I8NI\SX683^#+FY/,*#Q:5R!$3/"J\;,E6 M.2^1RT;,A*6D@MDD6]W))C47>^YEX5:L8MADH![8T!F1P(\WA,=6W^R!;X#7 MB=']DP-C,.M-C%&_/^B.1YWY:#!Z^>O$NF@%9ZC0!"[VL5B>YTXQE9PRGO8R MIDTW^4V$P('46B;O+\)91NVWG8(@0RC%V"0!0FH,D2%#I@]L22?)>R$+RMR+ M,&\CLN(65"$2)PQU=?`!D/7MGVS[W)>WMM_^:L*0=J_7,>7]K;7K*K-0(?+/ MEJI/^TDHNPFFG.QXM$_`:-:H8YOCB65,YIT^`&G-P.,<#HQ)=VCV.I-QO]T_ MD/0Y$YB-PNJ$$4U%VH%Y"1=%]+\V]B_4#@AP&>H23X)J6\7.FNNY7TA-3L3M MJ)M2'HC&UIL@VC(F?RZ:\X!MACW58JDO'EN`CF_0!94BW)]?4:GGW3.SK)8P M3W0@02-MCMRN0VR4$@GN+;%']2\:`?#75O8^;']?V7MW^/"R]Q>L>F^F;DK] MZ][]_C+U7EV9NJI,]JKVSS_>4J5>5CK'7MI_+\[VJ>Y_5I0UA'Y//X97UX`" M39;7!G"SPTU#D+MJ:C^!.X]MRZ7/GB<[['K@A]DBHZT/AR]3)_O\L%JZU1F\ M$E@'NFEV7PFL'=T[`?&U`=_1N[XE5UJDU:SB=?C0-_AK\-?@[7OP=O^_; MV:.?%+_G..YQ)F5P^%V4=+O3>Q%[Y/!QT];[+Q15.'S<6%TP9%_&93E\Y/3T M7N^)/9M3LW=/J;56@\$&@PT&CQV#]S3(>Y%<\E+RK[SO.$^TTAPM<;YI"Q:R MI9^HE>[W5YKO>2')F_NOX*&,L$H^F%.MU%UCXCK\GXM;5TJUP9KKQ/%V&<4W M5-J"8V*9K8V25*66[BZ#*-*ZCQYW+N2ADC]`1=;> M2.3X5LMSWMS2YRC+8L0\_J+3@G)59U827A`G#%7B?QG@V/_L$^'."&V?+;\\;?/2^O,YLQ/[#LQ&[+Y>7UTS])%,W25KW79J3 MHC@#I4'?%%?CR,)U6M/S9?>\!`:R:GRC#*N"B_Q16;!__X-92?_]3U+1_S-C M^?3P_8FAW0<:Y/Y'E1N*[G\8NU(7Z'KW_Y@3\_>O:K=&JU6,O73VV(0/@%@P MDGWW_D?_C1=S_E@\'O]APMTY*6=I0N675,"=W&'`/\HA?MD4E6[;U*W^2R M<*DE52,_3F'-QV^JW"U1,N_G^&3*NYZ)4N6Q;/;^&`3)H#5\F;2,@^;)8USS M:=DA\RA>,O\8+9%W[8X^L!Z=EG$44J-C-V+C1-9\:@D^IY,0^\.8O:'[$UGS M\;L*#XIJWG&^_CBK('B^C,[OUK#Z8-#5.[TC2'U]#'H>6[O::W5?YHKZ(R*= M0:O],J'E9\318Q.F;;T_-'73>F(B.C6CZI3R+1NSJEGS<4=.[C:B_LWHIE;, MZ\RO]$LB[1J^;HRJ7MO4^T\M_8_-J.JVVB_3'^&(2`>,JB.@FI MU>4U)[*&&B^_*>XWV="EM-%2^\GNMCITY1;=%G*'G:?+:\QNHC3PQ%58"\9" MK)EG_C5,M*!KT:Z8+#O6KJ+`PUL'KQRZ6:_Z-=WSAYS6@@71#=WB5ESIY,%.^7AG M/><1?('O(!Y@$-RC\MTS/[2-P&N[VJ7?^[YBZK[]\&+J.U[Y4=^_V-1-6?$Q M7G+2[%ISG\,.P,U]#@\*@N75VXZHS=966#YFT/6-2P>,$V&H;5@L.MP\R@_[ M'JO\L>69_=8+-1U\?ECM3LL^@).;XSE@_U!Q0\#JSLQ2]F*U3H_=?+WS:BXT M&6`KT2?.C#MU@3_!N^MSKY:NK5<=LYP!^+$P0,=^+>3?L?6^]<3`[A503BK4 M?$5&Q-_?6KW;O4KEF<*:&SS^Z/'4+?OF`L4CW+3&'6O_MTF5=ZTH=1>"U2-:56T#7'^T]* MWRRC^,U?BBJ9I>@YDL8,'KIQN/93UVKUM+4?!-3_/?1$QW>>^&L<'MZ]J5I< M<=9[E`IN\%_9,AS'Z[1,;8M=0W(BC%BXMS9XD7*_#/[EHP#X/U?86#M;]E@,R?&1?%S%F?O M^.XH]*9^D";47K9 M[G\--_"SOCB+9]'=MOJ7WZYF%X"R)>T2_RMYC$7L!5PLO9]#Q[T M+KOMP6#0[5^:\^FT8YH#8]*?S`U[:D^-T63<-@:3CMD>S6?VK#V[[%Q:]MM? MC4[+,@ODW`-/&?@YF+[_1MN@0&F!I\>#7@%F8H]FYMP<&J-A;VC8X\[8&%I3 MT[#M_J@]&PY[H][DTH(7?\7]EMO]Q+Q7:1A/CI3=TN9YSL6'D"=Q2I1#](VH MT@A7VN_,04SEUW,77MAS))7T:E:.?_CX!^H[76B]V9^I#Q(R!^!W)_[*1'K% M!7/3V$]\J?;\?/W/#LE>]VP`'7*?LG\P(>@*Y$JPU0(?X,/<&90F8ILH-R@" M[0&;&+S!.RX2"28FHZ.`(G\/Q&I^KP'E!6&6C$R.B6(M8)SN/EA@DI2+F&0% M)EL"MXC/ZD^P%#=(/:8MG/`K,#>`BW+08YN(^W(/1,;2FG9"6Z:AQT5:DH`" M\ZOPX@:`S@]Q^7;'0W6K1`E0G"B2WWW:A#5+KB*O!:JH(N,4/EBP;13B6(SL)T'[@<,Y#$1V&!A7_`JVPP`\ MKXN9@3F!G$F%"9`2M&8QRN<;`;,$A6ID2A+:7/$0T)^P7@TRE>X+`)EJ)YYBTE&AS@`;3@(1X9LF*NXY(:-)"0A!J M."\N!&PJGE^#DZWP&07IX"X;0+%48.&U%LW!JOUY(>!H3Y<^"0%QD1'[!KL7 M@BLA\I!IYT5>\8+E3CX*KPCV!"P%V'UQUQ2RK>/3IB>Q$_(EJDRP()R%'^#% M2.]@(/;-3\3`[X7VQ1GA,^!N`\B#(=9(=(YW[80)L$Z4\ER12T+()D,1G(^- M@A?$%N:0@E*AZ?%")F#!!4MN,!5:CK)Q0&;B9"2ILA6L"UM3)"^3921LEH!= MLX`+(05R2-H2:V>+^$AYA@LYA*H\I$1];>F]EFE^7WYO[^'IO>T[7E&N<*I_ MYCGBT1^1BHHMLW[>.QX4/'&Y6+;"?Z41*G)B3BXL&;S73C*.$,1">;ID]Q,? M"EM>LB'HIY;J4I1U'F%`L[+WI.&'.F]9MM@56Z!5O@DP@H7A58!4X"#'4\0` MSO^XW;TU)^"V(_[2(^J!XL%06/OP*.QLP5E\3;))BE+%@LC(0]"?KO'4O1*& MU9\EPD0RY/X:C)ZXG@0+TB7G5!`O/)+9M(4,1RLN*M8$S[@.*@QT)N)H0>X$ M2O?%5GU,4BFH"4 M.3PZ_Q)&.Y2>$QQ/-]+37&!X)4G(&P7""*.,M+*K).^GCXZDCY:,Y6`L$;0Q MFC'*I9+"1Q=^HA*9%H%M#P<";X%D%..9G5W`(&!1.OGR<@M-P*(81\0:\*QBPTF7#=$1PLIVD2A<63*J M.`TC725D0U$`ASS.A`\B<*MK/K@5X5;?1>X%&'=_@&B!90H^K=5;,!)!/(^` MGRW3^"?-MDQC$B?H9J?@!@H/7&!T9]W(_Z%7+!AD@WL5^G^F`$5E/VHVD+QD M=0L+G![4&8L:4ZS>E9HYW8S?BN=,TLG@BB+/A0>"^RIM[&J0!L]&T#,!UQ>G M)+\1QGA'7B9X$#`D?__:K/#OO;&T-WBX%=YYN2*[9NJFM+#NW:=.$I01VTJ` MY[03(Z6I_OI@5KRKUP>\UB3#/B@I*L?>??VYZN/"3YTK]&+/-6MNUGQB*<`C M!_ZX<2CP[:S^VGMKNZ\/!T5V-]GJ@K5O'?M!7 M7MS%1A&-0M/RAZZPP=3S%X0<4^/+5W3I78._!G\-_@X6?Z?E6'Z.$B?(3\;4 M0Z_'&:3!X;>>?D&3KL'.`6#GE,V^!K.-0;V??GQ5G>0;##88;#!XX!@\]6CO MQR+C[)$'.<]H/K[DFS3G:YNVR_3];KQP!K, M-I@]1H8^-8;##88;#!X[!@\K1@V3K/`OZ?,K98^6E3Z6"TF/61+^R6?:V!L M8'SIM;^NN,!W%7.>U$XW,#8P'@N,IV4_?7_IZ3-N[F,O5;,&^N"T<]D;[#QT MW4TTL<'LZPI%GLZ!88._!G\-_HX7?Z?NV+^^8MI78$0VV'FMAF"#V<;$WD]C MGM(Y88/!!H,-!H\=@Z<5K6Y*9QL8&QB/$L93]_E?F`-9D\3 MLP?.T*?F^)].;+[!7X._!G_'B[_3"Q8_`P[CR/F;BC/(RT)'9"OF0QUQ8LN6$LU.2-N70-O/B[K7DI MW5:.]Z&'?HC7O*]!ZUUQC84>\[0[;@UM[:#LI>YUC^$SAV_C&R?V"!3U6O:E MA+4#;_LA3^)TS<*$:^\X$)"_]%T'K(,TC!:W/[:+F[' MB]>_Y^+V_O#A%[=;W>8B\7O>+8NV'W_'\CR*B8'^`%E`7\;:7^4*?B>Y4*QO MA@*B\DR]N"@^U-PV_##L/,JP/>:CP^_/:OA.Y^D83GX/9;/&3N"$+L,XU(*M M_#!$'04*:,-B/_*>??N.W!\]9K8=N6[,'G^R_ST\^[!PR\[NM_5NWSJ&S3^4 MK9Y<.>$*C4:T0!DL0G/3.&:AN]56#AB<9&X'$>>,'QTQO&OK@X'Y6&IX_YHB M4LTIT;'(9D5+@Y/[O?HY.(;XZ08IQ*3^$09S,R,(WW/MR+$D/1S!5C,-$:XQUO6/?-BSD[+VNA2Q!!4YK M_IMQ8.<[FYSF@Z-^(H:G/79@^C1G_S+XEXR!RO_X*KVE_RQZ% M/0$3-$H))^=Q%,*?KEC0.2S2W8K_YF\3^N##)[;\^UL6!9?GLX'9[PPLP[!L MRS3^99J6=7GQ>7K9[G9;<]&`RZ_6I8QL@=]P^[VS,[,[MKS]NS2@A=_11@EB$]-B0,EX)9%.O`/'__X MQ#`0HA7HTLKXHKWP<^%41"Z>(_39NX.'/H3:[\Z68K$Z4>#<#T&Q^4Z@`@.4 M&'I.['%M',$_2/3%.>WDE_GH8EQ\GO[R'MB,IT#!M4-\V2!Y5\<877PI#_%' MU"K'?`QSJ&OJ*Y^`OT-@]64/3Y M%0SFY5P&0_R9^K%DZ)@%#@V>1")N[B3P#&R!OX9O<7[@<22?.`%AD6Q1`F1K MP)]'86`)/1K`"6C%."SS M28HNTR``P)(XP@W`:37X<1UYN!>(S/)OCA=M4`:VM)D3!]O\,RX\C!)4"*![QIOT6X8?`=#!;J)4:^N?+=JXS!..Q+Z*P(WS`*\H/8;P;/,:*ZA`ZY MG)BTN^<+K8I$>4U[E%R!61\[/D<*XND"-SQ!D8BV%2P]`Z".ST2D=8O+=]7E MPT@K`L`5`!`AP$.;.+H&\T*E!5PF6`L"99H;^\AU#BX73]980K2MK5(@-'1! M5)Y5.7:72V$T9$4I73)NCMDFBHD9LC<`7O%%9E;Y,5#$GRE\"\B+EH*E^SD3 M;C9@!S@9'Y9Y,.=`+V*"1]%<Y-9V^A,NE/#;O?:QJ@S&1MM MJ]N;3\;C>7_>`3_>+K,&X[D]L2>& M/9U98)>-1\;`'O:-T:1G#Z=VV^QUVH=EE^5H.5@#3&41\#?0K4`]Y6GJR3+Z M%<)5@*^)Y^$_JH;"-T&K@,K,F$:10\L4N1V]B,*%2*[B*%U=:1Y#@2;,%D`5 MO"#U5K@"T^#W0I`*KLW'`.$@%X2B)&0K1YH,BF&BBL#,*T)?B#-&Q]++%&V> MEC;BTO=@:L#OX!)&&X1(1[D%PE?:-N#,@3F$^MK_KR/]01B$[(,X\E(01[`5'BEW M`;3C7OGLFJP?+2!7L[#1X`D/\"GL7%@H3SH?:,81MBD8!J[@NY0XPJBBT"! M80Z)P"S:54`D7\N+V0"\`:D-.4,01^_7YZY"Z16A:^%PE\]8$LI"FEP@@Q?7$%*IO3CV?$K'SV#4F,,^_Q M(CD-??$6I]'?`B9=?^T$_.]O/_PQWQ'9W6Y_WN_8`V,TGLU!9'=`X5B=D0'_ MMZ?S]M"R)Q:([/;;7WNF;0\+Z!\.4QDG9XCP4I#B`P5,,$[Q!TO.EI^=;S\` M"SZ/[+;5O_QR,551871V,#&UQM/N"$:=6Q/08!V[9PRZW:'1[[2[8VLRF/5& MP\N!:;81&:"0X2_3-`N$[`-0&06S]2:(MHQ=L/C:=QFA;NP`IG`4&((X!MX: MLY`!,\^!3M5?9B*L]'1(JC%/VMWV=#BQC>YD/``M;\V-T0#IQAS.+""@R7`P MN&RC@E<0\V/`+*,.4!LS&`,\2OKW0TCH/\N4C^AL_JSTTYN,VP.S9QE]JS0W/%F'` M,4-E*IX#]#+@1)!_4>R!`H^W'\#AY'^`KX%^?Q0$\.H'-/@9Z)GG1)LYGTX[ MICDP)OT)$-+4GH*Y.&X;@TG';(_F,WO6GEV"S6L!TUEFN]?I5E'W5&BHR*ML M,XH9#Q%/0T*3W>T-R\)I=_5E\&H$UXM(X7W)H8=PMGOPOQ*<=X!1AO?@Q]Y0E860@,,T"KT9?$MV_B%NMP4.?ML:6K7;?3]( MU6.:Y+!EEM4AH=6UVN7]+BV\#-.4@3\`7G`NUB412!OB$/<4)%:_5][1>Z"H M@@R2#?Q/5&KP=T"'DK#KHS5&YZ1/>H!PP^9V^OUV!?#[8:G8RA3!/%O.OHES MTT_@R)V%$_!`X37\!XD??'5R]@X0"VUT&L"!*J'A(4#=8HU(BCE(OAZ`#+<& MUM"N-T6RI9PQ>*+DX3-:]@I,0R1"[@AQ#F M24.@GEM>R9*ZM]8A\D,7V*%CEMGAF=!1]:.$M2^I$2VI0R0S$!]=J^HU[JS\ M7M!`T@0IEN&\F-;8$UZP_^S.\#YX:\&IR),L?^>`K=T^6'O=?GEWJ^NNN&NU M.D*$X*K1A$-D_W:'[/M.MU]VWQX`UB-B::,@B%PIES\Q-UJ%_G^9)X8G\3P1 M063\5HB3`PRN60\/KCT<[C)R08?Y"?L(+C7L0@+BUE\$3`2E/N-Y2R!F\?Z3 M\F3]Q!98=Y?)AL-YUQX,C/;([!EV=S@WAK/NT!A->WUK/C&'W?%,X,UHFS8E M0BKI;@\%K2X*][+^Q[Y>%JB0MCVHRM0]/(^]:`QY%K/<$),8BLO"_F=+]3#@ M.?G)&G9GTVY[#*+(ZAKVT+:!+CICPVI/0-?TS?EX/!='&UW;ZIJ#!S+5?@#O MN.+XVKG(Z?#&VR\8I$%U>'61S(,4Y,!6[?[0'`ZJKOMW`%I&VB?& MF1.[J!BFQ?$L\:@,A'@4&?H,AN!GHA4AZ.'Z,+Y\MJR:& ML#X"5"&'B)C>VU\[=L5)WQ.<2C0>D<.\[(SNFH&S!F\]N[.]+P>A0P8D4;$5 M[X"B#.YO8$7%3H`!36\-.*&\$\#*`;N@-OACW4&W+%+O@>,^A2*S+/FYLZ5\ MKD/<:1./'@:[5O'=H-Q.W=DI'%B!E`GS)?18#.-A*O`U`TS6&Y-XA,,_A%*J M/(_%_!U8&^)91N=6YOCA2*BD4]6^?8B((JX"MBIAJG[Y^X"HA#W'V^(1>3`X MPLY$E:0K0*=P\ZF/*;W@?NGXL*@3RW>":U_#^ M>:=I<)`,.P`IU[>D=/\Q8"HH^P@^,GPU9XS#L[_[`5B4$;@A M6?W5`:H[(#2KTVMW"X3<`\0NN*-5S,0)Q(]/I!];D_FX-S2-_G3:!RB&4V,P MMGO&>&!.QG-[-IKTK7L3Z==.O/)#(XDV/UO4<$I^(6J&?Z8<=:P.-[C_7_:S M57Q>.FL_V/Y\1R\,2H^WK)8F<:$5R-@G?5Y96>\)%E9474:NCV?+H;_0WDW. M#*LWZ+U_6*;_'DO%'3=\RBK_V?Z?1RV]J+(T=34'7*/N652*G$2:H]U$<>#= M8#E0(!'O9(C/RAI'UW[@4)<^9\/2Q'>Y#L.[+>U=&-U0WC.FH4]8L`+C#N:) M-Y'P\=Z+6B@LIHG`M-6S7/B=['>8%#Z+V#PL[,I?^$F$93_:.L5"*%$7N*:B M9(2%;?`0#CA66\71#2QQZ;@)E4QBC0+\4:KSG/TV_U0J],3"*%RJS+)O:>JN MWF!%!&*>R@&QD`IG#)CC:5ZMA0Q]12>F\HO; M\1P7D%;K%=>.1Y50Z<98QM@:8B,T'R+]IW;+U(#<`K2*J,J!?6-N6A0MU,(L M:KY@UQ:!OZ+R0RR@`*J,HZT3T++A_9#A_G+8?-I?986ZMD`-G%6J7T=!NJ;J M/EENAC4J]!ZA@JH4O%9.B%=RZV1=I:CK$,=78GY8!U56++#6@058SB:J8V/F MKQ=IC*!H5*@F2O5Q,*6:0Y-%^)R*%&0)S6*K,INL=)4K6&.1(]`+RU/RD;W\ MD"KU`G_M(X9$01Q-!XPMJUPSD$3)J2!,>")*8U$>(8L.-[#FE)6():LW*2,V MJ[+[TKIH8;W"+,6\+RKD_1)2B0]6/XH:/*!!1M6+S@;@N4C=*UJ#RXA39"TA M[:Q^2&$1^CRX\U*`2O+/439=<2&50R M26T/,LF&6PA+P8H_6$Z&9J+.?!?NJ'I5M5O[227S/QR@WYBD<^??@(B_,@:$HYV#U;IV7!+28,X(,5TM>R^>+U>_XX0B]J3, M2NU8N!1L&R<1:D$IO^1X)WB$B5>2GJ7(UE#J%K)<5ME0N3.7(@-X,1&B\1P) MUR$R)FP`#@IAOR-6JN5%=PNNKJECGY(=H945W1>CBI+>&ZIKRTXTB1-D1`Z@ M,38B)H>RFRQ96_5!`H5>J*^^% M7@$9`&Z7`YBSL:J/S)4P="_^@5J-4J)=J;ZMUL%+KP/MBN'+A:MD,U[Z"%X(6 M"_)MAF7)U94G40)K?(UV]CH"8R&EIMF%MX$F5!1LM7>CZ;D!HT2T5%YB@^",4QVL1^<(_6V/C7=($2"`QY>D!2DP2:\!,+,M#K58C9 MLF]7(<*MDV3\`AH$?1&I0UY\2\HN:ZW#N@\[NY1IC2Y(MC'XJ(Y"/+.(]`SC M:/8(_#&R/U5/D;H693Y?Q@>Y$Z_J'V0>,1ZV*@'OD]9,KIT85Z@>L`X'K6Y. M"S#B,HVE;YTI4)V()E-0NJIY2J7]91>]3F<]0B<]$[NU[Y3ZNWX]2GH88H3\ M]__!TG(=[*#['=]S_VZB]1.>9 MP$\IC(_KS"4):4\)X:FZ0`\P@6DAJAEHMOJJU5MKVBK[5V.\[F^Z+H53*T61 M2M?DAL$;4;U(0L#4,)2Z^8=@=WY,71\0<+!VIQN%(;H@@$IB46Q^\@?L`L:& M*#PB2$_V7P'LSLXNJL2/O2V!G@JC\?;P9Y"A0Q<4%\48714&&.YMLHTCS'?3 MOOHA6GRYL*"6,5(YP/CHRQ&]O/IZ5@3CG.7[.#]\3X,0*J/H:'R]H+H"^Z+5I`*>GV6?5+6MV"7)$P127>.[76^HXET\(C@E`TN= MP@TJ'*4-OHQ@2#25N:M$9>4VQ12YZ;1ZN<[.$"?$5\;[>8LL1M(&3S$VFTC* M=ZFCF3BP(,LGITYI_TDO3#FQ.!<_G"V7L,8[V%=AQ;EH^GU[ M1^LZR6`^J6#(STVDU;XK&L2568M(:1Y]:ZPFVY,;[$TIQ;0JN161G58_U^@?P'P\C#OK!%%LM:NJJ[^ M*ED_%,ZT=C2OEU8)%3*GJRG,$<$Q?CZPH@(6E\:32 MS<3)9,69!*2W9$@7Y7BS3'XQY=/!;;8.N_Z?)+DDN4HEMJ+2#\6++`3>[..J M:5K*.$N!,,AO9'E+1! M/"0XPEBIC,8/>H&-D9#[:(8=&IAJ720HMT#[)%[,%`@N>AL\%'"GUN5H0`34F]L:,GL(,B*_:3>4/#5?)##50F1?H;)=6*B+4=)280!QK_4J=*.;9_2$ M3U7'0P#@*+[,LX1U/3()ZW51>)Q$K*7'Z(*C8FDBR^29RL.KEUCUS$[):_F+ MNT6B$%E(O/((7<*_^1W8IE^)TO?Z@*]\P.U?]>!5RG].+I)4%S5674K2`T_)G M*FCUE%5+S=JG\@:Z2J-#RTW==WFL2N*L$\!]7$I4H6*2*6E!L.D@I4^W482E MUW1XZ/P6?(0&%\824#Y06%O;!KZD34N:X9GRJ0IS#>W#U$ESXS7/%3=:QF,Y3QDP@JP,D?D39N'M8!_IF4YP#]B";8? MSC,S61AZTG!M+@PAP)%XP"Z#A`XE@1R8Q!7H/M0A$>5-FCF\=3C)E-C[J4PM MDAF2#!X3"-[]O%J;:-[``%M2`@RPX-U:Q?:FC6%[*T36;*[X M&W5_F$*`(C#DA^T(N4HK$9QYS#%,;H.P7"(4B",$,/;9_.L=`^G*N&=MVFK3*JG[?3L1K. M!/_&]%"E6ZHJ/(SGR1`9;)N"I141_Z^CM"D>BP^X7X3G/=4Y@*^84\$#QA'^ MDIHDJVU?JU/7,3)/WV*.>P28SBDD19UTIC]D!*=!J)SJ9O@0/_O?=+H/7(1= MYU@15]OK/Z+_@P!LIC(HB,4Y*7Y5O$?:[Y]D:GB3N^E,-;=#[/IS6GX>G@Z) MTKV$9ZJG#3=.]:9]E`WV^:D!.M(^?34C(M46)&98_*RI5ODG)DL@QHPW\!5X M['OL2=705C%`)\/KUX]G4QSW=9 M+I+4('L5).BR".FY5>'K64@R1P!'#`7(LU-;B0FK*-B"0:1!S>WT+KW^)IKQ M>P2(G,7P>[TQE(2:>T,V;J':]\PP-"W38)Y+#4$#87B,AL;`-DTWL`+?]0(= M.E-%M6D0OH'J#01LHGLP4QO;UP_OOVENC:Z3GYV<;%C_/D5W(T.7W<7MD6`1>9SGZP_[&.%'S%"A*:0'Y?IF"/I+8^E8@$SY:02=;@ MOZN@?]E1I8-K06\1D&'XO3%5S,B&1T3;!L^XTK1%`![&9":!D(Q*P_.E![I( M;9=+R2SI9`33RRR'V4[.6MH+F"V?]4(=P#K](5VF_1G>+QM0Z MXTZPC37UUR8+;+B2+_N1NI9S*?0J`E0G?@[NA^?DL>S6#(?@$W54W8A"PK.G M9V-I#)\N7#L3TPD>2`M^)/9C`4_+,:EG/X0%'[/JZ.O)1CR(P73VL5#B+%QP MH&)J3O\)Y;J/N;WNL:/Z2_BK-@\11D M8I3`Q"8RM[UP9^`I'6TIBAU9W1WL1#CVE;2(Q01\XMP2>1'>84S2!HKPGD^D MY?'0,`.F<%:DX0CX2&%M\A&YVZ$\6[YU!;YU:,O-!7YX5E[CWSW?V,CKDW"7 M)3&O@H6OL\51Q8$"YZHW/1+L+KW?A(B'>>_DV3,//!YE9>;MRH02II#+,.\M+CBMF3TE M5C5G&[3["CZ'4OC>@#N&8SL02YG$-IPPM"'GX(0ZTN*2VQF?[9+SW-'R:XV2 M?1?]5%_ML-QH]O&$?;A[1"1NGP&?=IZ/:X7,X@':)WE0E!)(*B4EDM# M-S`IE6[[#CH2H.20WHZP.FJBO-DG4_9IF1'W5J,\,M?4LZ08`W4K2"F:5 ME"3\8H/\\5)#C_+3'0E([?O)I^QXP#Y1&\>QDQ`L$?A'T0MQ MSIF]UM$LU_[8ZC)I<\\CT@(1>I]PIT*T`B'4[((`#N2<^#!1%"7#GP'^YI7'G;8YHVI5G>XYH,D\QHJE- M[3I6`XY`S7<,CIF\,N,<=RX$E0?KI/,M+P9O#M=^1.V71+%W^;H%]?\FXAO>+ MN3I&E+3[7J.O&(T7\UUFU*SC\"I']\5P9VK.$5PFRB,D]Z-L*5))VLJ!M:D( MFF7#/HI6EROB^2N#7%K%<7:;R=DC2H/U-ID4J&?AY-_L/.*F!HL:B,E49_.N M,=E6*JMF06),D@P(6IFBY47?IK,HF[D8Q>&O^6PXG8%"#FCY$SO():F99)<[ZBO>?6F\[VJL MNWL0?SQ5L!253):G*&T@HB)W`9E/RVQIVY4<0##N:9NK*Y2!D4?3 M))Q=;I&E^6>-S8ML;'C@T?@A,+>A!XP.//3`W.&4UCLAI[:U[*7!JNG:P12W?OA4U4@HY<[1K:OE.M/&<7;- MUIGT;I5]Z9A/JLZTRN'FZDQZGC;GDM&NUYF:4;2Z7,$Z$[VD]EG5F0X885JK MSD2?5IVI]4F=5->9N.3F^=:9CL`EK#,)2IX>C*_^3=(`,P$=-KN'B M'0_/'4[B`.+]@37PC,`6U!"#@6-(%V+-4-JA19R`"]O5AZCLLLPV$;"\?FD_ MFS`"3R9VD$)(]4U*E]:^2GPIX/DJOUIN8W<2FJ6%'D)#JJ#]FD_ M?^4XY31S^:VK(BY83Y)ODVBM@Z11K%!)5A$JK;Q]9RK=!\3D-9-B5>E^9'7N M(R@31[9)RSR+.O<1^`$9K\DL^]1U[D,HK5=^5(N?4)U?YU_G;M^]4+5VTO,O MG:L#1P.S0+U M?ONS0-T+[A;A=(R'Y!-\'B$F.`[OF#V+KV_!W/_\_'8^O__MQ8N?/W]>QM'U MY??ICQ?^Z[\^?P4$4F%9G(#OR'^6WRJ.OJMS)"]_?9V-;T:_1;]PG.)H_E;# M--Z,<&@#<.7/SQ,LB\(A,F#/"D:T^VL4/W^E&WFC.)U,!NMTG,!.ZQN_?%'Y MO%^*5ST M\D7AYJ`46H*'B;-D\IV29CERSZ#MWR0G1+08:P5D3U*@:M4Z7X%N"2F?D$A; M%^)YD1Q+GYK&;WI+LLS>0S(@7'98^V?*6Z9(MH]WN'6/]A.HO?#>^B@GIE,W&+ M$Z7?C*\?MX)M/(G>*8W*,7^2M3'\]P+>"NLYTTGN*@H[3GIH773S>3:T\P)+3U[Y_N/T>C2.YA#B?VW17Q&# MF#4,4EW6JD$V@//46V0[%OD["/Q?472_->#N3?$HH0-F]WYF5T7M%X81-2K/(MVM7Z?V1&]TK=4=<-]Y/^/)M'U\,M? MW\QO'J_ZLWKJSTZF_GW@]32,H0_!NF&-^T_0ZNWOK+>`NE'V!?5G]<(Q9C#G M!!90?]AA;P]G;0_5"U(^(VUY=%]OE4>PRG0B:]?:..IPA[?)G8VSC+OGB3J] ME5"_&:VUK80=1G=W2KCI^E$>`EX0YJ?H;N1.)HOA.'&;GR)@RDU#/C1;OJ:3 M[W-8LO`U<@^:;7M$D]%T]FXZC[8M'4]`B\!'$-/JZ*&.^FHT&,WB>:]%Q]:B M;JI-+[A*P?4=S8]3K/W9O$\A^^=?X)YH ME`]OT"3+XLTN>CVY7\QC=05_4D+M&Q0Z4`Y\`@T*W5+[;A7?NL.>'BSAV)W_ M1Y=H'Y`]%IEVRXEU@#TT\?!$]C6>'=8>"?_76GOPLK;$QBFE2FS$$9;$DJZ0 MW.JFW-(AWPJW-1[E3DI%6.'\=G0]'+\';S:>?G_X=#V*)M?1IWNW5=]$J4&W M2C&[K`4IDA+R0+]YMYLT1Q.<@3,O'95/_]::D(@#MO8+'*4I.QH2#&"%GT=O M$%7Z]028\7WT=1RY<1S-8^_A[?"?TYDZ]E-VG!F,:STQ2<"5_ MFO9T5)6ACTQE.J\D3UA2)Z\O'9-FUH=O3>DG.Y*LNJ2?K=/`)%Z5+!Z1@T]WUT.TD#V^-:*\EW3P-YVQK8 M@THW48MO64@]5/0>=F.UZ[DUVG^7?(5($>C;V[),VX>!>(:9&27F4@$1X2($ MA3A/2&%US(^T6TZL_?B/P\GWI>7S[6@RNEO<-?4$7)_??W-G,WP2,J<2F`J< MZ*?A&!;L%*"JU:8FW1-]--6T!689O6H>KIK#7[UJEE5S,1EIO1S%4\&H?15^ M^9BITUTTC!>SZ%7RW6_PW`L``00E#@``!#D!``#M76UOXS82_EZ@_T'G`H<[X!S' MR;:]#79;.-EL82"[-FQOK[@OA2)1MG`2Z9)2$O?7WPSU:EMOCJ10RO9+7FR2 M,\^0'`YGAN2[GY]<1WL@7-B,OA^,S\X'&J$&,VVZ?C_XLAQ.EC?3Z>#GG[[] MYMW?AD-ML=`^,$J)XY"=]IM!',)UCV@K_8E1YNZT&]TQ?$?WH#7MSJ;_N]<% M^9>&/TT-/OKM>G&G79R--6WC>=NKT>CQ\?&,F&N=#QEU;$K.#.:.M.$PHO=K MP-F5]L/9Q?CL,O7-@OG4A,]3']UP$E`V@:)\_&8X'@_/OU]=7%Z]N;@Z M?_O?=&FVW7%[O?&T?QC_A,+GWP^AQJ6V.%NF>.V>,KT=`YG(4%1Q\^XT6%+YZ$O9> MA90Q;$TB0/5]YN2]X/A.UN'3(( M/]MP8KT?&,Z#0,F_.7][>8[UO_O`#-\E%*":M]2SO=V46HR[DNN!ANU^64SW MV#<<]F`+!@/78>N='$1>."1'6'Y4V.2H+L,+J/G[TH-1AS1FUA08<SY<3XP[>#D=(.U"HT M&H0T$8)X*,\[6[^W'2!&Q">BXU?FQ/NHV_Q7W?')C"Z(X7,.UH04?&V8SZ7; M(/282$@7YY!HIU-/(-4@0-`X#C3\J',3%%TL4NN./!#G<@HV")=K*>B[-065 M9^C4^T+9/5I#^KU#IG3K>_6[NB$V&A3,#+0ZOX%A!52#@5@;9$:3#3(\18-G M;8,PXGGS"V/FH^TX[0S8DPDVW3L3P^`^,6^?MH0*TE#_'#;:(-,WC,+FRT.) M+0FU&?_,/-*2-CF%5H,0<>]B^@[,W!7SD`J8L$1XH33!KG5\DYA3*D4=F+GA M=Y^)-Z/`M6".C5LZ,[998`6?;7'K";SB(,/=&2<;J`26\1T3`M0_`ZWP)S$7 MQ,&J*R;1UA9BM]`TV4T>,_ZW88X).^Y;,"2\73NCL"J=1B>9NV54FKJ!ODW+ M-^@CE'(#$ZP:G29[;0.[C6MTKR`QH"2%%XZX9-A,*>BPP(,!)E'VP*O?LPWR MTKJ(6AK<)]!J$J+ONCK?S2PYN6;;0)$8GOT`TZL^J,+66UDI8AQ7)MHT^]B@EQ%OL\F)J2K&NT%G6O%*H M0K-U#7KD76MQ>2F@I1!G2[U;3K%MS+%?D9J'7L>7T&(GDF];&N$Z(F`7@N(' MKD*G92I.\A)B>2X?'95/2[.G'C=MR^J.T?6*>5FQ[$MH@.J4.R.#EOK_5/IMRR,5U;+2'JTPIG##!/!\Z,]JT6*JRT_' MY=72J&J&J];U[*$[L<6%))]4VRAO=4YAZR[FA$N1MPPGDF]]]?3O!?G#AS]O']J=P/F40HQ&DE2..>5[6*$LH29FJ`:? M(JT&4X,#!D8''+P$6X6YOY(!8`&DM$?6P=QNQO>[/J0J$[@M7=S++&Y?#->Z MOAWAD!@1QQ/1)W*0#,_'83+W=^''O^,.A:0"NA$-1[\GSOM!;K&1`EY_(91P M'??F$].UJ2T\+N56S'I9+15(INY6MWDT#/;]##"5;(\XP*&9@ZAJ;27(XGR( MCYRY@;KS0>,E20#7!.9A.HIW^P0]PK@)*H3OIC`[Q&><0-2#"0/\K:-DG#QI MM$A1G02!SW"`7L/XM>QB],>E3^/\>!G!3WX/;;"/A.#:]EQ.:7',7V\R8G/_ MX;8'MLS,LG*0-TZF.[(*>^_V";,ZH4\C/%,ZY\R0`')7FSHMQA)(F9@3OB\, M:#NB#'\>V9?[Q_7"$B.!J5S8VA#6?C>J;\%R^#++9(2`%<]Z#=HB7!Y'_??Y M^4![)'CB4OX/_VVYS6"T[-X/+@::+P`WVP;Y+E^7X$K45"+#M_V18>8*G$;= MJI!CD8W/7YW(,NS$!.XX#7?8;;RYYD\:XN+;EI0XS=.Y[J$.6/YWN.LPBIVA,<9.:6LYY1OQ,,6-E]HUQPZ5DZH MJ$C"ONO+J'71<3D\-VF!]9HO]Y-:48(T/I$QUVVP-F_TK>V!PLA!E%-:">?A M,?=L1M,'UE7P53(C]\JHX#+#@(SCNAZ>E+#-<-<:J8U=#I;GM*0",5XE@]%K M^(4I3P^Z(^/9WHW..1[WE!GA.1BKU56"BKDNHS*?JQ#`83$5O&*V87(Y1B2[ MB8OK:@[?A5748+`(S%H3]'5J/46O3>&$+ZVF)!8=)HKG!9VCK]5$$/?W=K!( MQKZ1$KXK556!*=7S.:RG2RCF$-3=<99H.=O9U11C*5Z,:]O%#<;VJA@/&045 M\UNJ_K++*N/Z%,U=4$$%_W,>KB2E2WY6244<;V&S$.[GBH=V=EDU7&/PRMO- M'3P*2TU49')?"JM)+O,%5=1$CCT=3',SRM!-[4?!'K&-W(2<"A55X*F\'A6M M0"HAE8#UC+YW&F;7Y2W)*>M2C)3B? MY<9-!/%Z.KS<+Y>@[I%M58JZR*.:(.Z1@56"N&C_GN#MD6U5U>66H]W2J'MD M>#T'=5:I&/Q%/U59P5*=EYW0R^398LBGI!'T,A&VS2-*V(^-7DHD<6KF]Q57-`)_.?L MRSJG=RG.8$ M)A$H7X,379`/)/A]4JI33A,J,W!..V->5DL-$E@70'7@P(&_'9G4CP=@7,:] M\-+B7#@5JJK`=&M9H%5FUNV3(6?,`E3/C&8/JAQL)S6AZ':#O6D0/!N1VJOE M)B:5U>L&FO3+0N4Y2]7K=PA=?+:B,(NX8N5&LNB/:86!B>0*SM,S[.LWJNBN M"YSF;T9XE1!#46Y7P8A9G2, M/WJ9#IG+3_W*K:$:021/>2=GY'FJ@".[7G?0R,LFQ1?8&N-C=C!^[`>\KCK[ M:23,0!+!$WCR9:_DM:B3)-$43279AG3K"NTTST$O`T3-;&P.,FSS395>YOFT*Z,<8ZB7 MN4$O):G&#*U>YB.U(.6B#5).#E/'+[YJ9H=^L(1FW[K7HQ!I\U*I%C'H9>IR M\\+*V_#T,M^Y>?&\6!2VEX>:VIB[)7'+7IZ':DY.345!!?YO9TMY?VB0E]9=/@--!-)-#9U/,+#@*W/BQ:_USNB"X%D/&)^R&SK! M>\Q=R'#P2%)G1;U@C@,K:Q_5\.(I7 MKL.;0@!C_&9[9RV'M(D?;[:_HLN/&^4>-F,6;"AD1^/EYI4@Y%52DN;M;AVV M(Y%FKMP;Y?74F3HG#JR22FKO`2G#LA=X+^_+7JZT)PFA;&+V/.RTO=>U\%@I M!G($[HZ5)R[,,JWZP:'L763(]M4PLGU+BD39LY-,'S1"2#A M^V23-2==C_RD7AWM+I.8E&M[@2310`USBPR[>TQ+RWC%XNL_4@J,KW4:+IF) M(6[+1+UTX#AU=TA2.9'%"GB\=C`]^6L`.8<&L)L["7:9!$/#X`0,RXCC;O=3 M1I9?7X98')Y.&.ZXL`LY7F$`IYOC^SB4WFTY%_#;82G',1YJ'D:`^C(E#S+B MDJ3,E,/PE6/I\`"[8W2](MS%O7RW99_):8^PJP+)]&>F5N>]P#Z0"T59Z MJQAZJJ4_ZFBCV/%EK":F#O?6T;ZXVQT1W4XY)US*N]O`L` M`00E#@``!#D!``#M?=MRX[:6Z/M4S3_X>*I.S:D:M]ON9,_NKF2FY%N/:]N6 MCZQ.]LQ+"B8AB3L4J8"DVLK7#T!2(B4!($`!`D@C#QU9PF6M!6#=L?#3?[[- MPY,E1$D01S^?7GSX>'H"(R_V@VCZ\^FWE[/!R_7]_>E__L<__]-/_^?L[&0T M.KF)HPB&(5R=_-V#(40@A2=C\!9'\7QU<@,G012D>+"3AR#Z_14D\-].R+_^ M"?[J[U>CAY/+#QGY^1C[^O?76-(,AG]C%(7TXN/U[\<'9Q_\.-/_YXAGM\.AE]&'VHX?A_3U[B*,&MYPL0 MK4X&87@R(KV2DQ%,(%I"_T,Y:%CB>X(I&B4_G]90?'M%X8<83<_Q-)_.UPU/ M__F?3HK&7]Z28*O#]T_KYA?G?W]\>/%F<`[.@BA)0>1M=22#T;I>?/[\^3S_ MM=X:P^&GF^9UL'X\+WXL6B?!ER2?\R'V4KQ'R1S#R3T&9`X'80I1A*=8PI90?-_@Q,7D&"+;=1!(SI#.8!AX(U>-V M#9+971A_3^XC/T#02P]'9G_(@Z&^"1(,09(A^`12_.]P=#`%Z#$$\&DT<(R$_^(+T#`?H%A!D<1B/H90AAU2,G_,%HMIU7(>J;2XA1JXB8R8*?T)_ M!$/2=1SGV!Y,1+NP4;E,:>S]/HM#']OGMUB12%=Z=J'H/$H/V7P11[FJ6_#; M.GV+-2)45G#`Q.91N6HS;&U<$6<,F0S/E!.OW''5MKF/,`\K_!U8):)OO,-7 M5B$LVDFD:7-+S*42Q6P^!V@UG.2':[@H&(F7!DM\O`Y'BCNZ%DG!H"-"6+LH M=LO5JFKS#%;DNP%1%14R^`.`4$B4A\`CYV\T M3J!6Q,R#M"`<$>!1BGD;C+Q`GS(G.:$:1U2N=HSCC?NKQK[1%&#^GD]6:3GD MP$1^W=M2\YU5G2N\QO`MO0HQGVE)H2,"V#6*/N,!R/ZPGK(;0'53^*7R'!"= M),L/T7IV?3M1<%K=V*^]HIB5O`91OD+'.(>"T^K&?N-1JB;7N.3\V8SB.B;. M,O5,061.[1QTS[NF4;QPYC*(IZ;5;9Y1-\X;OV+D[WH=C\'%)*?738U2CB38 M"B'DQU"53LM:G.089&D+AZ7TT71Z#H-&-ZT>XF@ZAFA^`U]3?3N%/HL1W#2M M,F\N[9KMGI>5M#T&!Q"?V1H::%I_V?EUTZ,6U9K4/5IE3.$Z3C#,N_XLC1K3 MH?!83B]-NTH-5-KY[*X[4:,@84^E&\M;@")LNB?/$.4DUXR;=.&Z\J,<0 M'MS)=&/*<:D>`W?)Z;5+S^PU@7]D^./M4N\!9L]4X@B0)XHF(V%YG0I-,I5_ MS+$'87AZ4@Y!?\%>_#?#4/IG^+@33]7`A>(7ASZ?[OY]KAZ=TAMUA M5@W"_X8`W4;^#69Q%-"83?5#N5ZS8FZL302Q?X>_2RA@LML>&TY"(S$HJY;' M@[&V[?$I@_=8K/$`I38W`FUN"XA!6C0]'I3%;F,?(7J[X\$WQL-RP,I_U@]- MP7:O\82(!/M]^/8WN**`16]W-/BP8AM'N3O`4TMKS;0C],8P3(+GY9S5_CD`+1]N\;>"I=;H"V(<.*X'J84B<4 M,V?*/A,4SP5$U'K*N$%(G,3(A^CGTXN/'S]\Q/_ACKG&^X68L-#_^31%&:R^ MQ'8N5D5OP]P6Q*HTG)(/IR<+S-@17I2?3R]/3[($HQ0OBJPF7239,194$*<0 M$VN"?/AX0H,/SWGF"XI[E7*/ZU\RBR'2(5EI\[CR55-=\@>/&Q)PCR M;;@*7T,*#M6'*H#UE@=DC?&>S5#M5U/+N>=PW\6-8>=L+^+:G)7%YZ?S;3_R M$7S+W,HGK2VT"4A>_D?PL6+O.MF.V,9NU MMR;;PTJY=DCNGD[&X(T!-J^'"0QVH]VDAH,WP.(C"+.TVE8[6#3UZHO7J#U= MO$(8GV#Y!OZ$+<$00\C:*:*] MC6"VN2=\A[E[D0:0X6U=78Z]@EA^U6^WW;[A%<%,/8@`6N5"_(FP5JQ;QB&& M;[J^I,ZBAL89S5$0PUENT"N\?RZG?)!O?BOSI>X@)'DFCUAS M3=(X@LD(+F&4[3(!H2XF5AD+J/K5?>K:;KCP#T7B&XFPZH]P"_!4;(=AN&$XF#,R53V,/K4>SE"##E]R$CFJ%`+C6:F,M>,Q.P;NS0/?_(#K24AD;AI>5V,!J9 M@/-72"KN0G^PQ$QL"I\RXJ@J2V[47$MBAE_+P?KIK#FF+U%8;R"H*6&`E:?1 MOGAC*VHTFN05QO:%'Q6N_R'*0D4B^X*7K4@D[-VH,+WZF&>DQQ!]K>$S>E` MZUJL_F!.]BP$WMXL9'"80\Q\?R_.:OD7$%Q&V]C-92*OR^/&5X$/MIIUP2M.?1LTXN)51`&3@]+0,+R-PIO>UAC4,GH'IX,)^)]1 MJ0KH03NZ%W0K M;X_NV>M"+DDS+J2"-.-*P\?>O(]F?!CJ;1=R/T0Y2S?2 M.[CQC:W\!C$'^P;G2]M9BP#.#.6ZPM%VEB*`(\TPKA"TG<<((,C$S12+>7^7 MK60=>?7EXSF>NI`]=@CNK<*XQG/--!.E.<+5A1MWAU&`%Z?LPNV[0[#G^1B[ M<*U.$3/LQDVZ0Y#E)C]TX8[=(Z2JO-&_GVU8:1%^6DGEGI$+57DDJB:KL M1:"*!#9S81D2B.195%C;Z_,XU/ZK8RGFW;#VLN4S(#KA#*:!AX$U>RL!PS)$ M.=A^SC#7E[49R0XB/0W?LRA>.QADZ0QOCS^9)>AX/:S`X#Y),G'HR]960,Y^ M+5"H2U_N6FB`YK=+=Q>!JM!*LC'!SN;Q$F1F#9ULP8/+TC@=;(&_F;$U]7*9 MK9HS6[4E*\`)R,)T6[?M8+:"RNP++(W,8^3\FFJ]?Z)RM3_^SB:):]S+J173 MM4SN0N)W>RSIC]]9G/\M7'6KV9#O0@JX-+J\8VIO6D!+-/?/J+UQ_Y8H,@ZH MH;B$+7$ELRY,DNQ^%\;?DWN\+@AZJ9$J(=B4RAUX:;`LPID-!8QT3&5W_:,!0@!_F^-\/2,?[Z,B MDQ(O?T.N[06#C,>:W=59THM5\0X[WOL(@@3>P.+_4L@QAC!9&4CNK<&F7F8P M66!F'.3'`7\.\]<7R',D\QBEP9_Y]TQT!+J:P.EV,L'R93BY??-R/C#"0F@8 MT3<5`S>I(:SRZANJF;1]*#'GW<[!9)"YN9\=V&QDT2#[)0:P!+_\XMI> M6J4X>HS^%F%7J56\6J."G974VMV?J[PC27AHVSJ\AP_J8H+%5L"J.DT]+U,Q MZNHY[<$%QOXZ<-#NT:&!4RH:W"*ZW$=+F*2*]X?HH-VC0[O](3NX172AF/>' M[P_10;M'AW;[0W9P0W3IP`OF6`_//2K#27Y3-DDRS)@A>8V3!3.OATD,QG'Y MOB2SGD\#0@(#&*K_YD'HKY]^6F+(2!T?0GQF7@F[AVD,UON%^.PV7GT!/.C] M[,&F"$Q\BWR($G&>R580G(AIGS+"/HD&QTKX#EC(ALKP7^E`]5Z\G=*)+-]$%TH,'0MP`72C!KG6#'12F-U[?W=U957N;2-56Z\^= M5E6RL3]W7U5II?VY)RN7<]^C2[-2MUUZ='M6\@D;4_=HW_'ERYL@(4([0_`) MI/C?X60=@,0+=P62(!E.GA%,,,Y%T'%3"O(^FL1H7D1P562Z7\=A"%[C,K89 M^0^!1T(D@RF"18R3D@8NT5%)-G[C5-3;-U)=^W)/R)8\?\9*/L#DH5B..,#; M^P6B90#1XQ;+JR\?M[T:B(H-<0?S(LB/V&9+TA@?Q!%4ESI>=T/UOAR]YA*:H M&ZU`QU=4B:66X8@I_81!JKX9XT$\')G"55O:SN*B0QK(Y@>5-OW\%HQ]1U7 MA`&!;C;3HC M;QX,2RGXX@4P\N#+8L`V]9NZ*('K+B.ZQG.AMS5X;ZR=[;EQB(@"&BR)DA7P6.'T4B[J. MT8XCRWCBI`*,MIU>QJOEB*>"MK3<.QPD5X%ZH_(M&S?O-AD8?H.2")_>!Q%J M3+Q$_`<;Q`Y/D'+]/5NW\62=*\;9@)C@U46`-H+::.I,4;TFSP/:5"YYA(#\ MY`_2.Q"@W`8:1B/H98A81GE6O9%TFAS4#4@5#AO06'DES1U=L%Q]<-7V!STV M&X)W!FH;OSC^:.L<[-F6.RNC=HZN4HD7^U$WO@74H<";`_@MBE\3B)8$SOMH MD:7KB^U%^4VL9Y#NUR%(Z%=PM$_G:-=Z.D.);AMTZA!QPG;L]H:AWWS\KP`+ M*>3-5@^DT*`8*KS.1O'*MTZ2`W/!33'@];`%@T_2&'RR`8/RB.>Z^_Y&$6,6 M0F.\"RP/XG/]2LBK:2@MS!'1WD:2^.((KAX!^AVF=UGD\_/U&8V/'1[6HL?7 M?0`*5>`>!YJU+X.(_6\^,F3EB4:=&EP5'Z5)(6.-\2BQ$ M906U[$@\D=Y>`CXE*O7$;&F;""*V@732PXXM(L&I91PF5*K0?'M=2(K50H%/ M^Q1XG]5LC(;QJ4NKN!"&B_NZN*^+^U*A+V3!.,[_?YFG!4T@2HKG[,0(P!_" M:L^[\_,Z/Z^^96@X6\85+^>)T=I(AT-,&"S[]$/$[">K3*J3I.,R&M6M4T M[R*UQ1HL?PW2V;XLV%Z7T8XF549POV(\R.-(Q1.!Y*6.6X`BW*SQ:&F?OTO4 M31CHE6\]**4D?RXU==IT@$;>NH6D5?4,]!9=CCGS.S*,K?+Z6V!D-#L*-.@G M5((ID^GOP6UPK$51R_C-1S?,D_BH$L5\4H-Y@AM0%8TG4,J[TQ1;5/9ZU:P@ M3>?2W"P*C)M*#7C'WMAA.H/H&N]W21:0=@S#/*C-H(A2*'_ M#%#^@F8!(,.^%.W=ERO=_;HLE._`8NOQEYG24(D/8/\(L+RNC=*IM]F2TP5>(+]OL36B#-!]'6TUW$?'?C]>H M[Z,41-,`X[5)]OD:Q_[W(`RM>9Y.H!0Z50-H[F?)\UE'??C+O`EEZQ-2B@*Z MY-C"AV!)_)7;A^MJ]0C^$:/&"C@2(UB&807=$YCS3Z?L*.\&4U-UFMA0YKFL M8?$0J_^/+$EI3Z:U'\<$MFLAQT!B\[,)V.[G6$]$A#;#R2X)"^J&A+H,T$5[ M&\$L>D:QA\79"":0N*JQNG%#?-#Q@@#,32X4ZZM$$G&4(JY'2JB?&;IO`_8$ MT]LW$E,+HFG#21#JZERH!;&J*LT\+BCTP%CC`%8]7:'N`2=3%?:/_I21!5O:B>DWUCO0VZ+?PG2SWKG>>BN(&D_6>]K;4H"VX=WS7Z:>:Q$U!'J0 MS=<.Z4;=VGABWI$((*5/RI:<,Y_;1E*G,^AO$J?-9+<1$&K)IHWY;(SV2MQ, M^\-SO4N\YIK@8>8[L9J:<+J4L&";88+91[[I[Z#@TK(ZF<#C=KX(XQ5`"9O*6OIJP@<20.O_7FJR3*37S; M>A-5$M^F\VZ]0=IN??FH6IT!UJ`0V6NRO>>+--=QM(0H)<;3"XPPI$]Q"E67 MF&PO]6_@:UK55N)D`5$:FM!2ML&X!@BM2,DO7L%`;A<+<*@V2/&1')1G%'CP M0@PA3G]+L1N1[7X`=F5_J[`;XUF261SZY*$0Z&5IL(1C!(C+_P:LQ$Z5Q'!V MXOZ,I1C^"4SAAO[F5Z,.X$N:WPS;\&>A]>`.8!X_EM.[J;5YR!]! MFA%#B/`A(>"W.IB'OS%SG=F\P[`;2J_?!J>2R3VN0A2.XR)`W`PD;2M%>YNG.RY.FM;0`8HAVU75. M0V/P)DD&(@^;]PGS$L]^N[[$$%V=;Y$ZWY?2=;XO;:CSW8$ZS/V*83_$T10; M%W/"+\9X,LX)H#:U`6;NMF`T[BCD% MSH-!%&4@+&W^W(M4?F9?.!?II@>^%U+MT)<'D-;/R-6X*A;'E2W[[4Q`^RT" M\QCON3^A7U>%RN1%!N@-GXF+''>LQ>[:-;7E,6PV:5ERR8I8+;W";L1'L M;ZK5P:39#6C;G&1U,+)\3[+-^58M4.RM>!>:B23\5 M/2[>!SVV4G\J['NHP,FDOU6$Z(4Z)QR3J_#NH6K'B!M7./=0J^-$EBN\^Z;3 MM,*HP[HKN(8,Q-015H6Q(!`M7Y^!D%]E[DT\5=OR`?7=*K`BB M*?GHFW`9%>L1I\6_2B1_L#QT]WX>!#;UTM_E/M-VA<&.&83GI4OQN+2->'). M\F%H6A&$%SBB_'RLK=*>^[DOU0D4\\X9O5)?U34;QRFY05_$FTJ#IGJ=-Z]P M@?^,YVMCYPFFPXAX*.,P\$G`.0\[Y\QL.!EBT5<\N3R(_.MXOD!P1G;7$I)' M?\GSKM.(&%%E391QG%/02.&PPI[+@I[%EUG+ET= M[UI`7Q+7=\XK)^V2UM(2B#?U?.L'2QP->G>KT[A=5IEI"2]!&O$=V[,,,[YH M[%E.&963&L\EZ[<'[#W7LLJS.TB0'Z+D]H^,(&A+':N\%G&9?\*]B4)I:$*E M.`!>0[=FZH`TJ>OTMD:@CN?S.,H!X=[SV&_7%T6]7S?\ZFG4ZTCF<%);/<;Z M-O6Z8<$9HF3_![_A,;%:'.YC1=M@RL*[D4#F[\U@#3>N4*2?KS M2I23WV,;5IQ`@EN_"_:K.-(U;MH%6U48,0&Q;=QN[5L0L,4[,4PMQ%Y[7#66 M`HJ#\?04P?!NH^ZS)68IPMCXXHK%=P_$LTV`UW!)\?DBCB!Y4BX/<6[%*HMX M)XE8&GK2*)MG>7R4!UJ3_T!Z&$,/_8@`26+.DS%X.PS5S2@68\JS6Z6&,(PC M]9%*KO=(L'-?7$H'/"J5>XTW#(SK^:2W[234![EL^^7`.X!56LL?-PK(SN(G M(HXF:I]C^RW:RNV=!W8DI$2/?1Q')&9U8KK@+E!!&%EJV!X$;Z-;]<`:;XNV M(,LU;Z(WGP:N5L'@!5S5U+PKM&<>-%D_"T_\;[VN2%]YF_`5<;<KEZ2$-,MUGC[7V!;K:R9/F,BMS9H_D)G(T61;`;P>%F'`M7CY?7J!A;/? M-[0=P022NW[X^-V02WSQ(A<%`N=6I*?A)!PJBQ\@K'1-"RY^M:K:E#?/!]\! M\@53=@XD7G/!%PN"C\LDO"])4_UR`SJG6>>=3[;?$G26L[U6HIV6L[,*WXU5J$IS MZ8(WTR`%V]A\YIVD1ET5>]&BPQR'U)O'*VI+,EW[4MV0;LDA=@]C:!08I917)?/N&DFD"< MF;I(L:^X8;I!X2LB=XOU4(PV4QCE/K5QA,9T3E6T($IO#V#2(O2)H=;T>8W1AE7YMQ>Y7&;02) M`I?7E<7'#7AI!D+R=M@EC\I'AJ2+>_F7PF*)?.*?\?(B^[_D]6WSK414L,%T MBK#*FL*C\-7V\/23^EK9L?#T_:2M`>9](%!=Y.G2*+,8+"L7PR(`>W1.:@+0 M"@D@`$\_J6]"`O1#3V]&SAX)T&>M7AIE2R1`&P"M/"=,'VN)_WJ+;?Q`.LZ% M6B`Z26>*>]($I67!Z"2MMQV;)L@L`8%UE<[KH;PUJ$RGO?Q`+N/,99RYC#.7 M<=;F'M)!48WWFWRF)23YCA//6DC/]YN@IB6#X/VFHQW/Z531^-\=C36%=BH: M_]716$\@OB+Q9T=B?7;TALP7]I9HL93,DBZXBM(7CM*:G7`5K9W-<-P`3$5Y MIS`?-_FAHOR[U*V/G<)6D5OLOH8`%] M!P*DD[RR4+C<(Y=[Y'*/7.[1,=-E!'BCRTS2*]K?;ZJ24F.M4S7`'S"Z40(' M4P0++FE-^6_R8EV&`2I(3GCT".;/33X#E`8PNJB!:NV_*JDQCJ_@(_`Q*09I6KC&7P"FR1B@*=S=!VU& M4`+U=1R&!4T(7XK\_0.V[V^0Z'@<&*EN&JFN'8'S*&_HZ7-],>AVEY'@^*C8= MB7]4^DE>H/3;`BL046,NCW@"5**5T"DC%.=#.(V#*)VUX-1#M, MI/R;1&69;+VQCW;(V$Q2H)?5T$ES;T'XDN*+&`W(DVO_`R/H@6]_>TA]SN:3 M'$(SW,L@!.,9MJ07,$L#+VD#.&,,O9!_Q=K:[Q`NN`==N+->6)\GP9^MX-SJ MJ!?&Y`G,H2AOHO0Z`G3B'(#:SWH(M7&IM56#1Q)>X=T^VB&3H-U^+ZNAT[:N MH]C#&FF*[=-7">:RWTL3=)D'%@#)P;;31P]D4@=!\PF0W%S:]WQK>`ZRD-M[ M_W8ARK4^[DONO!XJ:7H'88(MQXW1F(RP;1GMQ6Z%NBB!ZQ&\!?-LON7QJ-F[ MNPUW]R8- M_I8C*<%B!/W,RWW_]Q'WL>K\#8.*AKOTI>&E;&Q%F*Y=)[LN$[8L:.QC@KO0 M2;GE:"ERKL0,G*EM[24A(WLBM><_UI47`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`6 MB!)%T_I+HO)&2Z*RJ& MMC_A_\\`2B$*5^L)DQ$LXGER@#>.T^4B:3:6O%*C(SQG6,<&2>W\W+YY849> M7'F(HRE>T7GU$TOA.G`PZ_'F759L,9`=^&X>AWK$_\ZS^6!.?*?%[RGTM%A)[2ND;79\SW48H]!V,;#95P)/@J!#M`ZNI`>I)%`3#72>#J0 ML"^OO8A59F(9,$F>XA0;C/%=$`%L?8#P)<6KF-LE0S0%4?!G40@^CI(X#/RU M,_(9P81DHI`_AQ-*Y\K2&6,8K["F\'N7G7O]5:B5KS)=#U,^C9%*(FN(F@P+ M2D.C\'*KEVPW_2%.:?R_6VSD+$&8 M9\4(H276U_E6;50%'P*\8CZAB[!:Q^UB`H='@'Z'*>&C+]#+,%\D`94E"$+R M%;9-29IN]4NQ+QFXM1K*!,Y/\'N-C2#,A[/(*U/9)#B2]#!.!=>L@A\1SF_D M4;?;)`WF&!0637<:.5/!F0H&3`51MVA2C+,&Y;.&%-$=:4"CY*\Q`."!6(0<8(%8AU M=DYU*Y40)ZR=L';"6HLC4)"I.F%MH["^`P'Z!809K-:L?P9U>S[,)P^=+?/[ M.(GL)+*3R$XB:Y3(#4S+">+.">(<_P.RZWHGCA\"\!J$>>3F$0)"+'\8C4@T M!P71-(]-?XOBUP2BO*#;?;3(4OPS7AG<*]=1A:6XRJF<\"\/]J9@SX;,>5'H M)*^PTTCO_#@TA@Z4SN%4)*4Z>A"!O']_`U[1W3O=^R6GZ4M'% M`[VMD[Y.^CKIVQOIRV`(3M!V1M#VRRP^Y,GL%"*8I,7COT5(*/^B?,2XYE$0 M,4A;#^=4#2>TG=!V0ENCT&[/ZIQBQ8*(CV=W+X$=Z<%=[^,])Z)[WH`*IMG(5Y=O[@9 M$L\7",[(;E_"0ME^B),6`>T6HSI%QIGL3M3W1]0?RF2<`F"C`E")^N&$+"2F M2UYV9P3S!;Z.$ZPDS`""5P#O\V>PRGL9S6$_%&0ZESUT5)?3;J5JY!0"IQ`X MA4"'0G`P&W8*00\5@D/]!&K4@@K`.@H#A$`T+="\6NTA,?@.D"^C)JB8Q:D- M5JH-&V/G=KX(XQ6$+Q`M`P\RECS,8<&?AA-2O7(:!7_B!8?XX!<'1MS7HGH^ ML]2C@Y\['8$.B6T-TJH1D9M7#W50*3V_-AX M[64M=HL2/='XR_;.CJ&E&F,F$"5P,$40JO)9.I6;!I,7+I-\WH^?/WW,9R7? M_,99@&T(FEH[E:D-'0'QL8 M.L=CMW=^-RO];D[L.K'KQ*X.LY?#.IW@M5'P%IE48_#6XVLTAUR6Y5"'SH>Y M79P$=A+826`G@;5>>N6Q+">$;13"U_%\'J3YQT'D7^-=B74HB!M94]%9$D(Z M@Y0U$][L1W;),U@ES&X7Y2_::P#\R_/%VZ2+"3I[9),^."2?S M&#!`9K9WTMA)8Q/Y;.P-[`0O6_#^=$ZF>`4)Q'_\+U!+`P04````"`!Q:6=% M79R%D0Q9``"QT`0`%0`<`&-L=G,M,C`Q-#`Y,S!?;&%B+GAM;%54"0`#50M= M5%4+751U>`L``00E#@``!#D!``#EO7MSX[B2)_K_1NQWP.V=V*F.D*LD2M:C M=\YLJ%Q59QWC*OO:[C,SVW&C@R8AF],4J28IEWT^_<6#3XD@00I$PG4B9DZ[ M;#*1F__/3KW=GZ[N+R M\J?__:___;_]R_]S=H9N;]&G,`BP[^-7]!\.]G%D)QC=VR]A$&Y?T97]@/T8 M77G!'P]VC$>(_J^+P@#]Q\?;*V2]GR#TE"2[7SY\^/[]^WOL/MK161CX7H#? M.^'V`SH[RYKZ&U?J%S1_;TW>3TM_N0WW@4M^7_K5183MA#R-7*+.+\@:3V9G MD\G9^/S>FOXRLWX9K_YO^>EP]QIYCT\)>N?\3!X>GY^1-Z;H]OWM^Y)]_Q/= MA4%,GM[N[.`5K7T?W=*W8G2+8QP]8_=]*M1/[47$FT'\EY]*)KX\1/[[,'K\ M0)J9?L@>_.F__S?$'_[E)?8J+WR?9H]//OS'UZL[YPEO[3,OB!,[<"HO4F%U MKTY6J]4']E?^=.S]$C,I5Z'#O"2A(!(^0?]UECUV1G]U-K'.II/W+['[T[_2 M!O\E"GU\BS>(Z?!+\KK#?_DI]K8['_^4_NXIPIMZ+?PH^D#?_Q#@1_(M7=K" MBK8PF=,6_D?Z:Q9H/R'ZY*^WET*#5A59_*4/7$F?_H,&:D5-_)+@P,5NIBA] MO<%=3#KS-!-*Q89.1:!/?1Y&M88S61L[?F`"]_'9HVWO/M#@_8#]),Y^<\;" M>3Q)G?P_TE__OG8<@H2$0/4F]#W'P_'Z(4XBVTFRUIB-?_E)XH4/N?[TE8H% M$8[#?>3@3B[AGZ>C%K_[#_2EK4]>H?R#@[-?[WY"GON7GSSW]W-KN5R>+WY? MC9?3U>SWR>^3G_ZUD(4R8>BW3-S_]R]<#[6F)827\-7P]EG][%M'U?BS(R?3 MD_S88F#ZQ`+Z7$"4_>;'CA_$^PO>$?YH_NB=I>G'75<598-V/%E8%5#&*&T) MV8&+TK90J3%4M(9^H^TAUB`L;`=U#\/T=?*$H]P?GU]V.(AQ;`"6^T*A!NB] MO&@`"USLHP@'+?WGX<-P&$XUD(S!R6RVG-1#=(12449@KX]95L6L'1=D$*@. M(JL!,V7K(2%QBQWL/5.-;K%/A\\W=D3A*X>1MK01 M2F6C5+@AR%)I.X/:)_R,_7"W)2\C)XP3%.4M#&+I,XX>0OVV3IBQA41$04[H M)4H"XGH3^$42IG6$(^,H(`:*,%VH2`='XN]=?4POIU3:E@VJQ6(VS\F#2\B& M@&`$T=\0JVI(N"%4P&9YE!5V1-P/*!!4 MQ\VM':_@>BRWFA2=Z^&$$;XO56!<:0YHIR;BACG@Z6:%B>T/;]:\ MFUDZ(=^(HD/LBSW1C00<_SEFT!ZOIF,&;/J;FB:NO`!?)G@;'WR>UL<5P]H- MG3T=S3&6[JB+7*1,QK/IJH2ZUM(NH:WC8A?:DU MT.IKX-"(EX47!;R42P;"^ST=;\M](OXH/,Z9'K)A8LT6DUD#QIDP<'CW,$D, M[0%-ZHKJ'G:)$2VV"PC,%>PT`+GP`N#(_28*-SBF.0RV_P5+#M]%+^D?PPLT MD1T4GD]+VT$LM,H"$95HQG!>A9T5"#EAM`M96HR/'XFI&R*4;8'MR@Z@"22> M8\3@N"50:T;(33Y3V6W2/!MBS],Z<$OKC=F660,CMKP(U*4V:R49<=.9=9Z. MH2_L*'JEN0'/MK_'R([I"@R9@J$'VZ?)0BA^PCAA.5'T+^&#[STR'6/D!0[] M9BX/S'2?=A-&*$IU9']P2XN\MI-XS[QC^/[DT0*/),I8N)M^;8P;9*+\X+GD`("/=G/&`5A@EZ)[@\8!^G2,FV% M/.SY/OOK`R:_#UP0S6*%CG@FK891_![]2E/;DI`\N?$QD40][W`D(,(`V9(8_;5?ZE;? MN>1;??>2)X_\F0R97TDSW#+V*_IX$$9;ZL4=6S0C']AY=9GP/4.+1ZQU'M$XZBO%Q@.QH'=?6LP\K_AY'IS;[^<%DJY%/-P MGZDFGU.SF/>`_0B1ANB@AS0U".K)B,@+W<^!JP#YO7PRHSXA[=-163K,'M#0 MN\2.$BA3SZFI'_&C%P1#6ZN*S'O9><3E?`+@5,+\G<](W&--O0'Z/F2T'NQ= M<:;!Y%VWHMY+A'FTW6$Y=S49CQ>37D,UB/7KP1W19X0&M^!]2LCW@#;X`GFF MY'UD!['/%F76[G_MXX3.%[_B[0..V@.FZ648+#=H)#N]F"_'XV,4EP2C0C+Z MC158#[UVWB&&!1!M\QH(.%W72]C*_HWMN9?! MA;WS$EL8`H*G=<*O7@7Y#9QYMK>;"T)4$AGKH506$+P4&&8=&+8CDLZ(88[8 M,&T(:@ZT"F0:/*%FOZG4P"OCEB(W^CKXZODX3L(`KYTG#S]C]D#MHG$/,=KW MHKKK*)M/,%TNIM,T]6-+,\SI2H!=!%\0!N0C[`.7[39MLZ;H_A-KAVZFL&V= M=+N'Y=H[H4_4#WGV,%LN]SV'+B?G6?AHOPOYOHE=*$V;WD6ANZ=;/%E+\8AN MDKEXXP68X9N^1+R\PW1S"S>T93]&F,G5O?,R]-_H09FN1#O_N0J$G<0_3[AI/2 MQ":\L..GFRA\]ESL?GRE>[27P76VD;K.-[';2B4,T93609%Z_3M,OW->R;6@ MW)[KP5:)JW-O\F>J#LKT00^OZ!W;8?>"GU&N%2K4@B_T`.UCJ\;'4>[C@/B8 M+EK2W]*?'>K>/?=H*;6@R.OX!78T.!RVJT/)@3Z:HG'H,YGP/N'@B@]#PHBF M)?M.[8J(S!OZ1Y=-ZDCWQ-.IM4@'DIE`5):(KJXNAEW\:!B1J;-P`FEAVSA+ MG9E6LYF`XR<9M)6&2JTN44,"CV2R00M6I2.R^_`C_FJ[9#BV3A+;HYMQ=[9/ MLYRC1WPX@.DC03M)=%)/-M;FR_E\>3C[9+/"K+EL+(]H!A[I%>U\ALBG>6'4 M.I6,B5XH87JU32:Y3-;%0DT>!_0SIZ[_NM%-`4?=G=J_UECC)WWC^'S!Q=[?,)(?CB< M)Y)?_;XFFKA4FR^^_7@0"L=_US`C.VI4N@K<.#]/F+V.Z/MZX7.:^I:<^D-' MNS`P:"S76PBROK&E6>,\1?UZ\\4+;#(Y"1XOPOAHN5GJ%9WK#0UZ2)>4L&99 MOU*21GO?7!YB`H&F^ZI,M.I,=/%#@KPXWK.#&X[(3&W3<8E0K$RKVYP#@J0)LY* M;:!R(^BW3^&6]/M0RW$#.L-2ZPQM*.X'@`JP>W@5!.MQC,6])/^C3F2R%F6[ M!3+]SP[+LO>`"L%TUYE5?;FG@LE<6*2YMFBOA$`EB`O+X&*S;<>I^I#V6.U: MI/I\LEB48Q9^.Z:_&58S]/0&<./NQ;&-<`'=4M"@\HSV<.YVC-\:3ZU).9H' MKDT@1\5];"@Q%A+T?7ALU!AWOF&@=ET7!ONAK#X*68Q M,K^HQ#[LSG935`E!8`C'?[&]Z&^TND11M/T64V(AD_O&+]CXHG:8-&DCOW:3 M)PJGF*%2$1-;NLJ`5H!.)4,B2)G%I;$1LA.TH3:S>B/PF)()SF.`M7H&`FT? M[=B+KS<']Z2\\O]MNWQ$\F6-J)/32/KN#"NK0<#DTN720O*(WXSSBGY+_PM^ MD\@`QEL5XV]H]9!T?QT2A=V"MHS$#BX"0>,^]@(+U76`XRZ1/PI=GFW M!FDFASJRU/$-S>;=7-F3H[V09"0?YNI)ES!;]N.V-T10_7S"R:8/LYQLN\1E MA8-'!*^DDZ_6']#L&V37(PKHQY15=QK">O(7C4N^#,MM)]R3O9PUT9E95X8/ M8#E#[>?KN_)R/!MA####Z93YF-5E\; M`1'6F`+8ZAD(--&"">O`I?_Y3'B+C#A8OGB2W5#"]ML%GUKN78WXDE)(=C`V M7V1KE:R\"3TVP'XH21[1O(K\+I>_B7(K3K99JG:V>N-G%>-9%1)<2*:V8WKI MR@9Q_2"K::LW_KS5^(>\P/:P+FBE7/7&6XW&0Y)N)[XJLZ^\D\RAX1L65)>! M$V$R_?V$^7\[18%`!#@IU^LE?X?Y:M7*S;P)E+6!WF6M_`R3&CZ8(UCF>&XF MJQ'Z9I#;'.+M`&YPGT$XEDH&E'L7'KG]LN'FY/_:(6M80J!Z#^0]Z^C(?`/! MV9X/*.\A$#CZ=AQ?;^X2HD1C_E_-@SJ!=M2Z]$SYW,I01670D2B3`IS1=Z)! M5D>#M*%$&$X52-0;#QW_1\D=#=^L>!8(!=7,$JG4SWQ$>!`W5]`Y1:?;58N' M%KL@,'$48B)85-V@I/;>1;D"..F1KGC][W56P2VNR4;M\*+N2GM26DD&T?EL M.4OKZUTB0GV-A>W4V^TI\H7.$+U9#_M[/J96!+Q?&5Y/*XH!&^HKL ML^KL<\KBT+MO88+19%:[EJUM[-\>B)490(M[#,-2D?32DE[23889>#M63/H6 M]?/I4@*!E80OX)R4X?Q0B]2>?C``M>*0E\2QP)W&(KMU3Z:;$-.PW;UFP70R MZPIN^%V:X5S1CF_CD=R\?=/==5!8#@.V=-A8\??X.X&#_<:.KJ.[A-XXS/*3;G!T]V1'PA0@ MB3=A`"%21_K6M,ER=@R1$2)R41@A+CFMZ$5D(R8<'#A*K"Y#*>96[VP#*GEU M"%,!SAK=`XP\IDB\WB=/8>3]';OM'_OH#1BD':K1@;:M.H1Q>:@0"(ZJDRRL M05/,+;0;+01`E2@$!6BJ=8L1*+J,X[T\@M*G(='#5>@P45B(D3-"7)HAL.EA MFA@RGM`R,+A48ZT1*B57&`&3ZWT2)V1^*2[0VO@*)&!*>G0(K643:DHB#8%. M7R/%^`F;;00#44TD-B+IT#/`<&H\LW;X&`QL.AW)F>4UOZM084*,Z5^ZFU0# MC'\:OQ^/)\4$AYZKXF@9HL]$#67E&4;^V4`<` MO,6GH^J^(Q",=Q%^HO>O/F-^L_P!GU@. M#*&VJ#Q`4Z,G%"6G!6R#;6_[>6;*]8/OT7M=W2]AA!T[3OCQJ/K<(/G7]2>I M2>LF&5G3\>)\QA/5[I\P"O:,JPF*".LE3S':A!'Z_N0Y3^R.7]*8E%J=!R3B3,QH=&A^1'2%,.V>U-\MX2OW90'UY.SGU MQ2AKR2P25.J1!C;\,_=($5-Y'!K(B[(TTTB04L[M/R^+L?/^,7S^X&*/3\G( M#XGJ5U1`^G\ M`VN:8H/*,2FC5X%=5G>[="TW-`=9>:6AP0]0Z+@,B!)LX-IP_TO-@YI146U= M-G(FRRQ+@D5.(03TPI<3[;&ZV:,3!?7!=(B`&MOAHS\K+,:+N4M]N8-7P!!1 MU4-^\7:6]A978?!X1J)VBZC<$?IK)%B_U0V-$PS+9BK/.$H\NMH>X\`C,^`@ M3`8Z;B91BUS=9VLTC\S>'\D,A:[CD[56#/F,$0]X,1<4>,N`UBC M^`3\Q]@+@YO(<[#H$AKY]^'X1*R4['3F?#J9UW:\[)Z$3'KV#RH?L0:,8!U% MYK=@U`N\Q*.WQQ@.'W?+!1SI3H, M-Z<=4HJ-\\7.HU!Y*&T2T M1<.X0*5_BHFX5TS$"U88L*M4H]FA45?X$SW+1C42*9HO*B:QEE#9M*INH\QQ0XT>_>>D M\_CB+8PI^CJB;B`Q*L\OR'P";S:8YC#2!80\';(TJ`!-N.T%@&[(/VW@(,@_ M$S=;M'8380?3?]QB%V]W-+OK6Y@0UOEJOWC;_;8N$4>)7-WY:2J4E@O[R7@Y M7;+UX4)WD*GOU*_R*WA-OT M/MA@JT&I#@L5*P%I4.ET$,'DE[)7>0LFC+%4V5\/_N)".#?U!%^7\1RT$_L` M9D@E$=[BX52;&^'12Z_/;CH&+'H:#)FY"K)[">?62K0ARNX.Y[60BMPP$^#7 MS\AZL&WR"]+-`=51U(DA5'6%`8"AJ?4X<%ZO-S`R(-\:D[Z5=+-I M4V3@O`[C0+`1A1-6LFOSR]$\^<*<$=94=.B"1.&%JY99(T=-@F+SJ>J/B9+44'>&Y@KXJ4H5I]:=Y6DR#0=-1 ML(FAPC+WFM.14M\0(86LI:R&>M6N>"'BL3!W!&6K%]+=W1 M-C/4-:H[JHM",8:.G`,/HV_V%C=>S"U\'`Q"A0[R54"7HKD:%09\5[<2Z^HZ M'0GK8%!S''1BS!SX`QXQQ:[I)QP[D;>K67;I\B88CFK5D1_IK$20*N2.4$FR M">`ZW>3:#/%2=H';;#`,WAI#5@P]L;=,0B%?$R:SN2B1'@N*WS8`C0@N_L[VDA?*F>A#\)UHFSYN6K?UCIV/K. M><+NWF?)I=4J2R5PQ>@W)MZ(!:7NAEIJ#(7IC"L!*.YX"Z\8@!GB6;E/21^$ M0PQIO4.A#='R$!5C!"ZZFE/;LR0":X""OQ1)#;&?60X6^G&\MXEI%V&<-.YS M5Y[3'?CEQB4#Q1K/)I6MNE0&HD(`@[ZW*:68STQQJ!#PD*^+H*.(/S(;)N`W M.")S6Z;%A;WS$MNG%V;=D$&I[;GKP+U.GG"TCF. MIFIK)P98VY*]J=IDZW23]>1P=H!ID<4IZZWA+QC/5.$7._.#(U_([P[3<9J? MU73%N%`!Z?RMR7)^@*;T,FXN##%I^N\85V.8U<>PH5$B%639+>/-?M"-!GK- MN1P6BB=!D)`WW^%.^E4]#MBE]$:@H)]1M1AH-DH_`HX"JS[^JQ[0%_VEWNA* M4(6H]7'-.*C307KF-,Y7W;.XJ0PRKJ"*$2DUT.IMH$Y\-(7>(4B$+@%!2MV! ME\9'X1#2Z23(;#Z;-:$#XH"+,KL:0`%WGD4FP!JPH.)$2U<<\)':Y\"MJ;P@ M?DXS`BJ-2]=>GJX..X=T1$T$`=1-4&.0U=4@G3%?&TR'`7]LN[YHOR=B&SX+ M^[/FV*9M2M>OF2X.)\'T=;@X[JR\):6\SI@MA\1AJ.;F06R$?;8C>A%*3/#" MEJY;,G*$CVO M9;.*.A8'3V%08Q]#U#>"GRN*'VK?!KL#XC_'U!].Y@_V`V[VAS;<]@C\ M"I2[>A4$W=N='[YBG*98EDYB730>*VQ_3R>.VY21#MI)5D@C$WD6I1G)E<.% M%Y"'"M5:RR"Z=IQH3XPDP\XX#`)B!7B]#>G`K$!.RC60.+O#T;/G8$'RG\\T M(#]=;VZQ$SX&[,@_6WP\+`2P9N4H6T)$=6L`F%9L@BPV%LO5HLH$*-5$F#T\ M0H4ZM+<0XSY,7P3.&D@$-R%V_' MB#&50A!VYJP.'\!8GOI&+XR*R0"3'<>([T/"L14;"?=^"Y/_Q,DA*W\)H_17 M]+G)*9&L3@G3V$Z99?*GF>;CSH28:\E/+M%Q77FX0I4DSR3H%2>EH>`H&PMN MP@B5=#68,F$^!V/57X.H&$0S/FT8&:)LJIZ$*,@_#N=?\G6^8^_QB?SFS'[& M$:WN'V%ZOY,7/"+Z*/TOOZG#>(963C^=25QM2/Q0/*]JI'IRVS\"J_<9D\V7 MV4W+ZLB\CL??RHA7J]\5L_8/2<5*AM%*OJJQQ'MOOZ3E%ND4H?R7M!CC*8!H M%VX:=;9J+(O1Z6K2?:!+2RNFS?.);84:/XN7Y0PA0+7>*]5C$9/:B-9E1`^I MTPHV-)[/I('7F;#DOL+P:=7\"/0%#I+(]B\#%[_\&WZM21>N?TY3HG5MX[+3 MI]794*S[9^", MK_=)G-B!2R:]XH_5]))>'#1H(G]I36F.VTK3\07-K7`E=)@5E8J`"N+\M5B=;]$5S M;?A4@_K8:%VQ?8L?/7J*)TB^V=NZ@Y*UCVF-[FK;\F'T054.\QFZ0];,_]T29MH.5U8=TKF=56I8^P7%NI;6!^?OP!R?[ MFV%)FZ%MY:G$@"*]C.-0Y04FQU<_)D^?8_G7@A'[X^'KG>)CH?K=;?\7;!QP= M?!FI5W276&W11_;R],EL-9WS\JJT4Z6)A+9#G!^EZ^IV\(K.4-H8REI#:7.( MM/=>;[%5I79S_`N,&Z&[][OWZ_?H-RX:HLZJ4FLM&6O!*JM*8C(OJBKC&H@N M](OM17^S_3WF-T.N@_(AF*_8IK6GW>O@%M-;MKS@D3SP+:3[]?R?]*!V?"4H MPS=,&QJ[;*6*R^X:$M72E6?:/&+MC[*K3.F9QY(.*%,"L;LPTG;94V5%6$6$ M&+!6(+Q#+0B'ZAJH#`+B\@!'_7=[JUQ75TA1O?PWQG&=2ALN%UG-^`*.&>S8 M-0:C)N"!5'2$]94U@*_>$C,=E98ZC^P@WI"8;#RZ MVTD$'*\TZB5]K>UT/A,-C4:(B483FAC*?[10WLX(].#L8+Y@U)`+0`\X^8YQ MD'N"#6ZX*PPB`:DH;\!YN_L,@'(-_3"^^34('V(Y9N&SB$M-C: MR<=7]OJ%;\=QXW+F8,W!480R&V1[5VLR3Q=5F`3$1`"OIQKA$ZN+3X!81#G` M&AA'[5<`9:>R3NL7KW7)YNAY"'XX5$*^'.EB60-P*@(:WB>9=(Q/H4G:T2D* ML%IXU7H!&!_YC__'PQ'QP-,K&VC(@:7I91CD-&@DOTT]6QP/NW-YI@!*E:5' M2X4RE@+@3")0!:!K\Q0H`HL[+X]N#Q=]^[I7(-!6HX?T;?'GUM&J/RK)`\]P M46;DX7*6O)':,=80BK7($KG&%#RUE2]N?@<84=VO0Y_-SILA!5[*6)V='%5> M8)/I!SOI1,)OS^]/IJM`]CLP;$!`[5D,Z M?6LY.=K)&2$NKUB.A9&JFP*`K@*]9?.CEF.Y\>(;\_F M8\J,4%D=#B!45L`>!>2W6J/^8;YTBIG$I5S;Q-;NR4 M-3@^7]3,RU4"UX@D3`BO#DJ'!J5K*@;U0"QH2/*F`D-D%^95-O5&F;#S;7_G MBYJD4>6X1>9L)D`YF9'C;>C[9YLPHF5&Z?G,TLX#^5VP+[O;8U/"GW\41I3:W5#]\4"9L7Q4X3CI0"[!54H&!)?)*":==DG:/MJK M+.6=F)&3JMSBPUP`.8NU8[]+&->"6MIQIJ#UW[WDZ8AFXBK/5$DIXZW7OQ); MZ)VZEX'C[UWL7@;9';4=PFN8]H%98A"CY,^+9(7[RL.@DG;H.U&O9K@3'XQW M1L=CI%S-$:**HG=4U9]1IBSIQU&FKCD,!O\U^$50_(9;XB(R:,)D)(0<=O6D M\XH>23,\?8/>\0Y[%91VDFCCT>$^WUOBX%A@(I.E&`S-;;T!;FTT0!:YY_/5 MT4BM%X_&343*Y0Y"EOS2HL^!.P1AJG/QC+KXHTV>=#"R$X0#-IT47[FDR#%W MB1TE9KOF_,`U#_C1"]C%5(T.,KVKD.(R%=U"^Y=04K9K$/7HS=NX=`O"X:!: M9\NZBXCI,4L2BJOQ;+KBI79O**;Q@\",B/Q`B_!5_3:W4O"R<&C1^SAQZ$_OGZU_RN, M6L\0=Y"@<_8@KY9\IDQV0387?L:DHT)\5FWLX16Q%DPXB3R0&RR5;M`V9.T> M[)6!:$=?&H;G0D-:5+5Y5Z:C%#-P7:>:_.F/Y5(&VZ-*2+/JM,"[-@/Z0P+D M'?UA`-*;8"")=J%C#4,\*YKDL^'(VOVO?9RPG:GN@2208P;JZY6376E9K,XG M@7^8+C_A,D8U8[9GH57N,/F?;N[Q[0"F\.V->+:?8VDY+#( M3H`W-OJB1)(2&KRN9I5IGY#)!YTN.`EV/]'\FG!'VU@'[BU^W/M4TNN-_4I_ M5SNQ["1`^YI/%^TD8WEFS4D?QI9N>-$XMFX:)D0"/3OMV/$3VG&),4J>[`0Y MX=YW$3%P[Z=WVB9/).*=)X\HQ-8;B(28Z$C3F)!;:,EV[Z)<3T3^0H6Z>.,% M?&/41FZT?T2[*'3W3D)^<^9[#IGZL8J>CQ%FXC57K1_.Z9Q0F7B4R4>E!A!I M`15-H+0-B/66P7Q@E7R`,Q\TQ,Q.[`,]ZRM]&*98)NGLQV%IL6B3*'!G^SC^ MZI'_2<(`ITK4+ZF?(L\8TI105C*4Y]/IQ-+#H:,2&$8,'#'5_*USJ>IOT4JM M)5JE+,N:1'F;&=6"K&WK\E$;]99#K11IV]Q)NP8GP9)Q!UYKYV99ORNDZIN, M.RX(=5R$!+0NCAC#M=.RQ+LP%-RNF&3X3L^GXU.'K#;Y'7F<3,L"^N>2,LB. M(CI=XZ./.`X=SZ;(8)MH-GK8$P;%<!%$U+@RA.WEN.*`V2;]!K,[]%0=$%9_PZ]K=>@&[*C3QGG&Z\2=8 MWFE[2^/*6XLJLNM*J]4JW3M+!;)^MRHRVW>'65)3::AU:*A=$0FY$"89D.5E M+QG/&(BMQH(X0S?9:3*B@8GQYG^A1-@!>P'LX1EDI'Z$9DIZ"O@ZV\/XW% M=EOYC8Y"3$-WYVH.EK6<=H8W>/V+`7W!$'YL/G6*2;UKMR#O#&;XPA*7VYWM M173AYGISJ"?/P?!I#H8@0&3?UHA?296DUQC.)^EB2B&8KA379"VE64U,/`Q> MA[#=2E?(H\3[.U_")-8?)BD-8NXSCAY"_09/K(.O[3S9$4V\VH31<786)$EU MQ&Z9G;HX#H26`B?<8GJD_`LQ^8+MLNR]X/%ZEZXVQQ\QS8+CS]W;+SC^_$+& M16'D>H$=O;)*CM^("\F;Q)U$OT=B)B9A*)IN#-FB3OH;S@SY2@SC="K#&\F* M5[`MLT(C5*B$'IA.*'V>:35"%;UX4=,1JJJ&,MV&X=LPL?U&^C'$V7/J;*I& MYDB/.S*A+8(RU/`PKK#:P-\#C@GO$CMAF\DMBR:BI[4ST)$*TJ.A(F`N&G+@@;,'3D%X-PU'B"L?D=>"QUK*(XG4Y;T01Z#%&= MF6V(,N!TH51`2J`*^.1@/N*4WOYJ>D,[IFK5Z##N65001:29M(VERD2KKXEZ ML=08A,=($OO%$!RU;34UO@*+I,Y;)\N5-6^$$OB6D3(K#]!DPCI&<]BU0.>4 MK1Y!FG]I&>-*<"F6^#G=Z?MU2LB>-%G-K1E/U2\'Q/"72=7!68TQ$_W&-&?% MGVS1$5[!+Z-JQ4B>VBXT7C5,Z^YEJG\&$)Y=[O`Y7XX7JSIH#GB?D0PJN]M0 M@TB(.YE.-Z0&B'#7(#4"H`Y_L!<0Y8JDR;X?<8`W7NL4[>!IB$%E507Y$B19 MZ>72>#)+5G^7"JN]+4;C2/($T\I82(AI>(A3+RMN4(`?Z1&_H4V:S.1MTCX\ MKH=-[E=[(2/)?!VG'H<=#XQGYMN$6Q_3V]+-"LC&2$D=9*8U-> MDNA=)O1G6@\@DXM2P6#4H-#>K.@J-VPG-DPCG.1B\@!8$CXQ`V+I?GSP>&'O MO,3VVY="906`@DZDE2R_C\]7JT;TY0V@M`43UDZ'<$+I'A=6\"S,#;>+/&&_ MN-=MA`+,TC)+Y^G9/_.3]K^8!>@V!#0CN]''AD`\><(1K;V\)T.BXD/)AY'@ M?5B`URLEG5XZGDZ:\4WEH[2!\H6:QH!;@0,8MKFE=FHI;B@"#XC1YA!N@6B# MIPQ":,XD//6W6R`DKRFU)EJ*9K9TX7"K".?)K& MTF5W)N.T6M[]$V;#/R_'KIMCU]VS>TAH73RB!CW$0O[%+W2BN&;U\O+J3^$^ MB1,RLJ3/;,,`TT*1'B^#YSZSJZ'H$9`H59^-0?@M&[4 M`U.!WE@1;CT'/?`5#WZ>9).6#&(:Q8B=,#G4BH%2V&K6=U+S:3E@EPQY$Q2$ M"7HE/J$&O$>7-9Z)L$\+!=/*PKRM^-#:$5Z+JH>'<1QDG\Z^Y+1-#?4"=;_F7]O9BD9K);Y.>3^?RPV&"UQ&!.M(16 M>8U5S#J"/?GO84RSE8U*8=:\^BM_-8S>(]HM[G<;JFS1BIV6Z23264MLO23B MM5Z)+(?6)!1"R=L@C_PO+1!+YHY;5B.6]7"TX;PT+/EEII4;D@Z&=AI/]C.U M`MD^>3'@-9'2KH_9QT4DWA8?R"J*S-)V\0MV]H2-M/<*0T1#ROXHEXU*PA&3 MCG[=(28?L&KW,,:S18!?=V>5\`2DZ(XL5J+B+MZ!F?C?<%S7=PF-E=ODWM4Z M[9=0J,-*U]N[M^LAG=LQ6 M`BB.$!&,WN6B\Q`%2W13;/8A&DU8QI=LUK458T+LXGTAS1]K.T/<4!X+>KCO*G4\^7!WA.L_'3 MBJX5C%=/Y](&D0%G=#5XB&'^SGG"[I[8'&X0[V^/_$.4('CA.Q`\_R2K&I<^ M\3,?KXVD^DQ$$J)O(?!EN:<"M(Z->GW7_NP48^?]8_C\P<4>)R;RPR$?D5_]?H4? M;?]SD'C):TU=IKHG-+!&3;.R79NUM-*Z%DP`XA)`2BV=:H75P8JAD=$0*C38 M1:8J63PXJMTC:7]>]\)MDS)RT3`93U:SR92OV!)Q MJ"P/I0*'W0D1KM.JLVX"9UWSLJPZ$ZTF$\$67V70E2^ZMCH#8CC=?I(!Z*Q" MCV3\>7[6;_"#!FWK.7VU+ZWC^,TVZ!K.M9P3,.$D0$D'>A5M0@:`3Z'O$F;Z M_.>>]*CMWZC^-9AHK]5%-HC.)]/5$038!(++`4?#Z=;50X1G*9Y2'"D M*;/]>%B7H`VU_IE*-P1[,J$K`&*KH]2LO_-3/^OLT$_Z[WL<;>.:/2.Y=[2O MP[AE-HW*=N7BT39;YA0D"TU]:9:IYFJ M9XE>$H#%,KV,AP;GAMK[263?,HD?NESB,1G/9N?CZ5NCB#XFRK$$R*TL@]@K M1Q6`U[-T1*047?2^HD62,.*K]&STFDXF_B\.L&/_^F]7B=NPO]]1!#25M.@G M>Z;'FL\F`EJ)\Q/FB+6!>"/HUW]#I!G$VP%F&Y5>J&>>&%W5>P%Q-T`F$0SH MC'I::G&&,?0DB7\A5\EXO9\^_X)1_8.[Q//B?LPET"&.=15KZ!DH,XF M,^&LJ')8SOJK MG>`_,-XUIE%*OVP,2QUJ)CN^MY8D+*O\5!>4A7BH=,MA#&]E)EV&]V2DTZQO MY:)"O'D<)`)R._G4.FU8UKG9>'_OQ3B5%XUAF[)6TB$WI?E?K2,A+MJ4T4]_ M0UN9A8LVDE7Z6]W**%RT>6Q2!]!V)CERU+`L$G^SMUAVWZGF+6/X(U=)>AGR M?#*U6LDC1@&1:PIW]#2RC3AB1.6:LP=UJKUME-%J+RQQ'&&RG36JCM)`&?+; M4;7OF44;G>Z57YW/I^W++P;R1@\K98G#G&VIDTV6Y0[3=J::X"G)'X/O3J6% M0N^)).DAQ^$[X,QQH)!L3=AQ?L%S#6NDU6$1M0.:,TZQ3\07J4Q$A1HTS#C% M5!%/2)H*PQ$"`(KYH/Y./$"[Z'#(NCQ6^"$<:22;'0M+6N5)K&P M,6FXJ=Z84+ZOX.&573N`>>F3,U1J%)I-3K1?Q"8EL4:MB)YHKG7JYS:'8(0( M%A-,O?,&(IB]8^_LJ!N]'+P#3RY5A>0W\Z;67#06&:%<*CAWG&*>D#DRH6;Q MQBFF,M;()1A$`?48:R"`&B\,`W]1H8)IBCED45L94L8%`Q%$EV5,<]8O.ZYV+1:KJ3A3WH35B%X&B;!LV`IE M+]M$ZPU&+DG*KT5J6(3LN/IHTK)CU\6IU6PZ69H/[!XF-4/;H&7%GO8UP]NX M9<0NZXW^!D'>]Q`=,)7@/I*D3ZR MLR0R32-=M27/14E` M[XYG-P[3>XRCHJ*_%Y!_,7V1NZS4$> M@YQRJW%YA9%R/^?^I1)$=SZL#*SK!YFZ42% M*+P.05'K!!,P4;N`W/(P("XZK4".K=ELUH0,D.55A:8UH`-P954NU)H0`KRJ M^M6._L`)7:>XHR55>>G\9]OSZ:^^A-&=7?X+'YP+/G(O41KQU4<_Z>L59MF5 M[T4KJ!`V0GE#9YLP.HOM@S^GLQYC9C^#^\H2^@H2QJ>@H0SRWNY3LC+\U7[Q MMOOM17D]\Q-^QGZXH^LY%V&VU%F&[K7CK@I*I]PL%^,T MYRIM`MGYHG*4"N3K8C3/MV@1.;1)NLPKL9!<6BEFW1D1Q1>'XQUV$GIQK%A( MOC"G>>EX6(]/RAZOM(%*C2#6"BHW`["X/*PG+'Z_,Z$&VT>/?OA`_G,<9U&+ M"[2LR?9EFGR1MI;J,UI'-J6&Y;OA\P/4P>XA]S?"*AD!.WJH MB9'JL.#01)!0]H+V4*X\HS.4RPU+KRA.QND-(.GKT*'4PP*]\L/UE'[C-Z4""AW4&=ZT&\NOFJW0_@,E!7!!BDJ`#_G3#K$/# M0,._,:XJ.!!;KF0N]\U.]A&^WGSUR>WBAW7/SH2:R)9R M6(R7R^P$+16%KCY-*D:NR90=C5/:]089_4T3LN$I15.^M!A3_R`TIN^[3&T7XU5VE*TN-I@L8"SWL$<(Y`'MZ8;A'D8)`2PV M"@2[][4K"F('0`Q0O^'DPHZ?;J+PV7.Q^_'UUQB[E\$7+[`#QPL>UW2QC]\V M&0:)%^S)[ZYW::J=:`/_1*$:![RG:2J[>[Z<9TD!I#U$&T19BW0Y]AUM%'G! MSRAO%Q4-CU#1-"K:AKFI6*._YIF_'.JO7<#Q>SF>J20;\WF<`%[+1Q9,9Q MHGC\(BL4GF(D-97MCU>3L1RUY.U"C5]Z\LD0_K(JXY<]=Q'YO\Q#1A-+1_Q( M$$H7%[\](NDW=NDJ_,T02]>.EP!FJ9I@3!V[#.G"-#/C1Z*8'F.7/AXVB')2 M#=6.762%PE.,I*:RN)A-5E,I:LG;?6-K+T/X:UX[=@ES#QE-+!WQ(T$H75S\ M]HBDW]BEJ_`W0RP]%@W.51.,J6.7(5W(QB[7/Q3%]!B[]/$P$.5>KY;S`,7\?O:,2?D;K)(F\AST_"9*$Z,:.<%";`*0% MFCV-RUB/OCX.8T`/6I<-N`6X^SH1S$@S&3`=%RG MF<(ZKWO:!L(-9NA"BC!XRE"HM]B(6&^9L8J?AXS]CI,B0KK+J0@#X/-#-=8= M3/DR:/QB%#::)G'-;@#%2NOLK.Y)"'QTGP_,YM/Q(3(J\S7@+J*G1?.J1=#S MG(9(JH6``7.>Z^C1#KR_LR62BS"(R5C-9?]8!^X-^>99\OCU)DUOL?T[\AL^ MOFOK5)3(U@DP%0I+'W,]M]+R(N5FV>IFT3`K$E!NFE85R!M'1>OPW9MVWUF: M?*>-/51"L<(WRC[-FV,H^7JLRIMY*[S5OQ;J>#693Q126+ED+/C"$*A/R\=U MPM)Q'>K*CW;LQ?2W92W>+&])EJT=Y&N`L%GRA*.UXT1[[%YY]H/G\PVK?42W M1T2QV/R23J9IU$1Z=V*<[?\R>2@5B$H2"8EPF4#H5V;>?FGZ@&VOZD9) MBSZRPZGI8CHK@Z8BMKJ<39"$63%/(AX022H-9\"ZX?=..4_D>9`2D7U"]`AH M,FY14HV%M\;1S-%]U51KJ>EQW959&G21+?TQ7ZS&8UZ?)05,.C3A\@!++BDS M;@)G7'/-%F466KTMU%+`10)A>1F7-I\,!'EA"2;1H_!0[U#A9S5?3":+)I1# MU&%285(#ML%*,:FPJP'1P-686K#3`&38BDPU^K3M]C2\H7UT7*N&['[!^6J\ M:H0*^$:*(AN%L($?!C=&WO'H5^P+,/"45G/E5E[J7]`-G5HMY%?G9Y5.IK+[ M8,1"S.GFE4`3A,%9MC;I%X+!T=,8>D?@$;L$##M$C[":T96F-C9]6O%+NC$D MU$0ZT,XGE8E866"^*I/*'"C/4`I-:@PM(H0"VQ+5<.!YAJMDQ M$+BZL5_I@))>\LRV&VV_+=>PZ0V-B&I00_ID[^H\7>7,A+&TCTP<>**?*A.M MOB;J0I-$$):AU.87(!RQ#)CK#;V:\#*.]S8QF]W`(_ZZPC?TXDBDAC1;SU96 MCB.>8!9N^&7+F3Q^\Y1:&*VX<0%^M!/LM@!)C8VSDI'\`C-BHY?9Z(ALU(BC MMB`\P%&C6R!Q=!^NG3_W7H2SC#P<_S42GQ=I?0T`42)=Y$-N>0BK)$2I3%0( M'2$F%JR/4F)PD\V3;DD/>,N%R=)+Y,-(Q1AGV*./K+UR)0D M"0/RVC-C`]MY\LB/3)J-XDQS\E9Z7VU9I.;;:#5X>G+@Z>L-JK2$TJ9H1UXT MAHK6`#8=-;C%.@[`;V%P=AN^VCZ)M=-=I&7_\C1JRK[(CT6*TY,LZQT12&LF.!*S9,CUJDLM%3/"( M5B1#A/:X<,2D(R(>,?E`\Q;UMEM5VV-N^X[8_DQE@HY].@5N9=PC[R=X1#)= MXO4^>0HC[^_8E?KV1R^!(?!0$^ER)BBRX2=D)6^`(PJKD4'/E\U(XK+,P=-/>QK1)(GM`\21=7@ M:T-0R2>FH.=ZG\2)';A>\-CAXY;?`L91217I$B+SB6A@F(*I)-0<1/6UM!%6 M8;.ED-BJ"(1H:+&G/F$G_>V$_79J#D@KD2T&9N%^(##N;,]-DYK6@2M=,$#F3;U@;5-' MNL;J?&KEX*5"LT*9+.(,*C.@VF:K;'->CH.!$;H@1X/`"^DIC62@>NVDI8=0C[D3Z_B#TJWE/">1[V]+ MVZZ//UJ!6&619G=!$*_4*B,;CE M0.1B^`O=CV4]PQ<]/Y;,"KI!B4+"P;OR(@BAUH#ASY.M6O@8NC MRX"F&GC/=-S.?OW1CK%+"Z20D0E/.B#?/":/^7NZ3,#,N=XU76J%RHKQA(PR=PZUXT3$$JU,XF((!Q> M0V+X!4>.%S.',_9"(1?,DSFW.S]\Q3C]TR[+^C2/RQ2#OYT'57X_(`ZMSVDE M`VIQ((M?T9A7/P&A#C956V;S2PKUJS!X)%]Z6_SI2E`J[41A.N'72T/9?=7Y."M2 ME+6#"FDCE#>%:%MGM+'2WP'KDVGTCC64=[2A_B3`5/B@O[>-9XJZ"FLG"#*5 M(;J4^AI;\_GJ!':`J'"FR2G]20&N/-KIL.C-!;"EU8Y5O<5;VPN(JE_)_V[W MV_66WOW*_YZ(V+OVM$8=ZH;&\R&6\):.\+@PO`_50DQJ0Y)E_"Z!9[ MVX=]%-MLCSA_H*X:DUK9N@_,JU)]UY8DQ[P7E;U7?HCMP2-W MC_F^UQV.GCV8Q-1!*"X_9J_T:REB\\>]3Y]^I?MCMH_CKUGYC+AVY"'[EGX& M;E-)LJ.?K6;S:4:MF4R^L4VEHD(L^HT+UGS1@&)+)^"6MC&<4G,M"7,!B4<6 MC25*D7*/8K+(VTC+,`=.**H5T@VFJ;3^>R()HK:0VF-/,WEA)0:=\@, MN4B45=XT@A846'I("D>6&L`(S9"KX8,&OX`L9M2.=UIJ7+>\I'/)HU$3Z=V@ MQ23O<073#>ABUPH-M4XP5-L2BE185E95VAUD$+ZBB"X"\9E#P#2\#V]P1`]C MD$D&.SP$?V_ M1W0;,;C>;+J%;_]FX'FKM^[2AV@6,ZN-PZ@265'E[+1\0O1`J2)Y'7144F6$ M4F7.PLW&*#K3XU-&;;G3O(`?AB0^$BZ7"D\CG>PIB<.0L/%WZ*RS-F<92/$G MLYD$W9_V.EUPJY-&_F4W>DX0QV7B3*AZ%U)+$KE@G6:2@U.A]^%=2X7`HLVV="L M@DW*,3!8>\;!'K==[7GTF%8<5=N67\M;Y8L(7((!6QDGF&*53?D%%@7U05.- M^1I3E6SZ5W,*LNN7TK/U5^Q*$#J6;+SVJ+,,W4D!716439=;C"UKS+,$TG,N M]$JND,S'$\_V#V[32YYLN@"T]UG-N;V?%*5LTBN,V(B/%H/88<4L`,^ISNX)LD+SOS,"&1G5FC.31C6QXQY#A)Y4'XAW*]IG1*4MP-[O]&P MOK`*7QPEI,`E-_4EDCRUH9?3('KY.^<)NWL?7V_8MA`6T180:P)H2#&0#QAB MTQ+$J?6?#:@NVCV0RV.2CKX"1VHV26#?@58(BO`3Y91G?!DXX19?A7$/^/:0 M"H7I[JI*7\BPR!:R#H">SS9Y\%<:1;Q5](ZV^[.9%#"PRQ@O4+&DP^-#OU8_ M&<,7_>$D))&>WH9EEFQ/;EUH M4(F^6"B%N%;\?*B!0QA(?W-&8R[]>%PM-MO8+/G2"^B0D3QD!Z^\?BP9#/`% M'CHRVJ5W%ALR91H(__6L.,1WA*7/+[87L4N4^+4NZZ`\??R*[7A/\Y\"8L<^ MBD@T$&N]KM,S%6V`T*0"Q:7WXR?3&FJD"F1WGG$=V"Y]>FIXK@I@F M!A*A;H_R[=86S]E)R=$U?C2#Z!0BM9[<5'T;8$+S`B_!5V2RZEX&"8D0>G,& MMTAN!M@J`(:*6K22WW2=U\SZN/0S)AX5\C/.,62ZI]0'1Q.]_CX`X`+)(!<` M7<:/L"CF2T_\^JR29O)CCE8!("ANTTIZJ6*9'7`M1W"Z:,G%5^/6I#&`4B>4 MMG2JAIL!5-DXK@>JE*=@@7K"83FY[OCD!D"`?JK6TC?;SZ>+8R)0<\S3C$Y? MJR>/!@5#>U(_(ZD";#UC*?E:L(PF6-0I3(@_OA;/I/DQZ^]VY,H1VJGR0?CL M1*7E1^;+\V,Z$UYU56Z?[LB4'\R*YS`E3"$SG6X\XK)AW:B?R10!M9[(5'PI M$WFL?/'6VDF\9R]Y[3BUZBW8(.9JU[8#UFI&8.(MK,IM?".4-6[@/$V+YSA+ M[;=;.WIECBN[)_>.R80CCZ@N3"/I9F"*H4I^?+WP[5AR-G?\!@PI'*HA/TN8 MU2R?\J`E/2<3:,Q@XR0CCXO/760;"W_71,\,6+ MXJ2U?J?,:]I/Z[3K)'M@8C(^GZ_X`1TJ%7&QV>!RA)AD/?4NZPAB&',G)IC; M^`T4J.49,\T MG\PFLP8:X9)-XY%3[17SB$Y[.Q+)J4:+B20UVDPF:0"JF$I$O@(9W./`"Z-O M82*XF$#\G,Z!_&'C\EN&L[Q?IB(0DP%4T:]*S*\$SCA*6KY!:]FL0TT0= M['(;0CCU3^L$PRU&DC&D#6V\GP@P9(5$"A.M\HZ MM,HI+WJG-^:`XJ(QT"K@$'O#'(24%L=%:^-7+26P%0@&1UX7;:5S61.G90_G"KKVM6:_'?'`,'Z#98T^X&MGF,[?Y$VQ4;J\_OD%1XX7X_@RX(&"L.Y7O&FX5KGOGIB`T*T\TYG#98>Y>X\6S8`_Q*^++KUWJ+C/HEC#;8 M2\CL,S=OH*"O:^D-\66-^M)G.\]G<_7T6%*H($BU?+CB;@WP(ZTQ,20CGNS= M&75O*@43-WW;TX4)?@J6<^#U/HD3.Z!UGM\R"S8`5B7IB3[(6^2XOY('D]R, MOT9AK'Q2V]#2&^*X&O6EBW9-5C/U',<5*H__F%)O<]1WJG?9((\)^:$)K@&M M*@E.]#7>/L']._8>GTB,K)]Q9#]B]L=/I`//#PUKB>]V+=XL,;::)IU6NV^(AX5&R.;++HB>ZAFWI):>%(K2G(..NM<&>-\R*#+D&>YENV_OB9O8T^VN0%!_>8H[_! MCJ&'KUB'\!$_>D%PFKO>8-=0Y;:!NH32-WGC7<'!^#_;BKN)/$?#0+FQ];?9 M;329U&%N/,!V?Z4S.5JQR!1%3-,?HI=1]BEJ^QXX#^KL?93Y4-0G]7#C&^R5 M9&AVH+ZJ]0N"]6`/[?8]=+;O%F]MCX985EUG;_OW.-I:35C1K(GNGDVO>?)' M-A9#3YF.R"57&I6T1E1MP,5Y@S^/=;2TU,&EZ-U_8CL"OA\&CFB.^!S@.[_% MVWTR5[[@D;OZNK)[OQ>B?-_6#;BJ<3#8J1^VG?=0?D^L' MW:N0;OZ'8O+.*\I32.(><-O#`);N\2TJI/S#+NEW90:]//S&-P#:#038%SA1 MJ1^*HE4LNTZL\3DD<4,LD!O`Z,H^787G?^!E)@.M M=BI4\`TMP:NS6OHTS"!)G"?T'#_:LCW0)VWN47[LA7SUY*9R?5]Q0/Q`CT+7],+C9G@^`'/$]PFJ6R#+*:S4''YO](&P1#?+IV\O_'VS4`S+E7\.5_ MH%V#[AFKFG<-^BCX]G<->EC=84!J5G?R#[)K,/0G[='-_$-N)9S`>!JV$OI& MB9&S%^&%PZ**PD/,5M0J8=+L1*EE\EPSZ;#IW'PY=UN1\[,M$75'VSH<#>VP#2!-U;4%UW]4LA[R MTU@'M=I_9+KNR2)*";O/MWR3E-U8.U0+6W?0X"T1M;Q9'5:(.]00DN9HB=K' M/P0]#_1!JB7F?V1>[DX52BFYX_<#8^-6LH3ALDZ1/3N?EV?NX+COKCR_.-@/ M8[ID&2>A\P?:#68$B<&''HSY($1Z3T&WL9S"'6L M'2?_\.TXOM[< M489;OWC"VZ:$S^M$H4@)Z2D]B4`./":!!1^C]M^H%"B$*;'*ZF25-ORTA5D% M,HV.`$7)YS_W7O)*!]!A0(?,,DBI?0<"+76*R,=6MI7$I:!"C!F@.=DXJZMQ MVK'3%'RU^!'Z!!1#5X<7A8L^:?$@!%JN.MX&/YE,QLMT-)?):+W572-`^MEC M=;-'.R:.@JD6"%?PM\AGJEQO+NSXZ8L??H_7#S%+#FG[`1*;?0:* MR'M:7:'MJ_.'(%#&6I:O\C$[PM-O3`(T;+J;<3B8$YNA'0>5D*F-^,)0M\EGX=/JX2?Y^A!K3%^V+KLV&6VFF4[3B49_XS2&?$Z22+O89_0CT"S MU&_LB'R381`0)K;?C("3C)Q3(^]I(WP_)S<5,UFP!I'DDUNL(,,'T+$_S)BQT_C/<1 M;MTNE7X?%&H"I3I$X+0!>50Z*L2;L',ZB`=J,/C9P/ZK)8*;$=GD)S"`7L;Q M'KN?]A'=Q^67Q]$TB_@;_L[^)%[6EGI9-S1;->HPPUB6<(FX8,0EYZF-7/@( M$?'\B=IM?4V@5&L[WWD-M]LPX`/+$<\/BI''V@$'IG3D'J%2SE'&09+]\>`$ MD-LG(.H%F0+56NWDUZRG`]Q%47-$4"W.5]QG`:O6UGS[Z<"NFQTQ%^`X1G8A9H2<4F^>]N+(3LK/()?PCX&H%@:Y!);KW0F"X/U# MC/_IJ\80):6M>+A,\#XJ5[*OEYELM;$U3PBS]*S*O'C$E`:5[9:70"!%1R#5IZ ME./G-$+CJ''Y!<)INA13Q#]XYW&:-58G:W2A0!A&Y>BO-[Q_U,?8>?\8/G]P ML<<#GOQP&.?D5[_?1S:=E!:>&@Y:U#^KDZ?K%)`>$\^RVSRH&+IL M5%YNH\4!OX7!F5WZ'?E"04QHA*TM09Z].-UN:P"[M7%_4XA6^%_H)@AD_1K8 MVS!*O+^3.3]^2.CLWR:VTLJ&02Q*VFMY22/6FC61#;[E8C7CH"O)0U0@RB2B M5"0,M!2::1V:Z5(SOV0 M9_%C&-&6!!.%A@<5H$-G3UE#[8G(ZV%9*A8].S"[U,>*B4Q0\\:ZJ"NR)B) M=F.$J%9DD=75HJ$AW(X2"ML6Z]5`=?W=F&2D,^%X=V7-Y[S>A59!/'\`XQ:2@5EV\Z_\8E@H!9D8%6 MTT>#@W0[F@I@MW@"9(P;DP'WYSCQMH1S1-/&@X=TCF$K+4OG&$TGZ:(>>9_. MEW()(UXBY17]EOX7?-7[!`NM.@M!QZ>UP509CQY;"Q'U?-O6=;%[;[_<8@=[ MSS3]_&(?T=QSP9=J>4DC*IHUD9WRK*Q%6E*)R4-,("(242%RA%*A,.!0:"B_ M1V)]CR+LA+00'Y$#B16Y$"QC1\(9$%@ZJ&[(<[JN-RS+J93.]=&./6<=N)\\ M?Y\(4PM["M.(O7X:RO/Z-)V.'57G+)+E>`)9]?H9UAY;"TQ;A`&L!N_P'*3< M7)>+0-\S?]FIO[*$).ZLT(S$PM/`4F:#$SS-T9*ZX8H()O\F_R(_T$Q5\H__ M'U!+`P04````"`!Q:6=%E2%-L\XP``#Q+`0`%0`<`&-L=G,M,C`Q-#`Y,S!? M<')E+GAM;%54"0`#50M=5%4+751U>`L``00E#@``!#D!``#M?6USXSAV[O=4 MY3\XG:I;N55Q=]O=FVQ/S20EO_5UQ;9\9?7,)E^Z:!*2N$.!&I!46_/K`X`4 M24G$"TE0H$#LAUFW#1`'#X"#YQP<'/S\GV_+X&P-4.2'$=W%^\_OCL#T`T] M'\Y_>??MY7STSR_<79V>+.%[] M].'#CQ\_W@-O[J#S$`8^!._=3]Z5>_I^SEQ!&N/1RY<#-V2@(SB:D5G0VP7U%:^"] MSSX:9/T]PYC"Z)=WI2Z^O:+@?8CF'W`SGSYL"[[[QW\X2PO_]!;Y.Q5^?-H6 MO_CPM\>'%WY.1?*QJJH77[Y\^4#_FI:._)\B^I6'T*4H20AX MQBQ!_G6^+79.?G5^<7G^Z>+]6^2]^P_2X,\H#,`$S,ZH##_%FQ7XY5WD+U)?];H'`[)=W;K"."/*?/W[Y])'4_^>;T$V69!I![Q;&?KRYA[,0+:G4[\[( M=[]-[G?$=X-P[4X)K?7_"T!Z2-\>P> M"[($HR`&".(FUJ"AU-Q/*I?ZSH=X*+YS?/2K$R1@#"?`31#"=((" MW[J;3=M5V/6\D:Q=LH:B;@:U1E,*.X@U3H`__,-!'E9T.:2S![`&P:=[S$$0 MW4NQOIM#K/)%KA5M.)V+J3 M%9]4*/`](3QS'X.1KYNO8>C]\(.@FPE;NT'5HS-R790`[_9M!6`$%(W/_D<5 M"GT=0FQ]Q02Q%P#]$#V%,>A(F]1I2V$7B>WB)0%>N=,P)JU@"@NB.$,3\]H@ M\8!W#RG4*V)9R20CUAD""UP),^.' M,(JP^@^Q5O@3>!,0D*K3D/:V-8C]ZHW*88I#]_=%&'C8XK[%1"+>=#,+9=M1 MNLB6JQ!2JIOJVS*^Z1@1E!4L,+EV5([:`EL;5\2]0AK#+5'PLAE73)M[B'58 MZL'`E*AZXK4?686R=`Y11Y.[1ELJNY@LEP[:C&=T<8U7J2)Q8W^-EU?[3G&_ MWLE.P<`1(NN([P@;4;C%+/TZ!(QLXC+%N`]#UNR-S-1M4XXBBM&,:YNZODOI& MV=M2\IT5E8M^3<%;?!5@/=,0H2,*>&J(/N,/D/G1>V1S M0;M&^*7P'!!.DM!%M&V]NYDHV6S7O=]Z1;$J>?4A':%CK$/)9KON?>Y1*AKO M<,CYK6GMZY0XR]0K!9DV.]>@!]ZU#K<73EL:^]G1Z(I;[+K/N5\1>OM>QV-H ML9K-=XU&MH]$V`HA\&.I,J=EZ9SD&+`TE:.G^'2T>MI)TS56#R&<3P%:WH#7 MN+N94MV*EKYU-,J\MCIGM@=>5E+V&!I`ON7>8-#1^-=MOVL\2J=:L[)'*SM3 MN`XC+/.^/ZM#QM16GI[CU=&L4B-5YWIVWYW8X4;";JKK7MXZ"&+3/7H&B$+> M72?9+77=Q]R+>HS-@]M8USWEN%2/T?>:S7>^>R:O$?@CP3_>KKM=P.R6LCZN M2CY$$E2^TUE<&$"/A*BFOR6-*8P-IA)@&;`\.\T&)(HZ1+L@9ZW24.D(N._G MX?J#!_P/!'?R`QV`\X\76:#T/^-??1_AICW2_%W@S+>?"YQ7$/SR[O#O'SJ7 M)S/J[_"4ML/O3O\NZ@"2';98\M)1E%.RJ+D\60LC236`^`>*Q">H)7% MM4A+69>+74LV29@[I--#,9/SK)J9506ZUZZ!S!W@K3MT9M?I9;W2W0O MTQ0Y9!:_;):O85`AT>[?.D/AL@YCV4H1"G:.LQ!Y`-&[G/A_[\YP9V8`\S3O(>TW4U@J:0Q0!&A) M4M,/$9;FEW>7[\Z2"'C\NT7GT.XJX/GK MH.%A.^L*A+X,&J%*@RX'YV+8%%G&:U!@-0CBO..IV^)T8-L.S,:J!(4_T;8( M??QH(D8,9\?NNMKZM(XW67[^L']4=I0#-'[FFZPM/R:?O;C\C*?$V?E97F?G MYW!VEGZA^;G;S(E>*89)=#YWG%7J(`)!'&U_L^\IRG[]G<3@@=*5Q3V'$;-8 M4V>J'\R)?3J6D MA^5Z(:U@U;/+:Y5>."^J2FJ1F-SQPCH_W)6'3R0$E73T@^1IQ6;=@M!$DCLL M7-%-@#`!FC(/FV)4ZNG"@=,%"I/YHN*.ZF_8\L*&TG@V8_1<>3/]P2H;O=LW MDMT(C^FV/_?P&84N[0"3>;3YHAX$Z*XA4BX'Q73(FC.:`P_?GK05!;7*6Q4/ MQRBD0\[?`,GP#+S1&BNQ.7A*EJ\`90EA2LY1.9.UX<=TN+8DV35Q<[&&U&3/ M:$^]?GKFB)"-E6=)JVVE.($P*T:E$9)"]TZ!EEDA*PKG71OJ5\#;(.`%[P"O MH5$`2_OH"MS,BH)IA-KA24,!CUG1,(W@J7!+%/@TB8G36+EOV2P@.Q51]G94\_?PVEGYF%&R>L0HK47R[&FW M:D'+C[3ID$L0E[!72)^<`LVQ4T:[E%*@[I?5(77%Z52>*2XF;R_X7N9NV"KE M_?PE;;ZDY::#$Q$%3OZ/)%%=.P$@&?+B:PQ9";6T5/'U)K`._G);Y%'(9< M12NL9F_,;%/Y,Q#,_ZSGML#NF3JF='FXC$!NJ:JG?X]`#+75VMCWT1T#'IZIK[QJ?`K:WFKN251[\/C#A]H5G"Y*@HJ%E>X>9= M75:;U'5X!Z>"#OF?M\Y4(6&M*JE)XI7C;Q\=YT_MZK)ZI"91`O'F.7#2?(98 M(5.O&V8?3.$Y5?3<`(DQ%07>]N"PY&W#;-IWF9"X:18FK:Q;I:N&W,6/]#Z[BG8SN!3W+',SE>ER:K80F\ M&&9=@8_)ZE<"GRIW3@&.R?I8`APF+F;%]]J[UGL3I*Z_O#QG>/Y=TV-WV^#6 M*-+"]$C?-H"*#[!-O^C?#CU>"(/IE_[;(,<[NFAUF]]PW':.Q-M=W^\OU5`! M%#>6R_2+_6V`XY5N=^'?;-S$H2#MD@&^_BI*[-[KO<;;92NIMCH-)7B(1"S'$ MM(S\^`I[!;FW5Y!UX5*'9U<4VDS26-_VW;T%5)!J.X4XMV`+F,PDB#5A MJGLMNH#/5)Y4!SZ9B-4",5.94CO74QFAKK.]]3K_QC.%>@%BW\4"Z[U9BF49 M(RJV1[>7;0XG1G"G3$W-=V73%S9'2;S`4^1/9M)X7HU>].`^BA)YZ;/2O9!\ MYW53.?'+54RY+VO6_4AJ-27?G!5"*="7^07*Q)1+7L; MR-X&JGT;R`;B]<"OQG5?RVY&UMDOL\4-QL5?&Z7M!FKZ';#F".ULT:9?!9/. M5"NVKDV_#58;*IY:,C-`J2%$ASK)S*MB#>%A*"13CY+LX;4]O#;P\%J__Y[< MM[P+PA_1/=8E")36498U^R_D8(R7-9M\X8Q^0DN&;._O293&3$_#"7!QK_T` M[+Q?,0V)B,$@X)1N]I\B\C+D/D[/2,W]M=IB)`@>6L73?4[]^L((0?_EO;Y M>D%^O(?I51$\XQ/Z,SVRGSRJ+);HEIZ>H)W1';[YE+]-L'[ZAA63RI&WVI]PI0SQS9Y<'<7)=Y1=B]U,&`6U^M' M;W*ND06("3A-C0_TI'\TKT"X&W? MM5YCR4@V40(^,^Z-74-W#[;SA?@B\\,YB7Y4U^M/;]+SQ6_0`PBO:#Q7_#4@ MEV>S)X^!1^[48`).%1.96!$NEF:!I5T9KWC;0K=M:HG!JQ22%8M77=C&;]:* MW\P/K>3C-@^KV'A-B822'9ZN[28ED_'MFA[F<"RT61K+]"R.Q\+W:.>KIF>) M/)[Z$1R2F9Y0\EA`USFO,#T59?VSFSS)E@)_?+.$E5]2="&8DUA?$_&M>S;3 M+)_ED'$\.&\U/;-E)Q.QZ@C4U%27]O;8WHQ2>]"U]P82VT77*ADH_M1K:('E M>`Y-3PAU;'"5.3)-ST35X<#PSF2:9:XZ)>K4';!M0S[:I;WJ?])4M4?]55-: MYI"N6:HL`V:X`IS;!JVT2$ULDJ[8;#"'O+EXW[37USK#LANO&JFO_#6Z<1N M%>?4[OFX_F^:158V/35JB<@.UR4U4$FZ;"*7^[22;%<6I?:>P77H44W:4 MND__-DF4LJ(C@.5!\6`@^W[9,GU*"MHM[+D1*A,99M."[$>=V;0@-BW(;EJ0 M&S_"9:($@2S$"W3,#(5%PZOPR!P M7L,L2`KK']\E<0NC.0)IL%3%;;P:%95K'OT`&X,A7H@3L`;P(->& M5!4EJ1\E&$Y7GCE"C%[-%M">9 MZM`5[S:#,Z7D(*FCV'/S:L!0<=:B^2\J*N5&3$B/[O'1;LK?CE]HH$J6+;>] MR:XH;V?IYA,>X29KU)5^IVY-;\F*.A:G2_UI,^]S&)/0:R<@1S,[$VL;25DEH'3=TW=*JEDG MC\Z;OTR6W-URMXP6*7THEG*G3"_R\&PU"HB^(G8*)&$U'7V9$#;$V:&+OVN3 MCCL;RB64:*4)F),'C4.T(7=!G`!$A2N#K3`E:FG))^(N@)<$Y9.Z@JI$5YO2 MO[@91^I^1D_NE-#]/7T5YB9!F*BD034TTJ$L+JN/LM5U]&V*&QC/2M8,9\56 ME]6:/:"9+9<;Z3)+TO1G@*2MQ!PU(>TS_>TM@2E:E9&%@ZZIKMHZYB_WGM,! M"3+5W]\4,?D-RM2CM;K(U30338_*KCOA&GF#6H5IG\0E?AF7T!T$$H?\G>%^,OU-4Q$:NVXNT_-6-O5"B,(F/INZF-H` M)K1^C(VD4(D>P^&RQ\>\1..1/WBB^!$U;?[.F].*W9E>3@' ME.SRFJ7/?_Q_/E:SR%UL'DAJ;+FN\"IK[5>Q38H"X[A5M/:!3OZ(`GK!#0?A MU>A+#S[5[L&G/O0@4U*4?1].=CEU)_4-&[*7HE;:/QN09=G:6L+\0@@VCP[Z M'<1W"?3X,?R,PCHMUDX8YXZE*V$BF9Y/J7.06QZ/FADTTSGJTEK-]#,BY0:9 MZ+CDDZD.Q$Z0K&L?&'^L"7J? M;(8G;6&LVN,(*F>4XJP@]N#9'CS;@^=*Z=/M:QK2_[^D,4U8U43IF]]R`/`_ M,>RCR",<$.DW6=7[;.M-TL&0KF,Y;LTG_];SU:?1L%:NM32ZMS0F81!@8^*' M@[SQK`A0GJ4VZ#W$$R^AUD?DSZ$_\UT'Q@=.OA8!S,99(3:`[20"V$XT_(NO MVV5<\-*FKLJF3APS*<-753,VO/"8O?S-CQ>'^]GNN$SVV&@6AO05]X.\#IN^ M1T]>,+QU$,3%A$NK\_9/"=V(T;WL/3FE2/+;LJ@U:.O[I:(\I%T(-W)=!$BI MV[<5R6=?G<7T."U;?YD]%^^7QT`9,1H,PAW0;]'$5K`9M#I!/IDG6;L>I*/N M4H.)/>OIBFI`^0=S$Z2G0R9BJ>TNC9S((\M=.3U$AV/&II;I$E![N4$GV$K5 MV(#.)3L./;*/'L?Q`J!KO-Q(LBEZ>*TE#Y+KDH`9D@@Z#'S7%QYO M<2KH<"!FXA#V`WRJJ28@<&+@/6.+#0N7`WBFF MSENA7/B=$532^GB*<)?(743,.6BJE[3''$?#(\(2*G$GQXCL]MV*(??Z18`F ML(GTBZF7III@);6[F.IP;@(8'Y\FWMTP=H*3PF?8D?&RH(@GUS']0MH-^GO< M")S[&*0\%OUK&'H__"#HS8OF50GY[3O?IVO<]_6U947183[T8_#@K\E1X^[B MNMH\.G\/D3#-:XTO]*R'A71/SI*_.NM^I6<]I9?W@G1G\_Z>1''5B]O-OZ.C MMUO%S^A$_F>=LN']:1_!4BI_OA>XWC=T]/)^B5D_(C-@/-L7,9U#`9E#C/[) MUM;2,_B,0A=O9!-,;,BI$QZ$&W*<%*Z(P-R;'7)UE>Q!'#K$]9)*U=.#^ZY@ M3R"^?2.!,#Z<"]:[5%7KUD_!*IZSX>EZJ9?"A1_HPQ.0G;RF;&:Z4@'AMZ\I M[\8LU*?/.Q$+=;GI@/'DD?4RII)[M^D)GAM1T.KG<,5[A*G3LC;+VIV(,F3& MU+BD5M`UL&2-/H]I/`5E+;16AS/]/_MKBE_5,C4K]MX>K3-?^I0UC0:;C[\9 M5$)#P_@@]':XU3(YC$^JWPS+&IO"H,Y7T[@$UT4)\/*K@C9DNHG\!,+2!1!A MD#2CO!(_\>'GN>YA7O&.Y&$&T;**:AS59Q3.\+Y%%^X=D!Q:5B4=_;A=KH)P M`[9Q@-*S5%SOE,_YS?7VE[6Z]&`+*IU(J#13TYAJQLCJ^S*CE-`'1GNI:L(E MV@:,]D35Q$JD>HP."FXVK_@P&1@;+&"#PXP-E@!%/,?,O3/>8[>E=B/^.H1K M@&+BV'@!$$O[%,9`]=LNS=GH#7B-I8/@&(5UL&@B2I&MFA,06U%0O[S7#D(; MDIR=]$(MTH/^E!,[/1'0KZ>D>^""[D.<>KWM'<3LDQ;]"ZKWZO>37$KT2(, M//+V-G"3V%^#*7+(L?B-LY%;534^U\^^/P/DDMU@#L:SESAT?Z?S<(K\^9P9 M6=KVJ_U$0L70-Q]OAH>2W631TC,"+B#_F``/+"D)P#LMQOO1>?.7R;+*G:GD MN_K'\<:)Z8D+BN()H!%_WK.S(7^1TU6\^OI[E^<1DNI+4;H'DB.,)H#N9CQ[ MINGD?#?#5:XK[.H=K*I[B'DUP#,`3X:L&3S]1]![#&&\$*\>07W]HU$6\"6F M5^YS_2PU'MP/Z.\?ZQ!)5%J_Y(].G!`CCN@A*>%W*NB77WA=C5EI;E37[%./GHM4QM)3BUV[5STC1+*F^F+7[F`WF8!5@MR%$[&EE*VE M'W?>U9NJDCV0&*!]PLLIJ$W>*$H?CTL9\JIMGU[3.;=KLO:[W9= M]N'=KA-X5\FLJ(J'$,XQ/5\2?3'%C7%60&71/LC,G1:,PGK2%X8N`%YTA$E MR6E")&,(SZNAA'V\@*4_@C!Q@LSVI-Z,[&=V#A"9:MW(]T(R2WOU!:RJI^7. M@6.(S9(^^>6YB:I;`T5W]UH:E1:`]BX;,+4B+36TXMWMF#J[:[N'&@5,?[4P24<1%:A]L:A)1R?EJ%U8]MHV M\J?`\L)B62MVJ$#.K#LJG2#'BKTK0!R\F2!]%%I@9DT&F:/^`B]K+<@&$A28 M65NA?6!F@>9@;0CI$(H"*VM('(80%.A8@Z$B("2'YW+PEH'H1*B`RA)_5CAV M@=$0*'YUGE/YT^<"K2'PTCIH59Z%%W`-@6+5NF/]>1CGDLR<:]6Q/L8GJI-$ MI^[K\@,YY6;B514LL,7FTF)3S1+,S670+,BV<@'*!8&:'FS2*":V$L^JL."" M)ICEO>IQ2@T]TX@7X,LC!T/%A[V>*D(WBU74]3F#]GPL18K:*TB>!"`Y:VFN+/S/<+EU"CR!>`S)24T8^!X)Z*)A752=C6?C%=9C1'B2N/8Z M7.+^+'`E?PT>0O+XA1O.(7$V9%G=IB'%7TLVU]3O086E>7H=Z/IPSKN$PZVB MZ_;0Z6>M.?"ZG,R-W>/=B#/ESM:>GN'-Y]1P7,O/8%,3JC8`C4\/;-PZ5T^WC%?O;VI0!5[K@6@DZTL["2>&?CN4 M!)N2V#\L]>T?"8&G+SE!Z8LU63@L]TYR14$=3+4LALBFJBZK1>IPN0PA%81[ M@_:PG"G6E%D9",KWV+;A).-9:?08XRNNI_=-:BK#U88N'+E'J`]K:.G!`N]+ M-#J8)7!10(M\6^]A625QTE:PR^N1'K=.IBOP;A)$'O](8V0)IM$3^$'_Q.Z* M5&4EF1>^05P6S#$;^!-X#$\AIZ!.8LG>A\N\LF(?,?T"*'?#WSGJD)REIMO_ M\H"5E&8K6_\D+O=+PR*QMYMZ4[W'-ISN-RZ9S$CD"C$VK$@2&PD*9'PT7TVH M&*K*7-^1-$UFH62Z/A*SVYVEQIMN`W*[D=",$.*FQC,:X;$3JI&&>Y"`#4W/ M[";+A(:'\$03>;AJ?T;3XZTR0I*0F]G4>6O7U?PK@^GI]\L^]Y7G1:KU"K#5B2VY?QKJ^V^-77`^:[R;B$F0$>UWXQ]4C,GF>P'*P\ M,EV>08RI9BI.]?RL]73;@!RO]&3YRHD`O1V'\:!-9L'3Q?VX>X@1Q`4<2/+, M5]^PT_).>MX1>NZ;=R"[ST?#XVD77TD7LUPFD>AF6KN/6C?15P#QI`A&T!MY M2Q_Z!!B21#.;5EQ?G%Q=/3>OB)K(Y_X#:8GH.;9S@U>C1SW@NO'X=:P[+T5I M@M4UR9>`I^T-2800KNC6+3'?96IJCC2MW")&"-/4>;H+7&V*,IDZ'/UPD"<9 ME]KR^]JB6`]DYD6T'A;NC]PEK%E0BXXW%7Q8ZV4A)3R"<;+?=OV82N%K;*R[ M-_RXN]A`T6*[%J3V)E/]"HU1D^2PIMZ\M?X8=F"@&CXT6#]])TA*[27&N_`[ MA58%=S3?XZ^.88NQ/^;9(O=$'O.(\-A3G1'19'GEOY/^ M/(7Q?X-XOZ=W(K]##DR/#NM-U;5*?.VQ6VJV9^ MG#XK>W#BU`8V\<=-.9DQRW=N/_X(ZU$>AD?9>JUT>ZTLDM:UA:^()`+J!K&JEDX1L7$21[$#R8L:]S!&/HQ\ M-WL=NA/F\QJ5>P M]2GVD7>`)@+VM?)K@/F M&A+T[A&W\O'Z5E3F`5+]#]F0:1LR;4.F;1K[?D[[RD"L9G'5=C"ZB.YH%SY] M(D\\]',XY)W?Q1C]N]TG=(]/Q?%T,3Y_M>.C0YWQ'5S%\'RQO%?U(*GT1.8# M=6$MQ2,.4#>T#)G.UJQBPKAT<^C/**`@?L8EG>IX) M_MJ)%A/@`G\-/)):;VL6[>818H"BL@6;FF=?()N:QZ;F&59JGH/#!IK[[2AW MZZ2:/D5,N6=L](\W>`.[VNT M*<9U#),<*[3Q\ITE9);U$0SH,<0'#!:,P&B.0+IQ].8=Q)'KD@3\43I@9-O* M>.NS@V(?1-<)(E.-P?-E:]>SA-Q@'5%Y/W[Y])%*2W[SOHJ4;DUU$BU=5UG M:$S#*_#H>!B*41RGYWDO#L9DZJ`YV)\'3;Z@1.KK,`A23(A6@][A`CMTDM6H M>!P9*WV+M:J>LA>4@=I=0N(2MR; M,_![P'HZT]D^N4I(^!)`;$W/+:]&HCT5DOV;!&@PE:6P3N>2L56D1*U.I(O2 M7X1H1!QX_P,@<)UO__40>YS!K?F)CN5>^X$S76"K=062V'>C)H(SOM&MY%\Q MQ_@=@!5W(4E7[E;6YYG_9R,Y=RIV*V/TY"R![-JOJ'4$Z>37?V6];B3<\ES\ M)6GT]NMT+ED-Y`YK=2/=)'0Q6XFQ1?!:8V$G6XDJS71 M.IYA-:=6XSFEQKNQ+P]E!Y7C*U-#):)W`$28P^?T/9I@E@\/#E2EJBB1Z]%Y M\Y?)E+U/@+]\35!4$:'1[!M*)'\&R"5>O#D]@,5FAP?2IK%>2YTZ M+\EKL#\SJ^1O^"4EO9@`+W&I9_0>3D`$'.0N\&B7X,N>+J6OUA48[N-;U2]E MWU;4TZT1NV^\LC6OL(X.[5(-I2`R4%"I1_THF^YI0/\TQ"N$N*OQ/!G'F/Y' M!Z<%81)%(!ZY?R382/>HF-.%`Z<+%";SQ54289&CZ#I>.K`>YF#02 MCMW!(G:XT*2,5E,OGM?T5#+G6+7[<%"SC.=!%>/&/!XP]1Y]!Q@>'E2TNF\[ M+/!V3TZ*"Y1FQ5!VL7(9!Y(%A&:%.C:'4!2)52!F5DZ>6L=9[`E7<R5.-PER)E.,N?.IF9=4P#6_C'X\5)8 MZ+DI(7>*4WT_L[W7V-15V\794CYI:T2GFGX'2S6^W9U_F7[CJI.97C,:_GA7 MJ@S"N/YI9[-71P8.<[M+$JW>%ADJY$TCHTQ_)*03L(6!?:V>]E@#]!H.$M=& MUSY;O=,QU!E<]RJHZ6]L=`)R_3A;TQ_)Z,J$D;[:;OKK%IW,8W7QRJW>KC@! M^-4'&=K<3$JAE#P6R_,N671;HWL8.[9%U\Y=!7.W(FYJB^^EQ;<]OH=*X9.% MM3:LDH'<6X@_6XCK0*R6_1TSZ:#V=%WWN-`23)TWH#I1E_ZT.VHNSN0(%:`) M[KWQ:BA*69,/VH'5LIN=IJ*<:@FJ[@15E]$Z>IF)=@4@F/G"D=LKW>OD/1K4 MN,2:*)U@[T\54TTWX=HL[U7,B6GJ,3Y7;PS.S!>BP9E,YF9%[O$M-.U,[3I< M+OTX-1:@1YBLCUDM='WES*WY;LN149H]U?N&HO25^2M^N44V?@U\J=R?O_$P?A"1ULM@U&$Y`&+]437/B=4T[$V<>TBFI6WG." M[5XG*FF)VSP\AG.,1719_8AD-+3_6^W[STA9)J92SQZ3+#VSJYWNY$\SX>HTU=Q3 M!VX+RF-Z(':'X#+YK^F!U\T9Q>"<&&H@:SN9!W!>\Q3&()J&=SYT,.EQ@A?< M4GIN.$9S!_I_IJ_1A#`*`]_;'C(^EX0:SRHJ%]QIBF6\PK3U=XT/L^!Q?L;B M4X<&WT7`J6"MTSY:I\IG:?6\4-Z,ED1]6XE$5GI%0:WR#IA6MNNPT,E_HV ME__*B?QH/-N3:I/^5T37)"OKZ!=YV)-XFO'_W?Z1^&LG()-'KEMR=:VATD=# MY<''(^817*2-#FX5'7UX=-#O(";;R0MP$ZS;B9)8.WY`?G47(G*QL?A+.B\9 M?6OT*1U]?@(_2FH$X7TD@6YVN:6&1JK]&6L@=FP@'E'.;^3=YMLH]I=8%!:F M>X6L(=LW8FT-V4:&K"R1&XQYRD5K7U68?LXHAPJ?/)E^;BB'47VB8GH&)CG< M)`TRTW,GR8'5S`(P/162]3Q:SV,[S^.+/X?^S'<=&!^2;WN$;CU375K1#'O<;;T$UDO`)):R2F@P7@)+)2V5;$0E*S*(]R0:4U(RQI&N7&4M M1]6'HHE(,K>*I.3[Z MU0D24*P?%2[)?G&5YOML%3P"]L>MTI<^B`@YOXYEC98U'D.?RZP^RQHM:Y1D MC0)%:,FB)8N6+#8FBQ3&%K=A+&7L(65\\)U7/Z#Q/H_`(8)Y8S@A,4#(AW,: M_?D-AJ\10/3YF'NX2F+\9SR[<"TZ0:69ILJF+$'--%B>-SV'F3Y0&M%<\D*\ MZ9(6!@DH;$OC+8VW-)X73:!6J0V&]LO91DIW_,%<<+`FE36IFF4E(,_( M9.\LIEI,:Q3'388\?7CPVEGYL1/X?P*2(&'E^![6L%3@5%+IW-QMOVIC)OIH M7/"F;O4\X-6PQ-\\XJ](FUC;P-H&LHFU>#II,$S?LE'+1E6ST;;N?M=L^C7K:NTC ML:6J:U_]"E>*D,D9'7(Z*-]R++2"TCM8RT`T9J MUHT_R\YZQL[R@['#R5CS*%_X`(TUWW=ZC6N$C%86MN[)/A+@ZBE6/;#592TI-(<4RJWW(=(@2Y>; M/5I7K5XL];/4SU*_VM1/Y^4B2P#;HW@/\:0$47R/9\02I*%"]!>W;RL`HU+B M'RG/7>//6?)K::2ED99&]HD:<&ED<\5IF:9EFI9I`3L=Z^0Y5H#Y%I'E5-V^;*Z(%M?IUZO7GF605H&*7LP+;], M+&6TE-%21B64T:S01TLN]*23$LRU44_-E%5EGI:ZFFI)X]Z%B1S/".+"J\H*L0$T,5&$]*] M+##R5TX$O&=G0VOI#9Z4%?FU+++HC+W=1W70@;9#UQ((QE=-B4HPC/1;JMOM MR;P2G62IL:7&DM2XM?*WU-A28TN-.Z3&&H-++4$^$+D8J++P(X0<.$^'^VIS M,)BC'P[RZA!F%:U8`MU+`IV[HFZ7JR#<`/`"T-IW`6/(`RH+_FD\(\\4SB%- MYPZP$DR7BKP_775[>M&K%I\>@(WI?A"-W-A?XZ&N>>S0^,/6'+/FF#7'K#FF MZ*1"^?8P&$--$N#F.\A@G@66]APH8<4%K)_-AM5Z$JPGH=GE4[P1P`B,Y@@` M5>=GUMBKDLD-UA%M]^.73Q]IJ^0WWSD#L"N!J+0U%LR)],]'5>#Y.BQGB7F? M]J%*MB-<]H.AU9:UG`9KT8,+4PGVP_G1.RIWZR#HPWF$;75J&&F-A-H71A00 MSRJN)82?":2<\/;`I.<')D-BK3J"ZP5KOQ_ZVW+D?K`>KD>0HXHM2[8LN5$,+U\,G7>;(:/R@QM!^@(2"JO1D]Z(,XCQZEB^:'EA\=0Y1(KSU)$2Q&E M$\;QM*!EB98E6I;(8XG7X7+IQVF4&?2N0SQ;X!S@0KUY'-D550)``-5"UU450M=5'5X"P`!!"4.```$ M.0$``.U=W6_;.!)_7V#_!YX?[E)@'<=)V[L&S1[XM]F5!2[1- MK$RZ))7&^]??D)(L6A^T9+NM#>BE=<29X0Q_PR$YI,3W_WZ9!^B9"$DYNVIU M3\]:B#"/^Y1-KUJ?1NW>Z+K?;_W[YQ]_>/^W=AL-A^B&,T:"@"S1;QX)B,"* MH"?\PAF?+]'(FY$Y_@F-L20^X@S]]F%XC\Y/NPC-E%I<=CI?OGPY)?X4BS9G M`67DU./S#FJWDQI^C72Y1&]/S[NG%U;)D(?,A^?6HVM!L`)JY(,6E^C\K/NZ MW>VVS]X\G5]D&`AII+HB&11#P3_S06*HVU")J0R:N69>"7BU,NIAVHHMOY[>-] MU"JM'W]`$>WERU@$=(U#/TEX+CJ428691RP6:*L_'1RZ6#>Z74F.)5:K^^[= MNXXIM:A#V9YBO%C13[`<&^JXH&,:]ZS;ONBNW=Q9K$Q`"F<%S>#KT1'U]@!HC90$4$]FW4S7XY'T_AJ MQ6:W^)M.5&C;!/ZIQ'*=7!+O=,J?.W&A-NHBWQJA$-#KRECCTN*6]`DM9H." M8@[RXLV*671),0]EST2J8JZHK-@RAJDGB]E,D>;JYK@D]8IYH*"$0RU$"0N4 M9'D4%E.B'O"/*Q"[SMWZR6%`VX?&?\$!WT$O!`_($WHGTCT_#_B9=51R) M.YJ^<\.]4&N+F7_+%%7+/M0@YJ;>%J+^5SCPPL`PWL/?,7-,X6)<"(C13&W!F6I6 MSA<_34#9*U8C4-JXUF#2!ZHYZ06*"`:6/),(JR&0_>$D"&^+4+X@\XT),*-)H1HAH$]X/@(X;!6$TW!LP M?5,=4W2RILZK!N/J&%]C.;L+^!?99SX5Q%/%8.;)W.B]K1YTM6AD9#>X;<#M M@2LBG_BJ9Z4-.1!3S.A?QJ:TK>&/'O,?+7NM;IDRWU`)5!?63\8A?,Y%DL-N54!2FM`216-%VSM M!4D7@TGQF#)CVK9QHZ(HMQ>\RWK![6`$D'\.:33;:*#>&NH[3,6O.`A)VKXU M^[E;@A/8[ED6V)5\6%A+)<)HYJ`CO:X&F7K01X(UN2YKD-]^&@%S:'%M,F^J M)R7,K6O."!S\;M2[6=2-*!3+0I&P!MFMD?V%<_\+#0*8FO5UWFM*QP&)6G7; M,%Y3I!O_\RS^J<@8?-/CDSH;3]C:$^)ID7S$2ZP!8SX\$2'Q[RD>TP!T)EN[ MQ+:RW;YQ41P;8M'H]F5!F&PF=SOXQ#UGTR>B4_=C50_Q8DXWGJ^S>,+B\9D( M93K[B##*!3(U-HANOVA3@,.,!SX1\A8FQ6JI:;?MU]6EN9%_DUNZ68+_@2+1 M#>I;HYZV[6"B=R\@+AK[AB30F;=K+@'+&1;D@SZI`%':<-7SA5WK<'O(VYR' M:%%M(PO9U35>LGVTIYX>,'M30<@6#N!@=V.;2^#%DE`JJD%U:U1OL6"43>4C M$:;/U`.UG-N-:2X9]T"4V2I%CWKYQN=SSJ(^W$"[-;31EO<3?MEV_'8*<`.< MR[-%LO3AMV:"M@.FNFM0%:V:&(R:)E%-F+?#ZJNF2"?NY[DTG"4]/AUAR6\< M8?N9>CB6Y',(/V^?ZP_&Y=QN>'/YME00BB0UD![,;FRR??5==F57E;L=*I?` MJ[,[BTZ26IK#&U]IW^9))^2J>5`5.6YGR&7LZN[AH).HGL8=OLIF3@UGV"S% M[0JY9%_1QDX#]W?+Z]=PA=UJ<+M)+C-8G.-O'.4K)?MKN(&+WPUR+KE7EOAO M8/Z&.P`UH*\KT^T.N7Q@T6Y`XPK??5N@AH/LIR:WV^3/_Y5L$32N4_F-J55S M1JNVP219L\$@;U9L@XF]7NOYOM$6!_E7J_8BRNT!N9QDK;5F&Z5UVN]JH9,; MHC!MWA^HX2ZW@Y%UYK*26U1A<<)_D4M-9HY^-@CO$>%H@09]UYKDQPMUOZ=6 MJ8(!A'C]RBYE4]/KLJAO*\;M";DLIG54S*HHR2SX""L[X0`>L:HN#A:-A]3V MD!5X5OY&5@H%-3C=?I!+/A9GE603&?:(.TP%`VC`+UCX@TG:@R?WY)D$%U:> M3Z8O97QB?*R_)J'G97VV"%4N4.Q)JMM?I'H:4`HD:#5XU+U7>I?+(QZQX%%&ZH*^8?&ZSJ8I4]\PUC^^I$>)7@7YO? MC7,N@>@^0-Z,!/ONMG&J-LG4%G;<+(T;TERZL"PGW"!6%S$K\1KE74U*IU*_ MK7_RM-!S>==7_0Z\]R^6$`4ZHGKC18%H4_\/C.=+3KL M%9<]$#5@]IO\UB[A)/UVBCE[9'TY19\&A&46A^G27\2/,X%/W"";=:[#4L[M MOOD\9*R\GC(:]5&B?Q*K4&(!3!+C:!8?ISN)*5[]9$Y0@FOO\IT:E)J$8IN0 MXLG>2M-G:O>9W+Y'I5!9E<$?WADVB]87>PJ,/J M7I8?&:NQ.>%^773P,A)KNGZT>EGK\4D(T<*;9>--XUYZ\J]H`4H/5 M[1VY#&FI=S0#R1ZAC[Y,,YB8(7NPB*:@GJ+/,&3GP'82N^'-)33M;^)H<2B6 MAQ*!#9R[+)U*.J80F$WCC]PL<^<<>CJ[7+[BV4&FVSER*5![H5(:!^R*T7BY M1AA7CDSMC2?5]Z3<.Y25AH.*7&YOR"5*\V]A-F/`'J%>O7M7,;^VD=X-;RYI M:K^OUP"[WU5BV>MV%1.I-?G=P!=D4QTO[#6>`(_U/_KZ@"&9(',SP*7^)/Y5 M2]+Y(B"M^!D6GN9WWRG060B^T+EK(CN)V$1`CGO]$@/C5IGVB[5*),P$F5RU M]/4![>2S['\`Q^G+/$A(%%6ZENM4#M*"Y$$!T&K<[B6K\-8P7!@*##\9B7F M2.P.$@$%4T&V@*3[[6$([$VV\TK&`TL!4:O'>4LL/U]Q[Y2`/Y:OW+@/9C. MA4*L\!J$DOM(4'3ER3WWC"`'B_ZKG?"U]:-V][Q]T3U]D7ZL8AT-TI:NIT'" M5U<#YSTF93J8^@LO3NF00,F5K'8JJWYS%-YS4JE5;,Z'B%$WRSO=+-VWNVBR MG1;;J5!X"TM5KT@8=*5O:CM"]AZ<'?Q`/ZGK!ILNE'&J4\27_-%.A6RA2,'U M--4TL1E7?^W4*)D[;RJID?#H'SM5GKT]IU+M*R;S:Z?Z\_?P5-+`8HM_[^0. MN6M]*BF1L(\T@`@#JO>\ M&043#8'=$-MP'T>S/,/P-B,,UBHI<_G MF++OUVVG4T&F6)$8K"?^@7S$/B#54PH4TSNX.-!=55^X9AM9D_$8$+[F6@2/ MFM>\WY/-4;]0V]4KTG_[^.;3N3Y/P5EY?-NH^XUQS#K6)AR'Y-\Z4:BK"W&P M4G0P#JCV7/^."^)AJ1Y-[6NFUN"RX4UTK^797]W@_X98*"*"9:(ZA.3/(86. M4\GRS>R'U03Z8P[IZRW60=PG@?6UN#=X*1_!$J+_&!*?S,U^\@-7X-$?\0N= MAW.K2?8CSFXBRA29$G$H+92<[!RFT1QL@A[^$9QA5MH2F]ALBZ?F&10?BLU# ML@AAFH8E`1_V=!)N2DHM+2:.PQS$N$7T]#O:%M_B!!-5;!(^585[CS92YOYZ\WV[D+]H06MM`>CNK5:@VXQ)%.] M\\3%,HYL=B/6XSONMD@-`NO,A'ZU@DN6=U6:II*8(VJI1Z[@$<6!OO%1O]U` M_?A8:6FK5&$YAD62=::C*%]57'Q`8XFE8#9#E2\ZR-04J"D@?I,;$OW?9S#] M7&#JIU^QJYRVVH.LH^BV?18M5P%!ZS"@^8;3I\6=@-EI/M#7X/EZ;>"3\=Z: MH/0EY>*.7(7\@#KV/42<..$&:U,Y@OD,)2(W0W23'=+T,)M@B?_6WRO,9J(V MDQYD$LJE=B[_5(7XD.&++QOAHJ?5^)TPXN%/_[E7?MY%ZW(>A]G/-,!/,YCT M+`@(]&0-N\M8C\+P7[`B?Q*R*`I&U7F.PM3'"?VKCIGK]$=AHGR`\@WAMXCX M*`+PNN(;0W`Q^4'#F&Q7056;0,R1'@>$EMJ;`2P@/FCXAMRC`5&4T?'F*%-` M?-C&A1Y>8%')M"SI01N6N0>FV"2+:,T8E3S_?OGUO*X5PL>QQ8UJ`>/`(\4= M(7JENLHNRB%Y)BPD>9/**8\BH1%O+*YMREOI&9.E&!(Z'X="9M)<]5F/(;V1 M_41S44[#07-`B8RLEMDT94GY0>8J\]\X+,+%275`R!1<()/!II3B(-%)M[/U M)^[7MR2B\WJC^9#XH6J^X\*.BMF(:;7*_D0> MQ5#DV-S+YWBJ$!_2O"+5-[MCZ3"MC/20#"O>A?W$?/TQNG3CHZC7UV<]"C\> MD3GM`32KD\MW5$A5AG8EZH,"/*OP2)_Q\"O;5TA^2`9^8AY69,J%_@Q4P;&G MDO(#FE_$VXKQ"J4,&2?5=P3D?2=Z4P9^_A]02P$"'@,4````"`!Q:6=%DU\( M'1V/``!]K04`$0`8```````!````I($`````8VQV`L``00E#@``!#D!``!02P$"'@,4````"`!Q:6=%2Z!\FQH/ M``#-P@``%0`8```````!````I(%HCP``8VQV&UL M550%``-5"UU4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`<6EG11=>PE#( M+0``MX@#`!4`&````````0```*2!T9X``&-L=G,M,C`Q-#`Y,S!?9&5F+GAM M;%54!0`#50M=5'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'%I9T5=G(61 M#%D``+'0!``5`!@```````$```"D@>C,``!C;'9S+3(P,30P.3,P7VQA8BYX M;6Q55`4``U4+751U>`L``00E#@``!#D!``!02P$"'@,4````"`!Q:6=%E2%- ML\XP``#Q+`0`%0`8```````!````I(%#)@$`8VQV&UL550%``-5"UU4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`<6EG16UZ M&F2.#P``EJ```!$`&````````0```*2!8%'-D M550%``-5"UU4=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``#EG`0`` !```` ` end XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Senior Notes (Tables)
9 Months Ended

Sep. 30, 2014

Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes

The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):

 Three Months Ended
September 30, 2014 Nine Months Ended
September 30, 2014

Contractual interest expense
 $ 439 $ 439

Amortization of debt issuance costs
 72 72





Total interest expense
 $ 511 $ 511





X

- Definition

Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Stock Options Activity (Detail) (USD $)
9 Months Ended

Sep. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Beginning Balance, Number of Options Outstanding 2,520,170

Granted, Number of Options Outstanding 1,449,457

Exercised, Number of Options Outstanding (60,449)

Forfeited, Number of Options Outstanding (23,813)

Ending Balance, Number of Options Outstanding 3,885,365

Vested and expected to vest, Number of Options Outstanding 3,620,712

Vested, Number of Options Outstanding 1,503,631

Beginning Balance, Weighted Average Exercise Price $ 21.19

Granted, Weighted Average Exercise Price $ 62.00

Exercised, Weighted Average Exercise Price $ 8.96

Forfeited, Weighted Average Exercise Price $ 34.96

Ending Balance, Weighted Average Exercise Price $ 36.52

Vested and expected to vest, Weighted Average Exercise Price $ 35.23

Vested, Weighted Average Exercise Price $ 19.47

Outstanding, Weighted Average Remaining Contractual Term (Years) 8 years 3 months 15 days

Vested and expected to vest, Weighted Average Remaining Contractual Term (Years) 8 years 2 months 19 days

Vested, Weighted Average Remaining Contractual Term (Years) 7 years 3 months 18 days

Outstanding, Aggregate Intrinsic Value $ 64,790,012

Vested and expected to vest, Aggregate Intrinsic Value 63,341,213

Vested, Aggregate Intrinsic Value $ 41,643,182

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Debt Instrument [Line Items]

Contractual interest expense $ 439 $ 439

Amortization of debt issuance costs 72 72

Total interest expense $ 511 $ 511

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Financial Instruments and Fair Value Measurement
9 Months Ended

Sep. 30, 2014

Financial Instruments and Fair Value Measurement

4. Financial Instruments and Fair Value Measurement

Cash, Cash Equivalents and Marketable Securities

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.

Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include:

Level 1: Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of money market investments. The Company does not have Level 1 liabilities.

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company does not have Level 2 assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity. The Company does not have Level 3 assets. The contingent purchase consideration related to the undeveloped lucitanib product rights acquired in 2013 with the purchase of EOS is a Level 3 liability. The fair value of this liability is based on unobservable inputs and includes valuations for which there is little, if any, market activity. See Note 3 of the Company’s 2013 Form 10-K for further discussion of the unobservable inputs and valuation techniques related to the contingent purchase consideration liability.

The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):

 Balance Level 1 Level 2 Level 3

September 30, 2014


Assets:


Money market
 $ 447,986 $ 447,986 $ — $ —









Total assets at fair value
 $ 447,986 $ 447,986 $ — $ —









Liabilities:


Contingent purchase consideration
 $ 55,445 $ — $ — $ 55,445









Total liabilities at fair value
 $ 55,445 $ — $ — $ 55,445









December 31, 2013


Assets:


Money market
 $ 318,886 $ 318,886 $ — $ —









Total assets at fair value
 $ 318,886 $ 318,886 $ — $ —









Liabilities:


Contingent purchase consideration
 $ 55,754 $ — $ — $ 55,754









Total liabilities at fair value
 $ 55,754 $ — $ — $ 55,754









There were no transfers between Level 1 and Level 2 during the nine months ended September 30, 2014.

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:

 For the Nine
Months Ended
September 30, 2014

Liabilities:


Balance at beginning of period
 $ 55,754

Accretion
 2,571

Change in foreign currency gains and losses
 (2,880 )



Balance at end of period
 $ 55,445



The change in the fair value of Level 3 instruments is included in accretion of contingent purchase consideration and other income (expense), net for the change in foreign currency gains and losses on the Consolidated Statements of Operations and Comprehensive Loss.

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 22 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A M,V,Y-&5C-C$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O#I%>&-E;%=O3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-H87)E0F%S961?0V]M<&5N#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN8V]M95]487AE#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N M9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D]T:&5R7T-U#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D]T:&5R7T%C8W)U961?17AP96YS97-?5&%B;&5S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O5]486)L97,\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I7;W)K#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D]T:&5R7T%C8W)U M961?17AP96YS97-?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]!9&1I=&EO;F%L M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3=&]C:U]/<'1I;VYS M7T%C=&EV/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O&5S7T%D9&ET:6]N86Q?26YF;W)M/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^4V5P(#,P+`T*"0DR,#$T/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)U$S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M)SQS<&%N/CPO'0^)T-,3U9)4R!/3D-/3$]'62P@24Y#+CQS<&%N/CPO2!# M96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#$T-C8S,#$\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)TQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'!E;G-E*2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE M,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO'!E;G-E'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPOF5D(&%T(%-E<'1E;6)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE M,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ-2PU.#4\'0^)SQS M<&%N/CPO'!E M;G-E6%B;&4\+W1D/@T* M("`@("`@("`\=&0@8VQA'!E;G-E'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@R+#$Y,2D\'0^)SQS<&%N/CPO M65E('-T;V-K('!U6UE;G0@;V8@ M9&5B="!I'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M.'!T)SX-"B`\8CXQ+B!.871UFEN9R!I;FYO=F%T:79E#0H@86YT:2UC86YC97(@86=E;G1S(&EN M('1H92!5;FET960@4W1A=&5S+"!%=7)O<&4@86YD(&]T:&5R#0H@:6YT97)N M871I;VYA;"!M87)K971S+B!4:&4@0V]M<&%N>2!H87,@86YD(&EN=&5N9',@ M=&\@8V]N=&EN=64@=&\-"B!L:6-E;G-E(&]R(&%C<75I6UE;G1S(&%N9"!R;WEA;'1I97,@;VX@9G5T=7)E('-A M;&5S+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD-"B!G96YE2!O9B!D979E M;&]P:6YG(&EN+6QI8V5N2!E>&ET960@=&AE(&1E=F5L;W!M96YT M('-T86=E+"!W:71H('1H92!R96-O9VYI=&EO;B!O9B`D,3,N-@T*(&UI;&QI M;VX@:6X@;&EC96YS92!A;F0@;6EL97-T;VYE(')E=F5N=64@F5D(&ES('1H92!F:7)S="!S:6=N:69I M8V%N="!R979E;G5E(&9R;VT@<')I;F-I<&%L#0H@;W!E2!I2X\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@06QL(&9I;F%N8VEA;"!I;F9O M2!N;W0@8F4@:6YD:6-A=&EV M92!O9B!T:&4@2!B90T*(&5X<&5C=&5D(&9O0T*(&%C8V5P M=&5D(&EN('1H92!5;FET960@4W1A=&5S("@F(W@R,#%#.U4N4RX@1T%!4"8C M>#(P,40[*2!H879E(&)E96X-"B!C;VYD96YS960@;W(@;VUI='1E9"!P=7)S M=6%N="!T;R!T:&4@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[ M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('!R97!A2!D:69F97(@9G)O;2!T M:&]S92!E6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CX\:3Y,:7%U:61I='D\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`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`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXR+B!3=6UM87)Y(&]F M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,\+V(^/"]P/@T*(#QP M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@ M#(P,40[ M*2!.;RXF(WA!,#LR,#$T+3`Y+"`F(W@R,#%#.U)E=F5N=64@9G)O;2!#;VYT M#(P,4,[1&ES8VQO28C>#(P,3D[#(P,40[('=H:6-H(')E<75I M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@'0M:6YD96YT M.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O M;6%N)SX-"B!/;B!.;W9E;6)E$$P.S$Y+"`R,#$S+"!T:&4@0V]M<&%N M>2!A8W%U:7)E9"!A;&P@;V8@=&AE#0H@;W5T2!38VEE;F-E M+`T*(%,N<"Y!+B`H)B-X,C`Q0SM%3U,F(W@R,#%$.RDN(%1H92!I;FET:6%L M('!U&EM=6T@;V8-"B`D-C4N,"!M:6QL:6]N(&%N M9"`F(W@R,$%#.S$Q-2XP(&UI;&QI;VXN(%1H92!#;VUP86YY(')E8V]R9&5D M(&$-"B!L:6%B:6QI='D@9F]R('1H92!E'1087)T7S=C86(T9&1F7S@S,F)?-#8Y.5\X93-A7S4V,6$S8SDT96,V M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\W8V%B-&1D9E\X,S)B M7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@2!M87)K970@9G5N9',@=&AA M="!I;G9EF5D(&=A:6YS(&%N9"!L M;W-S97,@:7,@8F%S960@;VX@=&AE('-P96-I9FEC(&ED96YT:69I8V%T:6]N M#0H@;65T:&]D+B!);G9E0T* M(&)E;&]W(&ET2X\+W`^#0H@/'`@2!B92!U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#Y,979E;"8C>$$P.S$Z/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$=&]P/E%U;W1E9"!P$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`^3V)S97)V M86)L92!I;G!U=',@;W1H97(@=&AA;B!,979E;"`Q('!R:6-E6QE/3-$)T9/3E0M M4TE:13H@,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L2!L:71T;&4-"B!O2P@;6%R:V5T(&%C=&EV:71Y M+B!3964@3F]T92`S(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@,C`Q,R!& M;W)M(#$P+4L@9F]R(&9U28C>#(P,3D[$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($UO;F5Y(&UA#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T-RPY M.#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT M/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G1I M;F=E;G0@<'5R8VAA$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4U+#0T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X- M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XU-2PT-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE2!M87)K970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M,3@L.#@V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q."PX.#8\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R M:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q."PX.#8\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G1I;F=E;G0@<'5R8VAA M$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG M;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@ M86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XU-2PW-30\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@9F]L;&]W:6YG('1A M8FQE(')O;&QS(&9O6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.S,P M+"8C>$$P.S(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QI86)I M;&ET:65S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-H86YG92!I;B!F;W)E:6=N M(&-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH,BPX.#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XU-2PT-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@2!G86EN'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)VUA6QE/3-$)VUA3I4:6UE M$$P.SPO<#X-"B`\=&%B;&4@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@86QI9VX] M,T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^ M#0H@/'1D/CPO=&0^#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E$$P.S,Q+"8C>$$P.S(P,3,\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/"]TF4Z,3!P="<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD M96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0U/"]T9#X-"B`\=&0@;F]W6QE/3-$)VUA'!E;G-E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#,S-CPO=&0^#0H@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,C$\+W1D/@T*(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/"]TF4Z,7!X.SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)SX-"B!/=&AEF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,SDR/"]T9#X- M"B`\=&0@;F]W6QE/3-$9F]N="US:7IE.C%P M>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C,N M,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAAF4Z,3!P=#L@ M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CXV+B!);G1A;F=I M8FQE($%S6QE/3-$ M)VUA3I4:6UE65A6QE/3-$ M)VUA'0M:6YD M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!4:&4@86-Q=6ES:71I;VX@;V8@14]3(&EN($YO=F5M8F5R M(#(P,3,@9V5N97)A=&5D(&$@9V]O9'=I;&P-"B!B86QA;F-E(&]F("0W-"XX M(&UI;&QI;VX@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,RX@5&AI'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'!E;G-EF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)SX-"B`\8CXW+B!/=&AE'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/=&AE$$P.SPO<#X- M"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#6QE/3-$)T)/4D1%4BU#3TQ,05!313I# M3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I M>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W:61T:#TS M1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^ M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@/'1D/CPO M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P M.S,Q+"8C>$$P.S(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M M3I4:6UE6QE/3-$)VUA6QE/3-$)VUA'!E;G-E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L,3@S/"]T9#X-"B`\=&0@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P.C$N,#!P>"!S M;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/"]TF4Z,3!P="<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P M96T[('1E>'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE6QE/3-$9F]N="US:7IE.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#6QE/3-$9F]N="US:7IE M.CAP=#XF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS+#DX-#PO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L M93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD:78^#0H@/'`@2!O9B`D,C'!E;G-E2!T:&4@=&5R;7,@ M;V8@=&AE(&EN9&5N='5R92!B971W965N('1H90T*($-O;7!A;GDL(&%S(&ES M6%B;&4-"B!S M96UI+6%N;G5A;&QY(&EN(&%R$$P.S$U+"`R,#$U+B!4:&4@3F]T97,@=VEL;"!M871U2!C;VYV97)T(&%L M;"!O2!I;6UE9&EA=&5L>0T*('!R96-E9&EN9R!T:&4@;6%T=7)I='D@9&%T M92X@57!O;B!C;VYV97)S:6]N+"!T:&4@:&]L9&5R7,@*'=H971H97(@ M;W(@;F]T#0H@8V]N2!D871E(&]F('1H92!.;W1E2!P;W)T:6]N(&]F('1H92!.;W1E6UE;G0@=&\@86YY M(&]F(&]U<@T*(&EN9&5B=&5D;F5S2!S=6)O M6UE;G0@=&\-"B!A;GD@#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1% M6%0M24Y$14Y4.B`X)2<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O M'!E;G-E*2P@;F5T(&]N('1H92!#;VYS;VQI9&%T960@ M4W1A=&5M96YT$$P.S,P+"`R,#$T("AI;@T*('1H;W5S86YD6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.S,P+"8C>$$P.S(P M,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9#QB$$P.S,P+"8C>$$P.S(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($-O;G1R86-T=6%L(&EN=&5R97-T(&5X<&5N$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%M;W)T:7IA M=&EO;B!O9B!D96)T(&ES$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT"<^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T M)SX-"B`\8CXY+B!3=&]C:VAO;&1E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`V<'0G/@T*(#QB/CQI/D-O;6UO;B!3=&]C:SPO:3X\+V(^/"]P/@T* M(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`V<'0[(%1%6%0M24Y$14Y4.B`X)2<^#0H@26X@2G5N92`R,#$S+"!T:&4@ M0V]M<&%N>2!S;VQD(#,L.#$Y+#0T-"!S:&%R97,@;V8@:71S(&-O;6UO;B!S M=&]C:PT*(&EN(&$@<'5B;&EC(&]F9F5R:6YG(&%T("0W,BXP,"!P97(@#(P,3D[#0H@9&ES8V]U;G1S(&%N9"!C;VUM:7-S:6]N6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9O$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CQB6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0L-CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.S,P+"`R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*(%!E6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0L-C0S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT+#8Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#8Y M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1% M3E0Z(#0E)SX-"B!4:&4@<&5R:6]D(&-H86YG92!B971W965N($1E8V5M8F5R M)B-X03`[,S$L(#(P,3,@86YD#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,30@ M=V%S('!R:6UA2!D=64@=&\@=&AE(&-U&5S(&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R8E\T M-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CXQ M,"X@4VAA'!E;G-E(&9OF5D(&EN('1H92!A8V-O;7!A;GEI;F<@ M0V]N$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.U-E<'1E;6)E$$P M.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D)B-X03`[4V5P=&5M M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C@L,#`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS+#`Y-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XR+#0T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ+#8U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XW+#4X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M+#4V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#0S-CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-2PU M.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@0T*(&UA:6YT86EN M'!E;G-E('=AF5D(&]N(&]UF5S('1H92!A8W1I=FET>2!R96QA=&EN9R!T;R!T:&4-"B!#;VUP86YY M)B-X,C`Q.3MS(&]P=&EO;G,@=&\@<'5R8VAA6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#DR)2!A;&EG;CTS1&-E;G1E&5R8VES M93PO8CX\8G(@+SX-"B`\8CY0$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.S,Q+"`R,#$S/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C8R+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X M97)C:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V,"PT M-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N.38\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L.#@U+#,V-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS-BXU,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N,CD\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\ M<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L M-C(P+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-2XR,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C@N,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$L-3`S+#8S,3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ.2XT-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'@[($9/3E0M4TE:13H@,7!X.R!-05)'24XM5$]0.B`Q,G!X)SX-"B`F(WA! M,#L\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.U-E<'1E;6)E$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0S+C0S/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE&5R8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@U+#4X.3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT&5R8VES97,\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DYI;F4F(WA! M,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E$$P.S,P+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X+C0S/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O M<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9 M.B!4:6UE&5R M8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$L,C(S+#`R,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#PO=&%B;&4^#0H@/'`@'!E8W1E9"!F M;W)F96ET=7)E'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQD:78^#0H@/'`@F4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CX\:3Y2 M;V-I;&5T:6YI8B`H0T\M,38X-BD\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS M1"=M87)G:6XM=&]P.C9P=#L@;6%R9VEN+6)O='1O;3HP<'0[('1E>'0M:6YD M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!);B!-87D@,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E9"!I M;G1O(&$@=V]R;&1W:61E(&QI8V5NF4@82!C;W9A;&5N="!I;FAI8FET;W(@;V8@;75T86YT#0H@9F]R;7,@ M;V8@=&AE(&5P:61E2!A;F0@;W1H97(-"B!A8W1I=FET M:65S(&YE8V5S2!T;R!D979E;&]P(&%N9"!C;VUM97)C:6%L:7IE(')O M8VEL971I;FEB+B!4:&4-"B!#;VUP86YY(&UA9&4@86X@=7`M9G)O;G0@<&%Y M;65N="!O9B`D,BXP(&UI;&QI;VX@=7!O;B!E>&5C=71I;VX@;V8-"B!T:&4@ M;&EC96YS92!A9W)E96UE;G0@86YD(&ES(&]B;&EG871E9"!T;R!P87D@2!T:&4@0V]M M<&%N>2X@5&AI&5R8VES960@=VET:&EN(&$- M"B!L:6UI=&5D('!E$$P.S0L(#(P M,30L(&%N9"!O;B!397!T96UB97(F(WA!,#LR+"`R,#$T+"!W92!R96-E:79E M9`T*(&YO=&EF:6-A=&EO;B!F2!E;&5C=&5D(&YO="!T;R!E>&5R8VES90T*('1H:7,@;W!T:6]N+CPO<#X- M"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA2`R,#$S+"!T:&4@ M0V]M<&%N>2!E;G1E&-L=7-I=F4@2!M861E(&%N M('5P+69R;VYT('!A>6UE;G0@;V8@)#(U,"PP,#`@=7!O;B!E>&5C=71I;VX@ M;V8@=&AE#0H@86=R965M96YT+"!W:&EC:"!W87,@6UE;G0@=&\-"B!#96QG96YE(&%S(')E<75I2!M87D@8F4@6UE;G1S(&EF#0H@8V5R=&%I;B!C;&EN:6-A;"!S='5D>2!O M8FIE8W1I=F5S(&%N9"!R96=U;&%T;W)Y(&9I;&EN9W,L#0H@86-C97!T86YC M97,@86YD(&%P<')O=F%L0T*(&UA>2!B92!R97%U:7)E9"!T;R!P87D@=7`@=&\@86X@ M86=G2!E;G1E6UE;G0@=&\@4&9I>F5R+CPO<#X-"B`\<"!S M='EL93TS1"=M87)G:6XM=&]P.C$R<'0[(&UA0T*(&9O MF5R(&%S(')E<75I'!E;G-E+CPO<#X-"B`\<"!S='EL93TS1"=M87)G M:6XM=&]P.C$R<'0[(&UAF5R('=I;&P-"B!R96-E:79E M(')O>6%L=&EE2!A;F0-"B!S86QE3I4:6UEF%T:6]N(&]F(')U8V%P87)I8B!F;W(@=&AE('5S97,@8VQA:6UE9"!B>2!T M:&5S90T*('!A=&5N=',N(%!U6%L=&EE MF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX- M"B`\8CX\:3Y,=6-I=&%N:6(\+VD^/"]B/CPO<#X-"B`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`F(WA!,#L\+W`^#0H@/'`@&-H86YG92!F;W(@=&AE2!I6UE;G1S(&EF('-P96-I9FEE9"!A;FYU86P@ M2!I2!397)V:65R+CPO<#X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'0[ M(&UA0T*(&EF(&-E M2!T;R!P87-T#0H@<&5R9F]R;6%N M8V4L(&%R92!C;VUM96YS=7)A=&4@=VET:"!E2!O9B!A;GD@9G5R=&AE3I4:6UE7!E+`T*(')E:6UB=7)S96UE;G1S(&%R92!D971E2!T:&4-"B!#;VUP86YY M(&%N9"!397)V:65R(&]R(&%C='5A;"!C;W-T2P-"B!R96EM8G5R3I4 M:6UE$$P.S,P+"`R,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R M,#$S+"!R97-P96-T:79E;'DL#0H@9F]R('1H92!R96EM8G5R3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A M,V,Y-&5C-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D M9&9?.#,R8E\T-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQD:78^#0H@/'`@ M6QE/3-$)VUA3I4:6UE2!T:&4@=V5I9VAT960M879E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X M,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE,V%?-38Q83-C.31E M8S8Q+U=O'0O:'1M;#L@8VAA6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE2!O9F9S M970-"B!B>2!A(&1E9F5R"!B96YE9FET(')E8V]G;FEZ960@=7!O M;B!T:&4@=W)I=&4@9&]W;B!O9B!A;@T*(&EN=&%N9VEB;&4@87-S970@:6X@ M=&AE(&9I2!O9B!T:&4-"B!N970@9&5F97)R960@=&%X(&%S M$$P.S,P+"`R,#$T(&%N9"!I;G1E M;F1S#0H@=&\@;6%I;G1A:6X@=&AI'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA3I4:6UEF4Z M,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\:3Y2;WEA M;'1Y(&%N9"!,:6-E;G-E($9E92!#;VUM:71M96YT6UE;G0-"B!O9B!D979E;&]P;65N="!A;F0@2!M M:6QE6%L='D-"B!P87EM96YT2P@;F\@ M86UO=6YT28C M>#(P,3D['0M:6YD M96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W M(%)O;6%N)SX-"B!);B!&96)R=6%R>2`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E M2!I$$P.S,P+"`R,#$T+"!N;R!P=7)C:&%S90T*(&-O;6UI=&UE;G1S('=E M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQD:78^#0H@/'`@'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF M86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@0V]M<&%N>2!E=F%L=6%T M960@979E;G1S('5P('1O('1H92!F:6QI;F<@9&%T92!O9B!T:&5S92!I;G1E M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C M-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R M8E\T-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y"87-I2UO=VYE9"!S=6)S:61I87)I97,N($%L;"!S:6=N:69I8V%N=`T* M(&EN=&5R8V]M<&%N>2!B86QA;F-E2P@26YC+B!I;F-L=61E9"!H97)E:6X@'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A2!I;F-L=61E9"!I;B!A=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S M#0H@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I M;F-I<&QE#(P,4,[4T5#)B-X,C`Q1#LI+B!4:&5S M90T*(&9I;F%N8VEA;"!S=&%T96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O M;FIU;F-T:6]N('=I=&@@=&AE(&%U9&ET960-"B!C;VYS;VQI9&%T960@9FEN M86YC:6%L('-T871E;65N=',@86YD(&YO=&5S('1H97)E=&\@=VAI8V@@87)E M#0H@:6YC;'5D960@:6X@;W5R($%N;G5A;"!297!O65A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[ M(%1%6%0M24Y$14Y4.B`T)2<^#0H@5&AE('!R97!A2!D:69F97(@9G)O;2!T M:&]S92!E2!H87,@:6YC M=7)R960@F%T:6]N(&]F#0H@:71S('!R;V1U M8W0@8V%N9&ED871E2!M87D-"B!N979E2!W:6QL(&-O;G1I;G5E('1O(&YE960@=&\@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3Y296-E;G0@06-C;W5N=&EN9R!06QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T M)2<^#0H@26X@36%Y(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3 M=&%N9&%R9',@0F]A$$P.S$U+`T*(#(P M,38@86YD(&%L;&]W0T* M('1O($-O;G1I;G5E(&%S(&$@1V]I;F<@0V]N8V5R;BPF(W@R,#%$.R!W:&EC M:"!R97%U:7)E28C>#(P,3D[2!A<'!L:6-A=&EO;B!I2!M87)K M970@9G5N9',@=&AA="!I;G9E'0^)SQD:78^#0H@/'`@2!O8FQI9V%T:6]NF5D(&=A:6YS(&%N9`T*(&QO#(P,3D[2!I7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@28C>#(P M,3D[$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($%S$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($UO;F5Y(&UA#(P,30[)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0T-RPY.#8\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C M>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G1I;F=E;G0@ M<'5R8VAA$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U M+#0T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-2PT M-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\ M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE2!M87)K970\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,3@L.#@V M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q."PX.#8\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X- M"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q."PX.#8\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I9VAT/@T*("8C>#(P,30[)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($-O;G1I;F=E;G0@<'5R8VAA$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+#6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1')I M9VAT/@T*("8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XU-2PW-30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@'0^)SQD:78^#0H@/'`@6QE/3-$)T9/3E0M4TE: M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D9O$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[ M,S`L)B-X03`[,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#4W M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@R+#@X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($)A;&%N8V4@870@96YD(&]F('!E$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4U+#0T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)VUA3I4:6UE$$P M.SPO<#X-"B`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#6QE/3-$)T)/4D1%4BU#3TQ, M05!313I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F M;VYT+7-I>F4Z,3!P="<@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9"!W M:61T:#TS1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/CPO=&0^#0H@ M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]TF4Z.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.S,Q+"8C>$$P.S(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[ M(&9O;G0M3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T'0M:6YD96YT.BTQ+C`P96T[(&9O;G0M3I4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0U/"]T M9#X-"B`\=&0@;F]W6QE/3-$)VUA'!E;G-E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ+#,S-CPO=&0^#0H@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XU,C$\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]TF4Z,7!X.SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C$N,#!P>"!S;VQI9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O M$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@F4Z,3!P M=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!/=&AEF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0L,SDR/"]T9#X-"B`\=&0@;F]W6QE/3-$9F]N="US:7IE.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"=B;W)D97(M=&]P.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)VUA3I4:6UE M6QE/3-$9F]N="US:7IE.C$R<'0[;6%R9VEN+71O<#HP<'0[ M;6%R9VEN+6)O='1O;3HP<'0^#0H@)B-X03`[/"]P/@T*(#QT86)L92!C96QL M3I4:6UE3I4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)V)O6QE/3-$)VUA$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,S4V/"]T9#X-"B`\=&0@ M;F]W6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T M;W`^#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM M97,@3F5W(%)O;6%N)SX-"B!!8V-R=65D(&-O$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ,S(\+W1D/@T*(#QT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CL@9F]N="US:7IE.C$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^ M#0H@/'`@F4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@ M3F5W(%)O;6%N)SX-"B!!8V-R=65D(&5X<&5N#(P,3,[(&]T:&5R M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$9F]N="US:7IE.C%P>#L^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)V)O$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@"!S;VQI M9"`C,#`P,#`P)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT3I4:6UE6QE/3-$)VUA'!E;G-EF4Z.'!T/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0L-S$Y/"]T9#X-"B`\=&0@;F]W$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.3@T/"]T M9#X-"B`\=&0@;F]W6QE/3-$9F]N="US:7IE M.C%P>#L^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)V)O6QE/3-$)V)O$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=B;W)D97(M=&]P M.C,N,#!P>"!D;W5B;&4@(S`P,#`P,"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQD:78^#0H@/'`@F5D(')E;&%T960@=&\@=&AE($YO=&5S#0H@9'5R:6YG('1H M92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[ M,S`L(#(P,30@*&EN#0H@=&AO=7-A;F1S*3H\+W`^#0H@/'`@$$P.TUO;G1H$$P M.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q-#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X M03`[,S`L)B-X03`[,C`Q-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QTF%T:6]N M(&]F(&1E8G0@:7-S=6%N8V4@8V]S=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XW,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XW,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%1O=&%L(&EN=&5R97-T(&5X<&5N6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU M,3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA2`H5&%B;&5S*3QBF5D(&%S(&9O;&QO=W,@*&EN#0H@=&AO=7-A M;F1S*3H\+W`^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L3PO8CX\8G(@+SX-"B`\ M8CY4$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@1&5C96UB M97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT M+#8Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%!E$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,C$L,#`R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XH,C$L,#`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A M;&%N8V4@4V5P=&5M8F5R)B-X03`[,S`L(#(P,30\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH,38L,S`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,38L,S`V/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XU,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4 M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XT+#8T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M"<^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@1&5C96UB M97(F(WA!,#LS,2P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-CDV/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0L-CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E(&9OF5D(&EN('1H M92!A8V-O;7!A;GEI;F<@0V]N$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.U-E<'1E;6)E$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.TUO;G1H$$P.T5N M9&5D)B-X03`[4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%)E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L,#`U/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XS+#`Y-3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#0T-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8U,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XW+#4X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XS+#4V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#0S M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ-2PU.#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%1H92!F;VQL;W=I;F<@=&%B M;&4@28C>#(P,3D[6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@4$%'12U"4D5!2RU"149/4D4Z(&%L=V%Y$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D+3PO8CX\8G(@ M+SX-"B`\8CY!=F5R86=E/"]B/CQB6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-3(P+#$W,#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-#0Y+#0U-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XV,BXP,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@ M8F=C;VQO&5R8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-C`L-#0Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+CDV/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($9O$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R M,RPX,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,T+CDV/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($]U='-T86YD:6YG(&%T(%-E<'1E;6)E$$P.S,P+"`R,#$T M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#@X-2PS-C4\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX M+C(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8T+#$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT'!E8W1E9"!T;R!V97-T(&%T M(%-E<'1E;6)E$$P.S,P+"`R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS+#8R,"PW,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+C(R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C8S+#,T,2PR,3,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.S,P+"`R,#$T M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4P,RPV,S$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW M+C,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0Q+#8T,RPQ.#(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(%!R M97-E;G1E9"!I;B!T:&4@=&%B;&4@8F5L;W<@87)E(&9I;F%N8VEA;"!D971A M:6QS(&%S6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V M(&%L:6=N/3-$8V5N=&5R/@T*(#QB/E1H$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($-A$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!T)SX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!38VEE;F-E M+"!3+G`N02X\8G(^55-$("@D*3QB2!38VEE;F-E+"!3+G`N02X\8G(^4F5G=6QA=&]R>2!A;F0@4V%L97,@36EL M97-T;VYE2!38VEE;F-E+"!3+G`N02X\8G(^4F5G=6QA=&]R>2!A M;F0@4V%L97,@36EL97-T;VYE'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V M.3E?.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O M'0O:'1M M;#L@8VAA2!-87)K970\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS M<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E?.&4S M85\U-C%A,V,Y-&5C-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-V-A8C1D9&9?.#,R8E\T-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA M2!G86EN'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO M'!E;G-E M3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W8V%B-&1D9E\X,S)B7S0V.3E? M.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE,V%?-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@ M8VAA'0^)SQS<&%N/CPO M2!38VEE;F-E+"!3+G`N02X\+W1D/@T*("`@("`@ M("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\W M8V%B-&1D9E\X,S)B7S0V.3E?.&4S85\U-C%A,V,Y-&5C-C$-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-V-A8C1D9&9?.#,R8E\T-CDY7SAE,V%? M-38Q83-C.31E8S8Q+U=O'0O:'1M;#L@8VAA'!E;G-E'!E M;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA3QS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S,P(&1A>7,\'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)T]N(&]R(&%F=&5R(%-E<'1E M;6)E7,@*'=H971H M97(@;W(@;F]T(&-O;G-E8W5T:79E*2!D=7)I;F<@86YY(#,P(&-O;G-E8W5T M:79E('1R861I;F<@9&%Y('!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@9&%T M92!O;B!S96YI;W(@;F]T97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)RTM,#DM,34\'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E*2P@3F5T(&]N($-O;G-O;&ED871E9"!3=&%T96UE M;G1S(&]F($]P97)A=&EO;G,@86YD($-O;7!R96AE;G-I=F4@3&]SF5D(%)E;&%T960@=&\@3F]T97,@*$1E=&%I;"D@*%531"`D*3QB'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'!E;G-E(%)E8V]G;FEZ M960@:6X@06-C;VUP86YY:6YG(%-T871E;65N=',@;V8@3W!E6UE;G0@ M07=A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO M'!E;G-E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XR+#DY,3QS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@07=A'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D('-T;V-K+6)A M'!E;G-E(')E;&%T960@=&\@;F]N=F5S=&5D M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPOF5D('-T;V-K+6)A M'!E;G-E(')E;&%T960@=&\@;F]N=F5S=&5D M(&]P=&EO;G,L('=E:6=H=&5D+6%V97)A9V4@'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`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`@ M("`@("`\=&0@8VQA'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA#(P86,[*3QB2!T:&4@96YT:71Y("T@4F]C:6QE=&EN M:6(\8G(^55-$("@D*3QB2`S,2P@,C`Q,#QB6UE;G0\8G(^3&EC96YS92!!9W)E96UE;G0@5&5R;7,\8G(^3&EC96YS M92!!9W)E96UE;G1S($QI8V5N2!T:&4@96YT:71Y M("T@4F]C:6QE=&EN:6(\8G(^55-$("@D*3QB2!T:&4@96YT:71Y("T@4F]C M:6QE=&EN:6(\8G(^55-$("@D*3QB6UE;G0\8G(^3&EC96YS M92!!9W)E96UE;G0@5&5R;7,\8G(^3&EC96YS92!!9W)E96UE;G1S($QI8V5N M2!T:&4@96YT:71Y("T@4F]C:6QE=&EN:6(\8G(^ M55-$("@D*3QB'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E8W1E9"!D979E;&]P;65N="P@ M2!A;F0@6UE;G1S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!#;VYS:61E M6%B;&4@;VX@4W5B;&EC96YS92!!9W)E96UE;G1S/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO"!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XD(#(Y,CQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)S(T(&UO;G1H'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C M:&5M87,M;6EC XML 23 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average grant-date fair value per share $ 27.85 $ 43.43 $ 39.13 $ 18.43

Intrinsic value of options exercised $ 4,391 $ 85,589 $ 2,754,669 $ 5,801,963

Cash received from stock option exercises $ 341 $ 34,711 $ 541,508 $ 1,223,023

X

- Definition

Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 24 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

EOS Acquisition - Additional Information (Detail)
0 Months Ended

Sep. 30, 2014

USD ($)

Dec. 31, 2013

USD ($)

Nov. 19, 2013

Ethical Oncology Science, S.p.A.

USD ($)

Sep. 30, 2014

Ethical Oncology Science, S.p.A.

USD ($)

Dec. 31, 2013

Ethical Oncology Science, S.p.A.

USD ($)

Nov. 19, 2013

Ethical Oncology Science, S.p.A.

Regulatory and Sales Milestones

Maximum

USD ($)

Nov. 19, 2013

Ethical Oncology Science, S.p.A.

Regulatory and Sales Milestones

Maximum

EUR (€)

Nov. 19, 2013

Ethical Oncology Science, S.p.A.

Regulatory and Sales Milestones

Minimum

USD ($)

Business Acquisition [Line Items]

Business acquisition cash payments made on acquisition $ 11,800,000

Business acquisition, common stock issued at acquisition date 173,700,000

Future potential cash consideration payments 65,000,000 115,000,000 0

Fair value of contingent consideration $ 55,445,000 $ 55,754,000 $ 55,400,000 $ 55,800,000

X

- Definition

Amount of potential cash payments that could result from a contingent consideration arrangement associated with a business acquisition.

+ References

No definition available.

+ Details

Name: clvs_FuturePotentialCashConsiderationPayments

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 25 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Presentation - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
9 Months Ended 3 Months Ended

Sep. 30, 2014

Mar. 31, 2014

Les Laboratoires Servier

Nature Of Business [Line Items]

License and milestone revenue $ 13,625 $ 13,600

X

- Definition

Amount of up-front fees and ongoing milestone payments from collaboration and license partners that are recognized in revenue during the applicable period by the reporting entity.

+ References

No definition available.

+ Details

Name: clvs_LicenseFeesAndMilestonesRevenue

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: clvs_NatureOfBusinessLineItems

Namespace Prefix: clvs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8

License Agreements - Additional Information (Detail)
9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended

Sep. 30, 2014

USD ($)

Sep. 30, 2013

USD ($)

Dec. 31, 2013

USD ($)

Sep. 30, 2012

Les Laboratoires Servier

EUR (€)

Sep. 30, 2014

Les Laboratoires Servier

USD ($)

Mar. 31, 2014

Les Laboratoires Servier

USD ($)

Sep. 30, 2014

Les Laboratoires Servier

USD ($)

Dec. 31, 2013

Les Laboratoires Servier

USD ($)

Feb. 28, 2014

License Agreement Terms

License Agreements Licensor Avila Therapeutics

Name of drug product in-licensed by the entity - Rociletinib

USD ($)

Apr. 30, 2014

License Agreement Terms

License Agreements Licensor Pfizer

Rucaparib

USD ($)

Sep. 30, 2014

License Agreement Terms

License Agreements Licensor Pfizer

Rucaparib

USD ($)

Apr. 30, 2012

License Agreement Terms

License Agreements Licensor Astra Zeneca U K Ltd

Rucaparib

USD ($)

Oct. 31, 2008

License Agreement Terms

Advenchen Laboratories LLC

Mar. 31, 2014

License Agreement Terms

Advenchen Laboratories LLC

USD ($)

May 31, 2010

Up-front license payment

License Agreement Terms

License Agreements Licensor Avila Therapeutics

Name of drug product in-licensed by the entity - Rociletinib

USD ($)

Jan. 31, 2013

Up-front license payment

License Agreement Terms

License Agreements Licensor Gatekeeper

Name of drug product in-licensed by the entity - Rociletinib

USD ($)

Jun. 30, 2011

Up-front license payment

License Agreement Terms

License Agreements Licensor Pfizer

Rucaparib

USD ($)

Apr. 30, 2012

Up-front license payment

License Agreement Terms

License Agreements Licensor Astra Zeneca U K Ltd

Rucaparib

USD ($)

Feb. 28, 2014

Regulatory Milestone Payment

License Agreement Terms

License Agreements Licensor Avila Therapeutics

Name of drug product in-licensed by the entity - Rociletinib

USD ($)

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Up-front payment $ 2,000,000 $ 250,000 $ 7,000,000 $ 250,000

Acquired in process research and development costs 8,806,000 250,000 400,000 3,400,000 5,000,000

Future expected development and regulatory payment 110,000,000 700,000

Sales milestone payments 120,000,000

Future expected development, regulatory and sales milestone payments 258,500,000

Percentage of Non-Royalty Consideration Payable on Sublicense Agreements 25.00%

Sublicense agreement consideration 13,625,000 13,600,000 13,600,000

Additional payments receivable on achievement 90,000,000

Additional payments receivable on attaining the sales target 250,000,000

Initial global development costs reimbursable 80,000,000

Development cost receivable 6,544,000 2,921,000 6,500,000 6,500,000 2,900,000

Reduction in research and development expense for reimbursable development costs due from Servier $ 4,100,000 $ 7,900,000

X

- Definition

Amount of additional nonrefundable milestone payments to be received from collaboration and license partners upon the achievement of product milestones, as defined in the respective collaboration and license agreement.

+ References

No definition available.

+ Details

Name: clvs_AdditionalPaymentsReceivableOnMilestoneAchievements

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of the aggregate payment due to a product licensor upon the achievement of product sale targets, as defined in the respective licensing agreement.

+ References

No definition available.

+ Details

Name: clvs_AggregatePaymentToBeMadeOnAttainingSalesTarget

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of potential cash payments that could result from the achievement of specific development and regulatory events defined in a drug product in-licensing agreement.

+ References

No definition available.

+ Details

Name: clvs_FutureExpectedDevelopmentAndRegulatoryPayment

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of potential cash payments that could result from the achievement of specific development, regulatory, and sales events defined in a drug product in-licensing agreement.

+ References

No definition available.

+ Details

Name: clvs_FutureExpectedDevelopmentRegulatoryAndSalesMilestonePayments

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash payments incurred to license the use and development of a drug product from the licensor. The upfront payments are expensed to acquired in process research and development if it is determined that the in-licensed product does not have an alternative future use at the time the in-license agreement is executed.

+ References

No definition available.

+ Details

Name: clvs_InLicensingArrangementCostsUpFrontPayment

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of up-front fees and ongoing milestone payments from collaboration and license partners that are recognized in revenue during the applicable period by the reporting entity.

+ References

No definition available.

+ Details

Name: clvs_LicenseFeesAndMilestonesRevenue

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum amount of reimbursement of development costs by collaboration and license partners during the term of the respective collaboration and license agreement.

+ References

No definition available.

+ Details

Name: clvs_MaximumCollaborationDevelopmentCostsReimbursable

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage of consideration owed by the entity to a drug product licensor related to milestone events achieved by a sublicensor of the drug product.

+ References

No definition available.

+ Details

Name: clvs_PercentageOfConsiderationPayableOnSublicenseAgreements

Namespace Prefix: clvs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Reductions in Research and Development Expense for Reimbursable Development Costs

+ References

No definition available.

+ Details

Name: clvs_ReductionsInResearchAndDevelopmentExpenseForReimbursableDevelopmentCosts

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of potential cash payments that could result from the achievement of specific sales events defined in a drug product in-licensing agreement.

+ References

No definition available.

+ Details

Name: clvs_SalesMilestonePaymentsUnderInLicensingAgreements

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 27 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value $ 447,986 $ 318,886

Contingent purchase consideration 55,445 55,754

Liabilities at fair value 55,445 55,754

Money Market

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value 447,986 318,886

Fair Value, Inputs, Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value 447,986 318,886

Fair Value, Inputs, Level 1 | Money Market

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Assets at fair value 447,986 318,886

Fair Value, Inputs, Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent purchase consideration 55,445 55,754

Liabilities at fair value $ 55,445 $ 55,754

X

- Definition

This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_AssetsFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.

+ References

No definition available.

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 28 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value Measurements - Additional Information (Detail) (USD $)

Sep. 30, 2014

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Transfers between Level 1 and Level 2 $ 0

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 29 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

EOS Acquisition
9 Months Ended

Sep. 30, 2014

EOS Acquisition

3. EOS Acquisition

On November 19, 2013, the Company acquired all of the outstanding common and preferred stock of Ethical Oncology Science, S.p.A. (“EOS”). The initial purchase consideration was comprised of a cash payment of $11.8 million and the issuance of $173.7 million of the Company’s common stock to the former EOS shareholders. The Company may make additional purchase payments to the previous EOS shareholders if certain lucitanib regulatory and sales milestones are achieved. The range of the potential contingent milestone payments are zero to an estimated maximum of $65.0 million and €115.0 million. The Company recorded a liability for the estimated fair value of these payments, which totaled $55.4 million and $55.8 million at September 30, 2014 and December 31, 2013, respectively.

X

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) (Fair Value, Inputs, Level 3, USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2014

Fair Value, Inputs, Level 3

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Balance at beginning of period $ 55,754

Accretion 2,571

Change in foreign currency gains and losses (2,880)

Balance at end of period $ 55,445

X

- Definition

Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value, Accretion Expenses

+ References

No definition available.

+ Details

Name: clvs_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValueAccretionExpenses

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 31 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense $ 5,436 $ 2,791 $ 15,585 $ 6,663

Research and development

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense 2,991 1,138 8,005 3,095

General and administrative

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense $ 2,445 $ 1,653 $ 7,580 $ 3,568

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Operations and Comprehensive Loss (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Revenues:

License and milestone revenue $ 13,625

Operating expenses:

Research and development 34,965 16,063 87,556 44,001

General and administrative 5,267 4,312 15,852 11,022

Acquired in-process research and development 8,806 250

Amortization of intangible asset 3,409

Accretion of contingent purchase consideration 888 2,571

Total expenses 41,120 20,375 118,194 55,273

Operating loss (41,120) (20,375) (104,569) (55,273)

Other income (expense), net 1,770 55 1,934 (56)

Loss before income taxes (39,350) (20,320) (102,635) (55,329)

Income tax expense (292) (2,489)

Net loss (39,642) (20,320) (105,124) (55,329)

Basic and diluted net loss per common share $ (1.17) $ (0.68) $ (3.10) $ (2.00)

Basic and diluted weighted average common shares outstanding 33,921 30,047 33,871 27,614

Comprehensive loss $ (58,809) $ (20,299) $ (126,126) $ (55,314)

X

- Definition

Amount of up-front fees and ongoing milestone payments from collaboration and license partners that are recognized in revenue during the applicable period by the reporting entity.

+ References

No definition available.

+ Details

Name: clvs_LicenseFeesAndMilestonesRevenue

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 410

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 35

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866

+ Details

Name: us-gaap_AccretionExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 33 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Income Taxes [Line Items]

Income tax expense $ 292 $ 2,489

X

- Details

Name: clvs_IncomeTaxesLineItems

Namespace Prefix: clvs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Presentation
9 Months Ended

Sep. 30, 2014

Nature of Business and Basis of Presentation

1. Nature of Business and Basis of Presentation

Clovis Oncology, Inc. (the “Company”) commenced operations in May 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The Company has and intends to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, the Company generally expects to provide the licensor with a combination of up-front payments, milestone payments and royalties on future sales. In addition, the Company generally expects to assume the responsibility for future drug development and commercialization costs. The Company currently operates in one segment. Since inception, the Company’s operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities. In the first quarter of 2014, the Company exited the development stage, with the recognition of $13.6 million in license and milestone revenue related to its lucitanib collaboration and license agreement with Les Laboratoires Servier (“Servier”). The license and milestone revenue recognized is the first significant revenue from principal operations and therefore, the Company is no longer considered a development stage company.

Basis of Presentation

All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Accrued Liabilities [Line Items]

Accrued personnel costs $ 3,404 $ 3,356

Accrued corporate legal fees and professional services 132 257

Accrued expenses - other 1,183 371

Other accrued expenses $ 4,719 $ 3,984

X

- Details

Name: clvs_AccruedLiabilitiesLineItems

Namespace Prefix: clvs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 36 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Financial Instruments and Fair Value Measurement (Tables)
9 Months Ended

Sep. 30, 2014

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table identifies the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):

 Balance Level 1 Level 2 Level 3

September 30, 2014


Assets:


Money market
 $ 447,986 $ 447,986 $ — $ —









Total assets at fair value
 $ 447,986 $ 447,986 $ — $ —









Liabilities:


Contingent purchase consideration
 $ 55,445 $ — $ — $ 55,445









Total liabilities at fair value
 $ 55,445 $ — $ — $ 55,445









December 31, 2013


Assets:


Money market
 $ 318,886 $ 318,886 $ — $ —









Total assets at fair value
 $ 318,886 $ 318,886 $ — $ —









Liabilities:


Contingent purchase consideration
 $ 55,754 $ — $ — $ 55,754









Total liabilities at fair value
 $ 55,754 $ — $ — $ 55,754









Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs)

The following table rolls forward the fair value of Level 3 instruments (significant unobservable inputs) in thousands:

 For the Nine
Months Ended
September 30, 2014

Liabilities:


Balance at beginning of period
 $ 55,754

Accretion
 2,571

Change in foreign currency gains and losses
 (2,880 )



Balance at end of period
 $ 55,445



X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Senior Notes - Additional Information (Detail) (USD $)
0 Months Ended 9 Months Ended

Sep. 09, 2014

D

Sep. 30, 2014

D

Sep. 09, 2014

Debt Instrument [Line Items]

Convertible senior notes, aggregate principal amount $ 287,500,000

Net proceeds form convertible senior notes 287,500,000

Convertible Senior Unsecured Notes

Debt Instrument [Line Items]

Convertible senior notes, aggregate principal amount 287,500,000

Convertible senior notes, interest rate 2.50%

Net proceeds form convertible senior notes 278,300,000

Convertible senior notes, frequency of periodic payment Semi-annually

Debt instrument, beginning date of periodic payment Mar. 15, 2015

Convertible senior notes, maturity date Sep. 15, 2021

Convertible senior notes, initial conversion price per share $ 61.88

Common stock initial conversion rate per $1,000 in principal amount 16.1616

Last reported sale price of common stock 150.00%

Debt instrument, conversion in effect for number of trading days 20

Debt instrument conversion, consecutive trading day period 30 days

Debt instrument redemption price percentage to principal amount 100.00%

Debt instrument redemption description On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

Debt instrument, redemption period start date Sep. 15, 2018

Debt instrument, trading days preceding redemption notice, maximum 2

Debt instrument repurchase percentage 100.00%

Debt issuance costs 9,200,000

Debt instrument term 7 years

Unamortized debt issuance costs 9,100,000

Convertible Senior Unsecured Notes | Semi Annual Payment, First payment date

Debt Instrument [Line Items]

Interest payment date on senior notes --03-15

Convertible Senior Unsecured Notes | Semi Annual Payment, Second payment date

Debt Instrument [Line Items]

Interest payment date on senior notes --09-15

Convertible Senior Unsecured Notes | Fair Value, Inputs, Level 2

Debt Instrument [Line Items]

Debt instrument, fair value $ 297,300,000

X

- Definition

Debt Instrument, Convertible Trading Days Preceding Redemption Notice, Maximum

+ References

No definition available.

+ Details

Name: clvs_DebtInstrumentConvertibleTradingDaysPrecedingRedemptionNoticeMaximum

Namespace Prefix: clvs_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Debt Instrument, Interest Rate Payment, Day and Month

+ References

No definition available.

+ Details

Name: clvs_DebtInstrumentInterestRatePaymentDayAndMonth

Namespace Prefix: clvs_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

Debt instrument repurchase percentage.

+ References

No definition available.

+ Details

Name: clvs_DebtInstrumentRepurchasePercentage

Namespace Prefix: clvs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The price per share of the conversion feature embedded in the debt instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Conversion Rate

-URI http://asc.fasb.org/extlink&oid=6509012

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition

Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13476-108611

+ Details

Name: us-gaap_DebtInstrumentFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Description of the frequency of periodic payments (monthly, quarterly, annual).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of debt redemption features under terms of the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph e

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentRedemptionDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Start date of debt instrument redemption period, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph e

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentRedemptionPeriodStartDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph e

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentRedemptionPricePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).

+ References

No definition available.

+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_UnamortizedDebtIssuanceExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Accrued Expenses (Tables)
9 Months Ended

Sep. 30, 2014

Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):

 September 30, 2014 December 31, 2013

Accrued personnel costs
 $ 3,404 $ 3,356

Accrued corporate legal fees and professional services
 132 257

Accrued expenses – other
 1,183 371





Other accrued expenses
 $ 4,719 $ 3,984





X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Sep. 30, 2014

Dec. 31, 2013

Current assets:

Cash and cash equivalents $ 516,585 $ 323,228

Prepaid research and development expenses 2,241 976

Other current assets 7,925 4,392

Total current assets 526,751 328,596

Property and equipment, net 2,846 955

Intangible assets 220,723 244,518

Goodwill 68,482 74,811

Other assets 12,725 755

Total assets 831,527 649,635

Current liabilities:

Accounts payable 2,428 4,420

Accrued research and development expenses 23,832 12,548

Other accrued expenses 4,719 3,984

Total current liabilities 30,979 20,952

Contingent purchase consideration 55,445 55,754

Deferred income taxes, net 69,307 74,955

Convertible senior notes 287,500

Other non-current liabilities 6 88

Total liabilities 443,237 151,749

Commitments and contingencies (Note 14)

Stockholders' equity:

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013

Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2014 and December 31, 2013; 33,964,065 and 33,897,321 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively 34 34

Additional paid-in capital 778,700 762,170

Accumulated other comprehensive (loss) income (16,306) 4,696

Accumulated deficit (374,138) (269,014)

Total stockholders' equity 388,290 497,886

Total liabilities and stockholders' equity $ 831,527 $ 649,635

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for research and development activities which are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include contract research organizations, contract manufacturers and other research and development vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: clvs_AccruedResearchAndDevelopmentExpenses

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=47804770&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Net Loss Per Common Share
9 Months Ended

Sep. 30, 2014

Net Loss Per Common Share

12. Net Loss Per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury stock method for the stock options and the if-converted method for the Notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2014

Oct. 31, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

Trading Symbol CLVS

Entity Registrant Name CLOVIS ONCOLOGY, INC.

Entity Central Index Key 0001466301

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Entity Common Stock, Shares Outstanding 33,964,440

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 44 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
9 Months Ended

Sep. 30, 2014

Income Taxes

13. Income Taxes

Income tax expense of $2.5 million was recorded during the nine months ended September 30, 2014 due to taxable income earned in a foreign jurisdiction resulting from milestone revenue received during the first quarter of 2014. This expense was partially offset by a deferred tax benefit recognized upon the write down of an intangible asset in the first quarter of 2014 (see Note 6). The Company maintains a valuation allowance against the majority of the net deferred tax assets held at September 30, 2014 and intends to maintain this valuation allowance until there is sufficient evidence that consistent future earnings can be achieved, which is uncertain at this time.

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Parenthetical) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 33,964,065 33,897,321

Common stock, shares outstanding 33,964,065 33,897,321

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 46 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Accrued Expenses
9 Months Ended

Sep. 30, 2014

Other Accrued Expenses

7. Other Accrued Expenses

Other accrued expenses are comprised of the following (in thousands):

 September 30, 2014 December 31, 2013

Accrued personnel costs
 $ 3,404 $ 3,356

Accrued corporate legal fees and professional services
 132 257

Accrued expenses – other
 1,183 371





Other accrued expenses
 $ 4,719 $ 3,984





X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets and Goodwill
9 Months Ended

Sep. 30, 2014

Intangible Assets and Goodwill

6. Intangible Assets and Goodwill

Intangible acquired in-process research and development (“IPR&D”) assets were established as part of the purchase accounting of EOS in November 2013. The intangible asset balance at September 30, 2014 and December 31, 2013 was $220.7 million and $244.5 million, respectively. The balance decreased $20.4 million over the prior year due to changes in foreign currency translation rates. In addition, the Company recorded a $3.4 million reduction in the intangible assets driven by lower expected future milestone revenue cash flows from our lucitanib development activities due to the receipt of a lucitanib milestone payment from Servier during the first quarter of 2014. This reduction was reported as amortization of intangible asset on the Consolidated Statements of Operations and Comprehensive Loss.

Recurring amortization of these assets will commence when the useful lives of the intangible assets have been determined. IPR&D intangible assets are evaluated for impairment at least annually or more frequently if impairment indicators exist and any reduction in fair value will be recognized as an expense in the Consolidated Statements of Operations and Comprehensive Loss.

The acquisition of EOS in November 2013 generated a goodwill balance of $74.8 million at December 31, 2013. This balance decreased to $68.5 million at September 30, 2014 due to changes in foreign currency translation rates.

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets (Tables)
9 Months Ended

Sep. 30, 2014

Other Current Assets

Other current assets are comprised of the following (in thousands):

 September 30, 2014 December 31, 2013

Receivable from partners
 $ 6,544 $ 2,921

VAT recoverable
 45 950

Prepaid expenses and other
 1,336 521





Other current assets
 $ 7,925 $ 4,392





X

- Definition

Tabular disclosure of the carrying amounts of other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
9 Months Ended

Sep. 30, 2014

Commitments and Contingencies

14. Commitments and Contingencies

Royalty and License Fee Commitments

The Company has entered into certain license agreements, as identified in Note 11, with third parties that include the payment of development and regulatory milestones, as well as royalty payments, upon the achievement of pre-established development, regulatory and commercial targets. The Company’s payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, no amounts have been recorded in the Company’s Consolidated Balance Sheets at September 30, 2014 and December 31, 2013.

Development and Manufacturing Agreement Commitments

In February 2013, the Company entered into a development and manufacturing agreement with a third-party supplier for the production of the active ingredient for rucaparib. Under the Development and Manufacturing Agreement, the Company will provide the third-party supplier a rolling 24-month forecast that will be updated by the Company on a quarterly basis. The Company is obligated to order the quantity specified in the first 12 months of any forecast. As of September 30, 2014, no purchase commitments were established under this agreement.

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation
9 Months Ended

Sep. 30, 2014

Share-Based Compensation

10. Share-Based Compensation

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

Research and development
 $ 2,991 $ 1,138 $ 8,005 $ 3,095

General and administrative
 2,445 1,653 7,580 3,568









Total share-based compensation expense
 $ 5,436 $ 2,791 $ 15,585 $ 6,663









The Company did not recognize a tax benefit related to share-based compensation expense during the three and nine months ended September 30, 2014 and 2013, respectively, as the Company maintains net operating loss carryforwards and has established a valuation allowance against the entire net deferred tax asset as of September 30, 2014. No share-based compensation expense was capitalized on our Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013.

The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:

 Number of
Options Weighted-
Average
Exercise
Price Weighted-
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Outstanding at December 31, 2013
 2,520,170 $ 21.19

Granted
 1,449,457 62.00

Exercised
 (60,449 ) 8.96

Forfeited
 (23,813 ) 34.96





Outstanding at September 30, 2014
 3,885,365 $ 36.52 8.29 $ 64,790,012





Vested and expected to vest at September 30, 2014
 3,620,712 $ 35.23 8.22 $ 63,341,213





Vested at September 30, 2014
 1,503,631 $ 19.47 7.30 $ 41,643,182





The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $45.36 as of September 30, 2014, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date.

Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:

 Three Months Ended September 30,

 2014 2013

Weighted-average grant-date fair value per share
 $ 27.85 $ 43.43

Intrinsic value of options exercised
 $ 4,391 $ 85,589

Cash received from stock option exercises
 $ 341 $ 34,711

 Nine Months Ended September 30,

 2014 2013

Weighted-average grant-date fair value per share
 $ 39.13 $ 18.43

Intrinsic value of options exercised
 $ 2,754,669 $ 5,801,963

Cash received from stock option exercises
 $ 541,508 $ 1,223,023

As of September 30, 2014, the unrecognized share-based compensation expense related to nonvested options, adjusted for expected forfeitures, was $51.6 million and the estimated weighted-average remaining vesting period was 3.0 years.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Convertible Senior Notes
9 Months Ended

Sep. 30, 2014

Convertible Senior Notes

8. Convertible Senior Notes

On September 9, 2014, we completed a private placement of $287.5 million aggregate principal amount of 2.5% convertible senior notes due 2021 (the “Notes”) resulting in net proceeds to the Company of $278.3 million after deducting offering expenses. In accordance with the accounting guidance, the conversion feature did not meet the criteria for bifurcation, and the entire principal amount was recorded as a long-term liability on the Consolidated Balance Sheets.

The Notes are governed by the terms of the indenture between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. The Notes are senior unsecured obligations and bear interest at a rate of 2.5% per year, payable semi-annually in arrears on March 15 and September 15 of each year, beginning March 15, 2015. The Notes will mature on September 15, 2021, unless earlier converted, redeemed or repurchased.

Holders may convert all or any portion of the Notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate of 16.1616 shares per $1,000 in principal amount of Notes, equivalent to a conversion price of approximately $61.88 per share. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indenture, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or upon our issuance of a notice of redemption, we will increase the conversion rate for holders who elect to convert the Notes in connection with such a corporate event or during the related redemption period in certain circumstances.

On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.

If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the Notes, holders may require us to repurchase for cash all or any portion of the Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The Notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.

In connection with the issuance of the Notes, the Company incurred $9.2 million of debt issuance costs, which is included in other assets on the Consolidated Balance Sheets. The debt issuance costs are amortized as interest expense over the expected life of the Notes using the effective interest method. The Company determined the expected life of the debt was equal to the seven-year term of the Notes. As of September 30, 2014, the balance of unamortized debt issuance costs was $9.1 million.

The fair value of the Notes was $297.3 million at September 30, 2014 and was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the Notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system.

The following table sets forth total interest expense, included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss, recognized related to the Notes during the three and nine months ended September 30, 2014 (in thousands):

 Three Months Ended
September 30, 2014 Nine Months Ended
September 30, 2014

Contractual interest expense
 $ 439 $ 439

Amortization of debt issuance costs
 72 72





Total interest expense
 $ 511 $ 511





X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
9 Months Ended

Sep. 30, 2014

Stockholders' Equity

9. Stockholders’ Equity

Common Stock

In June 2013, the Company sold 3,819,444 shares of its common stock in a public offering at $72.00 per share. The net offering proceeds realized after deducting offering expenses and underwriters’ discounts and commissions were $259.1 million.

Accumulated Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

 Foreign
Currency
Translation
Adjustments Total
Accumulated
Other
Comprehensive
Income (Loss)

Balance December 31, 2013
 $ 4,696 $ 4,696

Period change
 (21,002 ) (21,002 )



Balance September 30, 2014
 $ (16,306 ) $ (16,306 )



Balance December 31, 2012
 $ 53 $ 53

Period change
 4,643 4,643



Balance December 31, 2013
 $ 4,696 $ 4,696



The period change between December 31, 2013 and September 30, 2014 was primarily due to the currency translation of the IPR&D intangible assets, goodwill and deferred income taxes associated with the acquisition of EOS in November 2013.

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

License Agreements
9 Months Ended

Sep. 30, 2014

License Agreements

11. License Agreements

Rociletinib (CO-1686)

In May 2010, the Company entered into a worldwide license agreement with Avila Therapeutics, Inc. (now part of Celgene Corporation) to discover, develop and commercialize a covalent inhibitor of mutant forms of the epidermal growth factor receptor (“EGFR”) gene product. Rociletinib was identified as the lead drug candidate to be developed under the license agreement. The Company is responsible for all preclinical, clinical, regulatory and other activities necessary to develop and commercialize rociletinib. The Company made an up-front payment of $2.0 million upon execution of the license agreement and is obligated to pay royalties on net sales of rociletinib, based on the volume of annual net sales achieved. Celgene has the option to increase royalty rates by electing to reimburse a portion of the development expenses incurred by the Company. This option must be exercised within a limited period of time after Celgene is notified of our intent to pursue regulatory approval of rociletinib in the U.S. or European Union as a first line therapy. Such notice was provided to Celgene on June 4, 2014, and on September 2, 2014, we received notification from Celgene that the company elected not to exercise this option.

In January 2013, the Company entered into an exclusive license agreement with Gatekeeper Pharmaceuticals, Inc. (“Gatekeeper”) to acquire exclusive rights under patent applications associated with mutant EGFR inhibitors and methods of treatment. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. If rociletinib is approved for commercial sale, the Company will pay royalties to Gatekeeper on future net sales.

In February 2014, the Company initiated a Phase II study for rociletinib which resulted in a $5.0 million milestone payment to Celgene as required by the license agreement. This payment was recognized as acquired in-process research and development expense. The Company may be required to pay up to an additional aggregate of $110.0 million in development and regulatory milestone payments if certain clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, the Company may be required to pay up to an aggregate of $120.0 million in sales milestones if certain annual sales targets are achieved.

Rucaparib

In June 2011, the Company entered into a worldwide license agreement with Pfizer Inc. to acquire exclusive development and commercialization rights to Pfizer’s drug candidate known as rucaparib. This drug candidate is a small molecule inhibitor of poly (ADP-ribose) polymerase (“PARP”), which the Company is developing for the treatment of selected solid tumors. Pursuant to the terms of the license agreement, the Company made a $7.0 million up-front payment to Pfizer.

In April 2014, the Company initiated a pivotal registrational study for rucaparib, which resulted in a $0.4 million milestone payment to Pfizer as required by the license agreement. This payment was recognized as acquired in-process research and development expense.

The Company is responsible for all development and commercialization costs of rucaparib and, if approved, Pfizer will receive royalties on the net sales of the product. In addition, Pfizer is eligible to receive up to $258.5 million of further payments, in aggregate, if certain development, regulatory and sales milestones are achieved.

In April 2012, the Company entered into a license agreement with AstraZeneca UK Limited to acquire exclusive rights associated with rucaparib under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of rucaparib for the uses claimed by these patents. Pursuant to the terms of the license agreement, the Company made an up-front payment of $250,000 upon execution of the agreement, which was recognized as acquired in-process research and development expense. The Company may be required to pay up to an aggregate of $0.7 million in milestone payments if certain regulatory filings, acceptances and approvals are achieved. If approved, AstraZeneca will also receive royalties on any net sales of rucaparib.

Lucitanib

In connection with its November 2013 acquisition of EOS, the Company gained rights to develop and commercialize lucitanib, an oral, selective tyrosine kinase inhibitor. As further described below, EOS licensed the worldwide rights, excluding China, to develop and commercialize lucitanib from Advenchen Laboratories LLC (“Advenchen”). Subsequently, rights to develop and commercialize lucitanib in markets outside the U.S. and Japan were sublicensed by EOS to Servier in exchange for up-front milestone fees, royalties on sales of lucitanib in the sublicensed territories and research and development funding commitments.

In October 2008, EOS entered into an exclusive license agreement with Advenchen to develop and commercialize lucitanib on a global basis, excluding China. The Company is obligated to pay Advenchen royalties on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, the Company is obligated to pay to Advenchen 25% of any consideration, excluding royalties, received pursuant to any sublicense agreements for lucitanib, including the agreement with Servier. In the first quarter of 2014, the Company recognized acquired in-process research and development expense of $3.4 million, which represents 25% of the sublicense agreement consideration of $13.6 million received from Servier upon the end of opposition and appeal of the lucitanib patent by the European Patent Office.

In September 2012, EOS entered into a collaboration and license agreement with Servier whereby EOS sublicensed to Servier exclusive rights to develop and commercialize lucitanib in all countries outside of the U.S., Japan and China. In exchange for these rights, EOS received an up-front payment and is entitled to receive additional payments upon achievement of specified development, regulatory and commercial milestones up to €90.0 million in the aggregate. In addition, the Company is entitled to receive sales milestone payments if specified annual sales targets for lucitanib are met, which, in the aggregate, could total €250.0 million. The Company is also entitled to receive royalties on net sales of lucitanib by Servier.

The development, regulatory and commercial milestones represent non-refundable amounts that would be paid by Servier to the Company if certain milestones are achieved in the future. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company’s performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.

The Company and Servier are developing lucitanib pursuant to a development plan agreed to between the parties. Servier is responsible for all of the initial global development costs under the agreed upon plan up to €80.0 million. Cumulative global development costs, if any, in excess of €80.0 million will be shared equally between the Company and Servier. Beginning in the third quarter of 2014, depending on the expense type, reimbursements are determined using a standard rate approved by the Company and Servier or actual costs incurred. Previously, reimbursements were determined based on actual costs. Reimbursements are recorded as a reduction to research and development expense in the Consolidated Statements of Operations and Comprehensive Loss.

The Company recorded a $6.5 million and $2.9 million receivable at September 30, 2014 and December 31, 2013, respectively, for the reimbursable development costs incurred under the global development plan, which is included in other current assets on the Consolidated Balance Sheets. For the three and nine months ending September 30, 2014, we recorded reductions in research and development expense of $4.1 million and $7.9 million, respectively, for reimbursable development costs due from Servier.

X

- Definition

The entire disclosure for product in-licensing and collaboration agreements entered into by the entity.

+ References

No definition available.

+ Details

Name: clvs_LicenseAgreementsTextBlock

Namespace Prefix: clvs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Intangible Assets and Goodwill - Additional Information (Detail) (USD $)
9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Intangible Assets And Goodwill [Line Items]

Intangible assets $ 220,723,000 $ 244,518,000

Decrease in intangible assets due to changes in foreign currency translation rates (20,400,000)

Impairment charges for intangible assets 3,409,000

Goodwill 68,482,000 74,811,000

In Process Research and Development

Intangible Assets And Goodwill [Line Items]

Intangible assets 220,700,000 244,500,000

Ethical Oncology Science, S.p.A.

Intangible Assets And Goodwill [Line Items]

Goodwill $ 68,500,000 $ 74,800,000

X

- Details

Name: clvs_IntangibleAssetsAndGoodwillLineItems

Namespace Prefix: clvs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 55 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Nature of Business and Basis of Presentation (Policies)
9 Months Ended

Sep. 30, 2014

Basis of Presentation

Basis of Presentation

All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.

Use of Estimates

Use of Estimates

The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.

Liquidity

Liquidity

The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures.

In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.

Cash, Cash Equivalents

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.

Marketable Securities

Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.

+ References

No definition available.

+ Details

Name: us-gaap_LiquidityDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for investments in debt and equity securities that are classified as available-for-sale. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section M

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 2, 12

-Article 5

+ Details

Name: us-gaap_MarketableSecuritiesAvailableForSaleSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity (Tables)
9 Months Ended

Sep. 30, 2014

Component of Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) are summarized as follows (in thousands):

 Foreign
Currency
Translation
Adjustments Total
Accumulated
Other
Comprehensive
Income (Loss)

Balance December 31, 2013
 $ 4,696 $ 4,696

Period change
 (21,002 ) (21,002 )



Balance September 30, 2014
 $ (16,306 ) $ (16,306 )



Balance December 31, 2012
 $ 53 $ 53

Period change
 4,643 4,643



Balance December 31, 2013
 $ 4,696 $ 4,696



X

- Definition

Tabular disclosure of the components of accumulated other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense, tax benefit recognized $ 0 $ 0 $ 0 $ 0

Capitalized share-based compensation expense 0 0

Closing stock price $ 45.36 $ 45.36

Unrecognized stock-based compensation expense related to nonvested options $ 51,600,000 $ 51,600,000

Unrecognized stock-based compensation expense related to nonvested options, weighted-average remaining vesting period 3 years

X

- Definition

Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Unrecognized cost of unvested options awarded to employees as compensation.

+ References

No definition available.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 58 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Operating activities

Net loss $ (105,124) $ (55,329)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 3,772 185

Share-based compensation expense 15,585 6,663

Change in value of contingent purchase consideration (309)

Deferred income taxes 761

Changes in operating assets and liabilities, net of acquisition of a business:

Prepaid and accrued research and development expenses 7,152 1,990

Other operating assets (3,941) (5)

Accounts payable (1,889) (1,463)

Other accrued expenses 892 81

Net cash used in operating activities (83,101) (47,878)

Investing activities

Purchases of property and equipment (2,191) (80)

Net cash used in investing activities (2,191) (80)

Financing activities

Proceeds from the issuance of convertible senior notes 287,500

Proceeds from the sale of common stock, net of issuance costs 259,071

Proceeds from exercise of stock options and employee stock purchases 763 1,403

Payment of debt issuance costs (9,165)

Net cash provided by financing activities 279,098 260,474

Effect of exchange rate changes on cash and cash equivalents (449) 11

Increase in cash and cash equivalents 193,357 212,527

Cash and cash equivalents at beginning of period 323,228 144,097

Cash and cash equivalents at end of period $ 516,585 $ 356,624

X

- Definition

The net increase (decrease) during the reporting period in the amount of outstanding money paid in advance for research and development goods and services that bring economic benefits for future periods or in the amount of other research and development expenses incurred but not yet paid. Increase (decrease) relates to amounts paid in advance, or incurred and not yet paid, to contract research organizations, contract manufacturers or other research and development vendors.

+ References

No definition available.

+ Details

Name: clvs_IncreaseDecreaseInPrepaidAndAccruedResearchAndDevelopmentExpenses

Namespace Prefix: clvs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 59 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Other Current Assets
9 Months Ended

Sep. 30, 2014

Other Current Assets

5. Other Current Assets

Other current assets are comprised of the following (in thousands):

 September 30, 2014 December 31, 2013

Receivable from partners
 $ 6,544 $ 2,921

VAT recoverable
 45 950

Prepaid expenses and other
 1,336 521





Other current assets
 $ 7,925 $ 4,392





X

- Definition

The entire disclosure for other current assets.

+ References

No definition available.

+ Details

Name: us-gaap_OtherCurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Share-Based Compensation (Tables)
9 Months Ended

Sep. 30, 2014

Share-Based Compensation Expense Recognized in Accompanying Statements of Operations

Share-based compensation expense for all equity based programs, including stock options and the employee stock purchase plan, for the three and nine months ended September 30, 2014 and 2013, respectively, was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows:

 Three Months Ended September 30, Nine Months Ended September 30,

 2014 2013 2014 2013

Research and development
 $ 2,991 $ 1,138 $ 8,005 $ 3,095

General and administrative
 2,445 1,653 7,580 3,568









Total share-based compensation expense
 $ 5,436 $ 2,791 $ 15,585 $ 6,663









Summary of Stock Options Activity

The following table summarizes the activity relating to the Company’s options to purchase common stock for the nine month period ended September 30, 2014:

 Number of
Options Weighted-
Average
Exercise
Price Weighted-
Average
Remaining
Contractual
Term (Years) Aggregate
Intrinsic
Value

Outstanding at December 31, 2013
 2,520,170 $ 21.19

Granted
 1,449,457 62.00

Exercised
 (60,449 ) 8.96

Forfeited
 (23,813 ) 34.96





Outstanding at September 30, 2014
 3,885,365 $ 36.52 8.29 $ 64,790,012





Vested and expected to vest at September 30, 2014
 3,620,712 $ 35.23 8.22 $ 63,341,213





Vested at September 30, 2014
 1,503,631 $ 19.47 7.30 $ 41,643,182





Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award

Presented in the table below are financial details associated with our stock options during the three and nine months ended September 30, 2014 and 2013:

 Three Months Ended September 30,

 2014 2013

Weighted-average grant-date fair value per share
 $ 27.85 $ 43.43

Intrinsic value of options exercised
 $ 4,391 $ 85,589

Cash received from stock option exercises
 $ 341 $ 34,711

 Nine Months Ended September 30,

 2014 2013

Weighted-average grant-date fair value per share
 $ 39.13 $ 18.43

Intrinsic value of options exercised
 $ 2,754,669 $ 5,801,963

Cash received from stock option exercises
 $ 541,508 $ 1,223,023

X

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 67 186 1 false 27 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.clovisoncology.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information false false R2.htm 103 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfIncomeAlternative Consolidated Statements of Operations and Comprehensive Loss true false R3.htm 104 - Statement - Consolidated Balance Sheets Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R4.htm 105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) false false R5.htm 106 - Statement - Consolidated Statements of Cash Flows Sheet http://www.clovisoncology.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R6.htm 107 - Disclosure - Nature of Business and Basis of Presentation Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Nature of Business and Basis of Presentation false false R7.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R8.htm 109 - Disclosure - EOS Acquisition Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock EOS Acquisition false false R9.htm 110 - Disclosure - Financial Instruments and Fair Value Measurement Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Financial Instruments and Fair Value Measurement false false R10.htm 111 - Disclosure - Other Current Assets Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOtherCurrentAssetsTextBlock Other Current Assets false false R11.htm 112 - Disclosure - Intangible Assets and Goodwill Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Intangible Assets and Goodwill false false R12.htm 113 - Disclosure - Other Accrued Expenses Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Other Accrued Expenses false false R13.htm 114 - Disclosure - Convertible Senior Notes Notes http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Convertible Senior Notes false false R14.htm 115 - Disclosure - Stockholders' Equity Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R15.htm 116 - Disclosure - Share-Based Compensation Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Share-Based Compensation false false R16.htm 117 - Disclosure - License Agreements Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock License Agreements false false R17.htm 118 - Disclosure - Net Loss Per Common Share Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Net Loss Per Common Share false false R18.htm 119 - Disclosure - Income Taxes Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R19.htm 120 - Disclosure - Commitments and Contingencies Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R20.htm 121 - Disclosure - Subsequent Events Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events false false R21.htm 122 - Disclosure - Nature of Business and Basis of Presentation (Policies) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockPolicies Nature of Business and Basis of Presentation (Policies) false false R22.htm 123 - Disclosure - Financial Instruments and Fair Value Measurement (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Financial Instruments and Fair Value Measurement (Tables) false false R23.htm 124 - Disclosure - Other Current Assets (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsOtherCurrentAssetsTextBlockTables Other Current Assets (Tables) false false R24.htm 125 - Disclosure - Other Accrued Expenses (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Other Accrued Expenses (Tables) false false R25.htm 126 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Convertible Senior Notes (Tables) false false R26.htm 127 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R27.htm 128 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.clovisoncology.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Share-Based Compensation (Tables) false false R28.htm 129 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformation Nature of Business and Basis of Presentation - Additional Information (Detail) false false R29.htm 130 - Disclosure - EOS Acquisition - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureEOSAcquisitionAdditionalInformation EOS Acquisition - Additional Information (Detail) false false R30.htm 131 - Disclosure - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) false false R31.htm 132 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformation Fair Value Measurements - Additional Information (Detail) false false R32.htm 133 - Disclosure - Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureRollforwardOfFairValueOfLevel3InstrumentssignificantUnobservableInputs Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) false false R33.htm 134 - Disclosure - Other Current Assets (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureOtherCurrentAssets Other Current Assets (Detail) false false R34.htm 135 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillAdditionalInformation Intangible Assets and Goodwill - Additional Information (Detail) false false R35.htm 136 - Disclosure - Other Accrued Expenses (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureOtherAccruedExpenses Other Accrued Expenses (Detail) false false R36.htm 137 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://www.clovisoncology.com/taxonomy/role/DisclosureConvertibleSeniorNotesAdditionalInformation Convertible Senior Notes - Additional Information (Detail) false false R37.htm 138 - Disclosure - Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) Notes http://www.clovisoncology.com/taxonomy/role/DisclosureScheduleOfTotalInterestExpenseIncludedInOtherIncomeExpenseNetOnConsolidatedStatementsOfOperationsAndComprehensiveLossRecognizedRelatedToNotes Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) false false R38.htm 139 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R39.htm 140 - Disclosure - Component of Other Comprehensive Income (Loss) (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureComponentOfOtherComprehensiveIncomeLoss Component of Other Comprehensive Income (Loss) (Detail) false false R40.htm 141 - Disclosure - Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationExpenseRecognizedInAccompanyingStatementsOfOperations Share-Based Compensation Expense Recognized in Accompanying Statements of Operations (Detail) false false R41.htm 142 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation Share-Based Compensation - Additional Information (Detail) false false R42.htm 143 - Disclosure - Summary of Stock Options Activity (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureSummaryOfStockOptionsActivity Summary of Stock Options Activity (Detail) false false R43.htm 144 - Disclosure - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAward Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) false false R44.htm 145 - Disclosure - License Agreements - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformation License Agreements - Additional Information (Detail) false false R45.htm 146 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R46.htm 147 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.clovisoncology.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false All Reports Book All Reports Element clvs_InLicensingArrangementCostsUpFrontPayment had a mix of decimals attribute values: -5 0. Element clvs_LicenseFeesAndMilestonesRevenue had a mix of decimals attribute values: -5 -3. Element us-gaap_AccountsReceivableRelatedPartiesCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessCombinationContingentConsiderationLiability had a mix of decimals attribute values: -5 -3. Element us-gaap_DebtInstrumentCarryingAmount had a mix of decimals attribute values: -5 -3. Element us-gaap_Goodwill had a mix of decimals attribute values: -5 -3. Element us-gaap_IntangibleAssetsNetExcludingGoodwill had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromConvertibleDebt had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. Element us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '130 - Disclosure - EOS Acquisition - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '135 - Disclosure - Intangible Assets and Goodwill - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '137 - Disclosure - Convertible Senior Notes - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Statements of Operations and Comprehensive Loss Process Flow-Through: 104 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 105 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows clvs-20140930.xml clvs-20140930.xsd clvs-20140930_cal.xml clvs-20140930_def.xml clvs-20140930_lab.xml clvs-20140930_pre.xml true true XML 62 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
9 Months Ended 1 Months Ended

Sep. 30, 2013

Sep. 30, 2014

Jun. 30, 2013

Common Stock

Class of Stock [Line Items]

Common stock, shares issued 3,819,444

Sale of stock price per share $ 45.36 $ 72.00

Proceeds from the sale of common stock, net of issuance costs $ 259,071 $ 259,100

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 63 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Subsequent Events
9 Months Ended

Sep. 30, 2014

Subsequent Events

15. Subsequent Events

The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended
	Feb. 28, 2013	Sep. 30, 2014
Purchase Commitment, Excluding Long-term Commitment [Line Items]
Purchase commitment		$ 0
Contractual agreement quarterly forecasts required period	24 months
Contractual agreement obligated forecast period	12 months

Other Current Assets (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Other Current Assets [Line Items]
Receivable from partners	$ 6,544	$ 2,921
VAT recoverable	45	950
Prepaid expenses and other	1,336	521
Other current assets	$ 7,925	$ 4,392

Summary of Stock Options Activity (Detail) (USD $)	9 Months Ended
Summary of Stock Options Activity (Detail) (USD $)	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options Outstanding	2,520,170
Granted, Number of Options Outstanding	1,449,457
Exercised, Number of Options Outstanding	(60,449)
Forfeited, Number of Options Outstanding	(23,813)
Ending Balance, Number of Options Outstanding	3,885,365
Vested and expected to vest, Number of Options Outstanding	3,620,712
Vested, Number of Options Outstanding	1,503,631
Beginning Balance, Weighted Average Exercise Price	$ 21.19
Granted, Weighted Average Exercise Price	$ 62.00
Exercised, Weighted Average Exercise Price	$ 8.96
Forfeited, Weighted Average Exercise Price	$ 34.96
Ending Balance, Weighted Average Exercise Price	$ 36.52
Vested and expected to vest, Weighted Average Exercise Price	$ 35.23
Vested, Weighted Average Exercise Price	$ 19.47
Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 3 months 15 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	8 years 2 months 19 days
Vested, Weighted Average Remaining Contractual Term (Years)	7 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value	$ 64,790,012
Vested and expected to vest, Aggregate Intrinsic Value	63,341,213
Vested, Aggregate Intrinsic Value	$ 41,643,182

Schedule of Total Interest Expense Included in Other Income (Expense), Net on Consolidated Statements of Operations and Comprehensive Loss Recognized Related to Notes (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Debt Instrument [Line Items]
Contractual interest expense	$ 439	$ 439
Amortization of debt issuance costs	72	72
Total interest expense	$ 511	$ 511

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per share	$ 27.85	$ 43.43	$ 39.13	$ 18.43
Intrinsic value of options exercised	$ 4,391	$ 85,589	$ 2,754,669	$ 5,801,963
Cash received from stock option exercises	$ 341	$ 34,711	$ 541,508	$ 1,223,023

EOS Acquisition - Additional Information (Detail)			0 Months Ended
EOS Acquisition - Additional Information (Detail)	Sep. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Nov. 19, 2013 Ethical Oncology Science, S.p.A. USD ($)	Sep. 30, 2014 Ethical Oncology Science, S.p.A. USD ($)	Dec. 31, 2013 Ethical Oncology Science, S.p.A. USD ($)	Nov. 19, 2013 Ethical Oncology Science, S.p.A. Regulatory and Sales Milestones Maximum USD ($)	Nov. 19, 2013 Ethical Oncology Science, S.p.A. Regulatory and Sales Milestones Maximum EUR (€)	Nov. 19, 2013 Ethical Oncology Science, S.p.A. Regulatory and Sales Milestones Minimum USD ($)
Business Acquisition [Line Items]
Business acquisition cash payments made on acquisition			$ 11,800,000
Business acquisition, common stock issued at acquisition date			173,700,000
Future potential cash consideration payments						65,000,000	115,000,000	0
Fair value of contingent consideration	$ 55,445,000	$ 55,754,000		$ 55,400,000	$ 55,800,000

Nature of Business and Basis of Presentation - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended	3 Months Ended
	Sep. 30, 2014	Mar. 31, 2014 Les Laboratoires Servier
Nature Of Business [Line Items]
License and milestone revenue	$ 13,625	$ 13,600

License Agreements - Additional Information (Detail)	9 Months Ended			1 Months Ended	3 Months Ended		9 Months Ended		1 Months Ended		9 Months Ended	1 Months Ended		3 Months Ended	1 Months Ended
License Agreements - Additional Information (Detail)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Dec. 31, 2013 USD ($)	Sep. 30, 2012 Les Laboratoires Servier EUR (€)	Sep. 30, 2014 Les Laboratoires Servier USD ($)	Mar. 31, 2014 Les Laboratoires Servier USD ($)	Sep. 30, 2014 Les Laboratoires Servier USD ($)	Dec. 31, 2013 Les Laboratoires Servier USD ($)	Feb. 28, 2014 License Agreement Terms License Agreements Licensor Avila Therapeutics Name of drug product in-licensed by the entity - Rociletinib USD ($)	Apr. 30, 2014 License Agreement Terms License Agreements Licensor Pfizer Rucaparib USD ($)	Sep. 30, 2014 License Agreement Terms License Agreements Licensor Pfizer Rucaparib USD ($)	Apr. 30, 2012 License Agreement Terms License Agreements Licensor Astra Zeneca U K Ltd Rucaparib USD ($)	Oct. 31, 2008 License Agreement Terms Advenchen Laboratories LLC	Mar. 31, 2014 License Agreement Terms Advenchen Laboratories LLC USD ($)	May 31, 2010 Up-front license payment License Agreement Terms License Agreements Licensor Avila Therapeutics Name of drug product in-licensed by the entity - Rociletinib USD ($)	Jan. 31, 2013 Up-front license payment License Agreement Terms License Agreements Licensor Gatekeeper Name of drug product in-licensed by the entity - Rociletinib USD ($)	Jun. 30, 2011 Up-front license payment License Agreement Terms License Agreements Licensor Pfizer Rucaparib USD ($)	Apr. 30, 2012 Up-front license payment License Agreement Terms License Agreements Licensor Astra Zeneca U K Ltd Rucaparib USD ($)	Feb. 28, 2014 Regulatory Milestone Payment License Agreement Terms License Agreements Licensor Avila Therapeutics Name of drug product in-licensed by the entity - Rociletinib USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Up-front payment															$ 2,000,000	$ 250,000	$ 7,000,000	$ 250,000
Acquired in process research and development costs	8,806,000	250,000								400,000				3,400,000					5,000,000
Future expected development and regulatory payment									110,000,000			700,000
Sales milestone payments									120,000,000
Future expected development, regulatory and sales milestone payments											258,500,000
Percentage of Non-Royalty Consideration Payable on Sublicense Agreements													25.00%
Sublicense agreement consideration	13,625,000					13,600,000								13,600,000
Additional payments receivable on achievement				90,000,000
Additional payments receivable on attaining the sales target				250,000,000
Initial global development costs reimbursable				80,000,000
Development cost receivable	6,544,000		2,921,000		6,500,000		6,500,000	2,900,000
Reduction in research and development expense for reimbursable development costs due from Servier					$ 4,100,000		$ 7,900,000

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	$ 447,986	$ 318,886
Contingent purchase consideration	55,445	55,754
Liabilities at fair value	55,445	55,754
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 1 \| Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets at fair value	447,986	318,886
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase consideration	55,445	55,754
Liabilities at fair value	$ 55,445	$ 55,754

Fair Value Measurements - Additional Information (Detail) (USD $)	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers between Level 1 and Level 2	$ 0

Roll-forward of Fair Value of Level 3 Instruments (significant unobservable inputs) (Detail) (Fair Value, Inputs, Level 3, USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Fair Value, Inputs, Level 3
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 55,754
Accretion	2,571
Change in foreign currency gains and losses	(2,880)
Balance at end of period	$ 55,445

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Income Taxes [Line Items]
Income tax expense	$ 292	$ 2,489

Other Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Line Items]
Accrued personnel costs	$ 3,404	$ 3,356
Accrued corporate legal fees and professional services	132	257
Accrued expenses - other	1,183	371
Other accrued expenses	$ 4,719	$ 3,984

Convertible Senior Notes - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended
	Sep. 09, 2014 D	Sep. 30, 2014 D	Sep. 09, 2014
Debt Instrument [Line Items]
Convertible senior notes, aggregate principal amount		$ 287,500,000
Net proceeds form convertible senior notes		287,500,000
Convertible Senior Unsecured Notes
Debt Instrument [Line Items]
Convertible senior notes, aggregate principal amount			287,500,000
Convertible senior notes, interest rate			2.50%
Net proceeds form convertible senior notes	278,300,000
Convertible senior notes, frequency of periodic payment		Semi-annually
Debt instrument, beginning date of periodic payment		Mar. 15, 2015
Convertible senior notes, maturity date		Sep. 15, 2021
Convertible senior notes, initial conversion price per share			$ 61.88
Common stock initial conversion rate per $1,000 in principal amount	16.1616
Last reported sale price of common stock	150.00%
Debt instrument, conversion in effect for number of trading days	20
Debt instrument conversion, consecutive trading day period	30 days
Debt instrument redemption price percentage to principal amount	100.00%
Debt instrument redemption description		On or after September 15, 2018, we may redeem the Notes, at our option, in whole or in part, if the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending not more than two trading days preceding the date on which we provide written notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.
Debt instrument, redemption period start date		Sep. 15, 2018
Debt instrument, trading days preceding redemption notice, maximum		2
Debt instrument repurchase percentage		100.00%
Debt issuance costs		9,200,000
Debt instrument term		7 years
Unamortized debt issuance costs		9,100,000
Convertible Senior Unsecured Notes \| Semi Annual Payment, First payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--03-15
Convertible Senior Unsecured Notes \| Semi Annual Payment, Second payment date
Debt Instrument [Line Items]
Interest payment date on senior notes		--09-15
Convertible Senior Unsecured Notes \| Fair Value, Inputs, Level 2
Debt Instrument [Line Items]
Debt instrument, fair value		$ 297,300,000

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 516,585	$ 323,228
Prepaid research and development expenses	2,241	976
Other current assets	7,925	4,392
Total current assets	526,751	328,596
Property and equipment, net	2,846	955
Intangible assets	220,723	244,518
Goodwill	68,482	74,811
Other assets	12,725	755
Total assets	831,527	649,635
Current liabilities:
Accounts payable	2,428	4,420
Accrued research and development expenses	23,832	12,548
Other accrued expenses	4,719	3,984
Total current liabilities	30,979	20,952
Contingent purchase consideration	55,445	55,754
Deferred income taxes, net	69,307	74,955
Convertible senior notes	287,500
Other non-current liabilities	6	88
Total liabilities	443,237	151,749
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013
Common stock, $0.001 par value per share, 100,000,000 shares authorized at September 30, 2014 and December 31, 2013; 33,964,065 and 33,897,321 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	34	34
Additional paid-in capital	778,700	762,170
Accumulated other comprehensive (loss) income	(16,306)	4,696
Accumulated deficit	(374,138)	(269,014)
Total stockholders' equity	388,290	497,886
Total liabilities and stockholders' equity	$ 831,527	$ 649,635

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	CLVS
Entity Registrant Name	CLOVIS ONCOLOGY, INC.
Entity Central Index Key	0001466301
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		33,964,440

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,964,065	33,897,321
Common stock, shares outstanding	33,964,065	33,897,321

Intangible Assets and Goodwill - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Intangible Assets And Goodwill [Line Items]
Intangible assets	$ 220,723,000	$ 244,518,000
Decrease in intangible assets due to changes in foreign currency translation rates	(20,400,000)
Impairment charges for intangible assets	3,409,000
Goodwill	68,482,000	74,811,000
In Process Research and Development
Intangible Assets And Goodwill [Line Items]
Intangible assets	220,700,000	244,500,000
Ethical Oncology Science, S.p.A.
Intangible Assets And Goodwill [Line Items]
Goodwill	$ 68,500,000	$ 74,800,000

Nature of Business and Basis of Presentation (Policies)	9 Months Ended
Nature of Business and Basis of Presentation (Policies)	Sep. 30, 2014
Basis of Presentation	*Basis of Presentation* All financial information presented includes the accounts of the Company’s wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to fairly state our financial position, results of operations and cash flows for the periods presented. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our Annual Report on Form 10-K for the year ended December 31, 2013 for a broader discussion of our business and the opportunities and risks inherent in such business.
Use of Estimates	*Use of Estimates* The preparation of these financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, revenue and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to contingent purchase consideration, the allocation of purchase consideration, intangible assets, clinical trial accruals and share-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Liquidity	*Liquidity* The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through debt and equity financings. Management expects operating losses and negative cash flows to continue for the foreseeable future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless or until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.
Recent Accounting Pronouncements	*Recent Accounting Pronouncements* In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 specifies the accounting for revenue from contracts with customers and establishes disclosure requirements relating to the nature, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. This update is effective for annual and interim periods beginning after December 15, 2016 and allows for either full retrospective or modified retrospective adoption. Early adoption is not permitted. The Company is currently evaluating its planned method of adoption and the impact the standard may have on its consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern,” which requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern and to provide disclosures when certain criteria are met. The guidance is effective for annual periods beginning in 2016 and interim reporting periods starting in the first quarter of 2017. Early application is permitted. The Company does not expect the standard will have an impact on its disclosures.
Cash, Cash Equivalents	The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in certificate of deposits, commercial paper and U.S. government and U.S. government agency obligations.
Marketable Securities	Marketable securities with original maturities greater than three months are considered to be available-for-sale securities and historically consisted of U.S. agency obligations, U.S. government obligations and corporate debt obligations. Available-for-sale securities are reported at fair value and unrealized gains and losses are included in accumulated other comprehensive income on the Consolidated Balance Sheets. Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are included in other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Investments with maturities beyond one year are classified as short-term based on management’s intent to fund current operations with these securities or to make them available for current operations. A decline in the market value of a security below its cost value that is deemed to be other than temporary is charged to earnings and results in the establishment of a new cost basis for the security.

Stockholders' Equity - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Jun. 30, 2013 Common Stock
Class of Stock [Line Items]
Common stock, shares issued			3,819,444
Sale of stock price per share		$ 45.36	$ 72.00
Proceeds from the sale of common stock, net of issuance costs	$ 259,071		$ 259,100

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2014
Subsequent Events	15. Subsequent Events The Company evaluated events up to the filing date of these interim financial statements and determined that no subsequent activity required disclosure.